Warning, /office/kbibtex-testset/isi/chinese.isi is written in an unsupported language. File is not indexed.
0001 FN ISI Export Format 0002 VR 1.0 0003 PT J 0004 AU Liu, W 0005 Zhang, B 0006 Wang, Q 0007 Xie, ZH 0008 Yao, WB 0009 Gao, XD 0010 Yu, LL 0011 AF Liu, Wei 0012 Zhang, Boce 0013 Wang, Qin 0014 Xie, Zhouhong 0015 Yao, Wenbing 0016 Gao, Xiangdong 0017 Yu, Liangli (Lucy) 0018 TI Effects of Sulfation on the Physicochemical and Functional Properties 0019 of Psyllium 0020 SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 0021 AB The sulfation of psyllium was carried out with sulfur trioxide-pyridine 0022 in dimethyl formamide. Three sulfated psyllium derivatives, named SP1, 0023 SP2, and SP3, were characterized by sulfur content determination, 0024 elemental analysis, FT-IR, and surface charge analysis. The sulfated 0025 derivatives were also evaluated for their morphological and 0026 rheological properties, water uptake capacities, swelling volumes, and 0027 in vitro bile acid-binding abilities. The results showed that sulfation 0028 reduced the gelling capacity of psyllium and the viscosity of its 0029 solution, and significantly increased its bile acid-binding capacity. 0030 Sulfation might also increase the water uptake ability of psyllium but 0031 might decrease its swelling capacity. The three sulfated psyllium 0032 derivatives had in vitro binding capacities against cholic and 0033 chenodeoxycholic acids comparable to that of cholestyramine resin on 0034 a per same as it is weight basis. The bile acid-binding capacity of 0035 SP1 was about 8.4-fold of that observed for the original psyllium 0036 preparation under the same assay conditions. The results from this 0037 study suggest that sulfation is a possible approach to obtain novel 0038 psyllium derivatives with desirable physicochemical, functional, and 0039 biological properties for utilization in functional foods or 0040 supplemental and pharmaceutical products. 0041 SN 0021-8561 0042 PD JAN 13 0043 PY 2010 0044 VL 58 0045 IS 1 0046 BP 172 0047 EP 179 0048 DI 10.1021/jf902731p 0049 UT ISI:000273268100023 0050 PT J 0051 AU Yan, JL 0052 Qian, ZY 0053 Sheng, L 0054 Zhao, BH 0055 Yang, LN 0056 Ji, H 0057 Han, XY 0058 Zhang, R 0059 AF Yan, Junling 0060 Qian, Zhiyu 0061 Sheng, Liang 0062 Zhao, Bohua 0063 Yang, Lina 0064 Ji, Hui 0065 Han, Xiaoyuan 0066 Zhang, Rong 0067 TI EFFECT OF CROCETIN ON BLOOD PRESSURE RESTORATION AND SYNTHESIS OF 0068 INFLAMMATORY MEDIATORS IN HEART AFTER HEMORRHAGIC SHOCK IN 0069 ANESTHETIZED RATS 0070 SO SHOCK 0071 AB Crocetin, a constituent of saffron, has been shown not only to prevent 0072 reactive oxygen species-induced hepatotoxicity and genotoxicity but 0073 also to increase whole-body oxygen consumption and survival. The 0074 present study was to determine whether crocetin has beneficial effects 0075 on cardiac injury caused by hemorrhagic shock and resuscitation in 0076 rats. Anesthetized rats were bled to reduce mean arterial pressure 0077 (MAP) to 35 +/- 5 mmHg for 60 min and then resuscitated with their 0078 withdrawn shed blood and isotonic sodium chloride solution. Crocetin 0079 was administered via the duodenum at 50 mg/kg 40 min after bleeding. 0080 We investigated MAP, serum creatine kinase activity, the activity of 0081 nuclear factor-kappa B, iNOS, and total superoxide dismutase (T-SOD), 0082 as well as levels of NO, malondialdehyde, TNF-alpha, and IL-6 in the 0083 heart at 2 h postresuscitation. Compared with control group, crocetin 0084 significantly increased MAP from 10 min after administration to the 0085 end of the protocol except the period between 75 and 90 min after initial 0086 bleeding, whereas serum creatine kinase activity was dramatically 0087 decreased at 2 h postresuscitation. Myocardial nuclear factor-kappa 0088 B activity, iNOS activity, NO, malondialdehyde, TNF-alpha, and IL-6 0089 were significantly elevated, whereas T-SOD activity was suppressed in 0090 the control group if compared with those of sham animals. These 0091 parameters tended to be normalized in rats administered crocetin. These 0092 results suggest that crocetin blocks inflammatory cascades by 0093 inhibiting reactive oxygen species production and preserving T-SOD 0094 activity to ameliorate the cardiac injury caused by 0095 hemorrhage/resuscitation. 0096 SN 1073-2322 0097 PD JAN 0098 PY 2010 0099 VL 33 0100 IS 1 0101 BP 83 0102 EP 87 0103 DI 10.1097/SHK.0b013e3181a98f55 0104 UT ISI:000272970200014 0105 PT J 0106 AU Zhang, J 0107 Deng, DW 0108 Qian, ZY 0109 Liu, F 0110 Chen, XY 0111 An, LX 0112 Gu, YQ 0113 AF Zhang, Jian 0114 Deng, Dawei 0115 Qian, Zhiyu 0116 Liu, Fei 0117 Chen, Xinyang 0118 An, Lianxiao 0119 Gu, Yueqing 0120 TI The Targeting Behavior of Folate-Nanohydrogel Evaluated by Near 0121 Infrared Imaging System in Tumor-Bearing Mouse Model 0122 SO PHARMACEUTICAL RESEARCH 0123 AB Purpose. To synthesize 0124 P[(Folate-Allylamine)-co-(N-isopropylacrylamine)-co-Acrylamide] (P 0125 (FoAAnco-NIPA- AAm), folate-NHG) with appropriate diameter and lower 0126 critical solution temperature (LCST) for targeting to folate receptor 0127 (FR) expressing tumors. 0128 Methods. Folate-NHG was synthesized by free-radical precipitation 0129 polymerization method reported in our previous work and other reports. 0130 LCST, diameter and morphology of folate-NHG were characterized by 0131 UV-vis spectrophotometer, laser particle size analyzer (LPSA) and 0132 transmission electron microscope (TEM), respectively. No. 12 near 0133 infrared dye (NIRD-12) was entrapped into folate-NHG by hydrophobic 0134 association to trace the in vivo dynamic behavior of folate-NHG. This 0135 process was evaluated by a homemade near infrared (NIR) imaging system. 0136 Results. Spherical folate-NHG with diameter of about 50 nm and LCST 0137 of about 40 C was successfully synthesized. The photo stability of 0138 NIRD-12 was strengthened after being entrapped into folate-NHG, which 0139 enabled NIRD-12 to better trace the in vivo dynamic process of 0140 folate-NHG. Folate-NHG showed good targeting capability for all three 0141 folate receptor expressing tumor models (SMMC-7721, Bel-7402 and HeLa) 0142 with different sizes, and this accumulation could last for more than 0143 96 h. D-folate-NHG, synthesized with double amount of FoAAn, showed 0144 better targeting effect for SMMC-7721 tumor model than that of 0145 folate-NHG. 0146 Conclusions. Folate-NHG could actively accumulate in three models of 0147 folate receptor positive tumors with different sizes and keep retention 0148 for more than 96 h, which enables it to be used as a diagnostic reagent 0149 or anti-tumor drug carrier for tumor therapy. 0150 SN 0724-8741 0151 PD JAN 0152 PY 2010 0153 VL 27 0154 IS 1 0155 BP 46 0156 EP 55 0157 DI 10.1007/s11095-009-0005-1 0158 UT ISI:000272905300005 0159 PT J 0160 AU Mu, R 0161 Lu, N 0162 Wang, J 0163 Yin, YH 0164 Ding, Y 0165 Zhang, XX 0166 Gui, H 0167 Sun, Q 0168 Duan, HQ 0169 Zhang, L 0170 Zhang, YC 0171 Ke, X 0172 Guo, QL 0173 AF Mu, Rong 0174 Lu, Na 0175 Wang, Jia 0176 Yin, Yueheng 0177 Ding, Yan 0178 Zhang, Xiaoxuan 0179 Gui, Huan 0180 Sun, Qiong 0181 Duan, Huaqin 0182 Zhang, Lun 0183 Zhang, Yuchen 0184 Ke, Xue 0185 Guo, Qinglong 0186 TI An oxidative analogue of gambogic acid-induced apoptosis of human 0187 hepatocellular carcinoma cell line HepG2 is involved in its anticancer 0188 activity in vitro 0189 SO EUROPEAN JOURNAL OF CANCER PREVENTION 0190 AB The objective of this study was to investigate the apoptosis-inducing 0191 effect of an oxidative analogue of gambogic acid (GA) on the human 0192 hepatocellular carcinoma cell line HepG2 and explore the related 0193 molecular mechanisms. HepG2 cells were treated with the analogue of 0194 GA and the growth inhibition was analysed by MTT assay. The 0195 morphological changes in cells were observed under an inverted light 0196 microscope and a fluorescence microscope. In addition, both the 0197 cell-cycle arrest and the apoptosis rate were detected by flow 0198 cytometry. Western blot was used to evaluate the alteration of protein 0199 expression. The viability of HepG2 cells was markedly inhibited in a 0200 concentration-dependent manner and obvious morphological changes were 0201 confirmed, including condensed chromatin and reduced volume. Increased 0202 percentage of apoptotic cells was displayed and altered expression 0203 level of several apoptosis-associated proteins, P53, Bcl-2, Bax and 0204 pro-caspase-3, was obtained. The newly synthesized analogue of GA 0205 exhibited potential anticancer activity, induced remarkable apoptosis 0206 in HepG2 cells, probably through the intrinsic mitochondrial pathway, 0207 and promised to be a new candidate for future cancer therapy. European 0208 Journal of Cancer Prevention 19:61-67 (C) 2010 Wolters Kluwer Health 0209 | Lippincott Williams & Wilkins. 0210 SN 0959-8278 0211 PD JAN 0212 PY 2010 0213 VL 19 0214 IS 1 0215 BP 61 0216 EP 67 0217 DI 10.1097/CEJ.0b013e328333fb22 0218 UT ISI:000272952200010 0219 PT J 0220 AU Zhao, L 0221 Chen, Z 0222 Wang, J 0223 Yang, L 0224 Zhao, Q 0225 Wang, J 0226 Qi, Q 0227 Mu, R 0228 You, QD 0229 Guo, QL 0230 AF Zhao, Li 0231 Chen, Zhen 0232 Wang, Jun 0233 Yang, Li 0234 Zhao, Qing 0235 Wang, Jia 0236 Qi, Qi 0237 Mu, Rong 0238 You, Qi-Dong 0239 Guo, Qing-Long 0240 TI Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on 0241 HepG2 human hepatocellular carcinoma and on H-22 transplanted mice 0242 SO CANCER CHEMOTHERAPY AND PHARMACOLOGY 0243 AB To investigate the synergistic inhibitory effects of the combination 0244 of 5-fluorouracil (5-FU) with the natural flavanoid oroxylin A on human 0245 hepatocellular carcinoma cells HepG2 in vitro and on transplanted 0246 murine hepatoma 22 (H-22) tumors in vivo and the preliminary 0247 mechanisms. 0248 The inhibitory effects of 5-FU combined with the natural flavanoid 0249 oroxylin A in vitro were detected by MTT assay and the effects in vivo 0250 were investigated by transplanted H-22 mice model. DAPI staining and 0251 Annexin V/propidium iodide (PI) double staining were used to detect 0252 the cell morphological changes and apoptosis. The mRNA levels of 0253 thymidine synthetase (TS) and dihydropyrimidine dehydrogenase (DPD) 0254 in HepG2 cells after oroxylin A and 5-FU combination treatment were 0255 observed by quantitative real-time PCR. Western blotting assay was used 0256 to reveal the expressions of apoptotic-inducing proteins P53, cleaved 0257 PARP, COX-2, Bcl-2, and pro-caspase3. 0258 Oroxylin A in combination with 5-FU presented synergistic effect (CI 0259 < 1) on HepG2 cells in vitro when the inhibitory rate was higher than 0260 7.5%. The inhibitory rate on H-22 murine solid tumor in vivo in the 0261 combination group was higher than monotherapy. 5-FU combined with 0262 oroxylin A exerted stronger apoptotic induction in HepG2 cells than 0263 either single drug treatment. Quantitative real-time PCR discovered 0264 the downregulation of TS mRNA and DPD mRNA in HepG2 cells after 0265 combination treatment. Western blotting assay revealed oroxylin A 0266 enhanced 5-FU-induced apoptosis in HepG2 cells by elevating the 0267 expressions of apoptotic-inducing proteins P53 and cleaved PARP and 0268 decreasing the expression of apoptotic-inhibitory proteins COX-2, 0269 Bcl-2, and pro-caspase3. 0270 The anti-hepatocellular carcinoma effects in vitro and in vivo of 5-FU 0271 and oroxylin A combinations were synergistic and oroxylin A increased 0272 the sensitivity of HepG2 cells to 5-FU by modulating the metabolic 0273 enzymes of 5-FU and apoptotic-related proteins. 0274 SN 0344-5704 0275 PD FEB 0276 PY 2010 0277 VL 65 0278 IS 3 0279 BP 481 0280 EP 489 0281 DI 10.1007/s00280-009-1053-2 0282 UT ISI:000273031400009 0283 PT J 0284 AU Zhang, YC 0285 Zhou, JP 0286 Pan, WH 0287 Wu, XM 0288 Wang, S 0289 AF Zhang, Yanchun 0290 Zhou, Jinpei 0291 Pan, Weihong 0292 Wu, Xiaoming 0293 Wang, Shuai 0294 TI Synthesis and Biological Study of 0295 3-Butyl-1-(2,6-dichlorophenyl)-1H-[1,2,4]triazol-5(4H)-one 0296 Derivatives as Anti-hypertension Drugs 0297 SO LETTERS IN DRUG DESIGN & DISCOVERY 0298 AB A series of nitric oxide-donating derivatives of 0299 [1,2,4]triazol-5(4H)-one (9a-f and 15a-f) as a novel class of 0300 angiotensin II receptor AT1 antagonists have been designed and 0301 synthesized by coupling furoxan and nitric oxide with lead compound 0302 1. The synthesized compounds were evaluated for their antagonism of 0303 AT1 receptor with induced contraction in the rabbit thoracic aortic 0304 ring and the results showed that compounds 9b, 15b and 15d exhibited 0305 potent antagonistic activity of AT1 receptor. Moreover 9b, 15b, 15d, 0306 15e had good maximum NO release amount of this series. 0307 SN 1570-1808 0308 PD JAN 0309 PY 2010 0310 VL 7 0311 IS 1 0312 BP 18 0313 EP 22 0314 UT ISI:000272791000005 0315 PT J 0316 AU Shu, XY 0317 Yu, L 0318 Tang, YP 0319 Zhang, L 0320 Ding, AW 0321 Luo, D 0322 Duan, JA 0323 Shen, XC 0324 AF Shu, Xiaoyun 0325 Yu, Li 0326 Tang, Yuping 0327 Zhang, Li 0328 Ding, Anwei 0329 Luo, Dan 0330 Duan, Jin-ao 0331 Shen, Xiangchun 0332 TI Bioassay-guided separation of the proinflammatory constituents from 0333 the roots of Euphorbia kansui 0334 SO JOURNAL OF NATURAL MEDICINES 0335 AB In view of the toxic inflammatory reaction induced by Euphorbia kansui 0336 roots, a traditional Chinese medicine used for the treatment of edema, 0337 ascites, and asthma, the 95% ethanol extract was found to have a 0338 significant stimulating effect on inflammatory cells. Bioassay-guided 0339 separation of the 95% ethanol extract from the roots of E. kansui led 0340 to the isolation of five diterpenoids whose structures were identified 0341 by H-1, C-13 NMR spectroscopy and HR-ESI-MS as kansuinine B (1), 0342 kansuinine A (2), kansuiphorin C (3), 3-O-benzoyl-20-deoxyingenol (4), 0343 and 3-O-(2'E,4'Z-decadienoyl)-20-O-acetylingenol (5). The 0344 proinflammatory effect of compounds 1-5 was evaluated in vitro in 0345 models of inflammation using exoteric mice splenic lymphocytes (SPL) 0346 and rat peritoneal macrophages (PM phi). Compounds 1, 2, and 5 markedly 0347 promoted SPL proliferation and NO production by PM phi at 0348 concentrations from 0.78 to 12.50 mu g/mL. Hence the three compounds 0349 are believed to be important proinflammatory components of the roots 0350 of E. kansui. 0351 SN 1340-3443 0352 PD JAN 0353 PY 2010 0354 VL 64 0355 IS 1 0356 BP 98 0357 EP 103 0358 DI 10.1007/s11418-009-0366-0 0359 UT ISI:000272849000017 0360 PT J 0361 AU Shen, J 0362 Sun, MJ 0363 Ping, QN 0364 Ying, Z 0365 Liu, W 0366 AF Shen, Jie 0367 Sun, Minjie 0368 Ping, Qineng 0369 Ying, Zhi 0370 Liu, Wen 0371 TI Incorporation of liquid lipid in lipid nanoparticles for ocular drug 0372 delivery enhancement 0373 SO NANOTECHNOLOGY 0374 AB The present work investigates the effect of liquid lipid incorporation 0375 on the physicochemical properties and ocular drug delivery enhancement 0376 of nanostructured lipid carriers (NLCs) and attempts to elucidate in 0377 vitro and in vivo the potential of NLCs for ocular drug delivery. The 0378 CyA-loaded or fluorescein-marked nanocarriers composed of Precifac ATO 0379 5 and Miglyol 840 (as liquid lipid) were prepared by melting-emulsion 0380 technology, and the physicochemical properties of nanocarriers were 0381 determined. The uptake of nanocarriers by human corneal epithelia cell 0382 lines (SDHCEC) and rabbit cornea was examined. Ex vivo fluorescence 0383 imaging was used to investigate the ocular distribution of 0384 nanocarriers. The in vitro cytotoxicity and in vivo acute tolerance 0385 were evaluated. The higher drug loading capacity and improved in vitro 0386 sustained drug release behavior of lipid nanoparticles was found with 0387 the incorporation of liquid lipid in lipid nanoparticles. The uptake 0388 of nanocarriers by the SDHCEC was increased with the increase in liquid 0389 lipid loading. The ex vivo fluorescence imaging of the ocular tissues 0390 indicated that the liquid lipid incorporation could improve the ocular 0391 retention and penetration of ocular therapeutics. No alternation was 0392 macroscopically observed in vivo after ocular surface exposure to 0393 nanocarriers. These results indicated that NLC was a biocompatible and 0394 potential nanocarrier for ocular drug delivery enhancement. 0395 SN 0957-4484 0396 PD JAN 15 0397 PY 2010 0398 VL 21 0399 IS 2 0400 AR 025101 0401 DI 10.1088/0957-4484/21/2/025101 0402 UT ISI:000272641800001 0403 PT J 0404 AU Tu, FP 0405 Chu, WH 0406 Zhuang, XY 0407 Lu, CP 0408 AF Tu, F. P. 0409 Chu, W. H. 0410 Zhuang, X. Y. 0411 Lu, C. P. 0412 TI Effect of oral immunization with Aeromonas hydrophila ghosts on 0413 protection against experimental fish infection 0414 SO LETTERS IN APPLIED MICROBIOLOGY 0415 AB Aims: 0416 To investigate whether oral immunization with Aeromonas hydrophila 0417 ghosts (AHG) vaccine can elicit mucosal and systemic immune responses 0418 of Carp (Carassius auratus gibelio) compared to conventional 0419 formalin-killed bacteria (FKC). 0420 Methods and Results: 0421 Fish were fed diets coated with AHG, FKC or phosphate buffered saline 0422 (PBS) alone, after immunization, more antigen-specific antibody was 0423 significantly detected in serum and intestinal mucus in AHG group than 0424 FKC group and PBS group. In addition, after challenged with the parent 0425 strain J-1, the survival of bacterial ghost-vaccinated fish was higher 0426 than PBS group and FKC group, the relative per cent survival (RPS) being 0427 76 center dot 8%, 58 center dot 9%, respectively. 0428 Conclusions: 0429 Oral immunization with A. hydrophila ghosts can elicit systemic and 0430 mucosal adaptive immune responses and has higher potential to induce 0431 protective adaptive immunity than normal vaccine. 0432 Significance and Impact of the Study: 0433 Oral immunization with bacterial ghosts is a promising new solution 0434 with potential application to prevent diseases in fish. 0435 SN 0266-8254 0436 PD JAN 0437 PY 2010 0438 VL 50 0439 IS 1 0440 BP 13 0441 EP 17 0442 DI 10.1111/j.1472-765X.2009.02746.x 0443 UT ISI:000272582600003 0444 PT J 0445 AU Du, JL 0446 Shen, NF 0447 Zhu, LY 0448 Wang, JL 0449 AF Du, Jinli 0450 Shen, Naifeng 0451 Zhu, Liyan 0452 Wang, Jinlan 0453 TI Emergence of noncollinear magnetic ordering in bimetallic Co6-nMnn 0454 clusters 0455 SO JOURNAL OF PHYSICS D-APPLIED PHYSICS 0456 AB Using spin-polarized density functional calculations, we have studied 0457 the magnetic states including collinear and noncollinear magnetic 0458 coupling in bimetallic Co6-nMnn clusters. The ground state of Co6-nMnn 0459 clusters displays collinear magnetic ordering for n <= 3, whereas a 0460 magnetic transition to noncollinear ordering occurs at n = 4 and the 0461 noncollinear magnetic structure remains to be energetically favoured 0462 afterwards. Moreover, the total magnetic moment of Co6-nMnn increases 0463 with n by 2 mu(B) for n = 0-3 and decreases sharply from n = 3 to n 0464 = 4, while the decreasing trend becomes smooth for n = 4-6. The 0465 competition of ferromagnetic and antiferromagnetic interactions 0466 between the neighbouring magnetic moments induces the emergence of 0467 noncollinear magnetic coupling in the small bimetallic clusters. 0468 SN 0022-3727 0469 PD JAN 13 0470 PY 2010 0471 VL 43 0472 IS 1 0473 AR 015006 0474 DI 10.1088/0022-3727/43/1/015006 0475 UT ISI:000272702300010 0476 PT J 0477 AU Zhang, XY 0478 Liu, JP 0479 Qiao, H 0480 Liu, H 0481 Ni, JM 0482 Zhang, WL 0483 Shi, YB 0484 AF Zhang, Xiaoyun 0485 Liu, Jianping 0486 Qiao, Hua 0487 Liu, Huan 0488 Ni, Jingman 0489 Zhang, Wenli 0490 Shi, Yanbin 0491 TI Formulation optimization of dihydroartemisinin nanostructured lipid 0492 carrier using response surface methodology 0493 SO POWDER TECHNOLOGY 0494 AB Response surface methodology (RSM) using the central composite 0495 rotatable design (CCRD) model was used to optimize formulations of 0496 dihydroartemisinin nancistructured lipid carrier (DHA-NLC). The CCRD 0497 consisting of three-factored factorial design with three levels was 0498 used in this study The drug encapsulation efficiency (EE), drug loading 0499 (DL) percentage and particle size of DHA-NLC were investigated with 0500 respect to three independent variables including DHA concentration 0501 (XI), lipid concentration (X-2) and ratio of liquid lipid to total lipid 0502 (X-3). The result showed that the optimal formulation could be obtained 0503 from this response surface methodology The optimal formulation for 0504 DHA-NLC was composed of DHA concentration (X-1) of 1 g/l, lipid 0505 concentration (X-2) of 1% and ratio of liquid lipid to total lipid (X-3) 0506 of 0.1:1. DHA-NLC under the optimized conditions gave rise to the EE 0507 of (98.97 +/- 2.3)%, DL of (15.61 +/- 1.9) mean diameter of (198 +/4.7) nm, polydispersity index (PI) of 0.146 and zeta potential value 0508 of (-21.6 +/- 1.3) mV TEM of the optimized NLC showed spherical 0509 particles. The in vitro experiments proved that DHA in the NLC released 0510 gradually over the period of 48 h. This study showed that the RSM-CCRD 0511 could efficiently be applied for the modeling of DHA-NLC. Published 0512 by Elsevier B.V. 0513 SN 0032-5910 0514 PD JAN 10 0515 PY 2010 0516 VL 197 0517 IS 1-2 0518 BP 120 0519 EP 128 0520 DI 10.1016/j.powtec.2009.09.004 0521 UT ISI:000272125000016 0522 PT J 0523 AU Zhang, T 0524 Liu, H 0525 Liu, XT 0526 Xu, DR 0527 Chen, XQ 0528 Wang, Q 0529 AF Zhang, Ting 0530 Liu, Hai 0531 Liu, Xue-Ting 0532 Xu, De-ran 0533 Chen, Xiao-qing 0534 Wang, Qiang 0535 TI Qualitative and quantitative analysis of steroidal saponins in crude 0536 extracts from Paris polyphylla var. yunnanensis and P. polyphylla var. 0537 chinensis by high performance liquid chromatography coupled with mass 0538 spectrometry 0539 SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 0540 AB High performance liquid chromatography coupled with electrospray 0541 ionization multi-stage tandem mass spectrometry (HPLC-ESI-MSn) and 0542 triple quadrupole mass spectrometric detection (HPLC-ESI-MS/MS), 0543 respectively, had been employed for the simultaneous identification 0544 and quantification of steroidal saponins in the rhizomes of Paris 0545 polyphylla var. yunnanensis and A polyphylla var. chinensis, which are 0546 the qualified plants of "Chonglou" in Chinese. The HPLC experiments 0547 were performed by means of a reversed-phase C-18 column and a binary 0548 mobile phase system consisting of 0.1% aqueous formic acid and 0549 acetonitrile under gradient elution conditions. The characteristic 0550 fragmentation patterns of diosgenin- and pennogenin-type steroidal 0551 saponins were investigated using ESI-MSn in negative ion mode. The MSn 0552 data of the [M-H](-) ions provided structural information on the sugar 0553 sequence of the oligosaccharide chains and the aglycones of steroidal 0554 saponins. As a result, ten and seven saponins were determined in A 0555 polyphylla var. yunnanensis and P. polyphylla var. chinensis, 0556 respectively, including four unknown compounds. One unknown compound 0557 was tentatively identified as 0558 diosgenin-3-O-alpha-L-rhamnopyranosyl(1 --> 4) 0559 [alpha-L-rhamnopyranosyl(1 --> 2)]-beta-D-glucopyranoside and the 0560 aglycones of the other three new compounds were reported from Chonglou 0561 for the first time. The developed HPLC-ESI-MS/MS method was validated 0562 and found to be satisfactorily linear, selective and robust. The limits 0563 of detection (LODs) and quantitation (LOQs) ranged, respectively, from 0564 0.5 to 10 ng/mL and 2 to 34 ng/mL depending on six various compounds. 0565 The intra- and inter-day precisions of the method were evaluated and 0566 were less than 5.0%. Recoveries ranged from 92% to 104% for all 0567 compounds. The established quality evaluation method was successfully 0568 used for simultaneous quantification of six predominant steroidal 0569 saponins in the rhizomes of these two Paris species. (C) 2009 Elsevier 0570 B.V. All rights reserved. 0571 SN 0731-7085 0572 PD JAN 5 0573 PY 2010 0574 VL 51 0575 IS 1 0576 BP 114 0577 EP 124 0578 DI 10.1016/j.jpba.2009.08.020 0579 UT ISI:000270748100018 0580 FN ISI Export Format 0581 VR 1.0 0582 PT J 0583 AU Zhang, M 0584 Liu, K 0585 Li, L 0586 Fan, JH 0587 Song, JN 0588 Liu, BL 0589 AF Zhang Min 0590 Liu Kang 0591 Li Lin 0592 Fan Jinghua 0593 Song Junna 0594 Liu Baolin 0595 TI Resveratrol Restores Lysophosphatidylcholine-induced Loss of 0596 Endothelium-dependent Relaxation in Rat Aorta Tissue Coinciding with 0597 Inhibition of Extracellular-signal-regulated Protein Kinase 0598 Activation 0599 SO PHYTOTHERAPY RESEARCH 0600 AB To investigate whether resveratrol could restore the 0601 lysophosphatidylcholine (LPC)-induced loss of endothelium-dependent 0602 relaxation in in vitro cultured rat aorta tissue, first the effect of 0603 resveratrol on the loss of EDR was examined in this preparation. The 0604 results showed that resveratrol effectively attenuated the inhibition 0605 of LPC (10 mu m) on both endothelium-derived relaxing factor (EDRF) 0606 and endothelium-derived hyperpolarizing factor (EDHF) in a 0607 concentration-dependent manner (1, 10, 100 mu m). In addition, 0608 resveratrol inhibited elevated K+-induced vascular contracture, but 0609 had no significant effects on ACh (1 mu m)-induced 0610 endothelium-dependent relaxation (EDR). A similar tendency was also 0611 observed with PD 98059 (30 mu m), a selective inhibitor of ERK. When 0612 the cells were exposed to LPC (20 mu M) the mRNA expression of eNOS 0613 and COX-1 mRNA were down-regulated, followed by a local induction of 0614 iNOS and COX-2. Resveratrol and PD 98059 successfully reversed the 0615 effects of LPC on relative mRNA expressions. Both resveratrol and PD 0616 98059 inhibited the activation of ERK induced by LPC. These findings 0617 demonstrate that resveratrol can restore the LPC-induced loss of EDR 0618 in rat aorta and protect the endothelium against LPC-induced injuries 0619 via the inhibition of the inflammation-like response. Copyright (C) 0620 2010 John Wiley & Sons, Ltd. 0621 SN 0951-418X 0622 PD DEC 0623 PY 2010 0624 VL 24 0625 IS 12 0626 BP 1762 0627 EP 1768 0628 DI 10.1002/ptr.3136 0629 UT ISI:000285679200004 0630 PT J 0631 AU Song, M 0632 Zhang, SY 0633 Xu, XY 0634 Hang, TJ 0635 Jia, L 0636 AF Song, Min 0637 Zhang, Siyun 0638 Xu, Xiaoyan 0639 Hang, Taijun 0640 Jia, Lee 0641 TI Simultaneous determination of three Panax notoginseng saponins at 0642 sub-nanograms by LC-MS/MS in dog plasma for pharmacokinetics of 0643 compound Danshen tablets 0644 SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL 0645 AND LIFE SCIENCES 0646 AB Compound Danshen tablets are composed of Panax notoginseng, Salvia 0647 miltiorrhiza and Borneol. The tablets are prescribed for treatment of 0648 cardiovascular diseases in China. The present study aimed at developing 0649 a specific and sensitive LC-MS/MS method to simultaneously determine 0650 three bioactive P. notoginseng saponins, i.e., notoginsenoside R1. 0651 ginsenoside Rg1 and Rb1, in dogs after a single oral administration 0652 of the compound tablets in order to obtain the clinically relevant 0653 saponin-related pharmacodynamics of the tablets in patients. The R1, 0654 Rg1 and Rb1 were extracted from dog plasma with acetone-methanol 0655 (80:20, v/v), separated by reversed phase liquid chromatography and 0656 determined by tandem mass spectrometry (LC-MS/MS) with positive 0657 electrospray ionization (ESI). The developed method reached lower 0658 limit of quantitation (LLOQ) at 0.10 ng/ml for the three saponins. The 0659 method was validated in terms of selectivity, matrix effects, 0660 linearity, precision and accuracy, and then was applied to a 0661 pharmacokinetic study of the three bioactive saponins simultaneously 0662 in dogs after a single oral administration of compound Danshen tablets 0663 at a clinical equivalent dose. The C-max and AUC((o-infinity)) for R1, 0664 Rg1 and Rb1 were 1.91, 3.34 and 28.6 ng/ml, and 7.5, 11.0, and 1712 0665 (h ng/ml), respectively. (c) 2010 Elsevier ay. All rights reserved. 0666 SN 1570-0232 0667 PD DEC 15 0668 PY 2010 0669 VL 878 0670 IS 32 0671 BP 3331 0672 EP 3337 0673 DI 10.1016/j.jchromb.2010.10.007 0674 UT ISI:000285951500001 0675 PT J 0676 AU Zhuang, J 0677 Ping, QN 0678 Song, YM 0679 Qi, JP 0680 Cui, Z 0681 AF Zhuang, Jie 0682 Ping, Qineng 0683 Song, Yunmei 0684 Qi, Jianping 0685 Cui, Zheng 0686 TI Effects of chitosan coating on physical properties and pharmacokinetic 0687 behavior of mitoxantrone liposomes 0688 SO INTERNATIONAL JOURNAL OF NANOMEDICINE 0689 AB The objective of this work was to evaluate the physical properties and 0690 in vivo circulation of chitosan (CH)-coated liposomes of mitoxantrone 0691 (MTO). Changes in particle size and zeta potential confirmed the 0692 existence of a coating layer on the surface of liposomes. The in vitro 0693 release of adsorbed CH from the liposomes was significantly slower than 0694 CH solution, indicating the stable interaction between CH and 0695 liposomes. The physical stability of the CH-coated liposomes was 0696 evaluated by measuring the change in particle size before and after 0697 freeze-drying and rehydration. The smallest change was observed when 0698 saturated adsorption of CH occurred (0.3%). The sustained release in 0699 vitro of MTO from CH-coated liposomes confirmed the increased stability 0700 of liposomes. Systemic circulation of CH-coated MTO liposomes was 0701 examined. The 0.3% CH-coated liposomes showed the longest circulation 0702 time. It could be concluded that the prolonged retention time of the 0703 liposomes was closely related with CH coating and its stability effect. 0704 SN 1176-9114 0705 PY 2010 0706 VL 5 0707 BP 407 0708 EP 416 0709 UT ISI:000283715300041 0710 PT S 0711 AU Gu, YQ 0712 Liu, F 0713 Fang, CS 0714 Qian, ZY 0715 Achilefu, S 0716 AF Gu, Yueqing 0717 Liu, Fei 0718 Fang, Chunsheng 0719 Qian, Zhiyu 0720 Achilefu, Samuel 0721 ED Achilefu, S; Raghavachari, R 0722 TI In vivo investigation of pharmacokinetics of model drug: comparison 0723 of near infrared technique with high-performance liquid chromatography 0724 SO REPORTERS, MARKERS, DYES, NANOPARTICLES, AND MOLECULAR PROBES FOR 0725 BIOMEDICAL APPLICATIONS II 0726 SE Proceedings of SPIE-The International Society for Optical Engineering 0727 CT Conference on Reporters, Markers, Dyes, Nanoparticles, and Molecular 0728 Probes for Biomedical Applications II 0729 CY JAN 25-27, 2010 0730 CL San Francisco, CA 0731 AB Near infrared spectroscopy possess great potential for in vivo 0732 quantitative monitoring of drugs in animal subject. The accuracy of 0733 the measurements by near infrared technique should be evaluated by an 0734 established method. In this study, a near infrared fluorescence dye, 0735 cypate and its conjugation cypate-PEG were used as model drug for in 0736 vivo dynamic study. The pharmacokinetics of the model drug in mice 0737 subjects were investigated by near infrared spectroscopy and high 0738 performance liquid chromatography, respectively. The results from the 0739 two techniques were compared. The pharmacokinetic parameters 0740 calculated based on the acquired data by DAS software showed that there 0741 were no statistical differences between the two methods. The dynamic 0742 distribution of the model drugs in mouse model imaged by NIR image 0743 system indicated that cypate firstly accumulated in liver and was 0744 cleared from the enteron system, while cypate - PEG clearance from the 0745 urine system. Results indicated that NIR monitoring technique provide 0746 a promising quantitative way for in vivo monitoring the dynamics of 0747 drugs in animal subjects. 0748 SN 0277-786X 0749 BN 978-0-8194-7972-3 0750 PY 2010 0751 VL 7576 0752 AR 75760A 0753 DI 10.1117/12.840332 0754 UT ISI:000285580600008 0755 PT S 0756 AU Deng, DW 0757 Chen, XY 0758 Zhang, JA 0759 Liu, F 0760 Cao, J 0761 Gu, YQ 0762 AF Deng, Dawei 0763 Chen, Xinyang 0764 Zhang, Jian 0765 Liu, Fei 0766 Cao, Jie 0767 Gu, Yueqing 0768 ED Achilefu, S; Raghavachari, R 0769 TI Aqueous synthesis of PbS quantum dots for noninvasive near-infrared 0770 fluorescence imaging in a mouse model 0771 SO REPORTERS, MARKERS, DYES, NANOPARTICLES, AND MOLECULAR PROBES FOR 0772 BIOMEDICAL APPLICATIONS II 0773 SE Proceedings of SPIE-The International Society for Optical Engineering 0774 CT Conference on Reporters, Markers, Dyes, Nanoparticles, and Molecular 0775 Probes for Biomedical Applications II 0776 CY JAN 25-27, 2010 0777 CL San Francisco, CA 0778 AB In this paper, we present a new facile and environmental friendly method 0779 to prepare water-soluble near-infrared (NIR)-emitting PbS quantum dots 0780 (QDs) at room temperature under ambient conditions, using 0781 dihydrolipoic acid (DHLA) as a stabilizer. The photoluminescence (PL) 0782 emissions of the prepared DHLA-capped PbS QDs are tunable between 870 0783 and 1010 nm. A PL quantum yield (QY) of similar to 10% can be achieved 0784 under optimized conditions without any post-preparative treatment. 0785 Here, we further use the produced DHLA-capped PbS QDs for NIR 0786 fluorescence imaging in a mouse model. The obtained experimental 0787 results showed that the NIR fluorescence of the PbS QDs in living 0788 tissues generated from the excitation with semiconductor laser 0789 (lambda(max)=765.9 nm) could penetrate living tissues and be detected 0790 easily by the noninvasive in vivo NIR fluorescence imaging system. In 0791 addition, the preliminary studies on the cytotoxicity and in vivo 0792 toxicity of the QDs also indicates fully that these water-soluble 0793 DHLA-capped PbS QDs are very lowly toxic, and as such they should have 0794 greater potential in biological and medical applications especially 0795 in noninvasive in vivo fluorescence imaging of mice, compared to other 0796 existing highly toxic aqueous NIR-emitting quantum dots (CdTe, HgTe, 0797 etc). 0798 SN 0277-786X 0799 BN 978-0-8194-7972-3 0800 PY 2010 0801 VL 7576 0802 AR 75761K 0803 DI 10.1117/12.840136 0804 UT ISI:000285580600036 0805 PT J 0806 AU Zhou, XA 0807 Li, MA 0808 Wang, XB 0809 Wang, T 0810 Kong, LY 0811 AF Zhou, Xiang 0812 Li, Miao 0813 Wang, Xiao-Bing 0814 Wang, Tao 0815 Kong, Ling-Yi 0816 TI Synthesis of Benzofuran Derivatives via Rearrangement and Their 0817 Inhibitory Activity on Acetylcholinesterase 0818 SO MOLECULES 0819 AB During a synthesis of coumarins to obtain new candidates for treating 0820 Alzheimer's Disease (AD), an unusual rearrangement of a benzopyran 0821 group to a benzofuran group occurred, offering a novel synthesis 0822 pathway of these benzofuran derivatives. The possible mechanism of the 0823 novel rearrangement was also discussed. All of the benzofuran 0824 derivatives have weak anti-AChE activities compared with the reference 0825 compound, donepezil. 0826 SN 1420-3049 0827 PD DEC 0828 PY 2010 0829 VL 15 0830 IS 12 0831 BP 8593 0832 EP 8601 0833 DI 10.3390/molecules15128593 0834 UT ISI:000285709000006 0835 PT J 0836 AU Liu, EH 0837 Qi, LW 0838 Li, P 0839 AF Liu, E-Hu 0840 Qi, Lian-Wen 0841 Li, Ping 0842 TI Structural Relationship and Binding Mechanisms of Five Flavonoids with 0843 Bovine Serum Albumin 0844 SO MOLECULES 0845 AB Flavonoids are structurally diverse and the most ubiquitous groups of 0846 dietary polyphenols distributed in various fruits and vegetables. In 0847 this study, the interaction between five flavonoids, namely 0848 formononetin-7-O-beta-D-glucoside, calycosin-7-O-beta-D-glucoside, 0849 calycosin, rutin, and quercetin, and bovine serum albumin (BSA) was 0850 investigated by fluorescence and UV-vis absorbance spectroscopy. In 0851 the discussion, it was proved that the fluorescence quenching of BSA 0852 by flavonoids was a result of the formation of a flavonoid-BSA complex. 0853 Fluorescence quenching constants were determined using the 0854 Stern-Volmer and Lineweaver-Burk equations to provide a measure of the 0855 binding affinity between the flavonoids and BSA. The binding constants 0856 ranked in the order quercetin > rutin > calycosin > 0857 calycosin-7-O-beta-D-glucoside approximate to 0858 formononetin-7-O-beta-D-glucoside. The results of thermodynamic 0859 parameters Delta G, Delta H, and Delta S at different temperatures 0860 indicated that the hydrophobic interaction played a major role in 0861 flavonoid-BSA association. The distance r between BSA and acceptor 0862 flavonoids was also obtained according to Forster's theory of 0863 non-radiative energy transfer. 0864 SN 1420-3049 0865 PD DEC 0866 PY 2010 0867 VL 15 0868 IS 12 0869 BP 9092 0870 EP 9103 0871 DI 10.3390/molecules15129092 0872 UT ISI:000285709000037 0873 PT J 0874 AU Wei, LB 0875 Lu, N 0876 Dai, QS 0877 Rong, JJ 0878 Chen, Y 0879 Li, ZY 0880 You, QD 0881 Guo, QL 0882 AF Wei, Libin 0883 Lu, Na 0884 Dai, Qinsheng 0885 Rong, Jingjing 0886 Chen, Yan 0887 Li, Zhiyu 0888 You, Qidong 0889 Guo, Qinglong 0890 TI Different Apoptotic Effects of Wogonin Via Induction of H2O2 Generation 0891 and Ca2+ Overload in Malignant Hepatoma and Normal Hepatic Cells 0892 SO JOURNAL OF CELLULAR BIOCHEMISTRY 0893 AB Wogonin, a major active constituent of Scutellaria baicalensis, 0894 possesses potent anticancer activities both in vivo and in vitro. This 0895 paper describes the different apoptotic effects of wogonin in HepG2 0896 and L02 cells and the possible mechanism for the differences. Through 0897 DAPI staining, Annexin-V/PI double-staining assay, JC-1 detection and 0898 the expressions of the key apoptotic proteins, we find that wogonin 0899 prefers to induce apoptosis in HepG2 cells through the mitochondrial 0900 pathway, while has much less effects on L02 cells. Moreover, 0901 overexpression of Bcl-2 can block wogonin-induced apoptosis in HepG2 0902 cells. To illustrate the specific selective mechanism of wogonin in 0903 apoptosis induction, H2O2, O-center dot(2)- and Ca2+ are measured by 0904 2',7'-dichlorfluorescein-diacetate, dihydroethidium and Flou-3 AM 0905 assay, respectively. The results show that the different apoptotic 0906 effects of wogonin in HepG2 and L02 cells are due to the different 0907 regulations to the redox balance of reactive oxygen species and the 0908 Ca2+ release from endoplasmic reticulum. IP3R-sensitive Ca2+ channels 0909 are the key targets of the wogonin-increased H2O2. Besides, the 0910 activation of PLC gamma 1 plays as a bridge between H2O2 signal 0911 molecules and Ca2+ release. Taken together, wogonin preferentially 0912 kills hepatoma cells by H2O2-dependent apoptosis triggered by Ca2+ 0913 overload. The results reveal that wogonin is a competitive anticancer 0914 drug candidate for the malignant hepatoma therapy. J. Cell. Biochem. 0915 111: 1629-1641, 2010. (C) 2010 Wiley-Liss, Inc. 0916 SN 0730-2312 0917 PD DEC 15 0918 PY 2010 0919 VL 111 0920 IS 6 0921 BP 1629 0922 EP 1641 0923 DI 10.1002/jcb.22898 0924 UT ISI:000286300700026 0925 PT J 0926 AU Guo, P 0927 Liu, JM 0928 Li, XK 0929 Yang, SL 0930 Yao, QZ 0931 AF Guo Ping 0932 Liu Jianmin 0933 Li Xiaokun 0934 Yang Shulin 0935 Yao Qizheng 0936 TI Chiral Resolution of Curcumol Epoxy Derivatives by Ionic Liquid 0937 [BMIm]BF4 0938 SO ACTA CHIMICA SINICA 0939 AB The isomers of 10,14-epoxycurcumol derivatives were separated by the 0940 ionic liquid [BMIm]BF4, in which there is a difference in the solubility 0941 of the complexes formed with the isomers and [BMIm]BF4. The yield 22% 0942 of (10R)-10,14-epoxycurcumol (E1) with 99% ee and the yield 49% of 0943 (10S)-10,14-epoxycurcumol (E2) with 92% ee were obtained respectively 0944 in the resolution. The ionic liquid could be recovered easily and used 0945 again with the same separation effect. 0946 SN 0567-7351 0947 PD DEC 28 0948 PY 2010 0949 VL 68 0950 IS 24 0951 BP 2619 0952 EP 2621 0953 UT ISI:000286352700020 0954 PT J 0955 AU Qin, KM 0956 Cai, H 0957 Zhang, L 0958 Shi, Y 0959 Ping, L 0960 Cai, BC 0961 AF Qin Kunming 0962 Cai Hao 0963 Zhang Li 0964 Shi Yun 0965 Ping, Li 0966 Cai Baochang 0967 TI Chemical Constituents and Effective Substances of Traditional Chinese 0968 Medicinal Formula 0969 SO PROGRESS IN CHEMISTRY 0970 AB Traditional Chinese medicinal formula (TCMF) is an important clinic 0971 guide for application of Chinese medicines. It is a reflection of both 0972 diagnosis and treatment of traditional Chinese medical theory, 0973 occupying a pivotal position in the system of Chinese medicine. At 0974 present, TCMF is facing difficulties because its curative effects are 0975 largely based on the prescribing doctor's experience and its effective 0976 constituents and mechanisms of action are unclear, which seriously 0977 restricts their development in the international market. Chemical 0978 constituents and effective substance basis of TCMF are two important 0979 parts of the study of Chinese medicines. In the recent years, the 0980 development of modern biological and analytical techniques have 0981 provided new techniques and approaches for the modern studies on 0982 chemical constituents and effective substances in TCMF. In this paper, 0983 we reviewed the latest progress of studying the chemical constituents 0984 and effective substance basis of TCMF, and put forward basic thoughts 0985 on improving research activities in the area. 0986 SN 1005-281X 0987 PD DEC 0988 PY 2010 0989 VL 22 0990 IS 12 0991 BP 2436 0992 EP 2449 0993 UT ISI:000285795300018 0994 PT J 0995 AU Zhang, F 0996 Wang, JS 0997 Gu, YC 0998 Kong, LY 0999 AF Zhang, Feng 1000 Wang, Jun-Song 1001 Gu, Yu-Cheng 1002 Kong, Ling-Yi 1003 TI Triterpenoids from Aglaia abbreviata and Their Cytotoxic Activities 1004 SO JOURNAL OF NATURAL PRODUCTS 1005 AB Six new triterpenoids (1-6), along with 10 known compounds, were 1006 isolated from the stems of Aglaia abbreviata. The structures of 1-6 1007 were elucidated on the basis of their spectroscopic data. Compounds 1008 1-6 were evaluated for their cytotoxic activities against a small panel 1009 of human tumor cell lines. 1010 SN 0163-3864 1011 PD DEC 1012 PY 2010 1013 VL 73 1014 IS 12 1015 BP 2042 1016 EP 2046 1017 DI 10.1021/np100599g 1018 UT ISI:000285560000013 1019 PT J 1020 AU Zhang, WB 1021 Wang, Z 1022 Shu, F 1023 Jin, YH 1024 Liu, HY 1025 Wang, QJ 1026 Yang, Y 1027 AF Zhang, Wen-bin 1028 Wang, Zhuo 1029 Shu, Fei 1030 Jin, Yong-hua 1031 Liu, Hong-yi 1032 Wang, Qiu-juan 1033 Yang, Yong 1034 TI Activation of AMP-activated Protein Kinase by Temozolomide Contributes 1035 to Apoptosis in Glioblastoma Cells via p53 Activation and mTORC1 1036 Inhibition 1037 SO JOURNAL OF BIOLOGICAL CHEMISTRY 1038 AB Methylating drugs such as temozolomide (TMZ) are widely used in the 1039 treatment of brain tumors including malignant glioblastoma. The 1040 mechanism of TMZ-induced glioblastoma cell death and apoptosis, 1041 however, is not fully understood. Here, we tested the potential 1042 involvement of AMP-activated protein kinase (AMPK) in this process. 1043 We found that methylating agents TMZ and 1044 N-methyl-N'-nitro-N-nitrosoguanidine induce AMPK activation in 1045 primary cultured human glioblastoma and glioblastoma cell lines. 1046 TMZ-induced O-6-methylguanine production is involved in AMPK 1047 activation. O-6-benzylguanine, an O-6-methylguanine-DNA 1048 methyltransferase inhibitor, enhances TMZ-induced O-6-methylguanine 1049 production, leading to enhanced reactive oxygen species production, 1050 which serves as an upstream signal for AMPK activation. Activation of 1051 AMPK is involved in TMZ-induced glioblastoma cell death and apoptosis. 1052 AMPK inhibitor (Compound C) or AMPK alpha siRNA knockdown inhibits 1053 TMZ-induced glioblastoma cell death and apoptosis, whereas AMPK 1054 activator 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside 1055 enhances it. In further studies, we found that activation of AMPK is 1056 involved in TMZ-induced p53 activation and subsequent p21, Noxa, and 1057 Bax up-regulation. Activation of AMPK by TMZ also inhibits mTOR complex 1058 1 (mTORC1) signaling and promotes anti-apoptosis protein Bcl-2 1059 down-regulation, which together mediate TMZ-induced pro-cell 1060 apoptosis effects. Our study suggests that activation of AMPK by TMZ 1061 contributes to glioblastoma cell apoptosis, probably by promoting p53 1062 activation and inhibiting mTORC1 signaling. 1063 SN 0021-9258 1064 PD DEC 24 1065 PY 2010 1066 VL 285 1067 IS 52 1068 DI 10.1074/jbc.M110.164046 1069 UT ISI:000285414400008 1070 PT J 1071 AU Zhang, C 1072 Qin, MJ 1073 Shu, P 1074 Hong, JL 1075 Lue, L 1076 He, DX 1077 AF Zhang, Cong 1078 Qin, Min-Jian 1079 Shu, Pan 1080 Hong, Jun-Li 1081 Lue, Lin 1082 He, Dan-Xia 1083 TI Chemical Variations of the Essential Oils in Flower Heads of 1084 Chrysanthemum indicum L. from China 1085 SO CHEMISTRY & BIODIVERSITY 1086 AB The volatile compositions of hydrodistilled essential oils in the 1087 flower heads of Chrysanthemum indicum L. from eight populations in 1088 China were analyzed by GC/MS. A total of 169 compounds representing 1089 88.79-99.53% of the oils were identified, and some remarkable 1090 differences were found in the constituent percentages of the eight 1091 populations. The predominant components of the essential oils were 1092 1,8-cineole (0.62-7.34%), (+)-(1R,4R)-camphor (0.17-27.56%), 1093 caryophyllene oxide (0.54-5.8%), beta-phellandrene (0.72-1.87%), 1094 (-)-(1S,2R,4S)-borneol acetate (0.33-8.46%), 1095 2-methyl-6-(p-tolyl)hept-2-ene (0.3-8.6%), 1096 4,6,6-trimethylbicyclo[3.1.1]hept-3-en-2-yl acetate (0.17-26.48%), 1097 and hexadecanoic acid (0.72-15.97%). The chemotaxonomic value of the 1098 essential-oil compositions was discussed according to the results of 1099 cluster analysis (CA) and principal-component analysis (PCA). The 1100 eight populations were divided into five groups as different chemotypes 1101 (Groups A-E), and the scores together with the loadings revealed 1102 clearly different chemical properties of each population. In 1103 conclusion, GC/MS in combination with chemometric techniques provided 1104 a flexible and reliable method for characterizing the essential oils 1105 of different populations of C. indicum L. 1106 SN 1612-1872 1107 PD DEC 1108 PY 2010 1109 VL 7 1110 IS 12 1111 BP 2951 1112 EP 2962 1113 UT ISI:000285393800014 1114 PT J 1115 AU Li, H 1116 Zhong, WY 1117 Xu, DK 1118 AF Li Hui 1119 Zhong Wen-Ying 1120 Xu Dan-Ke 1121 TI Preparation of Biotinylated Silver Nanoparticles and Its Application 1122 of Visual Detection Method for Protein Chip 1123 SO CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE 1124 AB Biotinylated silver nanoparticles (Bio-AgNPs) were successfully 1125 prepared using oligonucelotide as coupling molecules. The resulted 1126 bio-AgNPs could be used for visual detection for protein arrays by a 1127 catalytical reaction with hydroquinone/AgNO3. To probe the feasibility 1128 of visual detection, human IgG was used as a model protein sample to 1129 be immobilized on the glass slides and bio-AgNPs were employed to couple 1130 with the protein via stripavaidin labeled anti-human IgG. The results 1131 show that the linear relationship of protein concentration is between 1132 160 fg and 100 pg and the limit of detection is 160 fg(S/N = 3). Compared 1133 with the method using SA-labeled gold nanoparticle or silver 1134 enhancement, the sensitivity of this method is increased about 40 fold. 1135 The presented method shows its advantages including high sensitivity, 1136 stability and rapidity. 1137 SN 0251-0790 1138 PD NOV 10 1139 PY 2010 1140 VL 31 1141 IS 11 1142 BP 2184 1143 EP 2189 1144 UT ISI:000285538100015 1145 PT J 1146 AU Dai, YJ 1147 Wang, QA 1148 Zhang, XL 1149 Jia, SR 1150 Zheng, H 1151 Feng, DC 1152 Yu, P 1153 AF Dai, Yujie 1154 Wang, Qiang 1155 Zhang, Xiuli 1156 Jia, Shiru 1157 Zheng, Heng 1158 Feng, Dacheng 1159 Yu, Peng 1160 TI Molecular docking and QSAR study on steroidal compounds as aromatase 1161 inhibitors 1162 SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 1163 AB In order to develop more potent, selective and less toxic steroidal 1164 aromatase (AR) inhibitors, molecular docking, 2D and 3D hybrid 1165 quantitative structure activity relationship (QSAR) study have been 1166 conducted using topological, molecular shape, spatial, structural and 1167 thermodynamic descriptors on 32 steroidal compounds. The molecular 1168 docking study shows that one or more hydrogen bonds with MET374 are 1169 one of the essential requirements for the optimum binding of ligands. 1170 The QSAR model obtained indicates that the aromatase inhibitory 1171 activity can be enhanced by increasing SIC, SC_3_C, Jurs_WNSA_1, 1172 Jurs_WPSA_1 and decreasing CDOCKER interaction energy (E-CD), 1173 IAC_Total and Shadow_XZfrac. The predicted results shows that this 1174 model has a comparatively good predictive power which can be used in 1175 prediction of activity of new steroidal aromatase inhibitors. (C) 2010 1176 Elsevier Masson SAS. All rights reserved. 1177 SN 0223-5234 1178 PD DEC 1179 PY 2010 1180 VL 45 1181 IS 12 1182 BP 5612 1183 EP 5620 1184 DI 10.1016/j.ejmech.2010.09.011 1185 UT ISI:000285485000008 1186 PT J 1187 AU Zhang, Y 1188 Wang, JS 1189 Wei, DD 1190 Wang, XB 1191 Luo, J 1192 Luo, JG 1193 Kong, LY 1194 AF Zhang, Yao 1195 Wang, Junsong 1196 Wei, Dandan 1197 Wang, Xiaobing 1198 Luo, Jun 1199 Luo, Jianguang 1200 Kong, Lingyi 1201 TI Cytotoxic tirucallaneC(26) triterpenoids from the stem barks of 1202 Aphanamixis grandifolia 1203 SO PHYTOCHEMISTRY 1204 AB Five tirucallane type C-26 triterpenoids accompanied by two known 1205 compounds 3 alpha-hydroxy-24 25 26 1206 27-tetranortirucall-7-ene-23(21)-lactone and 3-oxo-24 25 26 1207 27-tetranortirucall-7-ene-23(21)-lactone were isolated from the stem 1208 barks of Aphanamixis grandifolia Their structures were established 1209 mainly by means of a combination of 1D and 2D NMR spectroscopic and 1210 mass spectrometry techniques as 3 alpha-hydroxyl-21 alpha-methoxy-24 1211 25 26 27-tetranortirucall-7-ene-23(21)-lactone 3 alpha-hydroxy-21 1212 beta-methoxy-24 25 26 27-tetranortirucall-7-ene-23(21)-lactone 1213 3-oxo-21 alpha-methoxy-24 25 26 1214 27-tetranortirucall-7-ene-23(21)-lactone 3-oxo-21 beta-methoxy-24 25 1215 26 27-tetranortirucall-7-ene-23 (21)-lactone and 3-oxo-21 1216 alpha-ethoxy-24 25 26 27-tetranortirucall-7-ene-23(21)-lactone All 1217 Isolates were in vitro evaluated for their cytotoxic activities against 1218 five tumor cell lines (MCF-7 HeLa HepG2 SGC-7901 and BGC-823) (C) 2010 1219 Elsevier Ltd All rights reserved 1220 SN 0031-9422 1221 PD DEC 1222 PY 2010 1223 VL 71 1224 IS 17-18 1225 BP 2199 1226 EP 2204 1227 DI 10.1016/j.phytochem.2010.08.017 1228 UT ISI:000285325500031 1229 PT J 1230 AU Xu, L 1231 Sun, H 1232 AF Xu, L. 1233 Sun, H. 1234 TI Pharmacological Manipulation of Brain Glycogenolysis as a Therapeutic 1235 Approach to Cerebral Ischemia 1236 SO MINI-REVIEWS IN MEDICINAL CHEMISTRY 1237 AB Brain ischemia resulting from multiple disease states including 1238 cardiac arrest, stroke and traumatic brain injury, is a leading cause 1239 of death and disability. Despite significant resources dedicated to 1240 developing pharmacological interventions, few effective therapeutic 1241 options are currently available. The basic consequence of cerebral 1242 ischemia, characterized by energy failure and subsequent brain 1243 metabolic abnormalities, enables the protective effects by 1244 pharmacological manipulation of brain metabolism. We present here the 1245 important roles of brain glycogen metabolism and propose inhibition 1246 of glycogenolysis as a therapeutic approach to cerebral ischemia. 1247 SN 1389-5575 1248 PD OCT 1249 PY 2010 1250 VL 10 1251 IS 12 1252 BP 1188 1253 EP 1193 1254 UT ISI:000285290000008 1255 PT J 1256 AU Qian, S 1257 Gu, Y 1258 Xiao, Y 1259 Mallik, S 1260 AF Qian, Steven 1261 Gu, Yan 1262 Xiao, Ying 1263 Mallik, Sanku 1264 TI Characterization of Carbon-Centered Radicals Formed from 1265 COX-Catalyzed Dihomo-Gamma-Linolenic Acid Peroxidation 1266 SO FREE RADICAL BIOLOGY AND MEDICINE 1267 CT 17th Annual Meeting of the Society-for-Free-Radical-Biology-Medicine 1268 /15th Biennial Meeting of the 1269 Society-for-Free-Radical-Research-International 1270 CY NOV 17-21, 2010 1271 CL Orlando, FL 1272 SN 0891-5849 1273 PY 2010 1274 VL 49 1275 SU Suppl. 1 1276 BP S214 1277 EP S214 1278 DI 10.1016/j.freeradbiomed.2010.10.624 1279 UT ISI:000284348000632 1280 PT J 1281 AU Chen, ZP 1282 Sun, J 1283 Chen, HX 1284 Xiao, YY 1285 Liu, D 1286 Chen, J 1287 Cai, H 1288 Cai, BC 1289 AF Chen, Zhi-peng 1290 Sun, Jun 1291 Chen, Hong-xuan 1292 Xiao, Yan-yu 1293 Liu, Dan 1294 Chen, Jun 1295 Cai, Hao 1296 Cai, Bao-chang 1297 TI Comparative pharmacokinetics and bioavailability studies of 1298 quercetin, kaempferol and isorhamnetin after oral administration of 1299 Ginkgo biloba extracts, Ginkgo biloba extract phospholipid complexes 1300 and Ginkgo biloba extract solid dispersions in rats 1301 SO FITOTERAPIA 1302 AB The aim of this study was to improve the oral bioavailability of Ginkgo 1303 biloba extract (GBE) through preparing G. biloba extract phospholipid 1304 complexes (GBP) and G. biloba extract solid dispersions (CBS). Firstly 1305 we prepared the GBP and GBS and studied their physicochemical 1306 properties by differential scanning calorimetry (DSC), powder X-ray 1307 diffraction (XRD) and dissolution. Then we studied the pharmacokinetic 1308 characteristics and bioavailability in rats. The results showed that 1309 the bioavailability of quercetin, kaempferol and isorhamnetin in rats 1310 was increased remarkably after oral administration of GBP and GBS 1311 comparing with GBE. The bioavailabilities of GBP increased more than 1312 that of GBS. (C) 2010 Elsevier B.V. All rights reserved. 1313 SN 0367-326X 1314 PD DEC 1315 PY 2010 1316 VL 81 1317 IS 8 1318 BP 1045 1319 EP 1052 1320 DI 10.1016/j.fitote.2010.06.028 1321 UT ISI:000285281800015 1322 PT J 1323 AU Wu, GZ 1324 Su, X 1325 AF Wu, Guanzhong 1326 Su, Xin 1327 TI Antipruritic activity of extracts of Humulus scandens, the 1328 combinations of bioactive flavonoids 1329 SO FITOTERAPIA 1330 AB The antipruritic effects of the ethanol fractions of Humulus scandens 1331 on the 4-AP (4-aminopyridine)-induced and chloroquine-induced 1332 scratching in ICR mice were examined. The 40% ethanol fractions of H. 1333 scandens suppressed both the 4-AP- and chloroquine-induced scratching 1334 behavior, which significantly inhibited degranulation of rat 1335 peritoneal mast cell and antigen-stimulated histamine release. Further 1336 studies proved that the 40% ethanol fractions of H. scandens decreased 1337 the content of IL4 in serum of chloroquine-induced scratching ICR mice. 1338 The results suggest that the 40% ethanol fractions of H. scandens has 1339 antipruritic effects on both antihistamine-resistant and -sensitive 1340 pruritus. (C) 2010 Elsevier B.V. All rights reserved. 1341 SN 0367-326X 1342 PD DEC 1343 PY 2010 1344 VL 81 1345 IS 8 1346 BP 1073 1347 EP 1078 1348 DI 10.1016/j.fitote.2010.07.003 1349 UT ISI:000285281800020 1350 PT J 1351 AU Xue, M 1352 Jiang, ZZ 1353 Liu, JP 1354 Zhang, LY 1355 Wang, T 1356 Wang, H 1357 Liu, L 1358 Zhou, ZX 1359 AF Xue, Mei 1360 Jiang, Zhen-zhou 1361 Liu, Ji-ping 1362 Zhang, Lu-Yong 1363 Wang, Tao 1364 Wang, Hao 1365 Liu, Li 1366 Zhou, Zhi-xing 1367 TI Comparative study on the anti-inflammatory and immune suppressive 1368 effect of Wilforlide A 1369 SO FITOTERAPIA 1370 AB Tripterygium Glycosides (TG) is effective in the treatment of patients 1371 with a variety of inflammatory and autoimmune diseases, especially 1372 rheumatoid arthritis (RA) in clinical. Wilforlide A (T-1) serves as 1373 a quality control standard of TG that be listed in Drug Standard of 1374 Ministry of Public Health of the People's Republic of China. The 1375 pharmacologic actions of T-1 remain to be unidentified. In this paper, 1376 we studied the anti-inflammatory and immune suppressive effect of T-1, 1377 and compared it with Triptolide (TP), which believed to be the major 1378 active component of TG. Carrageenan-induced rat pedal swelling, 1379 tampon-induced rat granulation, and mice ear inhibition rate of 1380 swelling trail results show that high-dose T-1 has obvious 1381 anti-inflammatory effect. Colorimetric detection contents of 1382 hemolysin, carbon elimination from plasma of mice, mice delayed 1383 hypersensitivity immune, and organ index were measured. The results 1384 show that T-1 has no significant immune suppressive activity, and there 1385 has a significant difference with TP and TG. Therefore, we think the 1386 content of TP also should be controlled as a supplement standard in 1387 order to ensure safe and effective medication. (C) 2010 Elsevier B.V. 1388 All rights reserved. 1389 SN 0367-326X 1390 PD DEC 1391 PY 2010 1392 VL 81 1393 IS 8 1394 BP 1109 1395 EP 1112 1396 DI 10.1016/j.fitote.2010.07.007 1397 UT ISI:000285281800026 1398 PT J 1399 AU Zhang, YM 1400 Yin, RT 1401 Jia, RR 1402 Yang, EH 1403 Xu, HM 1404 Tan, NH 1405 AF Zhang, Yu-Mei 1406 Yin, Run-Ting 1407 Jia, Rui-Rui 1408 Yang, En-Hu 1409 Xu, Han-Mei 1410 Tan, Ning-Hua 1411 TI A new abietane diterpene from Glyptostrobus pensilis 1412 SO FITOTERAPIA 1413 AB A new abietane diterpene, glypensin A (1) and four known compounds, 1414 12-acetoxy-ent-labda-8(17), 13E-dien-15-oic acid (2), quercetin 1415 3-O-alpha-L-arabinofuranoside (3), quercetin 1416 3-O-beta-D-galactopyranoside (4), beta-sitosterol (5) were isolated 1417 from the branches and leaves of Glyptostrobus pensilis (Staut.) Koch. 1418 Their structures were determined by MS, 1D- and 2D-NMR means. Compound 1419 1 showed cytotoxicity on human chronic myeloid leukemia cell line K562 1420 (IC50 = 21.2 mu M). (C) 2010 Elsevier B.V. All rights reserved. 1421 SN 0367-326X 1422 PD DEC 1423 PY 2010 1424 VL 81 1425 IS 8 1426 BP 1202 1427 EP 1204 1428 DI 10.1016/j.fitote.2010.08.001 1429 UT ISI:000285281800041 1430 PT J 1431 AU Li, HC 1432 Chang, JH 1433 Liu, GG 1434 AF Li, H. C. 1435 Chang, J. H. 1436 Liu, G. G. 1437 TI MEASUREMENT OF HRQOL USING EQ-5D IN TYPE 2 DIABETES MELLITUS PATIENTS 1438 TREATED WITH ORAL ANTI-DIABETIC DRUGS IN CHINA 1439 SO VALUE IN HEALTH 1440 SN 1098-3015 1441 PD NOV 1442 PY 2010 1443 VL 13 1444 IS 7 1445 BP A296 1446 EP A297 1447 UT ISI:000282818001287 1448 PT J 1449 AU Chang, J 1450 Sun, F 1451 Li, H 1452 AF Chang, J. 1453 Sun, F. 1454 Li, H. 1455 TI EVALUATING THE COST-EFFECTIVENESS OF THERAPY CONVERSION FROM BASAL 1456 INSULIN TO BIPHASIC INSULIN ASPART 30/70 IN PATIENTS WITH TYPE 2 1457 DIABETES IN CHINA: A MODELING STUDY OF LONG-TERM COSTS AND HEALTH 1458 OUTCOMES 1459 SO VALUE IN HEALTH 1460 SN 1098-3015 1461 PD NOV 1462 PY 2010 1463 VL 13 1464 IS 7 1465 BP A507 1466 EP A507 1467 UT ISI:000282818001531 1468 PT J 1469 AU Yao, W 1470 Shao, R 1471 Chen, Y 1472 Chang, F 1473 AF Yao, W. 1474 Shao, R. 1475 Chen, Y. 1476 Chang, F. 1477 TI RECOMMENDATIONS FOR A BIOLOGICS-SPECIFIC PRICING SYSTEM IN CHINA 1478 SO VALUE IN HEALTH 1479 SN 1098-3015 1480 PD NOV 1481 PY 2010 1482 VL 13 1483 IS 7 1484 BP A533 1485 EP A534 1486 UT ISI:000282818001668 1487 PT J 1488 AU Liu, XY 1489 Zhi, HY 1490 Du, F 1491 Ye, ZG 1492 Wang, NJ 1493 Qin, WJ 1494 Li, JR 1495 AF Liu, Xinyi 1496 Zhi, Hongying 1497 Du, Feng 1498 Ye, Zuguang 1499 Wang, Naijie 1500 Qin, Wenjie 1501 Li, Jianrong 1502 TI A HPLC-UV method for the determination of puerarin in rat plasma after 1503 intravenous administration of PEGylated puerarin conjugate 1504 SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL 1505 AND LIFE SCIENCES 1506 AB A sensitive and reproducible HPLC method for quantitative 1507 determination of puerarin (PUE) in rat plasma was developed and 1508 validated using 4-hydroxybenzaldehyde as an internal standard The 1509 separation of PUE was performed on a CAPCELL PAK C18 column by gradient 1510 elution with 0 2% aqueous phosphoric acid and acetonitrile as the mobile 1511 phase The method was validated and found to be linear in the range of 1512 80-12 000 ng/mL The limit of quantification was 80 ng/mL based on 100 1513 mu L of plasma The variations for intra- and inter-day precision were 1514 less than 8 3% and the accuracy values were between 98% and 105 2% The 1515 extraction recoveries were more than 85% The method was successfully 1516 applied in the comparative study of pharmacokinetics of PEGylated 1517 puerarin (PEG-PUE) versus PUE in rats Compared with PUE PEG-PUE showed 1518 a 5 2-fold increase in half-life of PUE and a 4 7-fold increase in mean 1519 residence time In addition this method was also successfully applied 1520 to determine the low plasma concentration of PUE regenerated from 1521 PEG-PUE in vitro (C) 2010 Elsevier B V All rights reserved 1522 SN 1570-0232 1523 PD DEC 1 1524 PY 2010 1525 VL 878 1526 IS 31 1527 BP 3297 1528 EP 3302 1529 DI 10.1016/j.jchromb.2010.10.011 1530 UT ISI:000285118100014 1531 A He, TT 1532 U Zou, QG 1533 Feng, ZB 1534 Zhang, ZJ 1535 A He, Tingting 1536 F Zou, Qiaogen 1537 Feng, Zhenbin 1538 Zhang, Zunjian 1539 T Study of sodium tanshinone II A sulfonate tissue distribution in rat 1540 I by liquid chromatography/tandem mass spectrometry 1541 ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH 1542 A A rapid and sensitive method based on liquid chromatography/tandem mass 1543 B spectrometry (LC-MS/MS) has been developed and fully validated for the 1544 quantitative determination of sodium tanshinone HA sulfonate (STS, 1545 sodium 1546 (1,6,6-trimethyl-10,11-dioxo-7,8,9-trihydrophenanthro[1,2-b]furan) 1547 -yl-2- sulfonate) in rat biosamples including plasma and different 1548 tissues using sodium tanshinone I sulfonate (sodium 1549 (1,6-dimethyl-10,11-dioxo-phenanthro[1,2-b]furan)-yl-2-sulfonate) 1550 as internal standard. Simple protein precipitation by acetonitrile was 1551 utilized for extracting STS from the rat biosamples. Chromatographic 1552 separation of the sample matrix from the analyte and the internal 1553 standard was performed using a commercially available analytical 1554 column with a mobile phase consisting of methanol-5 mmoL/L ammonia 1555 acetate (70:30, v/v) at a flow rate of 0.2 mL/min. Detection was 1556 performed on a triple quadrupole tandem mass spectrometer equipped with 1557 an electrospray ionization source and operated in the negative-ion 1558 mode. The intra- and inter-day precisions (RSD%) and deviations of the 1559 assay accuracies were within 10.0% for STS. The extraction recovery 1560 of STS was more than 86.5%. The limit of detection (LOD) of STS was 1561 1.0 ng/mL. The method was successfully applied to the tissue 1562 distribution study of STS intravenously administered to healthy 1563 Sprague-Dawley rats. The tissue distribution results showed that 1564 liver, kidney, lung, small intestine and duodenum were the major 1565 distribution tissues of STS in rats, and that STS had difficulty in 1566 crossing the blood-brain barrier. After 24 h, STS could be detected 1567 only in the kidney, stomach and small intestine, indicating that there 1568 was no long-term accumulation of STS in rat. 1569 0004-4172 1570 2010 1571 ISI:000285034000003 1572 PT J 1573 AU Jiao, J 1574 Xiang, H 1575 Liao, Q 1576 AF Jiao, J. 1577 Xiang, H. 1578 Liao, Q. 1579 TI Recent Advancement in Nonsteroidal Aromatase Inhibitors for Treatment 1580 of Estrogen-Dependent Breast Cancer 1581 SO CURRENT MEDICINAL CHEMISTRY 1582 AB Estrogen-dependent breast cancer (EDBC) is a kind of common malignant 1583 tumor in postmenopausal women with growing tendency in recent years. 1584 Aromatase (AR) is the key enzyme responsible for estrogen biosynthesis 1585 and has been considered as an important target for designing inhibitors 1586 as potent therapeutic agents for EDBC. AR inhibitors (AIs) are divided 1587 into steroidal and nonsteroidal compounds, and the latter shows high 1588 inhibitory potency against AR. This review summarizes recent 1589 advancement in nonsteroidal AIs. 1590 SN 0929-8673 1591 PD OCT 1592 PY 2010 1593 VL 17 1594 IS 30 1595 BP 3476 1596 EP 3487 1597 UT ISI:000284654300003 1598 PT J 1599 AU Ren, M 1600 Dong, J 1601 Xu, YG 1602 Wen, N 1603 Gong, GY 1604 AF Ren, Mei 1605 Dong, Jin 1606 Xu, Yungen 1607 Wen, Nan 1608 Gong, Guoying 1609 TI Synthesis of Novel Ligustrazine Derivatives as Na+/H+ Exchange 1610 Inhibitors 1611 SO CHEMISTRY & BIODIVERSITY 1612 AB A novel series of 3,5,6-trimethylpyrazine-2-methoxy (or methylamino) 1613 substituted benzoylguanidine derivatives were designed and 1614 synthesized as Na+/H+ exchange (NHE) inhibitors. In this study, 1615 compounds with electron-withdrawing substituents on the benzene ring 1616 seemed to improve NHE-1 inhibitory activities. Compounds 6d, 6k, and 1617 6l were found to be potent inhibitors of NHE-1 (IC50 = 3.0 +/- 1.6, 1618 3.0 +/- 1.4, and 1.6 +/- 0.4 nmol/l, resp.). Furthermore, they showed 1619 a remarkable reduction of infarct size in the rat myocardial infarction 1620 model in vivo. 1621 SN 1612-1872 1622 PY 2010 1623 VL 7 1624 IS 11 1625 BP 2727 1626 EP 2736 1627 UT ISI:000284967200007 1628 PT J 1629 AU Zhang, HJ 1630 He, H 1631 Li, SS 1632 Lu, JR 1633 Chuong, PH 1634 AF Zhang Huaijing 1635 He Hua 1636 Li Shanshan 1637 Lu Jinrong 1638 Chuong, Pham-Huy 1639 TI Study on the Interactions of Different PAMAM Dendrimers with Bovine 1640 Serum Albumin 1641 SO ACTA CHIMICA SINICA 1642 AB Polyamidoamine (PAMAM) dendrimers have been synthesized by divergent 1643 with ethylenediamine as core. The interaction between PAMAM including 1644 amine-terminated generation 4.0 (G4.0), generation 3.0 (G3.0) PAMAM 1645 and ester-terminated generation 3.5 (G3.5) PAMAM dendrimers and bovine 1646 serum albumin (BSA) under physiological condition was studied by 1647 fluorescence spectroscopy. The results showed that the fluorescence 1648 intensity of BSA decreased with the addition of different PAMAM 1649 dendrimers, the quenching extent strongly depends on the type and 1650 amounts of their surface groups. The quenching mechanism was static 1651 quenching mechanism. The quenching constants of G4.0 PAMAM, G3.5 PAMAM, 1652 G3.0 PAMAM with BSA were 2.73, 1.69, 1.55 L.mmol(-1), respectively. 1653 The influence of pH and ionic strength on the interactions was also 1654 investigated. Furthermore, synchronous fluorescence, 1655 ultraviolet-visible spectra analysis (UV), and red edge excitation 1656 shift (REES) showed that PAMAM dendrimers could change the conformation 1657 of BSA. 1658 SN 0567-7351 1659 PD SEP 14 1660 PY 2010 1661 VL 68 1662 IS 17 1663 BP 1741 1664 EP 1748 1665 UT ISI:000284511400012 1666 A Cai, ZY 1667 U Yang, Y 1668 Liu, XH 1669 Qi, XB 1670 A Cai, Zheng-Yu 1671 F Yang, Yang 1672 Liu, Xin-Hua 1673 Qi, Xing-Bao 1674 T Novel 1675 I 3-(1-acetyl-5-(substituted-phenyl)-4,5-dihydro-1H-pyrazol-3-yl)-7fluoro -2H-chromen-2-one Derivatives: Synthesis and Anticancer 1676 Activity 1677 LETTERS IN DRUG DESIGN & DISCOVERY 1678 A A series of novel coumarin derivatives containing 4,5-dihydropyrazole 1679 B moiety as potential telomerase inhibitors were synthesized. The 1680 bioassay tests showed that compound 3b exhibited potentially high 1681 activity against human gastric cancer cell SGC-7901 with IC50 value 1682 was 2.98 +/- 0.16. Docking simulation was performed to position 1683 compound 3b into the telomerase (3DU6) active site to determine the 1684 probable binding model. The result shows that some coumarin containing 1685 4,5-dihydropyrazole moiety can combine well with the telomerase active 1686 site and may have use as potential telomerase inhibitors. 1687 1570-1808 1688 2010 1689 ISI:000284692700003 1690 PT J 1691 AU Chen, JQ 1692 Zha, XM 1693 Sun, M 1694 Cai, J 1695 Zhou, W 1696 Ji, M 1697 AF Chen, Junqing 1698 Zha, Xiaoming 1699 Sun, Min 1700 Cai, Jin 1701 Zhou, Wen 1702 Ji, Min 1703 TI Synthesis and In Vivo Acute Antihyperglycemic Evaluation of Novel 1704 Isosteviol Derivatives 1705 SO LETTERS IN DRUG DESIGN & DISCOVERY 1706 AB Isosteviol is a beyerane tetracyclic diterpenoid with a large variety 1707 of biological activities. In this article, a series of novel isosteviol 1708 derivatives containing the modification of C-18 carboxyl group (5-12), 1709 C-16 carbonyl group (14-16) and heteroatom-containing frameworks fused 1710 with isosteviol structure (18-19) were synthesized and evaluated for 1711 their in vivo acute antihyperglycemeric effects. Among them, compound 1712 8 exhibited the most potent antihyperglycemeric effects. Furthermore, 1713 primarily, structure-activity relationship (SAR) was also analyzed. 1714 The structures of all the newly synthesized compounds were determined 1715 by H-1, (CNMR)-C-13, MS, IR and elementary analysis. 1716 SN 1570-1808 1717 PD NOV 1718 PY 2010 1719 VL 7 1720 IS 9 1721 BP 686 1722 EP 693 1723 UT ISI:000284692700011 1724 PT J 1725 AU Zhang, JH 1726 He, MC 1727 AF Zhang, Jinghuan 1728 He, Mengchang 1729 TI Effect of structural variations on sorption and desorption of 1730 phenanthrene by sediment organic matter 1731 SO JOURNAL OF HAZARDOUS MATERIALS 1732 AB Sorption and desorption isotherms of phenanthrene (PHE) on sediment 1733 organic matter (SOM) prepared at different combustion temperature were 1734 studied to examine the impact of SOM structure on sorption and 1735 desorption. With the increase of combustion temperature from 0 to 400 1736 degrees C, the aromatic groups (-C=C) in SOM samples increased, while 1737 the aliphatic groups (-CH, -CH2) and polar structures (-C-O, -OH) 1738 decreased. When the combustion temperature increased to 500 degrees 1739 C. aliphatic structures, polar structures and most aromatic structures 1740 were burnt out, and the mineral materials were dominant in the sample. 1741 The increase of combustion temperature decrease the sorption isotherm 1742 nonlinearity index n value, and enhanced the adsorption capacity and 1743 desorption hysteresis for PHE on SOM. However, higher n value, lower 1744 sorption capacity and sorption irreversibility were presented in the 1745 sample treated at 500 degrees C (T500). Positive correlations between 1746 single-point organic carbon-normalized distribution coefficient log 1747 K-oc values and aromatic carbon (p < 0.01) and negative correlations 1748 between log K-oc values and aliphaticity or H/C ratios (p < 0.05) were 1749 observed. There was a negative relation between hysteresis index (HI) 1750 value and aromatic carbon (p < 0.01) and a negative trend of the sorption 1751 isotherm nonlinearity index n values and aromatic carbon (p < 0.01). 1752 The above results indicated the dominance of aromatic structures in 1753 the sorption nonlinearity, sorption capacity and desorption hysteresis 1754 of PHE on SOM. (C) 2010 Elsevier B.V. All rights reserved. 1755 SN 0304-3894 1756 PD DEC 15 1757 PY 2010 1758 VL 184 1759 IS 1-3 1760 BP 432 1761 EP 438 1762 DI 10.1016/j.jhazmat.2010.08.123 1763 UT ISI:000284504800057 1764 PT J 1765 AU Zhang, L 1766 Yang, J 1767 Chen, XQ 1768 Zan, K 1769 Wen, XD 1770 Chen, H 1771 Wang, QA 1772 Lai, MX 1773 AF Zhang, Li 1774 Yang, Jie 1775 Chen, Xiao-qing 1776 Zan, Ke 1777 Wen, Xiao-dong 1778 Chen, Hong 1779 Wang, Qiang 1780 Lai, Mao-xiang 1781 TI Antidiabetic and antioxidant effects of extracts from Potentilla 1782 discolor Bunge on diabetic rats induced by high fat diet and 1783 streptozotocin 1784 SO JOURNAL OF ETHNOPHARMACOLOGY 1785 AB Aim of the study: Potentilla discolor Bunge, commonly found at the north 1786 temperate and boreal zone, has been used for diabetes in China for a 1787 long time. Flavonoids and triterpenoids are two major types of 1788 compounds in P. discolor. This study was designed primarily to 1789 investigate the effects of total flavonoids extract (TFE) and total 1790 triterpenoids extract (TTE) of P. discolor Bunge on blood glucose, 1791 lipid profiles and antioxidant parameters on diabetic rats induced by 1792 high fat diet and streptozotocin. 1793 Materials and methods: High fat diet-fed and streptozotocin-induced 1794 diabetic rats were treated with the TFE and TTE for 15 days, 1795 respectively. A range of parameters were tested including fasting blood 1796 glucose (FBG), serum insulin (SI), blood lipid profile, 1797 malondialdehyde (MDA), superoxide dismutase (SOD), glutathione (GSH), 1798 glycosylated serum protein (GSP), and nitric oxide (NO). 1799 Results: Diabetic rats treated with TFE or TTE had decreased 1800 concentration of FBG and GSP compared with the control group. 1801 Meanwhile, the levels of serum total cholesterol (TC), triglycerides 1802 (TG) and low-density lipoprotein cholesterol (LDL-c) in the TFE or TTE 1803 treated diabetic rats were lower, and the high-density lipoprotein 1804 cholesterol (HDL-c) level was higher than in the control diabetic rats. 1805 Furthermore, the extracts treatment decreased the MDA and NO level, 1806 while increased SOD and GSH levels in diabetic rats. Histopathologic 1807 examination also showed that the extracts have protective effects on 1808 beta-cells in diabetic rats which are supported by the increase of SI. 1809 Conclusions: All these experimental results highlighted the 1810 hypoglycemic and hypolipidemic properties of the two extracts from 1811 Potentilla discolor Bunge on diabetes and its complications, possibly 1812 through a strong antioxidant activity and a protective action on 1813 beta-cells. (C) 2010 Elsevier Ireland Ltd. All rights reserved. 1814 SN 0378-8741 1815 PD NOV 11 1816 PY 2010 1817 VL 132 1818 IS 2 1819 BP 518 1820 EP 524 1821 DI 10.1016/j.jep.2010.08.053 1822 UT ISI:000284569200021 1823 PT J 1824 AU Feng, Z 1825 Wenying, L 1826 AF Feng, Zheng 1827 Wenying, Liu 1828 TI Determination of 1,2-bis (2-aminophenoxy)ethane-N,N,N ',N 1829 '-tetraacetic acid (BAPTA free acid) in rat plasma, urine and feces 1830 by liquid chromatography with UV and tandem mass spectrometric 1831 detection 1832 SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL 1833 AND LIFE SCIENCES 1834 AB BAPTA free acid was identified as the main metabolic product of 1835 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid 1836 tetra(actoxymethyl ester) (BAPTA-AM), a neuroprotective agent in 1837 cerebral ischemia, in rats. In this paper, liquid 1838 chromatography-ultraviolet (LC-UV) and mass spectrometry/mass 1839 spectrometry (LC-MS/MS) methods were employed for the determination 1840 of BAPTA free acid in rat urine and feces and rat plasma, respectively. 1841 By liquid-liquid extraction and LC-UV analysis, a limit of quantitation 1842 of 1000 ng/ml using 0.2 ml rat urine for extraction and 250 ng/ml using 1843 1 ml rat fecal homogenate supernatant for extraction could be reached. 1844 The assay was linear in the range of 1000-50,000 ng/ml for rat urine 1845 and 250-10,000 ng/ml for rat fecal homogenate supernatant. Because the 1846 sensitivity of the LC-UV method was apparently insufficient for 1847 evaluating the pharmacokinetic profile of BAPTA in rat plasma, a 1848 LC-MS/MS method was subsequently developed for the analysis of BAPTA 1849 free acid. By protein precipitation and LC-MS/MS analysis, the limit 1850 of quantitation was 5 ng/ml using 0.1 ml rat plasma and the linear range 1851 was 5.0-500 ng/ml. Both methods were validated and can be used to 1852 support a thorough preclinical pharmacokinetic evaluation of BAPTA-AM 1853 liposome injection. (C) 2010 Elsevier B.V. All rights reserved. 1854 SN 1570-0232 1855 PD NOV 15 1856 PY 2010 1857 VL 878 1858 IS 30 1859 BP 3052 1860 EP 3058 1861 DI 10.1016/j.jchromb.2010.09.008 1862 UT ISI:000284672300002 1863 A Lei, J 1864 U Qian, SH 1865 Jiang, JQ 1866 A Lei, Jing 1867 F Qian, Shi-Hui 1868 Jiang, Jian-Qin 1869 Two new flavone glycosides from the seeds of Impatiens balsamina L. 1870 JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH 1871 A Two new flavone glycosides were isolated from the seeds of Impatiens 1872 B balsamina L. and their structures were determined as 1873 quercetin-3-O-[-l-rhamnose-(12)--d-glucopyranosyl]-5-O--d-glucopyr 1874 anosid e (1), and 1875 quercetin-3-O-[(6'''-O-caffeoyl)--l-rhamnose-(12)--d-glucopyranosy 1876 l]-5-O --d-glucopyranoside (2) on the basis of various spectral and 1877 chemical studies. 1878 1028-6020 1879 P 2010 1880 1033 1881 1037 1882 10.1080/10286020.2010.532315 1883 ISI:000284891600004 1884 PT J 1885 AU Liu, K 1886 Xu, QA 1887 AF Liu, Kang 1888 Xu, Qiang 1889 TI Roxithromycin inhibits the effector phase of delayed-type 1890 hypersensitivity (Retraction of vol 8, pg 126, 2008) 1891 SO INTERNATIONAL IMMUNOPHARMACOLOGY 1892 SN 1567-5769 1893 PD NOV 1894 PY 2010 1895 VL 10 1896 IS 11 1897 BP 1477 1898 EP 1477 1899 DI 10.1016/j.intimp.2010.08.019 1900 UT ISI:000284657000022 1901 PT J 1902 AU Zhou, P 1903 Gross, S 1904 Liu, JH 1905 Yu, BY 1906 Feng, LL 1907 Nolta, J 1908 Sharma, V 1909 Piwnica-Worms, D 1910 Qiu, SX 1911 AF Zhou, Ping 1912 Gross, Shimon 1913 Liu, Ji-Hua 1914 Yu, Bo-Yang 1915 Feng, Ling-Ling 1916 Nolta, Jan 1917 Sharma, Vijay 1918 Piwnica-Worms, David 1919 Qiu, Samuel X. 1920 TI Flavokawain B, the hepatotoxic constituent from kava root, induces 1921 GSH-sensitive oxidative stress through modulation of IKK/NF-kappa B 1922 and MAPK signaling pathways 1923 SO FASEB JOURNAL 1924 AB Kava (Piper methysticum Foster, Piperaceae) organic solvent-extract 1925 has been used to treat mild to moderate anxiety, insomnia, and muscle 1926 fatigue in Western countries, leading to its emergence as one of the 1927 10 best-selling herbal preparations. However, several reports of 1928 severe hepatotoxicity in kava consumers led the U. S. Food and Drug 1929 Administration and authorities in Europe to restrict sales of 1930 kava-containing products. Herein we demonstrate that flavokawain B 1931 (FKB), a chalcone from kava root, is a potent hepatocellular toxin, 1932 inducing cell death in HepG2 (LD50 = 15.3 +/- 0.2 mu M) and L-02 (LD50 1933 = 32 mu M) cells. Hepatocellular toxicity of FKB is mediated by 1934 induction of oxidative stress, depletion of reduced glutathione (GSH), 1935 inhibition of IKK activity leading to NF-kappa B transcriptional 1936 blockade, and constitutive TNF-alpha-independent activation of 1937 mitogen-activated protein kinase (MAPK) signaling pathways, namely, 1938 ERK, p38, and JNK. We further demonstrate by noninvasive 1939 bioluminescence imaging that oral consumption of FKB leads to 1940 inhibition of hepatic NF-kappa B transcriptional activity in vivo and 1941 severe liver damage. Surprisingly, replenishment with exogenous GSH 1942 normalizes both TNF-alpha-dependent NF-kappa B as well as MAPK 1943 signaling and rescues hepatocytes from FKB-induced death. Our data 1944 identify FKB as a potent GSH-sensitive hepatotoxin, levels of which 1945 should be specifically monitored and controlled in kava-containing 1946 herb products.-Zhou, P., Gross, S., Liu, J.-H., Yu, B.-Y., Feng, L.-L., 1947 Nolta, J., Sharma, V., Piwnica-Worms, D., Qiu, S. X. Flavokawain B, 1948 the hepatotoxic constituent from kava root, induces GSH-sensitive 1949 oxidative stress through modulation of IKK/NF-kappa B and MAPK 1950 signaling pathways. FASEB J. 24, 4722-4732 (2010). www.fasebj.org 1951 SN 0892-6638 1952 PD DEC 1953 PY 2010 1954 VL 24 1955 IS 12 1956 BP 4722 1957 EP 4732 1958 DI 10.1096/fj.10-163311 1959 UT ISI:000284824400013 1960 PT J 1961 AU Yang, GJ 1962 Yan, JK 1963 Qi, F 1964 Sun, C 1965 AF Yang, Gongjun 1966 Yan, Jiankang 1967 Qi, Fen 1968 Sun, Cheng 1969 TI High Sensitivity and Reproducibility of a Bismuth/Poly(bromocresol 1970 purple) Film Modified Glassy Carbon Electrode for Determination of 1971 Trace Amount of Cadmium by Differential Pulse Anodic Stripping 1972 Voltammetry 1973 SO ELECTROANALYSIS 1974 AB This work described a novel type of bismuth/poly(bromocresol purple) 1975 film modified glassy carbon electrode (denoted as Bi/Poly(BCP)/GCE) 1976 for anodic stripping analysis of trace Cd2+. The Bi/Poly(BCP)/GCE was 1977 fabricated in situ by depositing simultaneously bismuth and cadmium 1978 by reduction at -1.20 V on the poly(BCP) film using a differential pulse 1979 voltammetry. Under the optimum conditions, the anodic stripping peak 1980 current response increased linearly with the Cd2+ concentrations in 1981 a range of 2.0 x 10(-8)-1.0 x1.0(-7) M and 1.0 x 10(-7)-6.0x10(-6) M 1982 in 0.1 M NaAc-Ac buffer solution (pH 5.0) with the detection limit of 1983 6.5 x 10(-9) M (S/N =3). The Bi/poly(BCP)/GCE performed good 1984 reproducibility and high sensitivity. Finally, this proposed method 1985 was successfully applied to determine the concentration of Cd2+ in 1986 water samples. 1987 SN 1040-0397 1988 PD NOV 1989 PY 2010 1990 VL 22 1991 IS 22 1992 BP 2729 1993 EP 2738 1994 DI 10.1002/elan.201000260 1995 UT ISI:000284914800016 1996 PT J 1997 AU Li, P 1998 AF Li, Ping 1999 TI Plant Natural Products in Drug Discovery 2000 SO CURRENT ORGANIC CHEMISTRY 2001 SN 1385-2728 2002 PD OCT 2003 PY 2010 2004 VL 14 2005 IS 16 2006 BP 1669 2007 EP 1669 2008 UT ISI:000284825800001 2009 PT J 2010 AU Chu, C 2011 Qi, LW 2012 Li, B 2013 Gao, W 2014 Li, P 2015 AF Chu, Chu 2016 Qi, Lian-Wen 2017 Li, Bin 2018 Gao, Wen 2019 Li, Ping 2020 TI Radix Astragali (Astragalus): Latest Advancements and Trends in 2021 Chemistry, Analysis, Pharmacology and Pharmacokinetics 2022 SO CURRENT ORGANIC CHEMISTRY 2023 AB Radix Astragali (Astragalus) has been used in Traditional Chinese 2024 Medicine for over 2000 years, and still widely used in Asian countries 2025 to enhance the immune system and to protect the body against various 2026 stresses. In Europe and the United States, Astragalus is commonly used 2027 as nutritional dietary supplements and additives to foods and 2028 beverages. During the last several years, we have witnessed a steady 2029 expansion in the number of publications made associated with this herb. 2030 This review focuses on latest advancements and trends in chemistry, 2031 analysis, pharmacology and pharmacokinetics of Radix Astragali. 2032 Several types of constituents including triterpene saponins, 2033 flavonoids and astragalus polysaccharides have been summarized, and 2034 astragalus polysaccharides are still a challenging issue. With the 2035 rapid development of analytical techniques, a great number of methods 2036 have been developed for the identification and quantification of the 2037 plant material, extracts, and products of Radix Astragali. Separation 2038 was achieved using thin layer chromatography (TLC), high performance 2039 liquid chromatography (HPLC), callipary electrophoresis (CE), and 2040 high-speed counter-current chromatography (HSCCC). Among these 2041 techniques HPLC and hyphenated methods like HPLC with ultraviolet (UV), 2042 evaporative light scattering detection (ELSD), or mass spectrometry 2043 (MS) are by far the most employed. Radix Astragali has attracted 2044 ever-increasing attention in a variety of biological activity studies; 2045 its immunomodulatory effects, cardioprotective effects, 2046 antihyperglycemic effects, hepatoprotective effects and anticancer 2047 effects were strengthened in this review. Pharmacokinetic studies 2048 showed that the flavonoids could be absorbed and metabolized in vivo, 2049 and their major metabolic pathways are glucuronidation and sulfation, 2050 while the bioavailability of saponins is extremely low. 2051 SN 1385-2728 2052 PD OCT 2053 PY 2010 2054 VL 14 2055 IS 16 2056 BP 1792 2057 EP 1807 2058 UT ISI:000284825800010 2059 PT J 2060 AU Zheng, JH 2061 Zhang, G 2062 Lu, Y 2063 Fang, F 2064 He, JK 2065 Li, N 2066 Talbi, A 2067 Zhang, Y 2068 Tang, Y 2069 Zhu, JB 2070 Chen, XJ 2071 AF Zheng, Jianheng 2072 Zhang, Ge 2073 Lu, Yang 2074 Fang, Fang 2075 He, Jiake 2076 Li, Ning 2077 Talbi, Amer 2078 Zhang, Ying 2079 Tang, Yue 2080 Zhu, Jiabi 2081 Chen, Xijing 2082 TI Effect of Pulmonary Surfactant and Phospholipid Hexadecanol Tyloxapol 2083 on Recombinant Human-Insulin Absorption from Intratracheally 2084 Administered Dry Powders in Diabetic Rats 2085 SO CHEMICAL & PHARMACEUTICAL BULLETIN 2086 AB The purpose of the present study was to evaluate the enhancement effect 2087 of the natural pulmonary surfactant (PS) or its artificial substitute, 2088 phospholipid hexadecanol tyloxapol (PHT) on the bioavailability and 2089 hypoglycemic activity of recombinant human insulin (rh-insulin) in a 2090 pulmonary delivery system. PS- or PHT-loaded insulin formulation was 2091 administered to streptozotocin induced diabetic rats, at doses of 5 2092 U/kg, 10 U/kg and 20 U/kg insulin, respectively. The hypoglycemic 2093 effect caused by PS or PHT containing rh-insulin was analyzed and the 2094 area above the curves (AAC) of scrum glucose levels versus time, the 2095 minimum glucose concentration (C-min), the time to C-min (T-min) and 2096 the pharmacological availability (PA%) were derived from the serum 2097 glucose profiles. Results showed that PS and PHT caused significantly 2098 decrease in serum glucose levels. The decrease in plasma glucose levels 2099 continued for about 5 h after the nadir. The highest AAC value was 2100 obtained when 20 U/kg rh-Insulin with PS or PHT as absorption enhancer 2101 was administered to rats. AAC(0-360min) of PS- or PHT-loaded rh-insulin 2102 was 2-3 times as much as that without PS or PHT and PA% increased by 2103 1.3-2 fold. Thus, the extent of oral absorption of insulin from PSor PHT-loaded particles was significantly greater when compared with 2104 that without them. In addition, PHT as well as PS did not change the 2105 lactate dehydrogenase (LDH) activity, alkaline phosphatase (AKP) 2106 activity and N-acetyl-beta-D-glucoaminidase (NAG) activity in bronch 2107 fluid which are sensitive indicators of acute toxicity to lung cells 2108 in bronchoalveolar lavage (BAL). It is concluded that PS and PHT is 2109 a promising absorption enhancer for pulmonary delivery systems of large 2110 molecule drugs as rh-Insulin. 2111 SN 0009-2363 2112 PD DEC 2113 PY 2010 2114 VL 58 2115 IS 12 2116 BP 1612 2117 EP 1616 2118 UT ISI:000284860800011 2119 PT J 2120 AU Lai, YS 2121 Ma, L 2122 Huang, WX 2123 Yu, X 2124 Zhang, YH 2125 Ji, H 2126 Tian, JD 2127 AF Lai, Yisheng 2128 Ma, Lin 2129 Huang, Wenxing 2130 Yu, Xing 2131 Zhang, Yihua 2132 Ji, Hui 2133 Tian, Jide 2134 TI Synthesis and biological evaluation of 3-[4-(amino/methylsulfonyl) 2135 phenyl]methylene-indolin-2-one derivatives as novel COX-1/2 and 5-LOX 2136 inhibitors 2137 SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 2138 AB Fourteen new 3-[4-(amino/methylsulfonyl) 2139 phenyl]methylene-indolin-2-one derivatives were synthesized. Six 2140 compounds displayed potent inhibitory activities against COX-1/2 and 2141 5-LOX with IC50 in the range of 0.10-9.87 mu M. Particularly, 10f 2142 exhibited well balanced inhibitory action on these enzymes (IC50 = 2143 0.10-0.56 mu M). More importantly, 10f and several other compounds had 2144 comparable or stronger anti-inflammatory and analgesic activities, but 2145 better gastric tolerability in vivo, as compared with darbufelone 2146 mesilate and tenidap sodium. Therefore, our findings may aid in the 2147 design of new and safe anti-inflammatory reagents for the intervention 2148 of painful inflammatory diseases, such as rheumatoid arthritis at 2149 clinic. (C) 2010 Elsevier Ltd. All rights reserved. 2150 SN 0960-894X 2151 PD DEC 15 2152 PY 2010 2153 VL 20 2154 IS 24 2155 BP 7349 2156 EP 7353 2157 DI 10.1016/j.bmcl.2010.10.056 2158 UT ISI:000284332900035 2159 PT J 2160 AU Zheng, YF 2161 Qi, LW 2162 Zhou, JL 2163 Li, P 2164 AF Zheng, Yun-Feng 2165 Qi, Lian-Wen 2166 Zhou, Jian-Liang 2167 Li, Ping 2168 TI Structural characterization and identification of oleanane-type 2169 triterpene saponins in Glycyrrhiza uralensis Fischer by 2170 rapid-resolution liquid chromatography coupled with time-of-flight 2171 mass spectrometry 2172 SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY 2173 AB Oleanane-type triterpene saponins (OTS) are major active ingredients 2174 in Glycyrrhiza uralensis. In this work, a rapid-resolution liquid 2175 chromatography with time-of-flight mass spectrometry (RRLC/TOF-MS) 2176 method has been developed to characterize and identify OTS from G. 2177 uralensis. The major diagnostic ions and fragmentation pathways from 2178 thirteen OTS have been characterized for the first time. At a low 2179 fragmentor voltage of 120 V in positive ion mode, the precursor ion 2180 [M + H](+) or/and [M + Na](+) was obtained for accurate determination 2181 of molecular formula. When the fragmentor voltage was increased to 425 2182 V, abundant characteristic fragment ions were observed for structural 2183 characterization. Neutral losses of sugar moieties, such as glucuronic 2184 acid (G1cA, 176 Da), glucose (G1c, 162 Da) and rhamnose (Rha, 146 Da), 2185 were commonly observed in the MS spectra for prediction of the sugar 2186 number and sequences. Other typical losses included AcOH (60 Da), CH2O 2187 (30 Da), 2 x H2O (2 x 18 Da) and HCOOH (46 Da) from [Aglycone + H H2O](+) 2188 (named [B](+)), corresponding to the presence of a C-22-acetyl group, 2189 C-24-hydroxyl group, C-22-hydroxyl group or C-30-carboxyl group on the 2190 aglycone moiety, respectively. In particular, characteristic ring 2191 cleavages of the aglycone moieties on A- and B-rings were observed. 2192 Based on the fragmentation patterns of reference compounds, nineteen 2193 OTS have been identified in an extract of G. uralensis, thirteen of 2194 which were unambiguously identified and the other six were tentatively 2195 assigned. Copyright (C) 2010 John Wiley & Sons, Ltd. 2196 SN 0951-4198 2197 PD NOV 2198 PY 2010 2199 VL 24 2200 IS 22 2201 BP 3261 2202 EP 3270 2203 DI 10.1002/rcm.4768 2204 UT ISI:000284023400006 2205 PT J 2206 AU Ye, BP 2207 Rui, Q 2208 Wu, QL 2209 Wang, DY 2210 AF Ye, Boping 2211 Rui, Qi 2212 Wu, Qiuli 2213 Wang, Dayong 2214 TI Metallothioneins Are Required for Formation of Cross-Adaptation 2215 Response to Neurobehavioral Toxicity from Lead and Mercury Exposure 2216 in Nematodes 2217 SO PLOS ONE 2218 AB Metallothioneins (MTs) are small, cysteine-rich polypeptides, but the 2219 role of MTs in inducing the formation of adaptive response is still 2220 largely unknown. We investigated the roles of metallothionein genes 2221 (mtl-1 and mtl-2) in the formation of cross-adaptation response to 2222 neurobehavioral toxicity from metal exposure in Caenorhabditis 2223 elegans. Pre-treatment with mild heat-shock at L2-larva stage 2224 effectively prevented the formation of the neurobehavioral defects and 2225 the activation of severe stress response in metal exposed nematodes 2226 at concentrations of 50 and 100 mM, but pre-treatment with mild 2227 heat-shock did not prevent the formation of neurobehavioral defects 2228 in 200 mM of metal exposed nematodes. During the formation of 2229 cross-adaptation response, the induction of mtl-1 and mtl-2 promoter 2230 activity and subsequent GFP gene expression were sharply increased in 2231 50 mu M or 100 mM of metal exposed Pmtl-1::GFP and Pmtl-2::GFP 2232 transgenic adult animals after mild heat-shock treatment compared with 2233 those treated with mild heat-shock or metal exposure alone. Moreover, 2234 after pre-treatment with mild heat-shock, no noticeable increase of 2235 locomotion behaviors could be observed in metal exposed mtl-1 or mtl-2 2236 mutant nematodes compared to those without mild heat-shock 2237 pre-treatment. The defects of adaptive response to neurobehavioral 2238 toxicity induced by metal exposure formed in mtl-1 and mtl-2 mutants 2239 could be completely rescued by the expression of mtl-1 and mtl-2 with 2240 the aid of their native promoters. Furthermore, overexpression of MTL-1 2241 and MTL-2 at the L2-larval stage significantly suppressed the toxicity 2242 on locomotion behaviors from metal exposure at all examined 2243 concentrations. Therefore, the normal formation of cross-adaptation 2244 response to neurobehavioral toxicity induced by metal exposure may need 2245 the enough accumulation of MTs protein in animal tissues. 2246 SN 1932-6203 2247 PD NOV 18 2248 PY 2010 2249 VL 5 2250 IS 11 2251 AR e14052 2252 DI 10.1371/journal.pone.0014052 2253 UT ISI:000284356900014 2254 PT J 2255 AU Liu, F 2256 Deng, DW 2257 Chen, XY 2258 Qian, ZY 2259 Achilefu, S 2260 Gu, YQ 2261 AF Liu, Fei 2262 Deng, Dawei 2263 Chen, Xinyang 2264 Qian, Zhiyu 2265 Achilefu, Samuel 2266 Gu, Yueqing 2267 TI Folate-Polyethylene Glycol Conjugated Near-Infrared Fluorescence 2268 Probe with High Targeting Affinity and Sensitivity for In Vivo Early 2269 Tumor Diagnosis 2270 SO MOLECULAR IMAGING AND BIOLOGY 2271 AB The purpose of this study is to synthesize a folate-polyethylene glycol 2272 (PEG) conjugated near-infrared fluorescence probe (fPI-01) for 2273 diagnosis of folate receptor (FR)-overexpressed tumors with high 2274 sensitivity and specificity. 2275 fPI-01 was synthesized, purified, and characterized. Its cytotoxicity 2276 and affinity to tumor cells were determined in vitro. The dynamics and 2277 biodistribution of the probe was monitored in normal nude mice. And 2278 the tumor-targeting capability was investigated in nude mice bearing 2279 different tumor xenograft. 2280 fPI-01 was successfully synthesized with strengthened optical 2281 properties. Cells experiments showed the probe had high FR affinity 2282 and without apparent cytotoxicity. Animal experiments indicated the 2283 probe excreted through urine by kidney. And its tumor-targeting ability 2284 was demonstrated on different tumor-bearing mice, with high 2285 sensitivity and tumor-to-normal tissue contrast ratio (10:1). 2286 fPI-01 is a promising optical agent for diagnosis of FR-positive 2287 tumors, especially in their early stage. 2288 SN 1536-1632 2289 PD DEC 2290 PY 2010 2291 VL 12 2292 IS 6 2293 BP 595 2294 EP 607 2295 DI 10.1007/s11307-010-0305-1 2296 UT ISI:000284159300005 2297 PT J 2298 AU Zhang, JW 2299 Zhou, F 2300 Wu, XL 2301 Gu, Y 2302 Ai, H 2303 Zheng, YT 2304 Li, YN 2305 Zhang, XX 2306 Hao, G 2307 Sun, JG 2308 Peng, Y 2309 Wang, GJ 2310 AF Zhang, Jingwei 2311 Zhou, Fang 2312 Wu, Xiaolan 2313 Gu, Yi 2314 Ai, Hua 2315 Zheng, Yuanting 2316 Li, Yannan 2317 Zhang, Xiaoxuan 2318 Hao, Gang 2319 Sun, Jianguo 2320 Peng, Ying 2321 Wang, Guangji 2322 TI 20(S)-Ginsenoside Rh2 Noncompetitively Inhibits P-Glycoprotein In 2323 Vitro and In Vivo: A Case for Herb-Drug Interactions 2324 SO DRUG METABOLISM AND DISPOSITION 2325 AB P-glycoprotein (P-gp) is an ATP-dependent efflux transporter highly 2326 expressed in gastrointestinal tract and multidrug resistance tumor 2327 cells. Inhibition or induction of P-gp can cause drug-drug interactions 2328 and thus influence the effects of P-gp substrate drugs. Previous 2329 studies indicated that 20(S)-ginsenoside Rh2 [20(S)-Rh2] could 2330 synergistically enhance the anticancer effects of conventional 2331 chemotherapeutic agents at a nontoxic dose. The aim of present study 2332 was to investigate in vitro and in vivo whether 20(S)Rh2 was a P-gp 2333 inhibitor and analyze the possible inhibitory mechanisms and potential 2334 herb-drug interactions. Results showed that in vitro, 20(S)-Rh2 2335 significantly enhanced rhodamine 123 retention in cells and decreased 2336 the efflux ratio of digoxin, fexofenadine, and etoposide, which were 2337 comparable to the effects of the established P-gp inhibitor verapamil. 2338 However, the transport of 20(S)Rh2 suggested that 20(S)-Rh2 was not 2339 a P-gp substrate. Further-more, the inhibitory effect persisted for 2340 at least 3 h after removal of 20(S)-Rh2. Unlike P-gp substrates, 2341 20(S)-Rh2 inhibited both basal and verapamil-stimulated P-gp ATPase 2342 activities. It also significantly decreased UIC2 binding fluorescence, 2343 a marker for conformational change of P-gp. In situ and in vivo 2344 experiments showed that 20(S)-Rh2 increased the area under the plasma 2345 concentration-time curve and maximum plasma concentration of digoxin, 2346 fexofenadine, and etoposide significantly without affecting terminal 2347 elimination half-time. Long-term treatment with 20(S)-Rh2 failed to 2348 affect intestinal P-gp expression in vitro and in vivo. In conclusion, 2349 20(S)-Rh2 is a potent noncompetitive P-gp inhibitor, which indicates 2350 a potential herb-drug interaction when 20(S)-Rh2 is coadministered 2351 with P-gp substrate drugs. It could increase the absorption of P-gp 2352 substrate drugs without long-term induction of P-gp expression in rats. 2353 SN 0090-9556 2354 PD DEC 2355 PY 2010 2356 VL 38 2357 IS 12 2358 BP 2179 2359 EP 2187 2360 DI 10.1124/dmd.110.034793 2361 UT ISI:000284309900014 2362 PT J 2363 AU Liu, EH 2364 Qi, LW 2365 Li, K 2366 Chu, C 2367 Li, P 2368 AF Liu, E-Hu 2369 Qi, Lian-Wen 2370 Li, Kai 2371 Chu, Chu 2372 Li, Ping 2373 TI Recent Advances in Quality Control of Traditional Chinese Medicines 2374 SO COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING 2375 AB Traditional Chinese medicines (TCMs) have been used for disease 2376 prevention and therapy in China for a long history and are becoming 2377 increasingly popular over the world. However, TCMs are complex mixtures 2378 and contain usually hundreds of chemically different constituents, 2379 which make the quality control of crude drugs and their medical 2380 preparations extremely difficult. Therefore, better analytical 2381 strategies to assure their efficacy, safety and consistency are in 2382 great demand. The present work provides an overview of the development 2383 of quality control for TCMs based on microscopic and molecular 2384 identification, quantitative and qualitative analysis, fingerprint, 2385 combination of fingerprint and multi-component quantification, as well 2386 as activity-integrated fingerprint over the last five years. The 2387 biological fingerprinting analysis of TCMs with targeting absorption, 2388 distribution, metabolism, excretion by chromatographic and 2389 chemometric method are also highlighted due to its broad application 2390 in the quality control of TCMs. The comprehensive methods analyzed with 2391 modern hyphenated techniques are strongly recommended to assess the 2392 authenticity, quality consistency and stability of TCMs. 2393 SN 1386-2073 2394 PD DEC 2395 PY 2010 2396 VL 13 2397 IS 10 2398 BP 869 2399 EP 884 2400 UT ISI:000284622300006 2401 PT J 2402 AU Wang, TC 2403 Wei, JZ 2404 Guo, CS 2405 Zhang, HB 2406 Fan, HX 2407 AF Wang, Tian Cai 2408 Wei, Ju Zhi 2409 Guo, Chuan Sheng 2410 Zhang, Hui Bin 2411 Fan, Hou Xing 2412 TI Design, synthesis and anti-proliferative studies of a novel series of 2413 indirubin derivatives 2414 SO CHINESE CHEMICAL LETTERS 2415 AB A series of novel derivatives of indirubin were synthesized and 2416 evaluated for their anti-proliferative activity against human cancer 2417 cell lines of SGC7901, A549, HL-60, SK-BR-3 and HCT116. Most of the 2418 compounds displayed more potent activity than Sunitinib. In addition, 2419 the derivatives showed improved water solubility, which may be 2420 favorable to their pharmacokinetic performances. (C) 2010 Hui Bin 2421 Zhang. Published by Elsevier B.V. on behalf of Chinese Chemical 2422 Society. All rights reserved. 2423 SN 1001-8417 2424 PD DEC 2425 PY 2010 2426 VL 21 2427 IS 12 2428 BP 1407 2429 EP 1410 2430 DI 10.1016/j.cclet.2010.05.026 2431 UT ISI:000284389800005 2432 PT J 2433 AU Xi, BM 2434 Ni, PZ 2435 Jiang, ZZ 2436 Wu, DQ 2437 Zhang, SH 2438 Zhang, HB 2439 Wang, T 2440 Chen, WH 2441 AF Xi, Bao-Min 2442 Ni, Pei-Zhou 2443 Jiang, Zhen-Zhou 2444 Wu, Dian-Qing 2445 Zhang, Shou-Hua 2446 Zhang, Hui-Bin 2447 Wang, Tao 2448 Chen, Wen-Hua 2449 TI Synthesis and Blocking Activities of a New Class of 2450 alpha(1)-Adrenoceptor Antagonists 2451 SO CHEMICAL BIOLOGY & DRUG DESIGN 2452 AB Finding effective chemotherapeutic agents for clinical use is a 2453 long-lasting goal in medicinal chemistry. In this study, we report a 2454 new class of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists. 2455 Specifically, we describe the synthesis and the blocking activities 2456 toward alpha(1)-AR of 2457 7-(2-hydroxypropoxy)-3,4-dihydroisoquinolin-1(2H)-one 1 and its 2458 structurally perturbed analogs 2-11 that were designed according to 2459 the principle of bioisosterism. Their structures were identified with 2460 IR, 1H NMR, MS, HRMS and elemental analysis. The blocking activities 2461 of compounds 1-11 were evaluated on isolated rat anococcygeus muscles. 2462 The results indicated that these compounds showed moderate to good 2463 activities. Among them, compound 1 exhibited the highest activity that 2464 was comparable to those of known alpha(1)-AR antagonists tamsulosin 2465 and DDPH (1-(2,6-dimethylphenoxy)-2-(3,4-dimethoxyphenylethylamino)propane hydrochloride) and thus may be 2466 exploitable as a lead compound for the discovery of promising 2467 alpha(1)-AR antagonists. 2468 SN 1747-0277 2469 PD DEC 2470 PY 2010 2471 VL 76 2472 IS 6 2473 BP 505 2474 EP 510 2475 DI 10.1111/j.1747-0285.2010.01040.x 2476 UT ISI:000284170000006 2477 PT J 2478 AU Yao, J 2479 Fan, Y 2480 Du, RH 2481 Zhou, JP 2482 Lu, Y 2483 Wang, W 2484 Ren, J 2485 Sun, XJ 2486 AF Yao, Jing 2487 Fan, Ying 2488 Du, Ronghui 2489 Zhou, Jianping 2490 Lu, Yun 2491 Wang, Wei 2492 Ren, Jin 2493 Sun, Xiaojing 2494 TI Amphoteric hyaluronic acid derivative for targeting gene delivery 2495 SO BIOMATERIALS 2496 AB The study aimed to develop an amphoteric hyaluronic acid (HA) 2497 derivative with polyethyleneimine (PEI) chains (HAP) for gene delivery 2498 to overcome the disadvantages of PEI as gene carrier including the 2499 cytotoxicity caused by excess of positive charge, non-special 2500 interaction and aggregation in the blood, and non-target gene delivery. 2501 The HAP was synthesized by an imine reaction between periodate-oxidized 2502 HA and PEI. The HAP/DNA complex was prepared, and its characterization 2503 was investigated. The size of complex with higher molecular weight HA 2504 in PBS was about 200 nm at optimal charge ratio. No apparent aggregation 2505 among the particles was observed. The HAPs also showed high protection 2506 of DNA from nuclease, better dissociation of DNA from the complex and 2507 lower cytotoxicity. It also exhibited higher transfection efficiency 2508 in HepG2 cells than the PEI/DNA complex. Among all complexes, the 2509 HAP50/DNA complex was especially found to be most efficient, yielding 2510 comparable transfection efficiency with that of Lipofectamine/DNA 2511 lipoplexes. Moreover, the HAP-IR820 obviously accumulated in tumor 2512 after i.v. administration as compared to the PEI-IR820, which indicated 2513 that the HAP could assist the DNA targeting to the tumor. Therefore, 2514 HAP should be a promising non-viral gene vector. (C) 2010 Elsevier Ltd. 2515 All rights reserved. 2516 SN 0142-9612 2517 PD DEC 2518 PY 2010 2519 VL 31 2520 IS 35 2521 BP 9357 2522 EP 9365 2523 DI 10.1016/j.biomaterials.2010.08.043 2524 UT ISI:000284393300022 2525 PT J 2526 AU Lu, Y 2527 Sun, YX 2528 Xiong, QY 2529 Zhang, Y 2530 Hou, J 2531 Mekoo, DJL 2532 Zhang, F 2533 Hu, XB 2534 Ma, YJ 2535 Liu, JJ 2536 Li, TM 2537 AF Lu Yong 2538 Sun Yunxiao 2539 Xiong Qiyan 2540 Zhang Yu 2541 Hou Jing 2542 Mekoo, Didier J. L. 2543 Zhang Fan 2544 Hu Xiangbing 2545 Ma Yanjun 2546 Liu Jingjing 2547 Li Taiming 2548 TI Immunization with P277 induces vascular leak syndrome in C57BL/6 mice 2549 via endothelial damage 2550 SO AUTOIMMUNITY 2551 AB Accumulating evidence established a positive association of anti-heat 2552 shock protein 60 (HSP60) autoantibodies and the presence of 2553 atherosclerosis. However, whether anti-P277 (HSP60 437-460) 2554 autoantibodies may lead to the pathological increase in vascular 2555 permeability, a vascular leak syndrome (VLS), is unknown. In the 2556 present study, anti-P277 immunity was effectively induced in C57BL/6 2557 mice, causing a marked increase in VLS in both normal mice and those 2558 bearing melanoma as well. Further analysis of the pathological role 2559 of anti-P277 immunity revealed that the B-cell epitopes located in P277 2560 played a causal role in the development of VLS. Moreover, studies on 2561 endothelial cells (ECs) showed that the anti-P277 antibodies could 2562 cross-react with HSP60, highly expressed in both normal and stressed 2563 ECs, and mediate damage to cells in the presence of complement. These 2564 data suggested that humoral immune response induced by anti-P277 2565 immunity mediates EC damage and induces VLS. These negative effects 2566 may cast shadows on P277, used as a peptide vaccine. 2567 SN 0891-6934 2568 PD DEC 2569 PY 2010 2570 VL 43 2571 IS 8 2572 BP 654 2573 EP 663 2574 DI 10.3109/08916931003674683 2575 UT ISI:000284074300010 2576 PT J 2577 AU Qiu, FR 2578 Zhang, R 2579 Wang, GJ 2580 Gao, CL 2581 Sun, JG 2582 Jiang, JA 2583 Ma, YM 2584 AF Qiu, Furong 2585 Zhang, Rong 2586 Wang, Guangji 2587 Gao, Chenglu 2588 Sun, Jianguo 2589 Jiang, Jian 2590 Ma, Yueming 2591 TI Activation of CYP3A-mediated testosterone 6 beta-hydroxylation by 2592 tanshinone IIA and midazolam 1-hydroxylation by cryptotanshinone in 2593 human liver microsomes 2594 SO XENOBIOTICA 2595 AB 1. This study evaluated the in vitro activation of CYP3A-mediated 2596 midazolam 1-hydroxylation and testosterone 6 beta-hydroxylation by 2597 tanshinone I, tanshinone IIA, and cryptotanshinone. 2598 2. The abilities of tanshinones to activate CYP3A-mediated midazolam 2599 1-hydroxylation and testosterone 6 beta-hydroxylation in human liver 2600 microsomes (HLMs) were tested. Substrate-and effector-dependent 2601 activation of CYP3A by tanshinones were both observed. 2602 3. Cryptotanshinone was shown to activate CYP3A-mediated midazolam 2603 1-hydroxylation in a concentration-dependent manner. In contrast, 2604 tanshinone IIA and tanshinone I did not activate this hydroxylation 2605 reaction. In addition, tanshinone IIA activated CYP3A-mediated 2606 testosterone 6 beta-hydroxylation, whereas cryptotanshinone and 2607 tanshinone I did not. 2608 4. The results from our study enhance the understanding of CYP3A 2609 activation by tanshinone IIA and cryptotanshinone in HLMs. 2610 Additionally, these data allow for an accurate prediction of the 2611 magnitude and likelihood of Danshen-drug interactions. 2612 SN 0049-8254 2613 PD DEC 2614 PY 2010 2615 VL 40 2616 IS 12 2617 BP 800 2618 EP 806 2619 DI 10.3109/00498254.2010.519062 2620 UT ISI:000284003800002 2621 PT J 2622 AU Liu, CW 2623 Lu, YY 2624 Yang, ZZ 2625 Xing, YY 2626 Xi, T 2627 AF Liu, Cheng-Wei 2628 Lu, Yuan-Yuan 2629 Yang, Zhen-Zheng 2630 Xing, Ying-Ying 2631 Xi, Tao 2632 TI Rapid screening and characterization of metabolites from a 2633 marine-derived actinomycete by high-performance liquid chromatography 2634 coupled with electrospray ionization quadrupole time-of-flight mass 2635 spectrometry 2636 SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY 2637 AB A rapid and reliable method has been optimized and established for the 2638 analysis of the metabolites from a marine actinomycete by 2639 high-performance liquid chromatography coupled with electrospray 2640 ionization quadrupole time-of-flight mass spectrometry (HPLC/QTOF 2641 MS/MS). From MS/MS spectra, the product ions of [M+H](+) were recorded 2642 to provide abundant structural information of the mother nucleus and 2643 peptide moieties. Using the QTOF MS/MS and in-source collision-induced 2644 dissociation (in-source CID) techniques, three main metabolites 2645 including actinomycin D, actinomycin V and actinomycin I were 2646 determined and characterized by elemental compositions of precursor 2647 and product ions (<7 ppm). Additionally, this method provided 2648 information about the compositions of the peptide residues and the 2649 sequences of the amino acid from a series of fragment ions. It proved 2650 useful for the identification of the metabolites in marine samples 2651 which have similar structures especially when there were no reference 2652 compounds available. Copyright (C) 2010 John Wiley & Sons, Ltd. 2653 SN 0951-4198 2654 PD DEC 15 2655 PY 2010 2656 VL 24 2657 IS 23 2658 BP 3413 2659 EP 3418 2660 DI 10.1002/rcm.4744 2661 UT ISI:000284037800005 2662 PT J 2663 AU Qi, J 2664 Li, N 2665 Zhou, JH 2666 Yu, BY 2667 Qiu, SX 2668 AF Qi, Jin 2669 Li, Na 2670 Zhou, Jia-Hong 2671 Yu, Bo-Yang 2672 Qiu, Samuel X. 2673 TI Isolation and Anti-Inflammatory Activity Evaluation of Triterpenoids 2674 and a Monoterpenoid Glycoside from Harpagophytum procumbens 2675 SO PLANTA MEDICA 2676 AB A new triterpenoid glycoside, designated harproside (1), and a new 2677 iridoid glycoside, named pagide (2), along with six known triterpenoids 2678 (3-8), were obtained from the tubers of Harpagophytum procumbens D.C. 2679 (devil's claw), and their structures were established through chemical 2680 methods and spectroscopic analyses. In an in vitro assay, the six 2681 triterpenoids showed anti-inflammatory activity. Compounds 3, 7, and 2682 8 showed significant inhibitory activity against neutrophil 2683 respiratory burst stimulated by PMA, while compounds 4, 5, and 6 showed 2684 marginal inhibitory activity. 2685 SN 0032-0943 2686 PD NOV 2687 PY 2010 2688 VL 76 2689 IS 16 2690 BP 1892 2691 EP 1896 2692 DI 10.1055/s-0030-1250029 2693 UT ISI:000284144400020 2694 PT J 2695 AU Wei, KH 2696 Gao, SL 2697 Huang, HP 2698 AF Wei Kun-Hua 2699 Gao Shan-Lin 2700 Huang He-Ping 2701 TI Tissue culture and generation of autotetraploid plants of Sophora 2702 flavescens Aiton 2703 SO PHARMACOGNOSY MAGAZINE 2704 AB Background: Sophora flavescens Aiton is an important medicinal plant 2705 in China. Early in vitro researches of S. flavescens were focused on 2706 callus induction and cell suspension culture, only a few were concerned 2707 with in vitro multiplication. Objective: To establish and optimize the 2708 rapid propagation technology of S. flavescens and to generate and 2709 characterize polyploid plants of S. flavescens. Materials and Methods: 2710 The different concentrations of 6-benzylaminopurine (BAP), 2711 indole-3-acetic acid (IAA) and kinetin (KT) were used to establish and 2712 screen the optimal rapid propagation technology of S. flavescens by 2713 orthogonal test; 0.2% colchicine solution was used to induce polyploid 2714 plants and the induced buds were identified by root-tip chromosome 2715 determination and stomatal apparatus observation. Results: A large 2716 number of buds could be induced directly from epicotyl and hypocotyl 2717 explants on the Murashige and Skoog medium (MS; 1962) supplemented with 2718 1.4-1.6 mg/l 6-benzylaminopurine (BAP) and 0.3 mg/l indole-3-acetic 2719 acid (IAA). More than 50 lines of autotetraploid plants were obtained. 2720 The chromosome number of the autotetraploid plantlet was 2n = 4x = 36. 2721 All tetraploid plants showed typical polyploid characteristics. 2722 Conclusion: Obtained autotetraploid lines will be of important genetic 2723 and breeding value and can be used for further selection and plant 2724 breeding. 2725 SN 0973-1296 2726 PD OCT-DEC 2727 PY 2010 2728 VL 6 2729 IS 24 2730 BP 286 2731 EP 292 2732 DI 10.4103/0973-1296.71793 2733 UT ISI:000283922900008 2734 PT J 2735 AU Zhou, JL 2736 Xin, GZ 2737 Shi, ZQ 2738 Ren, MT 2739 Qi, LW 2740 Li, HJ 2741 Li, P 2742 AF Zhou, Jian-Liang 2743 Xin, Gui-Zhong 2744 Shi, Zi-Qi 2745 Ren, Mei-Ting 2746 Qi, Lian-Wen 2747 Li, Hui-Jun 2748 Li, Ping 2749 TI Characterization and identification of steroidal alkaloids in 2750 Fritillaria species using liquid chromatography coupled with 2751 electrospray ionization quadrupole time-of-flight tandem mass 2752 spectrometry 2753 SO JOURNAL OF CHROMATOGRAPHY A 2754 AB Liquid chromatography coupled with electrospray ionization quadrupole 2755 time-of-flight tandem mass spectrometry (LC/ESI-QTOF-MS/MS) was 2756 performed to study the fragmentation behaviors of steroidal alkaloids 2757 from Fritillaria species the antitussive and expectorant herbs widely 2758 used in traditional Chinese medicine We propose herein a strategy that 2759 combining key diagnostic fragment ions and the relative abundances and 2760 amounts of major fragment ions (the ions exceeding 10% in abundance) 2761 to distinguish different sub-classes of Fritillaria alkaloids (FAs) 2762 It was found that hydrogen rearrangement and induction effects result 2763 in ring cleavage of the basic skeletons occurred in the MS/MS process 2764 and produced characteristic fragment ions which are useful for 2765 structural elucidation This method was finally used to investigate the 2766 primary steroidal alkaloids in the extracts of eight major Fritillaria 2767 species As a result 41 steroidal alkaloids (29 cevanine type 1 jervine 2768 type 6 veratramine type and 5 secosolanidine type alkaloids) were 2769 selectively identified in these Fritillaria species Twenty-six 2770 compounds were unambiguously identified by comparing with the 2771 reference compounds and 15 compounds were tentatively identified or 2772 deduced according to their MS/MS data Logical fragmentation pathways 2773 for different types of FAs have been proposed and are useful for the 2774 identification of these types of steroidal alkaloids in natural 2775 products especially when there are no reference compounds available 2776 (C) 2010 Elsevier B V All rights reserved 2777 SN 0021-9673 2778 PD NOV 5 2779 PY 2010 2780 VL 1217 2781 IS 45 2782 BP 7109 2783 EP 7122 2784 DI 10.1016/j.chroma.2010.09.019 2785 UT ISI:000283973000014 2786 PT J 2787 AU Song, R 2788 Xu, L 2789 Xu, FG 2790 Li, Z 2791 Dong, HJ 2792 Tian, YA 2793 Zhang, ZJ 2794 AF Song, Ru 2795 Xu, Lei 2796 Xu, Fengguo 2797 Li, Zhe 2798 Dong, Haijun 2799 Tian, Yuan 2800 Zhang, Zunjian 2801 TI In vivo metabolism study of rhubarb decoction in rat using 2802 high-performance liquid chromatography with UV photodiode-array and 2803 mass-spectrometric detection A strategy for systematic analysis of 2804 metabolites from traditional Chinese medicines in biological samples 2805 SO JOURNAL OF CHROMATOGRAPHY A 2806 AB High-performance liquid chromatography with diode-array detection 2807 (HPLC-DAD) and tandem mass spectrometry (HPLC-MS/MS) was used for 2808 separation and identification of metabolites in rat urine bile and 2809 plasma after oral administration of rhubarb decoction Based on the 2810 proposed strategy 91 of the 113 potential metabolites were tentatively 2811 identified or characterized Besides anthraquinones metabolites gallic 2812 acid (-)-epicatechin and (+)-catechin metabolites were also detected 2813 and characterized in these biological samples Our results indicated 2814 that glucuronidation and sulfation were the main metabolic pathways 2815 of anthraquinones while methylation glucuronidation and sulfation were 2816 the main metabolic pathways of gallic acid (-)-epicatechin and 2817 (+)-catechin Phase I reactions (e g hydroxylation and reduction) played 2818 a relatively minor role compared to phase II reactions in metabolism 2819 of phenolic compounds of rhubarb decoction The identification and 2820 structure elucidation of these metabolites provided essential data for 2821 further pharmacological and clinical studies of rhubarb and related 2822 preparations Moreover the results of the present Investigations 2823 clearly indicated the relevance and usefulness of the combination of 2824 chromatographic spectrophotometric and mass-spectrometric analysis to 2825 detect and identify metabolites (C) 2010 Elsevier BV All rights 2826 reserved 2827 SN 0021-9673 2828 PD NOV 5 2829 PY 2010 2830 VL 1217 2831 IS 45 2832 BP 7144 2833 EP 7152 2834 DI 10.1016/j.chroma.2010.09.028 2835 UT ISI:000283973000018 2836 PT J 2837 AU Chen, JQ 2838 Du, YX 2839 Zhu, FX 2840 Chen, B 2841 AF Chen, Jiaquan 2842 Du, Yingxiang 2843 Zhu, Fenxia 2844 Chen, Bin 2845 TI Evaluation of the enantioselectivity of glycogen-based dual chiral 2846 selector systems towards basic drugs in capillary electrophoresis 2847 SO JOURNAL OF CHROMATOGRAPHY A 2848 AB Several chiral reagents including cyclodextrins (CDs) and derivatives 2849 crown ethers proteins chiral surfactants and polymers have been 2850 involved in dual selector systems for enantioseparation of a series 2851 of chiral compounds by capillary electrophoresis (CE) In comparison 2852 to the chiral reagents above-mentioned there is no report concerning 2853 the use of polysaccharides in dual chiral CE system In this paper we 2854 first investigate the enantioselectivity of polysaccharide-based dual 2855 selector systems towards some chiral drugs During our recent work 2856 glycogen belonging to the class of branched polysaccharides has been 2857 used as a novel chiral selector in CE In this study three glycogen-based 2858 dual chiral CE systems have been established for enantiomeric 2859 separations of several racemic basic drugs consisting of duloxetine 2860 cetirizine citalopram sulconazole laudanosine amlodipine propranolol 2861 atenolol and nefopam These three dual systems combined glycogen 2862 (neutral polysaccharide) with chondroitin sulfate A (CSA ionic 2863 polysaccharide) beta-CD and HP-beta-CD respectively It was found that 2864 the dual system of glycogen/CSA exhibited good enantioselective 2865 properties toward the tested drugs More importantly compared to the 2866 single selector systems synergistic effect was observed when glycogen 2867 was used with CSA for most of the analytes This indicated the 2868 enhancement of enantioseparation observed for these analytes in 2869 glycogen/CSA system might be due to some favorable interaction effects 2870 between glycogen and CSA Moreover in order to evaluate the 2871 stereoselectivity of glycogen/CSA the influences of buffer pH and 2872 selector concentration on enantioseparation of the studied drugs were 2873 also investigated (C) 2010 Elsevier B V All rights reserved 2874 SN 0021-9673 2875 PD NOV 5 2876 PY 2010 2877 VL 1217 2878 IS 45 2879 BP 7158 2880 EP 7163 2881 DI 10.1016/j.chroma.2010.09.017 2882 UT ISI:000283973000020 2883 PT J 2884 AU Zan, K 2885 Shi, SP 2886 Fu, QA 2887 Chen, XQ 2888 Zhou, SX 2889 Xiao, MT 2890 Tu, PF 2891 AF Zan, Ke 2892 Shi, She-Po 2893 Fu, Qiang 2894 Chen, Xiao-Qing 2895 Zhou, Si-Xiang 2896 Xiao, Mei-Tian 2897 Tu, Peng-Fei 2898 TI New Sesquiterpenoids from Artemisia anomala 2899 SO HELVETICA CHIMICA ACTA 2900 AB One new guaianolide, anomalactone A (1), and one new norcadinane 2901 sesquiterpene, anomallenodiol (2), along with two germacranolides, 2902 anomalactones B and C (3 and 4, resp.), were isolated from the aerial 2903 part of Artemisia anomala S. MOORE. Their structures were determined 2904 on the basis of extensive spectroscopic analyses. 2905 SN 0018-019X 2906 PY 2010 2907 VL 93 2908 IS 10 2909 BP 2000 2910 EP 2006 2911 UT ISI:000283908200015 2912 PT J 2913 AU Xu, GF 2914 Li, H 2915 Zhang, C 2916 Sun, ZY 2917 Zhong, WY 2918 Xu, DK 2919 Chen, HY 2920 AF Xu Guo-Feng 2921 Li Hui 2922 Zhang Cui 2923 Sun Zi-Yin 2924 Zhong Wen-Ying 2925 Xu Dan-Ke 2926 Chen Hong-Yuan 2927 TI Research and Application of Visual Detection Based on Quantum Dots 2928 Coupled with Silver Enhancement 2929 SO CHINESE JOURNAL OF ANALYTICAL CHEMISTRY 2930 AB CdTe quantum dot probe modified with streptavidin ( SA) was synthesized 2931 and prepared. A novel visual detection method based on the quantum dot 2932 coupled with silver enhancement was successfully established. Combined 2933 with the protein microarray analysis technique, this novel method did 2934 well in the detection of the reverse phase protein microarray. To detect 2935 the analytical performance, human IgG was used as a mode in this 2936 experiment. First, human IgG was immobilized on Aldehyde slides, then 2937 the optimized bio-goat anti-human IgG and CdTe-SA probe was added, 2938 finally silver enhancement coloration was carried out for 15 min. The 2939 results showed a good linear correlation between the signal gray level 2940 and the logarithm of human IgG immobilized on slides from 100 pg to 2941 1.6 ng with a correlation coefficient (R-2) of 0.997 while its lowest 2942 detectable limit was about 50 pg human IgG. This novel method could 2943 be used to the sensitive detection of micro-amount protein and showed 2944 the characteristics of the simple operation, lower request to the 2945 instruments and the visual results. 2946 SN 0253-3820 2947 PD OCT 2948 PY 2010 2949 VL 38 2950 IS 10 2951 BP 1383 2952 EP 1387 2953 DI 10.3724/SP.J.1096.2010.01383 2954 UT ISI:000283904400001 2955 PT J 2956 AU Yao, ZY 2957 Zhang, H 2958 Sheng, HM 2959 Wu, XM 2960 Bin Sun, H 2961 AF Yao, Zhang Yu 2962 Zhang, Hao 2963 Sheng, Huan Ming 2964 Wu, Xiao Ming 2965 Bin Sun, Hong 2966 TI An unexpected Hoffmann elimination during the alkylation of 2967 dihydrotetrabenazine 2968 SO CHINESE CHEMICAL LETTERS 2969 AB Dihydrotetrabenazine (DTBZ) is the major pharmacologically active form 2970 of tetrabenazine (TBZ), which was approved by FDA for the treatment 2971 of chorea associated with Huntington's disease (HD). An unexpected 2972 Hoffmann elimination was observed during the treatment of DTBZ with 2973 sodium hydrogen and alkyl halides, leading to the formation of both 2974 eliminated products (major) and hydroxyl-alkylated products (minor). 2975 (C) 2010 Xiao Ming Wu. Published by Elsevier B.V. on behalf of Chinese 2976 Chemical Society. All rights reserved. 2977 SN 1001-8417 2978 PD NOV 2979 PY 2010 2980 VL 21 2981 IS 11 2982 BP 1334 2983 EP 1337 2984 DI 10.1016/j.cclet.2010.06.022 2985 UT ISI:000283899700019 2986 PT J 2987 AU Zhang, QH 2988 Yang, J 2989 He, Y 2990 Liu, F 2991 Wang, JP 2992 Davey, AK 2993 AF Zhang, Qing-Hua 2994 Yang, Jin 2995 He, Ying 2996 Liu, Fang 2997 Wang, Ji-Ping 2998 Davey, Andrew K. 2999 TI Food effect on the pharmacokinetics of entecavir from dispersible 3000 tablets following oral administration in healthy Chinese volunteers 3001 SO ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH 3002 AB Objective: The aim of the present study was to assess the effect of 3003 food on the pharmacokinetics of entecavir (CAS 142217-69-4) from 3004 dispersible tablets. 3005 Methods: In an open-label, two-way crossover study, 12 healthy Chinese 3006 volunteers randomly received a single oral dose of 1 mg entecavir 3007 dispersible tablets under fasted and fed conditions. Blood samples were 3008 collected and determined for pharmacokinetic analyses. A solid phase 3009 extraction for sample preparation and a LC/MS method were developed 3010 and validated for determination of entecavir in human plasma. 3011 Results: The absorption of entecavir from dispersible tablets was 3012 altered significantly with food intake, as evidenced by a decrease in 3013 C m of 63%, a decrease in AUC(0-t) of 22%, and a delay in T-max of 1.5 3014 h. The calibration curve was linear from 0.2 to 25 ng/mL, with a lower 3015 limit of quantitation (LLOQ) of 0.2 ng/mL. 3016 Conclusion: Food intake has an obvious effect on the absorption of 3017 entecavir from dispersible tablets. It is better to take entecavir 3018 dispersible tablets on an empty stomach. 3019 SN 0004-4172 3020 PY 2010 3021 VL 60 3022 IS 10 3023 BP 640 3024 EP 644 3025 UT ISI:000283963500010 3026 PT J 3027 AU Zhang, PH 3028 Zhang, LY 3029 Jiang, ZZ 3030 Wang, T 3031 Chen, HK 3032 Xiong, YT 3033 Li, Z 3034 AF Zhang, Pinghu 3035 Zhang, Luyong 3036 Jiang, Zhenzhou 3037 Wang, Tao 3038 Chen, Hongkui 3039 Xiong, Yating 3040 Li, Zhan 3041 TI In Vitro Mitochondrial Toxicity of Metacavir, a New Nucleoside Reverse 3042 Transcriptase Inhibitor for Treatment of Hepatitis B Virus 3043 SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 3044 AB Therapy with nucleoside reverse transcriptase inhibitors (NRTIs) can 3045 be associated with mitochondrial toxicity. In vitro studies have been 3046 used to predict the predisposition for and characterize the mechanisms 3047 causing mitochondrial toxicity. Metacavir (PNA) is a novel synthetic 3048 nucleoside analog for oral administration with potent and specific 3049 antiviral activity against hepatitis B virus (HBV). We assessed the 3050 potential for mitochondrial toxicity of PNA in long-term cultures of 3051 HepG2 hepatoma cells by measuring mitochondrial function (through 3052 lactate secretion), levels of mitochondrial DNA (mtDNA), and the 3053 activities of respiratory-chain complexes I to IV. Exposure of HepG2 3054 cells to PNA at concentrations up to 50 mu M for 15 days resulted in 3055 no deleterious effect on cell proliferation, levels of lactate or 3056 mtDNA, or enzyme activities of respiratory-chain complexes I to IV. 3057 In contrast, dideoxycytosine at 10 mu M and zidovudine at 50 mu M have 3058 significant effects on cell proliferation, levels of lactate and mtDNA, 3059 and enzyme activities of respiratory-chain complexes I to IV. However, 3060 PNA at a supratherapeutic concentration of 250 mu M could result in 3061 significant alterations in the levels of mtDNA and the activities of 3062 respiratory-chain complex enzymes, revealing evidence of the potential 3063 mitochondrial toxicity of PNA. In summary, these in vitro results 3064 indicate that the potential for PNA to interfere with mitochondrial 3065 functions is low. 3066 SN 0066-4804 3067 PD NOV 3068 PY 2010 3069 VL 54 3070 IS 11 3071 BP 4887 3072 EP 4892 3073 DI 10.1128/AAC.00794-10 3074 UT ISI:000284155000049 3075 PT J 3076 AU Yang, R 3077 Zeng, HJ 3078 Yu, LL 3079 Chen, XL 3080 Qu, LB 3081 Li, P 3082 AF Yang Ran 3083 Zeng Huajin 3084 Yu Lanlan 3085 Chen Xiaolan 3086 Qu Lingbo 3087 Li Ping 3088 TI The Interaction of Flavonoid-BSA and the Relationship Between 3089 Molecular Structure of Flavonoids and Their Binding to BSA 3090 SO ACTA CHIMICA SINICA 3091 AB The interactions between eleven flavonoids and BSA were investigated 3092 by fluorescence spectroscopy The binding parameters, including binding 3093 constants, binding numbers and binding distance, were calculated By 3094 a comparison of the structures of flavonoids with their binding 3095 potency, the structural requirements of flavonoids for the binding were 3096 obtained Furthermore, to explore the effect of molecular structure on 3097 the binding, a study on quantitative structure and binding-property 3098 relationship (QSPR) was performed on SGI workstations 3099 SN 0567-7351 3100 PD OCT 14 3101 PY 2010 3102 VL 68 3103 IS 19 3104 BP 1995 3105 EP 1999 3106 UT ISI:000283976300012 3107 PT J 3108 AU Cen, JA 3109 Qi, Y 3110 Tao, YF 3111 Deng, Y 3112 Fang, WR 3113 Li, YM 3114 Zhang, LY 3115 Huang, WL 3116 AF Cen, Juan 3117 Qi, Yan 3118 Tao, Yi-fu 3119 Deng, Yan 3120 Fang, Wei-rong 3121 Li, Yun-man 3122 Zhang, Lu-yong 3123 Huang, Wen-long 3124 TI HZ08, a great regulator to reverse multidrug resistance via cycle 3125 arrest and apoptosis sensitization in MCF-7/ADM 3126 SO EUROPEAN JOURNAL OF PHARMACOLOGY 3127 AB In early studies, it was demonstrated that R-HZ08, S-HZ08 and the 3128 racemate had strong reverse efficacy of multidrug resistance in vitro 3129 and in vivo (Yan et al., 2008b). The effect was supposed to have direct 3130 interaction with multidrug resistance-associated protein (MRP1) in 3131 MCF-7/ADM and P-glycoprotein in K562/A02. According to our latest 3132 study, we found HZ08 could enhance chemotherapy induced apoptosis by 3133 synergistic action on reactive oxygen species generation, GSH 3134 depletion, mitochondrial membrane potential depolarization, 3135 cytochrome c release and caspase activation. Moreover, the potential 3136 selective effect of HZ08 on resistant cells suggested that HZ08 have 3137 specific targets for resistance reversal via apoptosis regulation. 3138 Therefore, we traced individual influence of HZ08, not only on 3139 apoptosis pathway per se but also on apoptosis related intracellular 3140 regulation systems. Then we found HZ08 could increase cells in 3141 G(0)/G(1) phase and regulate apoptosis related proteins (Bcl-2, Bax) 3142 as well as upstream functional molecules (c-Myc and c-Fos), which are 3143 usually abnormal in malignancy and responsible for multidrug 3144 resistance in MCF-7/ADM. Thereby, chemotherapy induced apoptosis was 3145 promoted. R-HZ08 showed better effect than S-HZ08 or the racemate did 3146 in most of targets above. Furthermore, HZ08 did not change the 3147 concentration of intracellular Ca2+ which means it would not have side 3148 effect as verapamil does. Considering multidrug resistance is 3149 multifactorial, HZ08, especially R-HZ08, which could sensitize 3150 apoptosis by multiple improvements of upstream malignant characters, 3151 will be a promising drug to enhance the effect of chemotherapy in the 3152 treatment of multidrug resistant tumor. (c) 2010 Elsevier B.V. All 3153 rights reserved. 3154 SN 0014-2999 3155 PD NOV 25 3156 PY 2010 3157 VL 647 3158 IS 1-3 3159 BP 21 3160 EP 30 3161 DI 10.1016/j.ejphar.2010.08.013 3162 UT ISI:000283835400003 3163 PT J 3164 AU Fu, RG 3165 You, QD 3166 Yang, L 3167 Wu, WT 3168 Jiang, C 3169 Xu, XL 3170 AF Fu, Rong-geng 3171 You, Qi-dong 3172 Yang, Lei 3173 Wu, Wu-tong 3174 Jiang, Cheng 3175 Xu, Xiao-li 3176 TI Design, synthesis and bioevaluation of dihydropyrazolo[3,4-b]pyridine 3177 and benzo[4,5]imidazo[1,2-a]pyrimidine compounds as dual KSP and 3178 Aurora-A kinase inhibitors for anti-cancer agents 3179 SO BIOORGANIC & MEDICINAL CHEMISTRY 3180 AB Four series of dihydropyrazolo[3,4-b]pyridines and 3181 benzo[4,5]imidazo[1,2-a]pyrimidines were designed and synthesized as 3182 dual KSP and Aurora-A kinase inhibitors for anti-cancer agents by 3183 introducing some fragments of Aurora-A kinase inhibitors into our KSP 3184 inhibitor CPUYL064. A total of 19 target compounds were evaluated by 3185 two related enzyme inhibition assays and a cytotoxicity assay in vitro. 3186 The results showed that some target compounds could inhibit both 3187 enzymes, and several of them showed significant inhibition activity 3188 against HCT116 cell line. Despite showing moderate KSP and Aurora-A 3189 kinase inhibition, the lead compounds 6a and 6e displayed significant 3190 cytotoxic activity in the micromolar range, especially against the 3191 HCT116 cell line and HepG2 cell line. The results may be useful for 3192 developing a new class of inhibitors having a dual function, KSP 3193 inhibition and Aurora-A kinase inhibition, for the treatment of cancer. 3194 (C) 2010 Elsevier Ltd. All rights reserved. 3195 SN 0968-0896 3196 PD NOV 15 3197 PY 2010 3198 VL 18 3199 IS 22 3200 BP 8035 3201 EP 8043 3202 DI 10.1016/j.bmc.2010.09.020 3203 UT ISI:000283649900040 3204 PT J 3205 AU Dong, J 3206 Yao, SW 3207 Xu, YG 3208 AF Dong Jin 3209 Yao Shuowei 3210 Xu Yungen 3211 TI Tumor Angiogenesis Inhibitors 3212 SO PROGRESS IN CHEMISTRY 3213 AB At present, drug inhibition of angiogenesis has become a hot topic in 3214 the treatment of tumor and several tumor angiogenesis inhibitors (TAIs) 3215 have been marketed. TAIs can suppress tumor growth and metastasis, and 3216 even induce tumor regression. Research and development on TAIs holds 3217 the promise of supplying drugs with high potency, low toxicity and 3218 broad-spectrum antitumor activity for tumor patients. This review 3219 summarizes recent research progress in TAIs. First of all, indirect 3220 TAIs are introduced. Among indirect TAIs, VEGF inhibitors are the most 3221 successful TAIs currently. Secondly, direct TAIs, which are unlikely 3222 switch on the angiogenic rescue program, are introduced. Thirdly, in 3223 the miscellaneous TAIs part, thalidomide and its derivatives, whose 3224 mechanisms of activity have not been defined well, are described in 3225 detail. Finally, several problems encountered in the research and 3226 development of TAIs, such as challenge from novel theory of 3227 anti-angiogenenic therapy and resistance, are analyzed and discussed, 3228 and future research directions are pointed out. 3229 SN 1005-281X 3230 PD OCT 3231 PY 2010 3232 VL 22 3233 IS 10 3234 BP 1993 3235 EP 2002 3236 UT ISI:000283615400013 3237 PT J 3238 AU Zhou, CH 3239 Xiang, M 3240 He, SY 3241 Qian, ZY 3242 AF Zhou, Cheng-Hua 3243 Xiang, Min 3244 He, Shu-Ying 3245 Qian, Zhi-Yu 3246 TI Protein Kinase C Pathway is Involved in the Inhibition by Crocetin of 3247 Vascular Smooth Muscle Cells Proliferation 3248 SO PHYTOTHERAPY RESEARCH 3249 AB Crocetin is a natural carotenoid compound isolated from Gardenia 3250 jasminoids Ellis. Our previous study showed that crocetin inhibits 3251 angiotensin II (Ang II)-induced proliferation of vascular smooth 3252 muscle cells (VSMCs). The present study investigated the involvement 3253 of the protein kinase C (PKC) pathway in the growth-inhibitory action 3254 of crocetin in VSMCs. The findings showed that PKC activity in the 3255 membrane fraction of VSMCs increased following stimulation with Ang 3256 II, which was suppressed significantly by pretreating the cells with 3257 crocetin. Inhibition of PKC activity by crocetin appeared to be 3258 associated with growth inhibition in VSMCs, because chelerythrine 3259 chloride, a specific PKC inhibitor, likewise decreased cell 3260 proliferation. PKC-alpha, a conventional PKC isoform, was detected in 3261 bovine aorta VSMCs by RT-PCR and western blotting analysis. Crocetin 3262 inhibited Ang II-induced membrane translocation of PKC-alpha, and the 3263 inhibition of crocetin on PKC activity in membrane fraction coincided 3264 with its suppression on membrane translocation of PKC-alpha. In 3265 addition, Ang II-induced mRNA expressions of c-fos, c-jun and c-myc 3266 were also decreased by crocetin. Taken together, the data suggest that 3267 the inhibition by crocetin of PKC activity, at least in part due to 3268 inactivation of PKC-alpha, and the subsequent suppression of 3269 proto-oncogene expressions might mediate its inhibitory effect on 3270 VSMCs proliferation. Copyright (C) 2010 John Wiley & Sons, Ltd. 3271 SN 0951-418X 3272 PD NOV 3273 PY 2010 3274 VL 24 3275 IS 11 3276 BP 1680 3277 EP 1686 3278 DI 10.1002/ptr.3194 3279 UT ISI:000283794300017 3280 PT J 3281 AU Sun, MJ 3282 Wang, Y 3283 Shen, J 3284 Xiao, YY 3285 Su, ZG 3286 Ping, QN 3287 AF Sun, Minjie 3288 Wang, Yu 3289 Shen, Jie 3290 Xiao, Yanyu 3291 Su, Zhigui 3292 Ping, Qineng 3293 TI Octreotide-modification enhances the delivery and targeting of 3294 doxorubicin-loaded liposomes to somatostatin receptors expressing 3295 tumor in vitro and in vivo 3296 SO NANOTECHNOLOGY 3297 AB Octreotide is believed to be the ligand of somatostatin receptors 3298 (SSTRs) which are widely used in tumor diagnosis and clinical therapy. 3299 In the present work, a new targeting conjugate, 3300 octreotide-polyethylene glycol-phosphatidylethanolamine 3301 (Oct-PEG-PE), was developed for the assembling of liposome, and the 3302 effect of octreotide-modification on the enhancement of the delivery 3303 and targeting of doxorubicin-loaded liposomes was investigated in 3304 vitro and in vivo. Oct-PEG-PE was synthesized by a three-step reaction 3305 involving two derivative intermediate formations of bis (p-nitrophenyl 3306 carbonate)-PEG ((pNP)(2)-PEG) and pNP-PEG-PE. The Oct-modified and 3307 unmodified liposomes (DOX-OL and DOX-CL) were prepared by the ammonium 3308 sulfate gradient method. Both drug uptake assay and cell apoptosis 3309 assay suggested that DOX-OL noticeably increased the uptake of DOX in 3310 SMMC-7721 cells and showed a more significant cytotoxicity, compared 3311 with DOX-CL. The effect of DOX-OL was remarkably inhibited by free 3312 octreotide. In contrast, no significant difference in drug cytotoxicty 3313 was found between DOX-OL and DOX-CL in CHO cells without obvious 3314 expression of SSTRs. The study of ex vivo fluorescence tissues imaging 3315 of BALB/c mice and in vivo tissue distribution of B16 tumor-bearing 3316 mice indicated that DOX-OL caused remarkable accumulation of DOX in 3317 melanoma tumors and the pancreas, in which the SSTRs are highly 3318 expressed. 3319 SN 0957-4484 3320 PD NOV 26 3321 PY 2010 3322 VL 21 3323 IS 47 3324 AR 475101 3325 DI 10.1088/0957-4484/21/47/475101 3326 UT ISI:000283673100001 3327 PT J 3328 AU Liu, DF 3329 Ge, YF 3330 Tang, Y 3331 Yuan, YB 3332 Zhang, Q 3333 Li, R 3334 Xu, QW 3335 AF Liu, Dongfei 3336 Ge, Yifan 3337 Tang, Yue 3338 Yuan, Yubing 3339 Zhang, Qing 3340 Li, Rui 3341 Xu, Qunwei 3342 TI Solid lipid nanoparticles for transdermal delivery of diclofenac 3343 sodium: preparation, characterization and in vitro studies 3344 SO JOURNAL OF MICROENCAPSULATION 3345 AB The aim of this study was to prepare diclofenac sodium (DNa) solid lipid 3346 nanoparticles (SLNs) by a modified emulsion/solvent evaporation method 3347 for transdermal delivery. Five independent processing parameters 3348 including the lipid matrix, emulsifiers, co-emulsifiers, 3349 water-dispersed phase and organic phase were assessed systematically 3350 to enhance the entrapment of DNa. The SLNs produced by optimal 3351 formulation were submicrometre size with low polydispersity index, the 3352 entrapment efficiency was about 89% and the drug loading was about 9.5%. 3353 Shape and surface morphology were determined by transmission electron 3354 microscopy, which revealed the fairly spherical and core-shell shapes 3355 of the SLNs. The in vitro release of SLNs showed a two-step release 3356 pattern: one initial burst release followed by a second slow-release 3357 phase. In the in vitro cutaneous permeation studies, value of flux 3358 obtained for DNa solution was higher than that of SLNs suspension. SLNs 3359 had also been shown to improve the dermal localization of DNa.</. 3360 SN 0265-2048 3361 PY 2010 3362 VL 27 3363 IS 8 3364 BP 726 3365 EP 734 3366 DI 10.3109/02652048.2010.513456 3367 UT ISI:000283689900007 3368 A Qu, B 3369 U Ou, BL 3370 Chen, DY 3371 Hu, YZ 3372 A Qu, Bin 3373 F Ou, Bei-Li 3374 Chen, De-Ying 3375 Hu, Yu-Zhu 3376 T Identification, Synthesis and Spectral Characterization of a Potential 3377 I Impurity of Ceftazidime 3378 JOURNAL OF FOOD AND DRUG ANALYSIS 3379 A During the process development of ceftazidime, a new impurity which 3380 B exceeded the limit of 0.1% was detected by a simple HPLC method. The 3381 molecular weight of the target impurity was determined by LC/MS. This 3382 suspected impurity was synthesized and purified for characterization. 3383 When co-injected with ceftazidime in HPLC, the retention time of the 3384 impurity was the same as the ceftazidime sample containing the 3385 impurity. The structural determination of the suspected impurity was 3386 conducted by ER, MS, H-1-NMR and C-13-NMR spectroscopic techniques. 3387 This new impurity was the methyl ester of ceftazidime, and its structure 3388 was determined as 3389 (6R,7R)-7-[[(Z)-2-(2-aminothiazol-4-y1)-2-[(1-methoxycarbonyl-1-me 3390 thylet hoxy) 3391 imino]acetyl]amino]-8-oxo-3-[(1-pyridinio)methyl]-5-thia-1-azabicy 3392 clo[4. 2.0]oct-2-ene-2-carboxylate, with molecular formula of 3393 C23H24N6O7S2 and molecular weight of 560 Da. 3394 1021-9498 3395 P 2010 3396 ISI:000283694800006 3397 PT J 3398 AU Zhao, YR 3399 Ding, L 3400 Fan, HW 3401 Yu, Y 3402 Qi, XM 3403 Leng, Y 3404 Rao, YK 3405 AF Zhao, Yan-rong 3406 Ding, Li 3407 Fan, Hong-wei 3408 Yu, Yong 3409 Qi, Xie-min 3410 Leng, Ye 3411 Rao, Ya-kun 3412 TI Determination of the unstable drug otilonium bromide in human plasma 3413 by LC-ESI-MS and its application to a pharmacokinetic study 3414 SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL 3415 AND LIFE SCIENCES 3416 AB Otilonium bromide (OB) degrades rapidly in plasma and readily undergoes 3417 hydrolysis by the plasma esterase. In this paper, an LC-ESI-MS method 3418 has been developed for the determination of OB in human plasma. The 3419 rapid degradation of OB in plasma was well prevented by immediate 3420 addition of potassium fluoride (KF, an inhibitor of plasma esterase) 3421 to the freshly collected plasma before prompt treatment with 3422 acetonitrile. The method was validated over the concentration range 3423 of 0.1-20 ng/ml. The data of intra-run and inter-run precision and 3424 accuracy were within +/- 15%. The mean extraction recoveries for OB 3425 and the internal standard were higher than 93.0% and the matrix effects 3426 were negligible. The method has been successfully used in a 3427 pharmacokinetic study. (C) 2010 Elsevier B.V. All rights reserved. 3428 SN 1570-0232 3429 PD OCT 15 3430 PY 2010 3431 VL 878 3432 IS 28 3433 BP 2896 3434 EP 2900 3435 DI 10.1016/j.jchromb.2010.08.003 3436 UT ISI:000283687200035 3437 PT J 3438 AU Luo, YB 3439 Liu, M 3440 Dai, Y 3441 Yao, XJ 3442 Xia, YF 3443 Chou, GX 3444 Wang, ZT 3445 AF Luo, Yubin 3446 Liu, Mei 3447 Dai, Yue 3448 Yao, Xiujuan 3449 Xia, Yufeng 3450 Chou, Guixin 3451 Wang, Zhengtao 3452 TI Norisoboldine Inhibits the Production of Pro-inflammatory Cytokines 3453 in Lipopolysaccharide-Stimulated RAW 264.7 Cells by Down-Regulating 3454 the Activation of MAPKs but Not NF-kappa B 3455 SO INFLAMMATION 3456 AB Norisoboldine is the main isoquinoline alkaloid occurring in Radix 3457 Linderae, the dry roots of Lindera aggregata (Lauraceae family). It 3458 has been previously implicated to be able to ameliorate the synovial 3459 inflammation and abnormal immune conditions in collagen-induced 3460 arthritis of mice. To get insight to the potential anti-inflammatory 3461 mechanisms of this alkaloid compound, the present study was undertaken 3462 to explore the effects of norisoboldine on the production of 3463 pro-inflammatory cytokines from macrophages stimulated by 3464 lipopolysaccharide. In vitro, norisoboldine substantially reduced the 3465 production of nitric oxide (NO), tumor necrosis factor (TNF)-alpha as 3466 well as interleukin (IL)-1 beta from RAW264.7 macrophage cells in a 3467 concentration-dependent manner, whereas it only slightly reduced the 3468 production of interleukin-6 (IL-6) at both protein and transcription 3469 levels. Of note, the preventive effects of norisoboldine on the release 3470 of pro-inflammatory cytokines were correlated with the inhibitory 3471 action on the phosphorylations of mitogen-activated protein (MAP) 3472 kinases including p38, extracellular signal-regulated kinase (ERK) and 3473 c-jun NH2-terminal kinase (JNK), but not on the activation and 3474 translocation of nuclear factor-kappa B (NF-kappa B). It can be 3475 therefore concluded that norisoboldine inhibits the macrophage 3476 activation and the resultant production of pro-inflammatory cytokines 3477 via down-regulating the activation of MAPKs signaling pathways rather 3478 than NF-kappa B. 3479 SN 0360-3997 3480 PD DEC 3481 PY 2010 3482 VL 33 3483 IS 6 3484 BP 389 3485 EP 397 3486 DI 10.1007/s10753-010-9197-0 3487 UT ISI:000283572900005 3488 PT J 3489 AU Du, YX 3490 Chen, B 3491 AF Du, Yingxiang 3492 Chen, Bin 3493 TI Recent advances in enantioseparation by capillary electrophoresis 3494 using antibiotics and polysaccharides as chiral selectors A review 3495 SO CHIMICA OGGI-CHEMISTRY TODAY 3496 AB This review gives an overview of the use of antibiotics and 3497 polysaccharides as chiral selectors in the field of enantioseparation 3498 by capillary electrophoresis (CE). Antibiotics and polysaccharides are 3499 two important types of chiral selectors in CE, and have been utilized 3500 successfully in enantioseparation of various compounds including 3501 pharmaceuticals, biochemicals, agrochemicals, fine chemicals, etc. In 3502 this review, recent advances covering literature published from 3503 January 2006 to April 2010 in chiral CE separation with antibiotics 3504 and polysaccharides are summarized. These developments focus on the 3505 introductions of new chiral selectors, investigations in different CE 3506 modes containing micellar electrokinetic chromatography and 3507 nonaqueous capillary electrophoresis, studies on separation 3508 mechanisms and improvements in separation methods. 3509 SN 1973-8250 3510 PD SEP-OCT 3511 PY 2010 3512 VL 28 3513 IS 5 3514 BP 37 3515 EP 42 3516 UT ISI:000283581600005 3517 PT J 3518 AU Wu, SM 3519 Tian, ZQ 3520 Zhang, ZL 3521 Huang, BH 3522 Jiang, P 3523 Xie, ZX 3524 Pang, DW 3525 AF Wu, Sheng-Mei 3526 Tian, Zhi-Quan 3527 Zhang, Zhi-Ling 3528 Huang, Bi-Hai 3529 Jiang, Peng 3530 Xie, Zhi-Xiong 3531 Pang, Dai-Wen 3532 TI Direct fluorescence in situ hybridization (FISH) in Escherichia coli 3533 with a target-specific quantum dot-based molecular beacon 3534 SO BIOSENSORS & BIOELECTRONICS 3535 AB Quantum dots (QDs) are inorganic fluorescent nanocrystals with 3536 excellent properties such as tunable emission spectra and 3537 photo-bleaching resistance compared with organic dyes, which make them 3538 appropriate for applications in molecular beacons. In this work, 3539 quantum dot-based molecular beacons (QD-based MBs) were fabricated to 3540 specifically detect beta-lactamase genes located in pUC18 which were 3541 responsible for antibiotic resistance in bacteria Escherichia coil (E. 3542 coli) DH5 alpha. QD-based MBs were constructed by conjugating 3543 mercaptoacetic acid-quantum dots (MAA-QDs) with black hole quencher 3544 2 (BHQ2) labeled thiol DNA vial metal-thiol bonds. Two types of 3545 molecular beacons, double-strands beacons and hairpin beacons, were 3546 observed in product characterization by gel electrophoresis. Using 3547 QD-based MBs, one-step FISH in tiny bacteria DH5a was realized for the 3548 first time. QD-based MBs retained their bioactivity when hybridizing 3549 with complementary target DNA, which showed excellent advantages of 3550 eliminating background noise caused by adsorption of non-specific 3551 bioprobes and achieving clearer focus of genes in plasmids pUC18, and 3552 capability of bacterial cell penetration and signal specificity in 3553 one-step in situ hybridization. (C) 2010 Elsevier B.V. All rights 3554 reserved. 3555 SN 0956-5663 3556 PD OCT 15 3557 PY 2010 3558 VL 26 3559 IS 2 3560 BP 491 3561 EP 496 3562 DI 10.1016/j.bios.2010.07.067 3563 UT ISI:000283804400030 3564 PT J 3565 AU Wang, Y 3566 Di, LL 3567 Lin, GW 3568 Lu, T 3569 AF Wang, Yue 3570 Di, Li Li 3571 Lin, Guo Wu 3572 Lu, Tao 3573 TI Crystal structure of 2-(2-amino-5-chlorophenyl)-1H-benzimidazole, 3574 C13H10ClN3 3575 SO ZEITSCHRIFT FUR KRISTALLOGRAPHIE-NEW CRYSTAL STRUCTURES 3576 AB C13H10ClN3, orthorhombic, Pna2(1) (no. 33), a = 8.685(2) angstrom, b 3577 = 6.648(1) angstrom, c = 19.264(4) angstrom, v = 1112.3 angstrom(3), 3578 Z= 4, R-gt(F) = 0.046, wR(ref)(F-2) = 0.149, T = 296 K. 3579 SN 1433-7266 3580 PY 2010 3581 VL 225 3582 IS 3 3583 BP 457 3584 EP 458 3585 DI 10.1524/ncrs.2010.0200 3586 UT ISI:000283462300016 3587 PT J 3588 AU Hou, ZG 3589 Luo, JG 3590 Wang, JS 3591 Kong, LY 3592 AF Hou, Zhiguo 3593 Luo, Jianguang 3594 Wang, Junsong 3595 Kong, Lingyi 3596 TI Separation of minor coumarins from Peucedanum praeruptorum using HSCCC 3597 and preparative HPLC guided by HPLC/MS 3598 SO SEPARATION AND PURIFICATION TECHNOLOGY 3599 AB Two minor coumarins, including a new compound qianhucoumarin J, were 3600 isolated from Peucedanum praeruptorum by a multi-step separation 3601 procedure using high-speed counter-current chromatography (HSCCC) and 3602 preparative high performance liquid chromatography (prep-HPLC) 3603 monitored by high performance liquid chromatography coupled with mass 3604 spectrometry (HPLC/MS) analysis. The crude extract was analyzed first 3605 by HPLC/MS to detect unknown compounds. The target compounds were 3606 enriched by HSCCC, using a two-phase solvent system of petroleum 3607 ether-ethyl acetate-methanol-water (5:5:6:4, v/v) and then isolated 3608 and purified by preparative HPLC monitored by HPLC/MS. The structure 3609 of the new compound was elucidated mainly by analysis of its 1D and 3610 2D NMR spectral data. Its absolute configuration was determined by 3611 chemical degradation followed by chiral HPLC analysis. (C) 2010 3612 Elsevier B.V. All rights reserved. 3613 SN 1383-5866 3614 PD OCT 13 3615 PY 2010 3616 VL 75 3617 IS 2 3618 BP 132 3619 EP 137 3620 DI 10.1016/j.seppur.2010.08.007 3621 UT ISI:000283402500006 3622 PT J 3623 AU Shao, M 3624 Wang, Y 3625 Liu, Z 3626 Zhang, DM 3627 Cao, HH 3628 Jiang, RW 3629 Fan, CL 3630 Zhang, XQ 3631 Chen, HR 3632 Yao, XS 3633 Ye, WC 3634 AF Shao, Meng 3635 Wang, Ying 3636 Liu, Zhong 3637 Zhang, Dong-Mei 3638 Cao, Hui-Hui 3639 Jiang, Ren-Wang 3640 Fan, Chun-Lin 3641 Zhang, Xiao-Qi 3642 Chen, He-Ru 3643 Yao, Xin-Sheng 3644 Ye, Wen-Cai 3645 TI Psiguadials A and B, Two Novel Meroterpenoids with Unusual Skeletons 3646 from the Leaves of Psidium guajava 3647 SO ORGANIC LETTERS 3648 AB Psiguadials A (1) and B (2), two novel sesquiterpenoid-diphenylmethane 3649 meroterpenoids with unusual skeletons, along with a pair of known 3650 epimers, psidial A (3) and guajadial (4), were isolated from the leaves 3651 of Psidium guajava. Their structures with absolute configurations were 3652 elucidated by means of NMR, X-ray diffraction, and quantum chemical 3653 CD calculation. Compounds 1, 2, and 4 exhibited potent inhibitory 3654 effects on the growth of human hepatoma cells. 3655 SN 1523-7060 3656 PD NOV 5 3657 PY 2010 3658 VL 12 3659 IS 21 3660 BP 5040 3661 EP 5043 3662 DI 10.1021/ol102179u 3663 UT ISI:000283531000085 3664 PT J 3665 AU Li, H 3666 Huo, MR 3667 Zhou, JP 3668 Dai, YD 3669 Deng, YP 3670 Shi, XJ 3671 Masoud, J 3672 AF Li, Hong 3673 Huo, Meirong 3674 Zhou, Jianping 3675 Dai, Yindi 3676 Deng, Yaping 3677 Shi, Xiangjie 3678 Masoud, Jumah 3679 TI Enhanced Oral Absorption of Paclitaxel in N-Deoxycholic Acid-N, 3680 O-Hydroxyethyl Chitosan Micellar System 3681 SO JOURNAL OF PHARMACEUTICAL SCIENCES 3682 AB The overall goal of this study was to develop a micellar system of 3683 paclitaxel (PTX) to enhance its oral absorption. An amphiphilic 3684 chitosan derivative, N-deoxycholic acid-N, O-hydroxyethyl chitosan 3685 (DHC), was synthesized and characterized by FTIR, H-1 NMR, elemental 3686 analysis, and X-ray diffraction (XRD) techniques. The degree of 3687 substitution (DS) of hydroxyethyl group and deoxycholic acid group 3688 ranged from 89.5-114.5% and 1.11-8.17%, respectively. The critical 3689 micelle concentration (CMC) values of DHC decreased from 0.26 to 0.16 3690 mg/mL as the DS of deoxycholic acid group increased. PTX was 3691 successfully loaded in DHC micelles with a high drug loading (31.68 3692 +/- 0.14%) and entrapment efficiency (77.57 +/- 0.51%). The particle 3693 size of PTX-loaded DHC micelles ranged from 203.35 +/- 2.19 to 236.70 3694 +/- 3.40 nm as the DS of deoxycholic acid group increased. After orally 3695 administration of PTX-loaded DHC micelles, the bioavailability was 3696 threefold compared with that of an orally dosed Taxol (R). The 3697 single-pass intestinal perfusion studies (SPIP) showed that the 3698 intestinal absorption of micelles was via endocytosis involving a 3699 saturable process and a p-glycoprotein (P-gp)-independent way. All 3700 these indicated that the DHC micelles might be a promising tool for 3701 oral delivery of poorly water-soluble drugs. (C) 2010 Wiley-Liss, Inc. 3702 and the American Pharmacists Association J Pharm Sci 99:4543-4553, 2010 3703 SN 0022-3549 3704 PD NOV 3705 PY 2010 3706 VL 99 3707 IS 11 3708 BP 4543 3709 EP 4553 3710 DI 10.1002/jps.22159 3711 UT ISI:000283477100012 3712 PT J 3713 AU Huang, XF 3714 Yang, YM 3715 Zhu, J 3716 Liu, JH 3717 AF Huang, Xingfu 3718 Yang, Yanmin 3719 Zhu, Jun 3720 Liu, Jinhan 3721 TI A Single Ethanoyl Changes the Effects on HERG K+ Channel: Comparative 3722 Effects of Acehytisine Hydrochloride and Guanfu Base G 3723 SO CIRCULATION 3724 CT World Congress of Cardiology Scientific Sessions 3725 CY JUN 16-19, 2010 3726 CL Beijing, PEOPLES R CHINA 3727 SN 0009-7322 3728 PD JUL 13 3729 PY 2010 3730 VL 122 3731 IS 2 3732 BP P1106 3733 UT ISI:000279801703274 3734 PT J 3735 AU Xiong, F 3736 Wang, H 3737 Geng, KK 3738 Gu, N 3739 Zhu, JB 3740 AF Xiong, Fei 3741 Wang, Hao 3742 Geng, Kun-kun 3743 Gu, Ning 3744 Zhu, Jia-bi 3745 TI Optimized Preparation, Characterization and Biodistribution in Heart 3746 of Breviscapine Lipid Emulsion 3747 SO CHEMICAL & PHARMACEUTICAL BULLETIN 3748 AB Breviscapine is a Traditional Chinese Medicine treating cardiovascular 3749 diseases by promoting blood circulation and removing blood stasis. The 3750 major active component of breviscapine has low aqueous solubility, poor 3751 chemical stability, short biological half-life and rapid elimination 3752 rate from the plasma. The use of a lipid emulsion formulation containing 3753 breviscapine might improve chemical stability, increase drug loading, 3754 exhibit sustained release profile. In the present study, we developed 3755 an optimized formulation and technological method for the preparation 3756 of sterile and stable breviscapine lipid emulsion (Bre-LE) for 3757 intravenous infusion. The average particle size, polydispersity index, 3758 zeta potential, stability constant (K-s) value and content of final 3759 product were (225.3 +/- 8.8)nm, 0.221 +/- 0.020, (-29.6 +/- 1.5) mV, 3760 (24.3 +/- 2.9)% and (94.5 +/- 0.6)% respectively (n=3). The results 3761 of in vitro release experiment suggest that lipid emulsion as 3762 breviscapine carrier showed a desirable sustained release profile. 3763 Dilution stability and long-term stability were also researched in the 3764 present paper. The results show the carrier could protect drug from 3765 degradation after dilution by phosphate buffered saline and fetal calf 3766 serum. And Bre-LE was stable for up to 6 months at room temperature 3767 storage condition. The biodistribution of drug in heart of mice 3768 increased dramatically after encapsulation into lipid emulsion which 3769 was beneficial to heart disease therapy. 3770 SN 0009-2363 3771 PD NOV 3772 PY 2010 3773 VL 58 3774 IS 11 3775 BP 1455 3776 EP 1460 3777 UT ISI:000283522300006 3778 PT J 3779 AU Cao, P 3780 Yu, JM 3781 Lu, WG 3782 Cai, XT 3783 Wang, ZG 3784 Gu, ZH 3785 Zhang, JA 3786 Ye, TM 3787 Wang, M 3788 AF Cao, Peng 3789 Yu, Jiemiao 3790 Lu, Wuguang 3791 Cai, Xueting 3792 Wang, Zhigang 3793 Gu, Zhenhua 3794 Zhang, Juan 3795 Ye, Tingmei 3796 Wang, Min 3797 TI Expression and Purification of an Antitumor-Analgesic Peptide from the 3798 Venom of Mesobuthus martensii Karsch by Small Ubiquitin-Related 3799 Modifier Fusion in Escherichia coli 3800 SO BIOTECHNOLOGY PROGRESS 3801 AB To prevent protein aggregation, some proteins are usually expressed 3802 as fusion proteins from which target proteins can be released by 3803 proteolytic or chemical reagents. In this report, small 3804 ubiquitin-related modifier (SUMO) linked with a hexa-histidine tag was 3805 used as a fusion partner for the antitumor-analgesic peptide from the 3806 venom of Buthus martensii (Karsch) scorpion (AGAP). The optimal 3807 expression level of the soluble fusion protein, SUMO-AGAP, was up to 3808 40% of the total cellular protein. The fusion protein was purified by 3809 Ni-NTA affinity chromatography and cleaved by a SUMO-specific protease 3810 (Ulp1) to obtain the recombinant AGAP (rAGAP), which was further 3811 purified by Ni-NTA affinity chromatography. The purified final product 3812 was >95% pure by SDS-PAGE stained with Coomassie brilliant blue R-250. 3813 Mass spectroscopic analysis indicated the protein to be 7142.63 Dalton, 3814 which equaled the theoretically expected mass. N-terminal sequencing 3815 of rAGAP showed the sequence corresponded to the native protein. MTT 3816 assay indicated the rAGAP could significantly inhibit the 3817 proliferation of Jurkat and Hut 78 T lymphoma cell lines. The further 3818 writhing experiment showed that the rAGAP had an intensive analgesic 3819 effect. The expression strategy presented in this study allows 3820 convenient high yield and easy purification of the rAGAP with native 3821 sequences. (C) 2010 American Institute of Chemical Engineers 3822 Biotechnol. Prog., 26: 1240-1244, 2010 3823 SN 8756-7938 3824 PD SEP-OCT 3825 PY 2010 3826 VL 26 3827 IS 5 3828 BP 1240 3829 EP 1244 3830 DI 10.1002/btpr.433 3831 UT ISI:000283482100005 3832 PT J 3833 AU Li, SS 3834 He, H 3835 Chen, Z 3836 Zha, J 3837 Chuong, PH 3838 AF Li Shan-shan 3839 He Hua 3840 Chen Zhe 3841 Zha Jun 3842 Chuong Pham-Huy 3843 TI Fluorescence Study on the Interactions between Carbon Nanotubes and 3844 Bovine Serum Albumin 3845 SO SPECTROSCOPY AND SPECTRAL ANALYSIS 3846 AB As a new family of nanomaterials, carbon nanotubes (CNTs) exhibit 3847 unique properties such as their capacity to penetrate into the cells 3848 and low immunogenicity, which have attracted increasing attention in 3849 biomedical field and make their application in drug and gene transfer 3850 systems being possible. So getting more information about the 3851 interaction of CNTs with biomacromolecules is crucial for further 3852 investigation of CNTs in therapeutic applications. The interaction 3853 between CNTs and BSA under physiological condition was investigated 3854 by fluorescence quenching, synchronous fluorescence and red edge 3855 excitation shift (REES)method. The results showed that CNTs could 3856 significantly decrease the fluorescence intensity of BSA. While the 3857 results of synchronous fluorescence and REES indicated that CNTs almost 3858 had no influence on the conformation of BSA. So the authors concluded 3859 that the mechanism of interaction between CNTs and BSA was non-specific 3860 adsorption. 3861 SN 1000-0593 3862 PD OCT 3863 PY 2010 3864 VL 30 3865 IS 10 3866 BP 2689 3867 EP 2692 3868 DI 10.3964/j.issn.1000-0593(2010)10-2689-04 3869 UT ISI:000283267900023 3870 PT J 3871 AU Li, YJ 3872 Wei, HL 3873 Qi, LW 3874 Chen, J 3875 Ren, MT 3876 Li, P 3877 AF Li, Yan-Jing 3878 Wei, Huan-Li 3879 Qi, Lian-Wen 3880 Chen, Jun 3881 Ren, Mei-Ting 3882 Li, Ping 3883 TI Characterization and identification of saponins in Achyranthes 3884 bidentata by rapid-resolution liquid chromatography with electrospray 3885 ionization quadrupole time-of-flight tandem mass spectrometry 3886 SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY 3887 AB A rapid-resolution liquid chromatography (RRLC) method coupled with 3888 electrospray ionization quadrupole time-of-flight tandem mass 3889 spectrometry (Q-TOF MS/MS) has been developed for analysis of 3890 oleanane-type triterpenoid saponins in Achyranthes bidentata. 3891 Collision-induced dissociation techniques were used to fragment the 3892 precursor molecular ions and the resulting product ions. A 3893 retro-Diels-Alder rearrangement from the oleanane aglycone skeleton 3894 in the MS/MS process yielded characteristic fragment ions in positive 3895 ion mode. These characteristic ions were helpful in predicting the 3896 aglycone structure. Losses of monosaccharide sequences, presence of 3897 sugar-chain fragment ions, and cleavage of CO2 were observed for 3898 important information on sugar types and attachment sequences. 3899 Fragmentation rules of three major groups of saponins from A. bidentata 3900 were summarized, and the possible fragmentation pathways were 3901 proposed. A total of 22 compounds including both the target and unknown 3902 oleanane-type triterpenoid saponins were rapidly screened and 3903 predicted in the herbal extract by the developed method. The RRLC-Q-TOF 3904 MS/MS method has provided a powerful approach for rapid separation, 3905 target screening and structural elucidation of oleanane-type saponins, 3906 and also opened perspectives for similar studies on other herbal 3907 medicines. Copyright (C) 2010 John Wiley & Sons, Ltd. 3908 SN 0951-4198 3909 PD OCT 3910 PY 2010 3911 VL 24 3912 IS 20 3913 BP 2975 3914 EP 2985 3915 DI 10.1002/rcm.4728 3916 UT ISI:000283103000007 3917 PT J 3918 AU Qi, J 3919 Xu, DR 3920 Zhou, YF 3921 Qin, MJ 3922 Yu, BY 3923 AF Qi, Jin 3924 Xu, Deran 3925 Zhou, Yi-Feng 3926 Qin, Min-Jian 3927 Yu, Bo-Yang 3928 TI New features on the fragmentation patterns of homoisoflavonoids in 3929 Ophiopogon japonicus by high-performance liquid 3930 chromatography/diode-array detection/electrospray ionization with 3931 multi-stage tandem mass spectrometry (vol 24, pg 2193, 2010) 3932 SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY 3933 SN 0951-4198 3934 PD OCT 3935 PY 2010 3936 VL 24 3937 IS 20 3938 BP 3076 3939 EP 3077 3940 DI 10.1002/rcm.4723 3941 UT ISI:000283103000019 3942 PT J 3943 AU Tang, H 3944 Guo, QA 3945 Zhang, C 3946 Zhu, J 3947 Yang, H 3948 Zou, YL 3949 Yan, Y 3950 Hong, D 3951 Sou, T 3952 Yan, XM 3953 AF Tang, Hui 3954 Guo, Qiang 3955 Zhang, Chao 3956 Zhu, Jun 3957 Yang, Hui 3958 Zou, Yun-Lian 3959 Yan, Yan 3960 Hong, Dong 3961 Sou, Tao 3962 Yan, Xin-Min 3963 TI Identification of an intermediate signature that marks the initial 3964 phases of the colorectal adenoma-carcinoma transition 3965 SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 3966 AB The colorectal adenoma-carcinoma sequence describes the stepwise 3967 progression from normal to dysplastic epithelium and then to carcinoma. 3968 Only a small proportion of colorectal adenomas (CRAs) progress to 3969 colorectal carcinomas (CRCs). Endoscopic intervention is currently 3970 being used on patients with high grade dysplasia CRAs, with diameters 3971 of >1 cm, or villous components of >25% who are at higher risk than 3972 other CRA sufferers. During the process, biopsy samples are taken for 3973 conventional histological diagnosis, but poor pathomorphological 3974 sensitivity and specificity greatly limit the diagnostic accuracy. 3975 Unfortunately, there are no reliable molecular criteria available that 3976 can predict the potential development of CRA to CRC. Gene expression 3977 profiles of normal colorectal mucosa (NOR), CRA and different Dukes' 3978 stages of CRC biopsy specimens, which represent the gradual progress 3979 of the CRA to CRC sequence, were determined by Affymetrix technology. 3980 Representative regulated genes were further analyzed by quantitative 3981 real-time PCR (qRT-PCR) and immunohistochemistry (IHC). 3982 Intersectional analyses of discriminative expression signatures of CRC 3983 vs. CRA and CRA vs. NOR allowed the identification of an intermediate 3984 signature of 463 probe sets (psets) that mark the NOR -> CRA -> CRC 3985 progression. This signature represents a reservoir of candidate 3986 markers for the early diagnosis of higher-risk CRA, thus allowing for 3987 timely therapeutic intervention and more selective treatment. A 3988 further 279 CRC-specific psets pointing to the malignant transition 3989 from CRA to CRC were identified and these could represent potential 3990 therapeutic targets for CRC. The reliability of the results was further 3991 confirmed by qRT-PCR and IHC analyses of the 4-gene sets randomly 3992 selected from the 463 psets. 3993 SN 1107-3756 3994 PD NOV 3995 PY 2010 3996 VL 26 3997 IS 5 3998 BP 631 3999 EP 641 4000 DI 10.3892/ijmm_00000508 4001 UT ISI:000283203200001 4002 PT J 4003 AU Xiong, Y 4004 Shen, L 4005 Liu, KJ 4006 Tso, P 4007 Xiong, YQ 4008 Wang, GJ 4009 Woods, SC 4010 Liu, M 4011 AF Xiong, Ye 4012 Shen, Ling 4013 Liu, Kristina J. 4014 Tso, Patrick 4015 Xiong, Yuqing 4016 Wang, Guangji 4017 Woods, Stephen C. 4018 Liu, Min 4019 TI Antiobesity and Antihyperglycemic Effects of Ginsenoside Rb1 in Rats 4020 SO DIABETES 4021 AB OBJECTIVE Obesity and type 2 diabetes are national and worldwide 4022 epidemics. Because currently available antiobesity and antidiabetic 4023 drugs have limited efficacy and/or safety concerns, identifying new 4024 medicinal agents, such as ginsenoside Rb1 (Rb1) as reported here, 4025 offers exciting possibilities for future development of successful 4026 antiobesity and antidiabetic therapies. 4027 RESEARCH DESIGN AND METHODS Changes in feeding behavior after acute 4028 intraperitoneal administration of Rb1 and the effects of 4029 intraperitoneal Rb1 for 4 weeks on body weight, energy expenditure, 4030 and glucose tolerance in high-fat diet (HFD)-induced obese rats were 4031 assessed. We also examined the effects of Rb1 on signaling pathways 4032 and neuropeptides in the hypothalamus. 4033 RESULTS Acute intraperitoneal Rb1 dose-dependently suppressed food 4034 intake without eliciting signs of toxicity. This inhibitory effect on 4035 feeding may be mediated by central mechanisms because Rb1 stimulated 4036 c-Fos expression in brain areas involved in energy homeostasis. 4037 Consistent with this, Rb1 activated the phosphatidylinositol 4038 3-kinase/Airt signaling pathway and inhibited NPY gene expression in 4039 the hypothalamus. Four-week administration of Rb1 significantly 4040 reduced food intake, body weight gain, and body fat content and 4041 increased energy expenditure in HFD-induced obese rats. Rb1 also 4042 significantly decreased fasting blood glucose and improved glucose 4043 tolerance, and these effects were greater than those observed in 4044 pair-fed rats, suggesting that although Rb1's antihyperglycemic effect 4045 is partially attributable to reduced food intake and body weight; there 4046 may be additional effects of Rb1 on glucose homeostasis. 4047 CONCLUSIONS These results identify Rb1 as an antiobesity and 4048 antihyperglycemic agent. Diabetes 59:2505-2512, 2010 4049 SN 0012-1797 4050 PD OCT 4051 PY 2010 4052 VL 59 4053 IS 10 4054 BP 2505 4055 EP 2512 4056 DI 10.2337/db10-0315 4057 UT ISI:000283205700023 4058 PT J 4059 AU Lai, YS 4060 Shen, LH 4061 Zhang, ZZ 4062 Liu, WQ 4063 Zhang, YH 4064 Ji, H 4065 Tian, J 4066 AF Lai, Yisheng 4067 Shen, Lihong 4068 Zhang, Zhenzhen 4069 Liu, Wenqing 4070 Zhang, Yihua 4071 Ji, Hui 4072 Tian, Jide 4073 TI Synthesis and biological evaluation of furoxan-based nitric 4074 oxide-releasing derivatives of glycyrrhetinic acid as 4075 anti-hepatocellular carcinoma agents 4076 SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 4077 AB A series of novel furoxan-based nitric oxide (NO)-releasing 4078 derivatives of glycyrrhetinic acid (GA) were designed, synthesized, 4079 and evaluated for their in vitro cytotoxicity against human 4080 hepatocellular carcinoma (HCC) and non-tumor liver cells. Five 4081 furoxan/GA hybrids, 7b-d, 7f, and 7g, displayed potent cytotoxicity 4082 against HCC cells (IC50: 0.25-1.10 mu M against BEL-7402 cells and 4083 1.32-6.78 mu M against HepG2 cells), but had a little effect on the 4084 growth of LO2 cells, indicating that these compounds had selective 4085 cytotoxicity against HCC cells. Furthermore, these compounds produced 4086 high concentrations of NO in HCC cells, but low in LO2 cells and 4087 treatment with hemoglobin partially reduced the cytotoxicity of the 4088 hybrid in HCC cells. Apparently, the high concentrations of NO produced 4089 by NO donor moieties and the bioactivity of GA synergistically 4090 contribute to the cytotoxicity, but the NO is a major player against 4091 HCC cells in vitro. Potentially, our findings may aid in the design 4092 of new chemotherapeutic reagents for the intervention of human HCC at 4093 clinic. (C) 2010 Elsevier Ltd. All rights reserved. 4094 SN 0960-894X 4095 PD NOV 15 4096 PY 2010 4097 VL 20 4098 IS 22 4099 BP 6416 4100 EP 6420 4101 DI 10.1016/j.bmcl.2010.09.070 4102 UT ISI:000283052900014 4103 PT J 4104 AU Hu, R 4105 Saw, CLL 4106 Yu, R 4107 Kong, ANT 4108 AF Hu, Rong 4109 Saw, Constance Lay-Lay 4110 Yu, Rong 4111 Kong, Ah-Ng Tony 4112 TI Regulation of NF-E2-Related Factor 2 Signaling for Cancer 4113 Chemoprevention: Antioxidant Coupled with Antiinflammatory 4114 SO ANTIOXIDANTS & REDOX SIGNALING 4115 AB Cancer chemoprevention is a process of using either natural or 4116 synthetic compounds to reduce the risk of developing cancer. 4117 Observations that NF-E2-related factor 2 (Nrf2)-deficient mice lack 4118 response to some chemopreventive agents point to the important role 4119 of Nrf2 in chemoprevention. Nrf2 is a member of basic-leucine zipper 4120 transcription factor family and has been shown to regulate gene 4121 expression by binding to a response element, antioxidant responsive 4122 element. It is generally believed that activation of Nrf2 signaling 4123 is an adaptive response to the environmental and endogenous stresses. 4124 Under homeostatic conditions, Nrf2 is suppressed by association with 4125 Kelch-like ECH-associated protein 1 (Keap1), but is stimulated upon 4126 exposure to oxidative or electrophilic stress. Once activated, Nrf2 4127 translocates into nuclei and upregulates a group of genes that act in 4128 concert to combat oxidative stress. Nrf2 is also shown to have 4129 protective function against inflammation, a pathological process that 4130 could contribute to carcinogenesis. In this review, we will discuss 4131 the current progress in the study of Nrf2 signaling, in particular, 4132 the mechanisms of Nrf2 activation by chemopreventive agents. We will 4133 also discuss some of the potential caveats of Nrf2 in cancer treatment 4134 and future opportunity and challenges on regulation of Nrf2-mediated 4135 antioxidant and antiinflammatory signaling in the context of cancer 4136 prevention. Antioxid. Redox Signal. 13, 1679-1698. 4137 SN 1523-0864 4138 PD DEC 4139 PY 2010 4140 VL 13 4141 IS 11 4142 BP 1679 4143 EP 1698 4144 DI 10.1089/ars.2010.3276 4145 UT ISI:000283053100006 4146 PT J 4147 AU Xie, YA 4148 Hao, HP 4149 Kang, A 4150 Liang, Y 4151 Xie, T 4152 Sun, SQ 4153 Dai, C 4154 Zheng, XA 4155 Xie, L 4156 Li, JA 4157 Wang, GJ 4158 AF Xie, Yuan 4159 Hao, Haiping 4160 Kang, An 4161 Liang, Yan 4162 Xie, Tong 4163 Sun, Shiqing 4164 Dai, Chen 4165 Zheng, Xiao 4166 Xie, Lin 4167 Li, Juan 4168 Wang, Guangji 4169 TI Integral pharmacokinetics of multiple lignan components in normal, 4170 CCl4-induced hepatic injury and hepatoprotective agents pretreated 4171 rats and correlations with hepatic injury biomarkers 4172 SO JOURNAL OF ETHNOPHARMACOLOGY 4173 AB Although pharmacokinetic alternations by hepatic injury have been 4174 extensively studied, little is known about the potential influence of 4175 hepatoprotective agent's treatment. This study was aimed to 4176 investigate the holistic pharmacokinetics of multiple lignans, CYP3A 4177 regulations, and their correlations with hepatic injury biomarkers, 4178 in hepatic Injured rats pretreated with or without schisandra lignan 4179 extract (SLE) and dimethyl-diphenyl-bicarboxylate (DDB). Integral 4180 pharmacokinetics of multiple lignans based on an AUC-weighting 4181 approach was determined in normal, CCl4 induced hepatic injury rats 4182 pretreated with or without SLE and DDB Protein expression and 4183 activities of CYP3A were determined Pharmacokinetic parameters and 4184 CYP3A activities were correlated with serum alanine aminotransferase 4185 (ALT) and aspartate aminotransferase (AST) levels. CCl4 induced acute 4186 hepatic injury resulted in a nearly 8-fold enhancement of integral 4187 plasma exposures of multiple lignans, which was caused by the 4188 significant down-regulation of CYP3A. SLE and DDB pretreatment 4189 exhibited potent hepatoprotective effects, accompanied with the 4190 restored expression and activity of CYP3A, and the recovery of the 4191 respective and integral pharmacokinetics of lignans components. The 4192 integral AUC(0-tn) and CYP3A activities correlated well with ALT and 4193 AST. This study suggested that the pharmacokinetic regulating effects 4194 of hepatoprotective agent's on themselves and co-prescribed drugs 4195 should be of concern, and hepatic injury biomarkers may serve as good 4196 predictors (C) 2010 Elsevier Ireland Ltd. All rights reserved. 4197 SN 0378-8741 4198 PD SEP 15 4199 PY 2010 4200 VL 131 4201 IS 2 4202 BP 290 4203 EP 299 4204 DI 10.1016/j.jep.2010.06.038 4205 UT ISI:000282709100008 4206 PT J 4207 AU Cheng, YW 4208 Wang, YL 4209 Zhang, YH 4210 Peng, SX 4211 Chiou, GCY 4212 AF Cheng, Yu-Wen 4213 Wang, Yu-Liang 4214 Zhang, Yi-Hua 4215 Peng, Si-Xun 4216 Chiou, George C. Y. 4217 TI Proliferation of retinal pigment epithelial cells induced by 4218 (R,R)-XY-10 and (S,S)-XY-10 and their action mechanisms 4219 SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY 4220 AB AIM: To investigate the mechanism of proliferation effect induced by 4221 (R,R)-XY-10 and (S,S)-XY-10 on retinal pigmented epithelial cells 4222 (ARPE-19). 4223 METHODS: Human retinal pigmented epithelial cells (ARPE-19) and human 4224 umbilical vein endothelial cells (HUVECs) were used to investigate the 4225 effect of (R,R)-XY-10 and (S,S)-XY-10 on cell growth, and their 4226 mechanisms of proliferative action by using ERK, AKT, PI3K, Protein 4227 kinase C (PKC) and Nitric oxide synthase (NOS) inhibitors. 4228 RESULTS: (R,R)-XY-10 and (S,S)-XY-10 dose-dependently increased 4229 ARPE-19 cell proliferation, but not on HUVECs. When treated with 4230 proliferative inhibitors, H-7 (5 mu mol/L), hyperidn (20 mu mol/L), 4231 PD98059 (2 mu mol/L), LY294002 (50 mu mol/L), SH-5 (10 mu mol/L) and 4232 L-NAME (100 mu mol/L), the proliferative effect was reduced by H-7, 4233 hyperidn, PD98059 and LY294002, but not by SH-5 and L-NAME. 4234 CONCLUSION: (R,R)-XY-10 and (S,S)-XY-10 can induce cell proliferation 4235 through MAPK and PI3K dependent pathway. 4236 SN 1672-5123 4237 PD MAR 18 4238 PY 2010 4239 VL 3 4240 IS 1 4241 BP 9 4242 EP 13 4243 UT ISI:000282934100003 4244 PT J 4245 AU Ten, SC 4246 Gu, SY 4247 Niu, YF 4248 An, XF 4249 Yan, M 4250 He, M 4251 AF Ten, Shi-Chao 4252 Gu, Shou-Yong 4253 Niu, Yun-Fei 4254 An, Xiao-Fei 4255 Yan, Ming 4256 He, Ming 4257 TI Central Administration of Kisspeptin-10 Inhibits Water and Sodium 4258 Excretion of Anesthetized Male Rats and the Involvement of Arginine 4259 Vasopressin 4260 SO ENDOCRINE RESEARCH 4261 AB Aim. To investigate the effect of hypothalamus kisspeptin on water and 4262 sodium excretion and the possible mechanism. Method. The 4263 intracerebroventricular (icv) administration and radioimmunoassay 4264 were used to observe the effect of kisspeptin-10 on urine flow, sodium 4265 and potassium excretion, plasma arginine vasopressin (AVP), and atrial 4266 natriuretic peptide (ANP) concentrations in anesthetized male rats. 4267 The mediation of renal sympathetic nerve was also investigated by 4268 studies conducted on rats with bilateral renal sympathetic 4269 denervation. Results. The urine flow, sodium excretion, and free water 4270 clearance decreased significantly by icv injection of 5 nmol 4271 kisspeptin-10 (p < 0.05) from 30 to 60 min post-injection. Meanwhile, 4272 plasma AVP concentrations increased significantly 30 min after the icv 4273 injection of 5 nmol kisspeptin-10 (p < 0.05), whereas the equal dose 4274 of kisspeptin-10 did not significantly change plasma ANP 4275 concentrations. The mean arterial blood pressure, heart rate, and 4276 potassium excretion did not significantly change during the 4277 experiment. Furthermore, pretreatment with 5 nmol kisspeptin-10 could 4278 still significantly decrease urine flow and sodium excretion in renal 4279 sympathetic denervated rats. Conclusion. Central administration of 4280 kisspeptin-10 could inhibit sodium excretion and urine flow in 4281 anesthetized male rats, which is probably mediated by increasing the 4282 plasma AVP concentration and is independent of plasma ANP concentration 4283 and renal sympathetic nerve activity. 4284 SN 0743-5800 4285 PY 2010 4286 VL 35 4287 IS 3 4288 BP 128 4289 EP 136 4290 DI 10.3109/07435801003769995 4291 UT ISI:000282885600004 4292 PT J 4293 AU Hao, HP 4294 Lai, L 4295 Zheng, CN 4296 Wang, QO 4297 Yu, G 4298 Zhou, XY 4299 Wu, LA 4300 Gong, P 4301 Wang, GJ 4302 AF Hao, Haiping 4303 Lai, Li 4304 Zheng, Chaonan 4305 Wang, Qiong 4306 Yu, Guo 4307 Zhou, Xueyan 4308 Wu, Liang 4309 Gong, Ping 4310 Wang, Guangji 4311 TI Microsomal Cytochrome P450-Mediated Metabolism of Protopanaxatriol 4312 Ginsenosides: Metabolite Profile, Reaction Phenotyping, and 4313 Structure-Metabolism Relationship 4314 SO DRUG METABOLISM AND DISPOSITION 4315 AB Although the biotransformation of ginsenosides in the gastrointestinal 4316 tract has been extensively studied, much less is known about hepatic 4317 cytochrome P450 (P450)-catalyzed metabolism. The major aims of this 4318 study were to clarify the metabolic pathway and P450 isoforms involved 4319 and to explore the structure-metabolism relationship of 4320 protopanaxatriol (PPT)-type ginsenosides in hepatic microsomes. 4321 Efficient depletion of ginsenoside Rh1, Rg2, Rf, and PPT was found, 4322 whereas the elimination of Re and Rg1, characterized by a glucose 4323 substitution at the C20 hydroxy group, was negligible in microsomal 4324 incubation systems. Based on high-performance liquid chromatography 4325 hybrid ion trap and time-of-flight mass spectrometry analysis, the 4326 oxygenation metabolism on the C20 aliphatic branch chain was identified 4327 as the predominant metabolic pathway of PPT ginsenosides in both human 4328 and rat hepatic microsomes. By a comparison with authentic standards, 4329 the C24-25 double bond was identified as one of the oxygenation sites 4330 to produce the metabolites of C20-24 epoxide (ocotillol-type 4331 ginsenosides). Both chemical inhibition and human recombinant P450 4332 isoform assays indicated that CYP3A4 was the predominant isozyme 4333 responsible for the oxygenation metabolism of PPT ginsenosides. Enzyme 4334 kinetic evaluations in rat and human hepatic microsomes and human 4335 recombinant CYP3A4 isozyme incubation systems showed generally 4336 consistent results in that the intrinsic clearance ranked as Rf <= Rg2 4337 < Rh1 < PPT, closely correlating with logP values and the number of 4338 glycosyl substitutions. Results obtained from this study suggest that 4339 CYP3A4-catalyzed oxygenation metabolism plays an important role in the 4340 hepatic disposition of ginsenosides and that glycosyl substitution, 4341 especially at the C20 hydroxy group, determines their intrinsic 4342 clearances by CYP3A4. 4343 SN 0090-9556 4344 PD OCT 4345 PY 2010 4346 VL 38 4347 IS 10 4348 BP 1731 4349 EP 1739 4350 DI 10.1124/dmd.110.033845 4351 UT ISI:000281969200015 4352 PT J 4353 AU Liang, Y 4354 Hao, HP 4355 Xie, L 4356 Kang, A 4357 Xie, T 4358 Zheng, XA 4359 Dai, C 4360 Hao, K 4361 Sheng, LS 4362 Wang, GJ 4363 AF Liang, Yan 4364 Hao, Haiping 4365 Xie, Lin 4366 Kang, An 4367 Xie, Tong 4368 Zheng, Xiao 4369 Dai, Chen 4370 Hao, Kun 4371 Sheng, Longsheng 4372 Wang, Guangji 4373 TI Development of a Systematic Approach to Identify Metabolites for Herbal 4374 Homologs Based on Liquid Chromatography Hybrid Ion Trap Time-of-Flight 4375 Mass Spectrometry: Gender-Related Difference in Metabolism of 4376 Schisandra Lignans in Rats 4377 SO DRUG METABOLISM AND DISPOSITION 4378 AB Metabolic research for herbal medicine (HM) is a formidable task, which 4379 is still in its infancy due to complicated components in HM, complex 4380 metabolic pathways, and lack of authentic standards. The present work 4381 contributes to the development of a powerful technical platform to 4382 rapidly identify and classify metabolites of herbal components based 4383 on a liquid chromatography hybrid ion trap time-of-flight mass 4384 spectrometry. Taking Schisandra lignans extract as an example, the 4385 metabolic studies were completed both in vitro and in vivo. In the in 4386 vitro study, metabolites for five representative Schisandra lignans 4387 were identified and structurally characterized. The major metabolic 4388 pathways were summed as demethylation, hydroxylation, and 4389 demethylation and hydroxylation. In the in vivo study, 44 metabolites 4390 were detected in rat urine. These metabolites were identified and 4391 classified rapidly according to the metabolic rules obtained in the 4392 in vitro studies, and hydroxylation was confirmed as the primacy 4393 metabolic pathway for lignans in rat urine. In addition, "relative 4394 cumulative excretion" (RCE) for the metabolites in female and male rats 4395 were calculated according to their relative intensities in the urine 4396 samples collected at 0 to 12, 12 to 24, and 24 to 36 h. As a result, 4397 great gender-related difference on RCE was observed. For most 4398 metabolites, RCE in female rats was significantly lower than that in 4399 male rats. In conclusion, the presently developed methodology and 4400 approach on metabolic research for Schisandra lignans will find its 4401 wide use in metabolic studies for herbal medicines. 4402 SN 0090-9556 4403 PD OCT 4404 PY 2010 4405 VL 38 4406 IS 10 4407 BP 1747 4408 EP 1759 4409 DI 10.1124/dmd.110.033373 4410 UT ISI:000281969200017 4411 PT J 4412 AU Liu, YT 4413 Hao, HP 4414 Xie, HG 4415 Lai, L 4416 Wang, QO 4417 Liu, CX 4418 Wang, GJ 4419 AF Liu, Yi-Tong 4420 Hao, Hai-Ping 4421 Xie, Hong-Guang 4422 Lai, Li 4423 Wang, Qiong 4424 Liu, Chang-Xiao 4425 Wang, Guang-Ji 4426 TI Extensive Intestinal First-Pass Elimination and Predominant Hepatic 4427 Distribution of Berberine Explain Its Low Plasma Levels in Rats 4428 SO DRUG METABOLISM AND DISPOSITION 4429 AB Berberine, one of the most commonly used natural products, exhibits 4430 a poor plasma concentration-effect relationship whose underlying 4431 mechanisms remain largely unclear. This study was designed to test the 4432 hypothesis that extensive first-pass elimination and abundant tissue 4433 distribution of berberine may be its specific pharmacokinetic 4434 properties. For that, four different dosing routes, intragastric, 4435 intraduodenal, intraportal, and intravenous, were used to investigate 4436 the gastric, intestinal, and hepatic first-pass elimination of 4437 berberine. After intragastric dosing, approximately half of berberine 4438 ran intact through the gastrointestinal tract and another half was 4439 disposed of by the small intestine, leading to an extremely low extent 4440 of absolute oral bioavailability in rats (0.36%). Moreover, the major 4441 berberine metabolites were identified and quantified in rat enterocyte 4442 S9 fractions, portal vein plasma, and intestinal perfusates; plasma 4443 concentrations and tissue distribution of berberine and its major 4444 metabolites were determined as well. Data indicated that M1, M2 4445 glucuronide, and M3 were the major metabolites generated from the small 4446 intestine and that there was a 70-fold increase in the ratio of the 4447 area under the concentration-time curve value for berberine (liver 4448 versus plasma). We conclude that intestinal first-pass elimination of 4449 berberine is the major barrier of its oral bioavailability and that 4450 its high extraction and distribution in the liver could be other 4451 important factors that lead to its low plasma levels in rats. 4452 SN 0090-9556 4453 PD OCT 4454 PY 2010 4455 VL 38 4456 IS 10 4457 BP 1779 4458 EP 1784 4459 DI 10.1124/dmd.110.033936 4460 UT ISI:000281969200020 4461 PT J 4462 AU Hao, C 4463 Zhang, YH 4464 Jiang, YW 4465 Ma, DW 4466 AF Hao Chao 4467 Zhang Yihua 4468 Jiang Yongwen 4469 Ma Dawei 4470 TI CuBr/N,N-Dimethylglycine-Catalyzed Coupling Reaction of 4471 2-Chlorotrifluoroacetanilides with Phenols at Mild Conditions 4472 SO CHINESE JOURNAL OF CHEMISTRY 4473 AB The ortho-substituent effect directed by the CF3CONH group exists in 4474 CuBr/N,N-dimethylglycine-catalyzed diaryl ether formation from 4475 o-chlorotrifluoroacetanilides and phenols, leading to this coupling 4476 reaction proceeding at 80 degrees C to afford a wide range of diaryl 4477 ethers. The halogen-exchange also plays an important role in this 4478 transformation because adding potassium iodide is essential for 4479 complete conversion. 4480 SN 1001-604X 4481 PD SEP 4482 PY 2010 4483 VL 28 4484 IS 9 4485 BP 1645 4486 EP 1650 4487 DI 10.1002/cjoc.201090279 4488 UT ISI:000282998700022 4489 PT J 4490 AU Tian, HY 4491 Wang, L 4492 Zhang, XQ 4493 Wang, Y 4494 Zhang, DM 4495 Jiang, RW 4496 Liu, Z 4497 Liu, JS 4498 Li, YL 4499 Ye, WC 4500 AF Tian, Hai-Yan 4501 Wang, Lei 4502 Zhang, Xiao-Qi 4503 Wang, Ying 4504 Zhang, Dong-Mei 4505 Jiang, Ren-Wang 4506 Liu, Zhong 4507 Liu, Jun-Shan 4508 Li, Yao-Lan 4509 Ye, Wen-Cai 4510 TI Bufogargarizins A and B: Two Novel 19-Norbufadienolides with 4511 Unprecedented Skeletons from the Venom of Bufo bufo gargarizans 4512 SO CHEMISTRY-A EUROPEAN JOURNAL 4513 SN 0947-6539 4514 PY 2010 4515 VL 16 4516 IS 36 4517 BP 10989 4518 EP 10993 4519 DI 10.1002/chem.201000847 4520 UT ISI:000283015500013 4521 PT J 4522 AU Jiang, B 4523 Zeng, Y 4524 Li, MJ 4525 Xu, JY 4526 Zhang, YN 4527 Wang, QJ 4528 Sun, NY 4529 Lu, T 4530 Wu, XM 4531 AF Jiang, Bo 4532 Zeng, Yi 4533 Li, Meng-Jie 4534 Xu, Jin-Yi 4535 Zhang, Yong-Na 4536 Wang, Qiu-Juan 4537 Sun, Ni-Yue 4538 Lu, Tao 4539 Wu, Xiao-Ming 4540 TI Design, Synthesis, and Biological Evaluation of 4541 1,5-Diaryl-1,2,4-triazole Derivatives as Selective Cyclooxygenase-2 4542 Inhibitors 4543 SO ARCHIV DER PHARMAZIE 4544 AB A series of 1,5-diaryl-1,2,4-triazole derivatives were synthesized and 4545 evaluated as cyclooxygenase-2 (COX-2) inhibitors. The results of the 4546 preliminary biological assays in vivo showed that eight compounds 5b, 4547 6b, 6c, 7c, 8b, 8d, 9c, and 9d have potent anti-inflammatory activity 4548 (P < 0.01), while compounds 6b, 6c, and 9c exhibit marked potency. 4549 Compound 6c was then selected for further investigation. In the COX 4550 inhibition assay in vitro, compound 6c was identified as a potent and 4551 selective inhibitor of COX-2 (COX-2 IC50 = 0.37 mu M; SI = 0.018), being 4552 equipotent to celecoxib (COX-2 IC50 = 0.26 mu M; SI = 0.015). In a rat 4553 carrageenan-induced paw edema assay, 6c exhibited moderate 4554 anti-inflammatory activity (35% inhibition of inflammation) at 2 h 4555 after administration of 15 mg/kg as an oral dose. A docking study also 4556 revealed that compound 6c binds in the active site of COX-2 in a similar 4557 mode to that of the known selective COX-2 inhibitor SC-558. 4558 SN 0365-6233 4559 PD SEP 4560 PY 2010 4561 VL 343 4562 IS 9 4563 BP 500 4564 EP 508 4565 DI 10.1002/ardp.200900227 4566 UT ISI:000282793400002 4567 PT J 4568 AU A, JY 4569 Qian, SX 4570 Wang, GJ 4571 Yan, B 4572 Zhang, SJ 4573 Huang, Q 4574 Ni, LN 4575 Zha, WB 4576 Liu, LS 4577 Cao, B 4578 Hong, M 4579 Wu, HX 4580 Lu, H 4581 Shi, JA 4582 Li, MJ 4583 Li, J 4584 AF A, Jiye 4585 Qian, Sixuan 4586 Wang, Guangji 4587 Yan, Bei 4588 Zhang, Sujiang 4589 Huang, Qing 4590 Ni, Lingna 4591 Zha, Weibin 4592 Liu, Linsheng 4593 Cao, Bei 4594 Hong, Ming 4595 Wu, Hanxin 4596 Lu, Hua 4597 Shi, Jian 4598 Li, Mengjie 4599 Li, Jianyong 4600 TI Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib 4601 Treatment Show Different Metabolic Responses 4602 SO PLOS ONE 4603 AB The BCR-ABL tyrosine kinase inhibitor imatinib is highly effective for 4604 chronic myeloid leukemia (CML). However, some patients gradually 4605 develop resistance to imatinib, resulting in therapeutic failure. 4606 Metabonomic and genomic profiling of patients' responses to drug 4607 interventions can provide novel information about the in vivo 4608 metabolism of low-molecular-weight compounds and extend our insight 4609 into the mechanism of drug resistance. Based on a multi-platform of 4610 high-throughput metabonomics, SNP array analysis, karyotype and 4611 mutation, the metabolic phenotypes and genomic polymorphisms of CML 4612 patients and their diverse responses to imatinib were characterized. 4613 The untreated CML patients (UCML) showed different metabolic patterns 4614 from those of healthy controls, and the discriminatory metabolites 4615 suggested the perturbed metabolism of the urea cycle, tricarboxylic 4616 acid cycle, lipid metabolism, and amino acid turnover in UCML. After 4617 imatinib treatment, patients sensitive to imatinib (SCML) and patients 4618 resistant to imatinib (RCML) had similar metabolic phenotypes to those 4619 of healthy controls and UCML, respectively. SCML showed a significant 4620 metabolic response to imatinib, with marked restoration of the 4621 perturbed metabolism. Most of the metabolites characterizing CML were 4622 adjusted to normal levels, including the intermediates of the urea 4623 cycle and tricarboxylic acid cycle (TCA). In contrast, neither 4624 cytogenetic nor metabonomic analysis indicated any positive response 4625 to imatinib in RCML. We report for the first time the associated genetic 4626 and metabonomic responses of CML patients to imatinib and show that 4627 the perturbed in vivo metabolism of UCML is independent of imatinib 4628 treatment in resistant patients. Thus, metabonomics can potentially 4629 characterize patients' sensitivity or resistance to drug intervention. 4630 SN 1932-6203 4631 PD OCT 8 4632 PY 2010 4633 VL 5 4634 IS 10 4635 AR e13186 4636 DI 10.1371/journal.pone.0013186 4637 UT ISI:000282676700005 4638 PT J 4639 AU Zhang, HW 4640 Zhang, J 4641 Hu, S 4642 Zhang, ZJ 4643 Zhu, CJ 4644 Ng, SW 4645 Tan, RX 4646 AF Zhang, Hua-Wei 4647 Zhang, Jie 4648 Hu, Sha 4649 Zhang, Zun-Jian 4650 Zhu, Cheng-Jian 4651 Ng, Seik Weng 4652 Tan, Ren-Xiang 4653 TI Ardeemins and Cytochalasins from Aspergillus terreus Residing in 4654 Artemisia annua 4655 SO PLANTA MEDICA 4656 AB Three new alkaloids, 15b-dehydro-5-N-acetylardeemin (3), 4657 10-phenyl-[12]-cytochalasins Z16 (6) andZ17(7), were characterized 4658 from the liquid culture of the endophytic fungus Aspergillus terreus 4659 IFB-E030 along with six known derivatives, 5-N-acetylardeemin (1), 4660 15b-beta-hydroxyl-5-N-acetylardeemin (2), cytochalasin E (4), 4661 rosellichalasin (5), cytochalasins Z11 (8), and Z13 (9). The structures 4662 of the new metabolites were established mainly by a combination of their 4663 1D- and 2D-NMR spectra, single crystal X-ray diffraction, and the 4664 modified Mosher reaction. Biological assays indicated that 4665 cytochalasin Z17 (7) had moderate cytotoxicity against human 4666 nasopharyngeal epidermoid tumor KB cell line with an IC50 value of 26.2 4667 mu M. 4668 SN 0032-0943 4669 PD OCT 4670 PY 2010 4671 VL 76 4672 IS 14 4673 BP 1616 4674 EP 1621 4675 DI 10.1055/s-0030-1249781 4676 UT ISI:000282366800023 4677 PT J 4678 AU Zhang, XY 4679 Qiao, H 4680 Liu, JP 4681 Dong, HJ 4682 Shen, CL 4683 Ni, JM 4684 Shi, YB 4685 Xu, Y 4686 AF Zhang, Xiaoyun 4687 Qiao, Hua 4688 Liu, Jianping 4689 Dong, Haijun 4690 Shen, Chenlin 4691 Ni, Jingman 4692 Shi, Yanbin 4693 Xu, Ying 4694 TI Dihydroartemisinin loaded nanostructured lipid carriers (DHA-NLC): 4695 Evaluation of pharmacokinetics and tissue distribution after 4696 intravenous administration to rats 4697 SO PHARMAZIE 4698 AB A simple and rapid LC-MS/MS method was established for the 4699 determination of dihydroartemisinin (DHA) in plasma and tissues of 4700 rats. Sample preparation was achieved by liquid liquid extraction with 4701 aether and analysis was performed on LC-MS/MS in positive ion mode using 4702 electrospray ionization (ESI) as an interface. Target compounds were 4703 quantified in a single ion-monitoring (SIM) mode. DHA was monitored 4704 at m/z 267.1 and the internal standard finasteride at m/z 305.2. 4705 Chromatography was carried out using a Synergi fusion RP 80 column with 4706 a mixture of ethanol and 0.1% formic acid mixture (75:25) as the mobile 4707 phase. The pharmacokinetics and tissue distribution after intravenous 4708 administration of DHA in nanostructured lipid carrier (NLC) and in 4709 solution were then compared. The mean residence times (MRT) of the 4710 DHA-NLC was much longer than that of the DHA solution. In the tested 4711 organs, the AUC values of the DHA-NLC were higher than that of the DHA 4712 solution in liver, spleen, lung, brain and muscle, and lower than the 4713 DHA solution in heart and kidney. DHA-NLC prepared in this study is 4714 a promising sustained-release and drug-targeting system for antitumor 4715 drugs. It may also allow a reduction in dosage and a decrease in systemic 4716 toxicity. 4717 SN 0031-7144 4718 PD SEP 4719 PY 2010 4720 VL 65 4721 IS 9 4722 BP 670 4723 EP 678 4724 DI 10.1691/ph.2010.0082 4725 UT ISI:000282457400007 4726 PT J 4727 AU Huang, FJ 4728 Wu, T 4729 AF Huang, Feng-Jie 4730 Wu, Tong 4731 TI PURIFICATION AND CHARACTERIZATION OF A NEW PEPTIDE (S-8300) FROM SHARK 4732 LIVER 4733 SO JOURNAL OF FOOD BIOCHEMISTRY 4734 AB S-8300, a small (8200.901 Da) antidiabetic peptide, was purified and 4735 characterized from shark livers (Chiloscyllium plagiosum). It was 4736 isolated by extraction of the water-soluble fraction, dialysis, 4737 ultrafiltration and dicthylaminoethyl Sepharose, Bio-Gel P-10 and fast 4738 protein liquid chromatography monoQ chromatography. The new peptide 4739 (S-8300) contained 17 amino acids and the 15 N-terminal amino acid 4740 residues of S-8300 were 4741 NH2-Met-Leu-Val-Gly-Pro-Ile-Gly-Ala-Ala-Lys-Val-Val-Tyr-Glu-Gln-. 4742 The new peptide was stable at 95C for 30 min and stable between pH 3.0 4743 and 9.0. It was not inactivated by DNase and RNase, but totally 4744 inactivated by trypsin and proteinase K digestion. In addition, S-8300 4745 could remarkably protect the structure integrity and recover the damage 4746 of NIT-1 cell after exposure to the toxin of streptozotocin. Homology 4747 search of NH2-terminal sequence showed that S-8300 was a totally new 4748 protein. 4749 PRACTICAL APPLICATIONS 4750 The experiments suggested that S-8300 could reduce the adverse effect 4751 of beta-cell toxins and protect the structure integrity and mitigate 4752 the damage. S-8300 could markedly decrease the level of fasting plasma 4753 glucose, glycohemoglobin-A1, triglyceride, cholesterol, free fatty 4754 acid and malondialdehyde, increased the activity of superoxide 4755 dismutase and attenuated the injury of beta-cell in pancreatic islet. 4756 Therefore, S-8300 has a significant protective effect on diabetes in 4757 mice. These might indicate that S-8300 could have clinical therapy 4758 significance. 4759 SN 0145-8884 4760 PD OCT 4761 PY 2010 4762 VL 34 4763 IS 5 4764 BP 962 4765 EP 970 4766 DI 10.1111/j.1745-4514.2010.00336.x 4767 UT ISI:000282637300005 4768 PT J 4769 AU Zhipeng, C 4770 Jiabi, Z 4771 Hongxuan, C 4772 Yan-yu, X 4773 Jun, C 4774 Cai, BC 4775 AF Zhipeng, C. 4776 Jiabi, Z. 4777 Hongxuan, C. 4778 Yan-yu, X. 4779 Jun, C. 4780 Cai, Bao-chang 4781 TI Distribution of liposomal bifendate in liver following intravenous 4782 injection in mice 4783 SO JOURNAL OF DRUG TARGETING 4784 AB The purpose of this study was to develop and study the behaviors of 4785 bifendate (DDB) liposome in vivo. DDB liposome was prepared by the 4786 rotary evaporationextrusion method. The particle size, 4787 zeta-potential, encapsulation efficiency (EE), and in vitro drug 4788 release from liposome were determined and the in vivo studies were 4789 tested in mice and rats. The concentrations of DDB in plasma and liver 4790 at different sampling time points were determined by RP-HPLC. The liver 4791 concentration time curves of DDB liposome and free drug solution in 4792 mice were determined, and the pharmacokinetic parameters in rats and 4793 mice were calculated and compared by statistical analysis. The average 4794 liposome diameter was 323 +/- 29 nm (n=3) and the EE was 91.52 +/- 2.38%. 4795 There were significantly different parameters of k10 and area under 4796 the plasma concentrationtime curve (AUC(0-T)) between liposome and 4797 solution. The mean residence time (MRT0-T) in plasma of liposomal 4798 formulation was 3.72 times longer than that of solution. Compared with 4799 solution, DDB liposome delivered about 2.57 times higher DDB into 4800 liver. Thus, an optimum intravenous liposonne formulation for DDB could 4801 be developed as an alternative to the commercial DDB preparations. 4802 SN 1061-186X 4803 PD SEP 4804 PY 2010 4805 VL 18 4806 IS 8 4807 BP 627 4808 EP 636 4809 DI 10.3109/10611861003639788 4810 UT ISI:000281961600006 4811 PT J 4812 AU Li, NG 4813 Shi, ZH 4814 Tang, YP 4815 Yang, JP 4816 Wang, ZJ 4817 Song, SL 4818 Lu, TL 4819 Duan, JA 4820 AF Li, Nian-Guang 4821 Shi, Zhi-Hao 4822 Tang, Yu-Ping 4823 Yang, Jian-Ping 4824 Wang, Zhen-Jiang 4825 Song, Shu-Lin 4826 Lu, Tu-Lin 4827 Duan, Jin-Ao 4828 TI Targeting the Development of Resveratrol as a Chemopreventive Agent 4829 SO DRUG DEVELOPMENT RESEARCH 4830 AB Tumor development consists of several separate, but closely linked, 4831 stages: tumor initiation, promotion, and progression. This long and 4832 complex process provides opportunities for intervention both in 4833 preventing cancer initiation and in treating the neoplasm during its 4834 premalignant stages. Resveratrol, a polyphenolic compound found in 4835 many plant species, including grapes, peanuts, and various herbs, has 4836 recently been investigated intensely for its cancer chemopreventive 4837 property. The present work is an overview of the chemopreventive 4838 mechanisms of resveratrol in anti-initiation, anti-promotion, and 4839 anti-progression. These, together with the low toxicity of 4840 resveratrol, suggest promise for novel chemopreventive agents. 4841 However, the low bioavailability and rapid clearance of resveratrol 4842 from the circulation require the design of new resveratrol-like 4843 chemopreventive agents, the structural modifications and the structure 4844 activity relationship of which are also discussed in this review. Drug 4845 Dev Res 71:335-350, 2010. (C) 2010 Wiley-Liss, Inc. 4846 SN 0272-4391 4847 PD SEP 4848 PY 2010 4849 VL 71 4850 IS 6 4851 BP 335 4852 EP 350 4853 DI 10.1002/ddr.20380 4854 UT ISI:000282539900002 4855 PT J 4856 AU Chen, YJ 4857 Tao, JA 4858 Xiong, F 4859 Zhu, JB 4860 Gu, N 4861 Zhang, YH 4862 Ding, Y 4863 Ge, LA 4864 AF Chen Yue-Jian 4865 Tao Juan 4866 Xiong Fei 4867 Zhu Jia-Bi 4868 Gu Ning 4869 Zhang Yi-Hua 4870 Ding Ye 4871 Ge Liang 4872 TI Synthesis, self-assembly, and characterization of PEG-coated iron 4873 oxide nanoparticles as potential MRI contrast agent 4874 SO DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY 4875 AB Aim: Investigated the self-assembly and characterization of novel 4876 antifouling polyethylene glycol (PEG)-coated iron oxide nanoparticles 4877 as nanoprobes for magnetic resonance imaging (MRI) contrast agent. 4878 Method: Monodisperse oleic acid-coated superparamagnetic iron oxide 4879 cores are synthesized by thermal decomposition of iron oleate. The 4880 self-assembly behavior between iron oxide cores and PEG-lipid 4881 conjugates in water and their characteristics are confirmed by 4882 transmission electron microscope, X-ray diffraction, 4883 thermogravimetric analysis, Fourier transform infrared spectroscopy, 4884 and vibrating sample magnetometer. Result: Dynamic light scattering 4885 shows superparamagnetic iron oxide nanoparticles coated with PEG are 4886 stable in water for pH of 3-10 and ionic strengths up to 0.3 M NaCl, 4887 and are protein resistant in physiological conditions. Additionally, 4888 in vitro MRI study demonstrates the efficient magnetic resonance 4889 imaging contrast characteristics of the iron oxide nanoparticles. 4890 Conclusion: The result indicates that the novel antifouling PEG-coated 4891 superparamagnetic iron oxide nanoparticles could potentially be used 4892 in a wide range of applications such as biotechnology, MRI, and magnetic 4893 fluid hyperthermia. 4894 SN 0363-9045 4895 PD OCT 4896 PY 2010 4897 VL 36 4898 IS 10 4899 BP 1235 4900 EP 1244 4901 DI 10.3109/03639041003710151 4902 UT ISI:000282523500011 4903 PT J 4904 AU Cao, F 4905 Zhang, XL 4906 Ping, QN 4907 AF Cao, Feng 4908 Zhang, Xiaolin 4909 Ping, Qineng 4910 TI New method for ophthalmic delivery of azithromycin by 4911 poloxamer/carbopol-based in situ gelling system 4912 SO DRUG DELIVERY 4913 AB This study focused on preparation and evaluation of a thermosensitive 4914 and mucoadhesive in situ gelling ophthalmic system of azithromycin 4915 (ATM). Poloxamer 407 (P407) and poloxamer 188 (P188) were used as 4916 gelling agents. Addition of Carbopol 974P (CP 974P) to the gelling 4917 systems could increase the solubility of ATM by salt effect and enhance 4918 the mucoadhesive property of the systems. Gelation temperature of these 4919 systems ranged from 31.21-36.31 degrees C depending on the ratio of 4920 P407 and P188. Mucoadhesion force of the system composed of 4921 P407/P188/CP 974P (21/5/0.3%, w/v) was 2.3-fold that without carbopol 4922 974P. Viscosity of the formulation was in a suitable range at 25 degrees 4923 C and pseudoplastic behavior was observed at 35 degrees C. The 4924 formulation exhibited a 24-h sustained release of ATM. In vivo resident 4925 experiments showed AUC(0-12) of ATM in rabbit tears increased by 4926 1.78-fold for in situ gel compared with eye drop. At 12 h, tear 4927 concentrations exceeded minimum inhibitory concentration (MIC) 4928 breakpoint for the most common causative pathogens of bacterial 4929 conjunctivitis by 2.8-fold. Results in vitro and in vivo indicated that 4930 this droppable gel performed better than ATM eye drop did. 4931 SN 1071-7544 4932 PD SEP-OCT 4933 PY 2010 4934 VL 17 4935 IS 7 4936 BP 500 4937 EP 507 4938 DI 10.3109/10717544.2010.483255 4939 UT ISI:000282521100003 4940 PT J 4941 AU Xia, XF 4942 Yang, JA 4943 Li, FH 4944 Li, Y 4945 Zhou, XB 4946 Dai, Y 4947 Wong, STC 4948 AF Xia, Xiaofeng 4949 Yang, Jian 4950 Li, Fuhai 4951 Li, Ying 4952 Zhou, Xiaobo 4953 Dai, Yue 4954 Wong, Stephen T. C. 4955 TI Image-Based Chemical Screening Identifies Drug Efflux Inhibitors in 4956 Lung Cancer Cells 4957 SO CANCER RESEARCH 4958 AB Cancer cells with active drug efflux capability are multidrug resistant 4959 and pose a significant obstacle for the efficacy of chemotherapy. 4960 Moreover, recent evidence suggests that high drug efflux cancer cells 4961 (HDECC) may be selectively enriched with stem-like cancer cells, which 4962 are believed to be the cause for tumor initiation and recurrence. There 4963 is a great need for therapeutic reagents that are capable of eliminating 4964 HDECCs. We developed an image-based high-content screening (HCS) 4965 system to specifically identify and analyze the HDECC population in 4966 lung cancer cells. Using the system, we screened 1,280 4967 pharmacologically active compounds that identified 12 potent HDECC 4968 inhibitors. It is shown that these inhibitors are able to overcome 4969 multidrug resistance (MDR) and sensitize HDECCs to chemotherapeutic 4970 drugs, or directly reduce the tumorigenicity of lung cancer cells 4971 possibly by affecting stem-like cancer cells. The HCS system we 4972 established provides a new approach for identifying therapeutic 4973 reagents overcoming MDR. The compounds identified by the screening may 4974 potentially be used as potential adjuvant to improve the efficacy of 4975 chemotherapeutic drugs. Cancer Res; 70(19); 7723-33. (C) 2010 AACR. 4976 SN 0008-5472 4977 PD OCT 1 4978 PY 2010 4979 VL 70 4980 IS 19 4981 BP 7723 4982 EP 7733 4983 DI 10.1158/0008-5472.CAN-09-4360 4984 UT ISI:000282647700036 4985 PT J 4986 AU Tian, HL 4987 Yu, T 4988 Xu, NN 4989 Feng, C 4990 Zhou, LY 4991 Luo, HW 4992 Chang, DC 4993 Le, XF 4994 Luo, KQ 4995 AF Tian, Hong-Lei 4996 Yu, Ting 4997 Xu, Nai-Ning 4998 Feng, Chao 4999 Zhou, Li-Ying 5000 Luo, Hou-Wei 5001 Chang, Donald C. 5002 Le, Xiao-Feng 5003 Luo, Kathy Qian 5004 TI A novel compound modified from tanshinone inhibits tumor growth in vivo 5005 via activation of the intrinsic apoptotic pathway 5006 SO CANCER LETTERS 5007 AB A novel compound, acetyltanshinone IIA (ATA) was obtained from chemical 5008 modifications of tanshinone TIIA (TIIA) isolated from a medicinal 5009 plant, Salvia miltiorrhiza. ATA exhibited increased water solubility 5010 and stronger apoptotic activity on multiple cancer cell lines than 5011 TIIA. ATA displayed a higher growth inhibition ability on breast cancer 5012 especially HER2 positive cells than normal cells and it inhibited 5013 xenografted tumor growth in mice. Mechanistic studies showed that ATA 5014 could induce significant reactive oxygen species (ROS) generation, Bax 5015 translocation to mitochondria, resulting in mitochondria damage, 5016 cytochrome c release, caspase-3 activation and apoptotic cell death. 5017 ATA-mediated ROS production and its downstream apoptotic events could 5018 be blocked by an antioxidant agent, propyl gallate, indicating the 5019 prominent role of ROS in ATA-induced apoptosis. Overexpression of Bcl-2 5020 protein reduced ATA-induced cell death. In conclusion, ATA is a novel 5021 anticancer agent with potent in vitro and in vivo anticancer ability. 5022 ROS-mediated Bax activation should be the mechanism by which ATA 5023 induces apoptosis and inhibits tumor growth. (C) 2010 Elsevier Ireland 5024 Ltd. All rights reserved. 5025 SN 0304-3835 5026 PD NOV 1 5027 PY 2010 5028 VL 297 5029 IS 1 5030 BP 18 5031 EP 30 5032 DI 10.1016/j.canlet.2010.04.020 5033 UT ISI:000282715000003 5034 PT J 5035 AU Wang, L 5036 Ling, Y 5037 Chen, Y 5038 Li, CL 5039 Feng, F 5040 You, QD 5041 Lu, N 5042 Guo, QL 5043 AF Wang, Ling 5044 Ling, Yun 5045 Chen, Yan 5046 Li, Cheng-Ling 5047 Feng, Feng 5048 You, Qi-Dong 5049 Lu, Na 5050 Guo, Qing-Long 5051 TI Flavonoid baicalein suppresses adhesion, migration and invasion of 5052 MDA-MB-231 human breast cancer cells 5053 SO CANCER LETTERS 5054 AB Baicalein is a widely used Chinese herbal medicine that has been used 5055 historically in anti-inflammatory and anti-cancer therapy. However, 5056 the molecular mechanism of its anti-cancer activity remains poorly 5057 understood and warrants further investigations. The purpose of this 5058 study is to verify the activity of baicalein to inhibit the invasion 5059 of MDA-MB-231 human breast cancer cells. The results indicated that 5060 baicalein suppressed MDA-MB-231 cell adhesion to fibronectin-coated 5061 substrate, wound healing migration and invasion through the Matrigel 5062 in a concentration-dependent manner. Western blot and gelatin 5063 zymography analysis showed that baicalein significantly inhibited the 5064 expression and secretion of matrix metalloproteinases 2/9 (MMP-2/9) 5065 in MDA-MB-231 cells. Additionally, treatment of MDA-MB-231 cells with 5066 baicalein down-regulated the expression of MMP-2/9 involved 5067 mitogen-activated protein kinases (MAPK) signaling pathway. Taken 5068 together, baicalein had potential to suppress the adhesion, migration 5069 and invasion of MDA-MB-231 cancer cells in vitro and it could serve 5070 as a promising drug for the treatment of cancer metastasis. (C) 2010 5071 Elsevier Ireland Ltd. All rights reserved. 5072 SN 0304-3835 5073 PD NOV 1 5074 PY 2010 5075 VL 297 5076 IS 1 5077 BP 42 5078 EP 48 5079 DI 10.1016/j.canlet.2010.04.022 5080 UT ISI:000282715000005 5081 PT J 5082 AU Zhou, L 5083 Wang, W 5084 Feng, YY 5085 Wei, SH 5086 Zhou, JH 5087 Yu, BY 5088 Shen, JA 5089 AF Zhou, Lin 5090 Wang, Wei 5091 Feng, Yuying 5092 Wei, Shaohua 5093 Zhou, Jiahong 5094 Yu, Boyang 5095 Shen, Jian 5096 TI Delivering a hydrophobic anticancer drug for photodynamic therapy by 5097 amorphous formulation 5098 SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 5099 AB An amorphous formulation of hypocrellin A for photodynamic therapy is 5100 reported which can provide stable aqueous dispersion of such 5101 hydrophobic photosensitizers. In vitro studies have demonstrated the 5102 active uptake of amorphous formulation of hypocrellin A into the 5103 mitochondria of tumor cells. Compared with Tween-80 micelle embedded 5104 hypocrellin A, low dark-toxicity but similar light-toxicity of the 5105 amorphous one to drug impregnated tumor cells was observed. Thus, the 5106 potential of using amorphous formulation of hypocrellin A as drug 5107 delivery system for photodynamic therapy has been demonstrated. (C) 5108 2010 Elsevier Ltd. All rights reserved. 5109 SN 0960-894X 5110 PD NOV 1 5111 PY 2010 5112 VL 20 5113 IS 21 5114 BP 6172 5115 EP 6174 5116 DI 10.1016/j.bmcl.2010.08.132 5117 UT ISI:000282677900001 5118 PT J 5119 AU Du, JL 5120 Wu, GF 5121 Wang, JL 5122 AF Du, Jinli 5123 Wu, Guangfen 5124 Wang, Jinlan 5125 TI Density Functional Theory Study of the Interaction of Carbon Monoxide 5126 with Bimetallic Co-Mn Clusters 5127 SO JOURNAL OF PHYSICAL CHEMISTRY A 5128 AB Using spin-polarized density functional calculations, we have studied 5129 the interaction of carbon monoxide (CO) with bimetallic ConMn (n = 1-6) 5130 and ConMn6-n (n = 0-6) clusters. Various adsorption sites including 5131 atop, hollow, and bridge adsorption patterns and different possible 5132 spin states are considered. The CO molecule prefers to adsorb at the 5133 Co site rather than at the Mn site. Atop adsorption structure is 5134 energetically more favored over the hollow and bridge adsorption ones 5135 for the bimetallic clusters with an exception of Co5Mn. Large 5136 adsorption energy is found at Co3Mn, Co2Mn4, and Co3Mn3, associating 5137 with the relative stability of the bare Co Mn clusters and the 5138 electrostatic interactions as well as adsorption patterns. The 5139 activation of the C-O bond and the red shift of the C-O stretching 5140 frequency are sensitive to the adsorption sites and high chemical 5141 activity is identified for Co-6, Co5Mn, and Mn-6 clusters. More 5142 interestingly, the adsorption of CO has different influence on the 5143 magnetism of the clusters: the magnetic moment remains unchanged for 5144 CoMn and Co2Mn, while it is reduced by 2 mu(B) for ConMn (n = 3-6) and 5145 Co Mn6-n (n = 0-5) and is enhanced by 2 mu(B) for Mn-6 when a CO molecule 5146 is loaded to the cluster. 5147 SN 1089-5639 5148 PD OCT 7 5149 PY 2010 5150 VL 114 5151 IS 39 5152 BP 10508 5153 EP 10514 5154 DI 10.1021/jp106321s 5155 UT ISI:000282210000005 5156 PT J 5157 AU Yu, LZ 5158 Jiye, A 5159 Sun, M 5160 Xu, J 5161 Cheng, LP 5162 Shi, RH 5163 AF Yu, Lianzhen 5164 Jiye, A. 5165 Sun, Min 5166 Xu, Jin 5167 Cheng, Liping 5168 Shi, Ruihua 5169 TI Research on metabolic phenotype of gastric cancer tissue and plasma 5170 by gas chromatography-time of flight mass spectrometry 5171 SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 5172 SN 0815-9319 5173 PD SEP 5174 PY 2010 5175 VL 25 5176 SU Suppl. 2 5177 BP A140 5178 EP A140 5179 UT ISI:000282181400458 5180 PT J 5181 AU Xu, Y 5182 Jin, XF 5183 Ping, QN 5184 Cheng, JA 5185 Sun, MJ 5186 Cao, F 5187 You, WL 5188 Yuan, DF 5189 AF Xu, Ying 5190 Jin, Xuefeng 5191 Ping, Qineng 5192 Cheng, Juan 5193 Sun, Minjie 5194 Cao, Feng 5195 You, Weiliang 5196 Yuan, Dongfen 5197 TI A novel lipoprotein-mimic nanocarrier composed of the modified protein 5198 and lipid for tumor cell targeting delivery 5199 SO JOURNAL OF CONTROLLED RELEASE 5200 AB Ursodeoxycholic acid (UA) modified protein-lipid nanocomplex (uP-LNC) 5201 as a novel biomimetic nanocarrier was developed for tumor-targeting 5202 delivery. Bovine serum albumin (BSA) was used as a model protein and 5203 its amino groups were covalently modified by UA. Lipid nanoparticle 5204 (LNP) composed of phospholipids, triglycerides and octadecylamine was 5205 prepared by using solvent evaporation method and was used as the core. 5206 UA modified BSA (uP) was attached onto the surface of LNP by post-insert 5207 method and generated the protein-lipid nanocomplex. As the control, 5208 cholesteryl hemiglutarate (CH), a non-targeting ligand was also used 5209 to modify BSA and then formed CH modified protein-lipid nanocomplex 5210 (cP-LNC). The combining efficiency of modified BSA with LNP, determined 5211 by Bradford protein assay, increased with the enhancement of 5212 substitution degree. The modified BSA and nanocomplex were 5213 characterized for the substitute degree, average molecular weight, 5214 surface tension, particle size and zeta potential by various 5215 physicochemical analyses. In vitro dissolution tests and cell uptake 5216 studies were performed by loading coumarin-6 as a fluorescent probe. 5217 The results indicated that the UA modified protein attached on the 5218 nanoparticles significantly decreased drug release from the 5219 nanocomplex in pH 7.4 medium, The uptake of uP-LNC was higher in hepatic 5220 carcinoma cells (HepG2 and Bel 7402) than in normal liver cells (L02). 5221 Furthermore, the uptake of uP-LNC was significantly higher than that 5222 of cP-LNC and LNP in these cells. The uptake was dependent on time, 5223 temperature and concentration, and could be inhibited by free UA. In 5224 addition, the MTT assay of uP-LNC and u(x)P with various degrees of 5225 substitution showed very low cytotoxicity at tested concentrations in 5226 all cells. The UA modification served to facilitate the specific 5227 receptor and energy mediated endocytosis process of the protein-lipid 5228 nanocomplex and enabled this nanocomplex to be a potential nanocarrier 5229 for tumor-targeting drug delivery. (c) 2010 Elsevier B.V. All rights 5230 reserved. 5231 SN 0168-3659 5232 PD SEP 15 5233 PY 2010 5234 VL 146 5235 IS 3 5236 BP 299 5237 EP 308 5238 DI 10.1016/j.jconrel.2010.05.022 5239 UT ISI:000282398100005 5240 PT J 5241 AU Xu, HM 5242 Wei, J 5243 Pan, L 5244 Lin, HY 5245 Wang, WQ 5246 Zhang, YH 5247 Shen, ZL 5248 AF Xu, Han-Mei 5249 Wei, Jin 5250 Pan, Li 5251 Lin, Hongying 5252 Wang, Weiqiang 5253 Zhang, Yihua 5254 Shen, Zilong 5255 TI The Mechanism of (R,R) ZX-5 on Increasing NO Release 5256 SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 5257 AB (R,R) ZX-5 has been proven to have positive effects on choroidal blood 5258 flow without affecting the sclera and ciliary bodies in New Zealand 5259 white rabbits. This study was designed to investigate the mechanisms 5260 of (R,R) ZX-5 on improving the choroidal blood flow and promoting NO 5261 production. HUVECs (human umbilical vein endothelial cells) were used 5262 to determine the production of eNOS, p-eNOS, AKT and Erk1/2 by Western 5263 blot analysis. iNOS and eNOS mRNA levels were investigated by RT-PCR 5264 and the effect of (R,R) ZX-5 on NO production were determined by eNOS 5265 activity assay. We found (R,R) ZX-5 upregulated protein expression of 5266 eNOS and iNOS, increased NO production, and reduced ERK and Akt protein 5267 level. Therefore, (R,R) ZX-5 may promote the choroidal blood flow in 5268 New Zealand white rabbits without affecting the blood flow in the iris 5269 or ciliary bodies via increasing NO production. These results suggest 5270 that (R,R) ZX-5 may function to cure and prevent Age-related macular 5271 degeneration (AMD). 5272 SN 1422-0067 5273 PD SEP 5274 PY 2010 5275 VL 11 5276 IS 9 5277 BP 3323 5278 EP 3333 5279 DI 10.3390/ijms11093323 5280 UT ISI:000282223500019 5281 PT J 5282 AU Yang, J 5283 Ding, L 5284 Hu, LL 5285 Jin, SH 5286 Liu, WY 5287 Wang, ZZ 5288 Xiao, W 5289 You, QD 5290 Guo, QL 5291 AF Yang, Jing 5292 Ding, Li 5293 Hu, Linlin 5294 Jin, Shaohong 5295 Liu, Wenyuan 5296 Wang, Zhenzhong 5297 Xiao, Wei 5298 You, Qidong 5299 Guo, Qinglong 5300 TI Comparison of electron capture-atmospheric pressure chemical 5301 ionization and electrospray ionization for the analysis of gambogic 5302 acid and its main circulating metabolite in dog plasma 5303 SO EUROPEAN JOURNAL OF MASS SPECTROMETRY 5304 AB Gambogic acid (GA), a promising anticancer candidate, is a 5305 polyprenylated xanthone abundant in the resin of Garcinia morella and 5306 Garcinia hanburyi. Electron capture-atmospheric pressure chemical 5307 ionization (EC-APCI) and electrospray ionization (ESI) techniques, 5308 both in the negative ion mode, were evaluated regarding ionization, 5309 fragmentation patterns and sensitivity for simultaneous liquid 5310 chromatography-tandem mass spectrometry (LC-MS/MS) analysis of GA and 5311 its main circulating metabolite, 10-hydroxygambogic acid (10-OHGA) in 5312 dog plasma. Both analytes underwent extensive in-source fragmentation 5313 in EC-APCI, which was not desirable for reliable quantification of 5314 these analytes, whereas the substitution of ESI for EC-APCI almost 5315 eliminated the source instability of both analytes. Negative ion ESI 5316 was, therefore, chosen for the development of an LC-MS/MS method for 5317 simultaneous determination of these analytes. After protein 5318 precipitation by acetonitrile, all analytes were separated on a Luna 5319 C18 HST column (50 x 2.0 mm id., 2.5 mu m) with a mobile phase of 20 5320 mmol L-1 ammonium acetate water solution containing 0.2% acetic 5321 acid :acetonitrile (18:82, v/v). The detection was performed on a 5322 tandem mass spectrometer using selective reaction monitoring mode. 5323 Calibration curves were linear over the range of 10-6000 ng mL(-1) for 5324 GA and 3-2000 ng mL(-1) for 10-OHGA. The method was successfully applied 5325 to the pharmacokinetics study of GA injection in six beagle dogs. 5326 SN 1469-0667 5327 PY 2010 5328 VL 16 5329 IS 5 5330 BP 605 5331 EP 617 5332 DI 10.1255/ejms.1095 5333 UT ISI:000282257200006 5334 PT J 5335 AU Liu, J 5336 He, T 5337 Lu, QA 5338 Shang, J 5339 Sun, HB 5340 Zhang, LY 5341 AF Liu, Jun 5342 He, Ting 5343 Lu, Qian 5344 Shang, Jing 5345 Sun, Hongbin 5346 Zhang, Luyong 5347 TI Asiatic acid preserves beta cell mass and mitigates hyperglycemia in 5348 streptozocin-induced diabetic rats 5349 SO DIABETES-METABOLISM RESEARCH AND REVIEWS 5350 AB Background Type 1 diabetes is a chronic condition in which the pancreas 5351 produces little or no insulin due to the loss or dysfunction of 5352 pancreatic beta cells. This study investigated the beneficial effects 5353 of asiatic acid - a triterpenoid compound - preserved beta mass and 5354 mitigated hyperglycemia in streptozocin-induced diabetic rats. 5355 Methods Diabetes mellitus was induced in adult male Wistar rats by a 5356 single intraperitoneal injection of streptozocin (60 mg/kg body 5357 weight). The diabetic rats were divided into untreated and asiatic acid 5358 (25 mg/kg) groups. Controls were intraperitoneal injection with 5359 citrate buffer. Blood glucose level, plasma insulin, and pancreas 5360 immunohistochemistry analysis were examined after a 2-week 5361 experimental period. AKT and Bcl-xL expression in the pancreatic islets 5362 of rats were evaluated by Western blot methods. 5363 Results Blood glucose levels were significantly reduced in rats 5364 receiving asiatic acid after streptozocin administration. Asiatic acid 5365 concomitantly increased serum insulin levels in diabetic rats. 5366 Immunohistochemical staining revealed a marked preservation by asiatic 5367 acid of insulin-producing beta cells in the pancreatic islets of the 5368 diabetic rats. Furthermore, asiatic acid in vivo induced pro-survival 5369 Akt kinase activation and Bcl-xL expression in the pancreatic islets 5370 of diabetic rats. 5371 Conclusions These results suggest that asiatic acid exerts its 5372 glucose-lowering effects, in part through influences on beta-cell 5373 mass. Asiatic acid administration resulted in preservation and 5374 restoration of beta-cell mass and function in diabetic rodent models. 5375 Copyright (C) 2010 John Wiley & Sons, Ltd. 5376 SN 1520-7552 5377 PD SEP 5378 PY 2010 5379 VL 26 5380 IS 6 5381 BP 448 5382 EP 454 5383 DI 10.1002/dmrr.1101 5384 UT ISI:000282202400003 5385 PT J 5386 AU Liu, WY 5387 Yang, XJ 5388 Feng, F 5389 Wu, CY 5390 Ding, L 5391 AF Liu, Wenyuan 5392 Yang, Xiaojing 5393 Feng, Feng 5394 Wu, Chunyong 5395 Ding, Li 5396 TI SPE and LC for Analysis of the Tissue Distribution of Wogonin and Its 5397 Metabolite in Tumor-Bearing Nude Mice 5398 SO CHROMATOGRAPHIA 5399 AB The tissue distribution of wogonin was investigated for study of its 5400 anticancer activity. A robust, reliable, and sensitive LC method was 5401 developed for simultaneous analysis of wogonin and its major 5402 metabolite, wogonoside, in tissues of tumor-bearing nude mice. To reach 5403 the required level of detection in different tissues, sample 5404 pretreatment was by solid-phase extraction. Good LC separation was 5405 achieved on a C-18 column with methanol-0.5% formic acid 68:32 (v/v) 5406 as mobile phase. UV detection was performed at 275 nm and calibration 5407 plots for both analytes were linear over the range 0.16-80.0 mu g g(-1) 5408 for all the biological samples studied with correlation coefficients > 5409 0.9980. Inter-day and intra-day precision were no more than 15% at the 5410 limit of quantification and 10% at other concentrations; recovery from 5411 all tissues was 92.3-101.4% for wogonin and 66.7-74.3% for wogonoside. 5412 The method was ideal for this tissue distribution study and results 5413 obtained reflect the potential of wogonin for further pharmaceutical 5414 development as an anticancer agent. 5415 SN 0009-5893 5416 PD OCT 5417 PY 2010 5418 VL 72 5419 IS 7-8 5420 BP 753 5421 EP 757 5422 DI 10.1365/s10337-010-1714-7 5423 UT ISI:000282211200027 5424 PT J 5425 AU Wang, XJ 5426 Gu, K 5427 Xu, JS 5428 Li, MH 5429 Cao, RY 5430 Wu, J 5431 Li, TM 5432 Liu, JJ 5433 AF Wang, Xue Jun 5434 Gu, Kai 5435 Xu, Jin Shu 5436 Li, Ming Hui 5437 Cao, Rong Yue 5438 Wu, Jie 5439 Li, Tai Ming 5440 Liu, Jing Jing 5441 TI Immunization with a recombinant GnRH vaccine fused to heat shock 5442 protein 65 inhibits mammary tumor growth in vivo 5443 SO CANCER IMMUNOLOGY IMMUNOTHERAPY 5444 AB Gonadotrophin-releasing hormone (GnRH) is the prime decapeptide 5445 hormone in the regulation of mammalian reproduction. Active 5446 immunization against GnRH has been a good treatment option to fight 5447 against hormone-dependent disease such as breast cancer. We designed 5448 and purified a novel protein vaccine Hsp65-GnRH(6) containing heat 5449 shock protein 65 (Hsp65) and six copies of GnRH in linear alignment. 5450 Immunization with Hsp65-GnRH(6) evoked strong humoral response in 5451 female mice. The generation of specific anti-GnRH antibodies was 5452 detected by ELISA and verified by western blot. In addition, anti-GnRH 5453 antibodies effectively neutralized endogenous GnRH activity in vivo, 5454 as demonstrated by the degeneration of the ovaries and uteri in the 5455 vaccinated mice. Moreover, the growth of EMT-6 mammary tumor allografts 5456 was inhibited by anti-GnRH antibodies. Histological examinations have 5457 shown that there was increased focal necrosis in tumors. Taken 5458 together, our results showed that immunization with Hsp65-GnRH(6) 5459 elicited high titer of specific anti-GnRH antibodies and further led 5460 to atrophy of reproductive organs. The specific antibodies could 5461 inhibit the growth of EMT-6 murine mammary tumor probably via an 5462 indirect mechanism that includes the depletion of estrogen. In view 5463 of these results, the protein vaccine Hsp65-GnRH(6) appears to be a 5464 promising candidate vaccine for hormone-dependent cancer therapy. 5465 SN 0340-7004 5466 PD DEC 5467 PY 2010 5468 VL 59 5469 IS 12 5470 BP 1859 5471 EP 1866 5472 DI 10.1007/s00262-010-0911-4 5473 UT ISI:000282184700010 5474 PT J 5475 AU Wang, Y 5476 Lin, GW 5477 Hong, J 5478 Li, L 5479 Yang, YM 5480 Lu, T 5481 AF Wang, Yue 5482 Lin, Guo-Wu 5483 Hong, Jin 5484 Li, Li 5485 Yang, Yu-Mei 5486 Lu, Tao 5487 TI Synthesis, structure, DNA binding and cleavage ability of a new copper 5488 ciprofloxacin complex 5489 SO JOURNAL OF COORDINATION CHEMISTRY 5490 AB The structure of 1 consists of [Cu(HCp)(phen)(H2O)]2+ (HCp is 5491 ciprofloxacin and phen is 1,10-phenanthroline), two acetates, and four 5492 free water molecules. In each cation, copper displays a distorted 5493 square pyramid, coordinated to ring 3-carboxylate and 4-oxo oxygen from 5494 HCp, two nitrogens from phen, and one water molecule. There are five 5495 water molecules in each discrete complex with one coordinated to Cu 5496 center, and the other four linked to each other by intermolecular 5497 hydrogen bonds. Two uncoordinated acetates make the compound neutral. 5498 The complex exhibits higher DNA binding compared to HCp at the same 5499 conditions by fluorescence and viscosity measurements. Combining its 5500 structure with the DNA-binding result, the binding mechanism may be 5501 explained by intercalation. Moreover, 1 shows significant cleavage of 5502 DNA in the presence of a reducing agent, such as ascorbate by gel 5503 electrophoresis using supercoiled pBR322 DNA in Tris-HCl buffer (pH 5504 7.4). The complex also has a higher activity against Gram-positive 5505 bacteria Staphylococcus aureus and Gram-negative bacteria Klebsiella 5506 pneumoniae than HCp. 5507 SN 0095-8972 5508 PY 2010 5509 VL 63 5510 IS 20 5511 BP 3662 5512 EP 3675 5513 DI 10.1080/00958972.2010.515986 5514 UT ISI:000282028300014 5515 PT J 5516 AU Li, ZY 5517 Wang, YY 5518 Tang, CH 5519 Xu, JY 5520 Wu, XM 5521 Yao, HQ 5522 AF Li Ziyuan 5523 Wang Yiyun 5524 Tang Changhua 5525 Xu Jinyi 5526 Wu Xiaoming 5527 Yao Hequan 5528 TI Synthesis of 3-Benzoyl Acrylates/Acrylamides via Dehydrogenation of 5529 3-Benzoyl Propionates/Propionamides Using IBX/p-TsOH 5530 SO CHINESE JOURNAL OF CHEMISTRY 5531 AB Dehydrogenation by IBX/p-TsOH is applied to the conversion of 3-benzoyl 5532 propionates/propionamides to 3-benzoyl acrylates/acrylamides in 5533 moderate to excellent yields. The reaction time for the dehydrogenation 5534 of 3-benzoyl propionamides was remarkably shorter than that for the 5535 dehydrogenation of esters. 5536 SN 1001-604X 5537 PD JUL 5538 PY 2010 5539 VL 28 5540 IS 7 5541 BP 1301 5542 EP 1305 5543 DI 10.1002/cjoc.201090225 5544 UT ISI:000282083700040 5545 PT J 5546 AU Liu, LS 5547 Aa, JY 5548 Wang, GJ 5549 Yan, B 5550 Zhang, Y 5551 Wang, XW 5552 Zhao, CY 5553 Cao, B 5554 Shi, JA 5555 Li, MJ 5556 Zheng, TA 5557 Zheng, YT 5558 Hao, G 5559 Zhou, F 5560 Sun, JG 5561 Wu, ZM 5562 AF Liu, Linsheng 5563 Aa, Jiye 5564 Wang, Guangji 5565 Yan, Bei 5566 Zhang, Ying 5567 Wang, Xinwen 5568 Zhao, Chunyan 5569 Cao, Bei 5570 Shi, Jian 5571 Li, Mengjie 5572 Zheng, Tian 5573 Zheng, Yuanting 5574 Hao, Gang 5575 Zhou, Fang 5576 Sun, Jianguo 5577 Wu, Zimei 5578 TI Differences in metabolite profile between blood plasma and serum 5579 SO ANALYTICAL BIOCHEMISTRY 5580 AB In metabolomic research, blood plasma and serum have been considered 5581 to possess similar compositions and properties. Their perceived 5582 equivalence has resulted in researchers choosing arbitrarily between 5583 serum and plasma for analysis. Here, routine serum and plasma were 5584 prepared and their low-molecular-weight compounds were determined 5585 using gas chromatography/time-of-flight mass spectrometry. Principal 5586 components analysis was applied to process the acquired data, and 5587 marked differences in metabolite profiles were observed between serum 5588 and plasma. Of the 72 identified compounds, 36 (50%) discriminate serum 5589 from plasma, with 29 and 7 metabolites showing a significantly higher 5590 abundance (t test, P < 0.05) in serum and plasma, respectively. 5591 Incubation of blood had distinct effects on the analyte peak areas, 5592 with the effects being more pronounced for plasma than for serum and 5593 more pronounced for a shorter incubation than for a longer incubation. 5594 These results highlight the importance in choosing serum or plasma as 5595 the analytical sample and in stipulating the incubation time. Because 5596 incubation affected the analyte peak areas less in serum than in plasma, 5597 we recommend serum as the sample of choice in metabolomic studies. (C) 5598 2010 Elsevier Inc. All rights reserved. 5599 SN 0003-2697 5600 PD NOV 15 5601 PY 2010 5602 VL 406 5603 IS 2 5604 BP 105 5605 EP 112 5606 DI 10.1016/j.ab.2010.07.015 5607 UT ISI:000281925300002 5608 PT J 5609 AU Xie, WJ 5610 Tanabe, G 5611 Morimoto, H 5612 Hatanaka, T 5613 Minematsu, T 5614 Wu, XM 5615 Muraoka, O 5616 AF Xie, Weijia 5617 Tanabe, Genzoh 5618 Morimoto, Hiroyuki 5619 Hatanaka, Takanori 5620 Minematsu, Toshie 5621 Wu, Xiaoming 5622 Muraoka, Osamu 5623 TI Another mode of heterocyclization of an enantiopure C-2-symmetric 5624 bis-epoxide leading to the symmetric dialkyl sulfide 5625 SO TETRAHEDRON 5626 AB Reexamination of heterocyclization of an enantiopure C-2-symmetric 5627 bis-epoxide (7) with sodium sulfide is described. In addition to the 5628 reported processes leading to thiane (4a) and thiepane (6), another 5629 mode of cyclization was found to occur to a considerable extent, 5630 affording a symmetric dialkyl sulfide (5), and the structure of the 5631 main product reported (4a) has been revised. Conditions for the 5632 chemoselective formation of 6 were established, and effective 5633 transformation of 6 into 4 was accomplished by the modification of the 5634 processes. (C) 2010 Elsevier Ltd. All rights reserved. 5635 SN 0040-4020 5636 PD SEP 18 5637 PY 2010 5638 VL 66 5639 IS 38 5640 BP 7487 5641 EP 7491 5642 DI 10.1016/j.tet.2010.07.064 5643 UT ISI:000281836300005 5644 PT J 5645 AU Tian, HY 5646 Wang, L 5647 Zhang, XQ 5648 Zhang, DM 5649 Wang, Y 5650 Liu, JS 5651 Jiang, RW 5652 Ye, WC 5653 AF Tian, Hai-Yan 5654 Wang, Lei 5655 Zhang, Xiao-Qi 5656 Zhang, Dong-Mei 5657 Wang, Ying 5658 Liu, Jun-Shan 5659 Jiang, Ren-Wang 5660 Ye, Wen-Cai 5661 TI New bufadienolides and C-23 steroids from the venom of Bufo bufo 5662 gargarizans 5663 SO STEROIDS 5664 AB Six new bufadienolides (1-6) and two new C-23 steroids (7 and 8), 5665 together with three known compounds (9-11) were isolated from the venom 5666 of Bufo bufo gargarizans. Their structures were elucidated by 5667 spectroscopic analysis and single-crystal X-ray diffraction. In vitro 5668 cytotoxicities of all compounds were evaluated in A549 cancer cell 5669 line. Compounds 2, 3 and 10 showed significant cytotoxic activities. 5670 (C) 2010 Elsevier Inc. All rights reserved. 5671 SN 0039-128X 5672 PD DEC 5673 PY 2010 5674 VL 75 5675 IS 12 5676 BP 884 5677 EP 890 5678 DI 10.1016/j.steroids.2010.05.013 5679 UT ISI:000281932500012 5680 PT J 5681 AU Zheng, YF 5682 Qi, LW 5683 Cui, XB 5684 Peng, GP 5685 Peng, YB 5686 Ren, MT 5687 Cheng, XL 5688 Li, P 5689 AF Zheng, Yun-Feng 5690 Qi, Lian-Wen 5691 Cui, Xiao-Bing 5692 Peng, Guo-Ping 5693 Peng, Yong-Bo 5694 Ren, Mei-Ting 5695 Cheng, Xiao-Lan 5696 Li, Ping 5697 TI Oleanane-type Triterpene Glucuronides from the Roots of Glycyrrhiza 5698 uralensis Fischer 5699 SO PLANTA MEDICA 5700 AB Investigation of characteristic constituents of the roots of 5701 Glycyrrhiza uralensis Fischer led to isolation of four new triterpene 5702 glucuronides, namely uralsaponins C-F (1-4), an artificial product, 5703 namely the methyl ester of glycyrrhizin (5), as well as six known 5704 triterpene glucuronides (611). These new compounds were identified by 5705 1D and 2D NMR spectroscopic analysis. The cytotoxicity of the selected 5706 compounds and their aglycones were evaluated against HeLa and MCF-7 5707 cancer cell lines, and the preliminary structure-activity relationship 5708 was also elucidated. 5709 SN 0032-0943 5710 PD SEP 5711 PY 2010 5712 VL 76 5713 IS 13 5714 BP 1457 5715 EP 1463 5716 DI 10.1055/s-0029-1240907 5717 UT ISI:000281742700012 5718 PT J 5719 AU Wang, F 5720 Zhou, L 5721 Zhou, JH 5722 Gu, XT 5723 Feng, YY 5724 AF Wang, Fang 5725 Zhou, Lin 5726 Zhou, Jiahong 5727 Gu, Xiaotian 5728 Feng, Yuying 5729 TI Characterization of anticancer hypocrellin A encapsulated with silica 5730 nanoparticles 5731 SO JOURNAL OF THERMAL ANALYSIS AND CALORIMETRY 5732 AB Hypocrellins, natural photosensitizers including hypocrellin A (HA) 5733 and hypocrellin B (HB), have been used as a traditional Chinese herbal 5734 medicine to cure various skin diseases. Hypocrellins have excellent 5735 antiviral activity, which can inhibit the growth of human 5736 immunodeficiency virus. They also exhibit significant light-induced 5737 antitumor property. In this article, thermal analysis technologies 5738 (e.g., differential scanning calorimetry and thermogravimetry) are 5739 employed to characterize whether the photosensitive hypocrellin A 5740 could be encapsulated with silica nanoparticle (SN) material or not, 5741 and evaluate the stability of inclusion complex. The results show that 5742 the inclusion complex exhibits improved performance in both stability 5743 and hydrophilicity than natural hypocrellin A. Fluorescence 5744 spectrophotometry studies have also been performed to verify the 5745 thermal analysis results. The results suggest that the thermal analysis 5746 technology could be used as an effective and rapid tool to characterize 5747 the encapsulation properties of the novel anticancer HA-SN complex. 5748 SN 1388-6150 5749 PD OCT 5750 PY 2010 5751 VL 102 5752 IS 1 5753 BP 69 5754 EP 74 5755 DI 10.1007/s10973-009-0630-2 5756 UT ISI:000281705500012 5757 A Chen, GH 5758 U Wang, L 5759 Yao, XM 5760 Zhang, ML 5761 Wu, FH 5762 A Chen Guohua 5763 F Wang Li 5764 Yao Xiumei 5765 Zhang Mingliang 5766 Wu Feihua 5767 T Synthesis and Biological Activity of Dihydropyridine Calcium 5768 I Antagonists 5769 CHINESE JOURNAL OF ORGANIC CHEMISTRY 5770 A Sixteen new dihydropyridine calcium antagonists 4a similar to 4l and 5771 B 9a similar to 9d were designed and synthesized based on 5772 5-(methoxycarbonyl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyri 5773 dine-3 -carboxylic acid (1) or diketene. The structures of the target 5774 compounds were confirmed by IR,H-1 NMR, ESI-MS techniques and elemental 5775 analysis. The results of preliminary pharmacological test showed that 5776 compounds 4e, 4g, 4h, 4i and 4j had obvious relaxation effect on the 5777 contraction of vascular ring of aorta induced by KCI, which were better 5778 than positive control (levoamlodipine besylate). 5779 0253-2786 5780 2010 5781 1004 5782 ISI:000281722600007 5783 PT J 5784 AU Liu, XH 5785 Liu, HF 5786 Chen, J 5787 Yang, Y 5788 Song, BA 5789 Bai, LS 5790 Liu, JX 5791 Zhu, HL 5792 Qi, XB 5793 AF Liu, Xin-Hua 5794 Liu, Hui-Feng 5795 Chen, Jin 5796 Yang, Yang 5797 Song, Bao-An 5798 Bai, Lin-Shan 5799 Liu, Jing-Xin 5800 Zhu, Hai-Liang 5801 Qi, Xing-Bao 5802 TI Synthesis and molecular docking study of novel coumarin derivatives 5803 containing 4,5-dihydropyrazole moiety as potential antitumor agents 5804 SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 5805 AB A series of novel coumarin derivatives containing 4,5-dihydropyrazole 5806 moiety as potential telomerase inhibitors were synthesized. The 5807 bioassay tests show that compound 3d exhibited potentially high 5808 activity against human gastric cancer cell SGC-7901 with IC50 value 5809 of 2.69 +/- 0.60 mu g/mL. All title compounds were assayed for 5810 telomerase inhibition by a modified TRAP assay, the results show that 5811 compounds 3d and 3f can strongly inhibit telomerase with IC50 values 5812 of 2.0 +/- 0.07 and 1.8 +/- 0.35 mu M, respectively. Docking simulation 5813 was performed to position compound 3d into the telomerase (3DU6) active 5814 site to determine the probable binding model. (C) 2010 Elsevier Ltd. 5815 All rights reserved. 5816 SN 0960-894X 5817 PD OCT 1 5818 PY 2010 5819 VL 20 5820 IS 19 5821 BP 5705 5822 EP 5708 5823 DI 10.1016/j.bmcl.2010.08.017 5824 UT ISI:000281735600022 5825 PT J 5826 AU Xiong, Y 5827 Yang, YQ 5828 Yang, J 5829 Chai, HY 5830 Li, Y 5831 Yang, J 5832 Jia, ZM 5833 Wang, ZR 5834 AF Xiong, Yu 5835 Yang, Yuqing 5836 Yang, Jin 5837 Chai, Hongyan 5838 Li, Ying 5839 Yang, Jing 5840 Jia, Ziming 5841 Wang, Zhengrong 5842 TI Tectoridin, an isoflavone glycoside from the flower of Pueraria lobata, 5843 prevents acute ethanol-induced liver steatosis in mice 5844 SO TOXICOLOGY 5845 AB In traditional Chinese medicine, the flower of Pueraria lobata 5846 (Puerariae Flos) has been used in therapy to counteract the problems 5847 associated with alcohol drinking and liver injury. In this study, we 5848 investigated the hepatoprotective effects and its mechanisms of 5849 tectoridin, an isoflavone glycoside from the flower of P. lobata 5850 (Willd.) Ohwi. Ethanol (5 g/kg) was given orally every 12 h for a total 5851 of three doses. 1 h after the last dose of ethanol, tectoridin (25, 5852 50 and 100 mg/kg) was given intragastrically five times in three 5853 consecutive days. The mice were sacrificed at 4 h after tectoridin 5854 treatment. Peroxisome proliferators-activated receptor alpha (PPAR 5855 alpha), sterol regulatory element-binding protein (SREBP)-1c and their 5856 target genes were evaluated by biochemical analysis and quantitative 5857 real-time polymerase chain reaction (qPCR). Mitochondria were isolated 5858 for the mitochondrial permeability transition (MPT) and membrane 5859 potential (Delta Psi(m)) assay. Acute ethanol exposure resulted in the 5860 significant increase of the alanine aminotransferase (ALT), aspartate 5861 aminotransferase (AST) and triglyceride (TG) levels and hepatic 5862 mitochondria dysfunction shown as the increase of MPT and the decrease 5863 of Delta Psi(m). However, tectoridin treatment dramatically attenuated 5864 these effects. In addition, tectoridin remarkably alleviated the 5865 over-production of thiobarbituric acid-reactive substance. 5866 Furthermore, tectoridin inhibited the decrease of PPAR alpha 5867 expression and its target genes, including medium-chain acyl-CoA 5868 dehydrogenase (MCAD), acyl-CoA oxidase (ACO) and cytochrome P450 4A 5869 (CYP 4A) at mRNA and enzyme activity levels. These data showed that 5870 tectoridin protected against ethanol-induced liver steatosis mainly 5871 through modulating the disturbance of PPAR alpha pathway and 5872 ameliorating mitochondrial function. (C) 2010 Elsevier Ireland Ltd. 5873 All rights reserved. 5874 SN 0300-483X 5875 PD SEP 30 5876 PY 2010 5877 VL 276 5878 IS 1 5879 BP 64 5880 EP 72 5881 DI 10.1016/j.tox.2010.07.007 5882 UT ISI:000281624800010 5883 PT J 5884 AU Zhu, BL 5885 Xu, HM 5886 Zhao, LM 5887 Huang, XF 5888 Zhang, FG 5889 AF Zhu, Beili 5890 Xu, Han-Mei 5891 Zhao, Liming 5892 Huang, Xiaofeng 5893 Zhang, Fengguo 5894 TI Site-specific modification of anti-angiogenesis peptide HM-3 by 5895 polyethylene glycol molecular weight of 20 kDa 5896 SO JOURNAL OF BIOCHEMISTRY 5897 AB HM-3, an RGD modified endostatin-derived polypeptide, is a potent 5898 angiogenesis inhibitor synthesized in our laboratory. Its robust 5899 inhibitory effects on endothelial cell migration and tumour growth have 5900 been demonstrated by in vivo and in vitro activity assays. However, 5901 the drug has relatively short half-life in vivo. For the purpose of 5902 prolonging HM-3 half-life and retaining the safety and efficacy of the 5903 peptide, the study chose methoxy-polyethylene glycol-Succinimidyl 5904 Carbonate (SC-mPEG, molecular weight 20 kDa, named SC-mPEG(20k)) to 5905 specifically modify its N terminus. Compared with HM-3, the 5906 site-specific mono-PEGylated peptide PEG(20k)-HM-3 was shown the same 5907 activity in the inhibition of B16F10 tumour in vivo (the inhibitory 5908 effect of PEG(20k)-HM-3, HM-3 and Taxol were 44.35, 39.68%, 5909 respectively), while the frequency of drug-administering reduced from 5910 twice a day to once every 3 days. Its rate of in vitro degradation in 5911 serum was markedly reduced (72.78% could still be detected after 132 5912 h). Histochemistry and immunohistochemistry analysis showed that both 5913 HM-3 and PEG(20k)-HM-3 induced large areas of continuous necrosis 5914 within tumours and significantly reduced the vessel density compared 5915 to control. It might be a breakthrough in PEG modification field to 5916 modify a small peptide with a large PEG and reach a good result. 5917 SN 0021-924X 5918 PD SEP 5919 PY 2010 5920 VL 148 5921 IS 3 5922 BP 341 5923 EP 347 5924 DI 10.1093/jb/mvq070 5925 UT ISI:000281534100010 5926 PT J 5927 AU Chen, DQ 5928 Jiang, XQ 5929 Huang, YY 5930 Zhang, C 5931 Ping, QN 5932 AF Chen, Daquan 5933 Jiang, Xiaoqun 5934 Huang, Yanyu 5935 Zhang, Can 5936 Ping, Qineng 5937 TI pH-Sensitive mPEG-Hz-Cholesterol Conjugates as a Liposome Delivery 5938 System 5939 SO JOURNAL OF BIOACTIVE AND COMPATIBLE POLYMERS 5940 AB Hydrazone (Hz)-based pH-sensitive methoxy(polyethylene glycol)cholesterol conjugates (mPEG-Hz-Chol), were synthesized and used to 5941 fabricate liposomes. The structures of the mPEG2000-Hz-Chol conjugate 5942 were confirmed by FT-IR and H-1-NMR; they were stable at pH 7.4 but 5943 sensitive to mild acid conditions (pH 5.5). Plain liposomes were also 5944 prepared with S100PC/Chol, and the pH-insensitive liposomes with 5945 S100PC/Chol/mPEG2000-Chol for comparison; all the liposomes were 5946 similar in diameter similar to 20 0 nm. In vitro, the pH-sensitive 5947 liposomes released more of the model drug, paclitaxel (PTX), than the 5948 plain liposomes. The pH-sensitive liposomes were less toxic than the 5949 plain liposomes and exhibited higher cellular uptake of PTX compared 5950 with pH-insensitive liposomes by human breast cancer cells (MCF-7). 5951 The pH-sensitive mPEG2000-Hz-Chol liposomes are now being investigated 5952 as a potential new liposome drug delivery system. 5953 SN 0883-9115 5954 PD SEP 5955 PY 2010 5956 VL 25 5957 IS 5 5958 BP 527 5959 EP 542 5960 DI 10.1177/0883911510379996 5961 UT ISI:000281598800007 5962 PT J 5963 AU Liu, XP 5964 Du, YX 5965 AF Liu, Xiangping 5966 Du, Yingxiang 5967 TI Study on the binding of chiral drug duloxetine hydrochloride to human 5968 serum albumin 5969 SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 5970 AB Duloxetine holds a special promise as an antidepressant, and its effect 5971 depends on its binding to human serum albumin (HSA). For this reason, 5972 the binding mechanism of duloxetine with HSA was investigated. The 5973 specific binding site in HSA was identified and binding constants were 5974 determined. Duloxetine could compete with dansyl-L-proline (DLP), a 5975 site II marker for binding to site II. Binding constants between 5976 duloxetine and HSA were 1.75 x 10(3) L mol(-1) and 3.74 x 10(3) L mol(-1) 5977 at pH 7.4 and pH 8.5, respectively. The interaction process of 5978 enantiomers and HSA was susceptible to pH change. It was concluded that 5979 specific binding position of duloxetine was located in site II, and 5980 the B conformation of HSA possibly excelled the N conformation in 5981 identifying and binding to enantiomers. (C) 2010 Elsevier Masson SAS. 5982 All rights reserved. 5983 SN 0223-5234 5984 PD SEP 5985 PY 2010 5986 VL 45 5987 IS 9 5988 BP 4043 5989 EP 4049 5990 DI 10.1016/j.ejmech.2010.05.063 5991 UT ISI:000281568600064 5992 PT J 5993 AU Wang, JX 5994 Ma, JH 5995 You, QD 5996 Zhao, L 5997 Wang, F 5998 Li, C 5999 Guo, QL 6000 AF Wang, Jinxin 6001 Ma, Junhai 6002 You, Qidong 6003 Zhao, Li 6004 Wang, Fan 6005 Li, Chong 6006 Guo, Qinglong 6007 TI Studies on chemical modification and biology of a natural product, 6008 gambogic acid (II): Synthesis and bioevaluation of gambogellic acid 6009 and its derivatives from gambogic acid as antitumor agents 6010 SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 6011 AB Gambogic acid (GA) has been reported to be a potent apoptosis inducer. 6012 The fact that it is amenable to chemical modification makes GA an 6013 attractive molecule for the development of anticancer agents. We 6014 firstly reported the synthesis of gambogellic acid, which was generated 6015 under acid catalysis from readily available GA by a base-catalyzed 6016 diene intramolecular annelation. Sequentially, thirteen new compounds 6017 were synthesized and their inhibitory activity on HT-29, Bel-7402, 6018 BGC-823, and A549 cell lines were evaluated in vitro by MTT assay, and 6019 (38, 40)-epoxy-33-chlorogambogellic acid (4) was identified as a 6020 BGC-823 cell apoptosis inducer through MTT cell assay, observations 6021 of morphological changes, and Annexin-V/PI double-staining assay. 6022 Compound 4 showed significant effects in inducing apoptosis and might 6023 serve as a potential lead compound for discovery of new anticancer 6024 drugs. Further structure activity relationships (SARs) of gambogic 6025 acid derivatives were discussed. (C) 2010 Elsevier Masson SAS. All 6026 rights reserved. 6027 SN 0223-5234 6028 PD SEP 6029 PY 2010 6030 VL 45 6031 IS 9 6032 BP 4343 6033 EP 4353 6034 DI 10.1016/j.ejmech.2010.04.037 6035 UT ISI:000281568600101 6036 PT J 6037 AU He, LQ 6038 Gu, HX 6039 Yin, DK 6040 Zhang, YH 6041 Wang, XS 6042 AF He Li-Qin 6043 Gu Hong-Xia 6044 Yin Deng-Ke 6045 Zhang Yi-Hua 6046 Wang Xiao-Shan 6047 TI Synthesis and Anti-cancer Activity of Nitric Oxide Donor-based Matrine 6048 Derivatives 6049 SO CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE 6050 AB Matrine, one of the major active alkaloids isolated from the Sophora 6051 alopecuroides L which is a useful Chinese herbal drug, possesses 6052 antipyretic, anti-inflammatory, analgesic, and notable antiviral 6053 activities, and has been used for the treatment of 6054 lipopolysaccharide-induced liver injury. Recently, it was reported 6055 that matrine could inhibit the growth of tumor cells. Nitric oxide(NO), 6056 a free radical molecule, is involved in numerous physiological and 6057 pathological processes. High levels of NO usually are toxic to tumor 6058 cells. It was therefore of interest to determine whether the hybrid 6059 of matrine and NO donor furoxan would provide a hitherto unknown class 6060 of matrine derivatives that possess potent anticancer activity. Herein 6061 furoxan-based matrine compounds 11a-11m were designed and synthesized, 6062 and their structures were confirmed by MS, IR, H-1 NMR spectra and 6063 elemental analysis. All target compounds exhibited expectedly much 6064 more stronger anti human hepatocellular carcinoma cells(HepG2 cells) 6065 activity than that of parent compound matrine in vivo. Furthermore, 6066 compounds 11a-11c, 11h and 11i had stronger cytotoxic activities than 6067 that of control 5-flu-orouracil. The concept of designing NO 6068 donor-based matrine derivatives that possess potent anticancer 6069 activity warrants further investigation. 6070 SN 0251-0790 6071 PD AUG 10 6072 PY 2010 6073 VL 31 6074 IS 8 6075 BP 1541 6076 EP 1547 6077 UT ISI:000281590200012 6078 PT J 6079 AU Xiu, AH 6080 Kong, Y 6081 Zhou, MY 6082 Zhu, B 6083 Wang, SM 6084 Zhang, JF 6085 AF Xiu, Aihui 6086 Kong, Yi 6087 Zhou, Mengyi 6088 Zhu, Bin 6089 Wang, Shiming 6090 Zhang, Jianfa 6091 TI The chemical and digestive properties of a soluble glucan from 6092 Agrobacterium sp ZX09 6093 SO CARBOHYDRATE POLYMERS 6094 AB A salt-tolerant strain Agrobacteriurn sp. ZX09 produced a high 6095 molecular mass, water-soluble extracellular polysaccharide (EPS) 6096 composed of D-glucose. By examining periodate oxidation, H-1 NMR and 6097 C-13 NMR spectra, it was proven that the EPS consisted of the following 6098 repeating unit: -> 3)-beta-D-Glcp-(1 -> 3)-[beta-D-Glcp-(1 -> 6099 3)-beta-D-Glcp-(1 -> 3)]3-alpha-D-Glcp-(1 -> 3)-alpha-D-Glcp-(1 -> . 6100 In vitro the EPS was indigestible by alpha-amylase, and strongly 6101 inhibited pancreatic alpha-amylase activity. Fasting mice fed on the 6102 EPS failed to increase blood glucose levels. Experimental diets 6103 containing the EPS suppressed steep increase in blood glucose 6104 concentration. These results suggest that the novel water-soluble 6105 glucan could be potentially useful for decreasing absorption of dietary 6106 carbohydrate and postprandial blood glucose level. (C) 2010 Elsevier 6107 Ltd. All rights reserved. 6108 SN 0144-8617 6109 PD OCT 15 6110 PY 2010 6111 VL 82 6112 IS 3 6113 BP 623 6114 EP 628 6115 DI 10.1016/j.carbpol.2010.05.027 6116 UT ISI:000281524900014 6117 PT J 6118 AU Dai, J 6119 Wu, Y 6120 Chen, SW 6121 Zhu, S 6122 Yin, HP 6123 Wang, M 6124 Tang, JA 6125 AF Dai, Jun 6126 Wu, Yan 6127 Chen, Shang-wei 6128 Zhu, Song 6129 Yin, Hong-ping 6130 Wang, Min 6131 Tang, Jian 6132 TI Sugar compositional determination of polysaccharides from Dunaliella 6133 salina by modified RP-HPLC method of precolumn derivatization with 6134 1-phenyl-3-methyl-5-pyrazolone 6135 SO CARBOHYDRATE POLYMERS 6136 AB A modified high-performance liquid chromatography method of pre-column 6137 derivatization with 1-phenyl-3-methyl-5-pyrazolone (PMP) has been 6138 established for high resolution separation and high sensitivity 6139 determination of ten monosaccharides simultaneously, which frequently 6140 occur in algae polysaccharides. The effects of volume proportion of 6141 acetonitrile and pH value of mobile phase (0.1 M phosphate buffer 6142 acetonitrile) on retention and separation of the monosaccharide 6143 derivatives were investigated with Eclipse XPB-C18 column screened 6144 out. The hydrolyzation condition of polysaccharides and derivatization 6145 procedure of hydrolysates were also optimized. The modified analysis 6146 method was used for the determination of monosaccharide compositions 6147 in five polysaccharide fractions isolated from Duanaliella salina. The 6148 results showed that PD1 and PD4a were acidic heteropolysaccharide 6149 mainly containing glucose and galactose respectively, and PD4a 6150 contained sulfated groups; PD2 and PD3 all were a glucan; while PD4b 6151 was a complex of polysaccharide linked with nucleic acids by covalent 6152 bonds. (C) 2010 Elsevier Ltd. All rights reserved. 6153 SN 0144-8617 6154 PD OCT 15 6155 PY 2010 6156 VL 82 6157 IS 3 6158 BP 629 6159 EP 635 6160 DI 10.1016/j.carbpol.2010.05.029 6161 UT ISI:000281524900015 6162 PT J 6163 AU Wu, JF 6164 Xiang, BR 6165 Li, KX 6166 AF Wu, Jing-Fang 6167 Xiang, Bing-Ren 6168 Li, Kui-Xing 6169 TI Bioequivalence evaluation of menthol after oral administration of 6170 peppermint oil soft capsules in dogs 6171 SO ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH 6172 AB A randomized, two-way, crossover, bio-equivalence study in 6 beagle 6173 dogs was conducted to compare the bioavailability of two peppermint 6174 oil formulations, soft capsule and hard capsule. The drug was given 6175 in a single dose of two capsules (total, 200 mg), and blood samples 6176 were withdrawn during the 12 h after drug administration. Menthol (CAS 6177 2216-51-5) as the main component of peppermint oil was determined by 6178 a gas chromatography-tandem mass spectrometry (GC-MS/MS) method after 6179 cleavage with beta-glocuronidase. The following pharmacokinetic 6180 variables were computed for the two formulations: maximum 6181 concentration (C-max), time to maximum concentration (T-max), 6182 half-life of elimination (t(1/2)), mean residence time (MRT), and areas 6183 under the plasma concentration-time curve (AUC(0-t), and 6184 AUC(0-infinity)). For calculation of the 90% confidence interval (CI), 6185 an analysis of variance (ANOVA) was carried out. 6186 The results indicated that treatment and subject had statistically 6187 significant effect on AUC(0-t), AUC(0-infinity) and C-max, and the 90% 6188 CIs for AUC(0-t), AUC(0-infinity) and C-max were outside the acceptable 6189 bioequivalence range. The relative bioavailability was 121.4 +/- 10.6% 6190 for AUC(0-infinity) Therefore, it can be concluded that the two 6191 formulations are not bioequivalent and the bioavailability of soft 6192 capsules is significantly higher than that of hard capsules. 6193 SN 0004-4172 6194 PY 2010 6195 VL 60 6196 IS 8 6197 BP 479 6198 EP 482 6199 UT ISI:000281581900002 6200 PT J 6201 AU Wang, XS 6202 Liao, JM 6203 Yin, DK 6204 Zhan, F 6205 Dai, SF 6206 Xie, GY 6207 Sang, XB 6208 AF Wang, Xingsheng 6209 Liao, Jianmin 6210 Yin, Dengke 6211 Zhan, Fan 6212 Dai, Sufei 6213 Xie, Guangyan 6214 Sang, Xiaobing 6215 TI Establishment of a Novel Model for Studying the Effects of Extracts 6216 of Chinese Herb Medicine on Human Type II 5 alpha-Reductase in Vitro 6217 SO YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN 6218 AB Human steroid 5 alpha-reductase type II (hSRD5A2) and 6219 dihydrotestosterone (DHT) play important roles in benign prostatic 6220 hyperplasia (BPH). The aim of our study was to establish a novel model 6221 to investigate the inhibitory effects of extracts and compounds of 6222 Chinese herb medicine on hSRD5A2. The gene, hSRD5A2, was artificially 6223 synthesized and cloned into pcDNA3.1 (+) vector, which was transfected 6224 into CHO cells by liposome. Transfected cells were screened through 6225 G418 and MTX. The expressed protein of hSRD5A2 by cells was purified 6226 and detected by western blotting. A minim reactive system comprising 6227 hSRD5A2 and testosterone (T) as substrate together with NADPH as 6228 hydrogen donor was established for screening inhibitors of hSRD5A2. 6229 The reaction system was optimized in the concentrations of T, NADPH, 6230 and hSRD5A2 and reaction temperature, time, and activity of hSRD5A2 6231 were determined by the production of DHT. Furthermore, we screened some 6232 extracts and compounds of Chinese herb medicine using this model. The 6233 concentrations of T, NADPH, and hSRD5A2 were 0.02 mu M, 0.8 mM, and 6234 0.05 U/mu l, respectively, in the model; maximum activity of hSRD5A2 6235 was achieved at 37 degrees C and 60 min reaction, and mangiferin had 6236 significant inhibitory effect on the activity of hSRD5A2. The model 6237 in this study is convenient and reliable for screening and evaluation 6238 of inhibitors of hSRD5A2; mangiferin may be a potential medicine for 6239 the treatment of BPH. 6240 SN 0031-6903 6241 PD SEP 6242 PY 2010 6243 VL 130 6244 IS 9 6245 BP 1207 6246 EP 1214 6247 UT ISI:000281433800012 6248 PT J 6249 AU Hong, JL 6250 Qin, XY 6251 Shu, P 6252 Wu, G 6253 Wang, QA 6254 Qin, MJ 6255 AF Hong, Jun-Li 6256 Qin, Xiao-Ying 6257 Shu, Pan 6258 Wu, Gang 6259 Wang, Qiang 6260 Qin, Min-Jian 6261 TI Analysis of catalpol derivatives by characteristic neutral losses 6262 using liquid chromatography combined with electrospray ionization 6263 multistage and time-of-flight mass spectrometry 6264 SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY 6265 SN 0951-4198 6266 PD SEP 6267 PY 2010 6268 VL 24 6269 IS 17 6270 BP 2680 6271 EP 2686 6272 DI 10.1002/rcm.4676 6273 UT ISI:000281355000026 6274 PT J 6275 AU Ma, C 6276 Gao, MM 6277 Liu, WC 6278 Zhu, J 6279 Tian, H 6280 Gao, XD 6281 Yao, WB 6282 AF Ma, Chen 6283 Gao, Mingming 6284 Liu, Wenchao 6285 Zhu, Jing 6286 Tian, Hong 6287 Gao, Xiangdong 6288 Yao, Wenbing 6289 TI Intein-Mediated Expression and Purification of an Analog of 6290 Glucagon-like Peptide-1 in Escherichia coli 6291 SO PROTEIN AND PEPTIDE LETTERS 6292 AB To facilitate expression and purification of an analog of GLP-1 6293 (mGLP-1), an intein system was employed in this study. A recombinant 6294 fusion protein, CBD-DnaB-mGLP-1, was constructed and expressed in the 6295 form of inclusion body. After refolding, the intein-mediated 6296 self-cleavage was triggered by pH and temperature shift. By using 6297 chitin beads column followed by single step purification, about 2.58 6298 mg of mGLP-1 with the purity of up to 98% could be obtained from 1 L 6299 medium. Tricine-SDS-PAGE, RP-HPLC, and ESI-MS were undertaken to 6300 determine the purity and molecular weight of mGLP-1. The 6301 glucose-lowering activity of mGLP-1 was also preliminarily determined. 6302 SN 0929-8665 6303 PY 2010 6304 VL 17 6305 IS 10 6306 BP 1245 6307 EP 1250 6308 UT ISI:000281430400009 6309 PT J 6310 AU Zhou, JP 6311 Ni, SJ 6312 Zhang, HB 6313 Qian, H 6314 Chi, YS 6315 Huang, WL 6316 Yu, L 6317 Hu, XW 6318 Chen, W 6319 AF Zhou, Jinpei 6320 Ni, Shuaijian 6321 Zhang, Huibin 6322 Qian, Hai 6323 Chi, Yushi 6324 Huang, Wenlong 6325 Yu, Lu 6326 Hu, Xiaowen 6327 Chen, Wei 6328 TI Synthesis and Bioactivity Evaluation of Dipeptidyl Peptidase IV 6329 Resistant Glucagon-like Peptide-1 Analogues 6330 SO PROTEIN AND PEPTIDE LETTERS 6331 AB Glucagon-like peptide -1 (GLP-1) is an incretin hormone displaying 6332 glucose-dependent stimulation of insulin secretion and trophic effects 6333 on the pancreatic beta-cells. However, GLP-1 is rapidly degraded to 6334 GLP-1(9-36) by dipeptidyl peptidase-IV (DPP-IV), which removes the 6335 N-terminal dipeptide His(7)-Ala(8). The rapid inactivation of GLP-1 6336 in the blood circulation limits its clinical application. Hence, we 6337 replaced the enzymatic hydrolyzation position Ala(8) with other 6338 natural amino acids. The GLP-1 analogues were synthesized rapidly and 6339 efficiently under microwave irradiation, using Fmoc/tBu orthogonal 6340 protection strategy. Studies on blood-glucose-lowering effect of GLP-1 6341 analogues in vivo were undertaken using 10-week-old male Kunming mice. 6342 The metabolic stability was tested by incubation with dipeptidyl 6343 peptidase-IV (DPP-IV). Generally, Xaa(8)-GLP-1 analogues exhibit 6344 resistance to DPP-IV degradation in vitro and stronger hypoglycemic 6345 effect than GLP-1. This may help to understand the structure-activity 6346 relationship of GLP-1 analogues. 6347 SN 0929-8665 6348 PY 2010 6349 VL 17 6350 IS 10 6351 BP 1290 6352 EP 1295 6353 UT ISI:000281430400016 6354 PT J 6355 AU Wang, X 6356 Yao, J 6357 Zhou, JP 6358 Lu, Y 6359 Wang, W 6360 AF Wang, X. 6361 Yao, J. 6362 Zhou, J. P. 6363 Lu, Y. 6364 Wang, W. 6365 TI Synthesis and evaluation of chitosan-graft-polyethylenimine as a gene 6366 vector 6367 SO PHARMAZIE 6368 AB The objective of this study was to prepare a series of 6369 chitosan-graft-polyethylenimine (chitosan-g-PEI) copolymers as gene 6370 carriers with high transfection efficiency and low cytotoxicity. 6371 Chitosan-g-PEIs with different molecular weights and segments were 6372 successfully synthesized by both oxidation and imine reactions and then 6373 characterized by H-1 NMR, IR, UV and DSC. All types of Chitosan-g-PEIs 6374 prepared were found to interact efficiently with plasmid DNA 6375 (pIRES2-EGFP-p53) on DNA retardation assays. The Chitosan-g-PEI/DNA 6376 complex had a diameter of approximately 200 nm and a surface potential 6377 of zeta = +10.0 mV when the N/P ratio was 15/1. Optimal transfection 6378 efficiency of the chitosan-g-PEI/DNA complex was observed at N/P = 45/1 6379 on HepG2 cells, with significantly lower toxicity compared with the 6380 gold standard PEI 25 kd. Moreover, the results showed that the toxicity 6381 increased with increasing molecular weight of the PEI segment in 6382 chitosan-g-PEI. Based on these results, chitosan-g-PEI with different 6383 chitosan and PEI segments of could be used for gene expression on 6384 different levels, and some of them may appear as potential candidates 6385 for gene delivery systems. 6386 SN 0031-7144 6387 PD AUG 6388 PY 2010 6389 VL 65 6390 IS 8 6391 BP 572 6392 EP 579 6393 DI 10.1691/ph.2010.9422 6394 UT ISI:000281349100003 6395 PT J 6396 AU Wu, GQ 6397 Wu, HB 6398 Fan, XB 6399 Zhao, R 6400 Li, XF 6401 Wang, SL 6402 Ma, YH 6403 Shen, ZL 6404 Xi, T 6405 AF Wu, Guoqiu 6406 Wu, Hongbin 6407 Fan, Xiaobo 6408 Zhao, Rui 6409 Li, Xiaofang 6410 Wang, Shenglan 6411 Ma, Yihua 6412 Shen, Zilong 6413 Xi, Tao 6414 TI Selective toxicity of antimicrobial peptide S-thanatin on bacteria 6415 SO PEPTIDES 6416 AB S-thanatin, an analog of thanatin, was synthesized by substituting the 6417 15th amino acid of threonine with serine, which showed a broad 6418 antimicrobial activity against bacteria. We reported earlier that 6419 membrane phospholipid was found to be the target for S-thanatin with 6420 different mechanism from other antimicrobial peptides. In this study, 6421 we have performed its structural characterization by circular 6422 dichroism (CD) spectroscopy. The CD analysis showed that S-thanatin 6423 retained its overall conformation beta-sheet in aqueous buffer, 6424 beta-turn in 50% trifluoroethanol (TFE) and beta-hairpin in 0.4 mM 6425 POPC-LUVs. In hemolysis assay, S-thanatin exhibited low hemolytic 6426 activity and bacteria selectivity. We investigated the effect of the 6427 presence of 33 mol percent cholesterol on the interactions of the 6428 antimicrobial peptide S-thanatin with phosphatidylcholine (PC) model 6429 membrane systems. The results showed that S-thanatin was more potent 6430 at disrupting cholesterol-free bacterial than cholesterol-containing 6431 eukaryotic membranes. Thus, in all respects, fluorescence dye leakage 6432 experiments indicated that cholesterol inhibited the 6433 S-thanatin-induced permeabilization of PC vesicles. Finally, flow 6434 cytometry was used to monitor changes in bacterial cell membrane 6435 potential and cell membrane integrity, with specific fluorescent dyes 6436 DiBAC(4)(3) and PI. Adding the respiratory poison CCCP seemed to 6437 prevent peptide-induced membrane damage, which suggested that 6438 S-thanatin acted at the metabolic level on respiratory chain. These 6439 findings might explain why S-thanatin was selective toxicity towards 6440 bacteria, but low toxicity towards erythrocytes. It might be due to 6441 three factors at least: electrostatic interaction (namely anionic 6442 phospholipids); cholesterol; respiratory chain. (C) 2010 Elsevier Inc. 6443 All rights reserved. 6444 SN 0196-9781 6445 PD SEP 6446 PY 2010 6447 VL 31 6448 IS 9 6449 BP 1669 6450 EP 1673 6451 DI 10.1016/j.peptides.2010.06.009 6452 UT ISI:000281368400007 6453 PT J 6454 AU Lin, GW 6455 Wang, Y 6456 Zhou, QF 6457 Tang, WF 6458 Wang, JA 6459 Lu, T 6460 AF Lin, Guowu 6461 Wang, Yue 6462 Zhou, Qingfa 6463 Tang, Weifang 6464 Wang, Jian 6465 Lu, Tao 6466 TI A Facile Synthesis of 3-Substituted 9H-Pyrido[3,4-b]indol-1(2H)-one 6467 Derivatives from 3-Substituted beta-Carbolines 6468 SO MOLECULES 6469 AB A mild and efficient two-step synthesis of 3-substituted 6470 beta-carbolinone derivatives from 3-substituted beta-carboline in 6471 good yields is described. A possible reaction mechanism for the 6472 formation of the skeleton of beta-carbolin-1-one is proposed. The 6473 structures of these compounds were established by IR, H-1-NMR, 6474 C-13-NMR, mass spectrometry and elemental analysis, as well as X-ray 6475 crystallographic analysis of 4-2 and 6-2. 6476 SN 1420-3049 6477 PD AUG 6478 PY 2010 6479 VL 15 6480 IS 8 6481 BP 5680 6482 EP 5691 6483 DI 10.3390/molecules15085680 6484 UT ISI:000281481100037 6485 PT J 6486 AU Dong, J 6487 Yao, SW 6488 Zhou, XD 6489 Zhang, LJ 6490 Xu, YG 6491 AF Dong, Jin 6492 Yao, Shuowei 6493 Zhou, Xiaodong 6494 Zhang, Lijuan 6495 Xu, Yungen 6496 TI Synthesis of N-Heteroaroyl Aminosaccharide Derivatives as Fibroblast 6497 Growth Factor 2 Signaling Modulators 6498 SO CHEMICAL & PHARMACEUTICAL BULLETIN 6499 AB Fibroblast growth factor 2 (FGF2) signaling plays an important role 6500 in angiogenesis. Heparin/heparan sulfate (HS) is required for FGF2 6501 signaling but heparin mimics either promotes or inhibits FGF2 6502 signaling. To take advantage such properties of heparin mimics, a 6503 series of N-heteroaroyl aminosaccharide derivatives were designed and 6504 synthesized as FGF2 signaling modulators. The bioactivity was 6505 determined in a FGF2 and heparin-dependent cell proliferation assay 6506 using FGFR1c expressing BaF3 cells. We found that most of the compounds 6507 inhibited heparin- and FGF2-dependent BaF3 cell proliferation while 6508 three compounds promoted the cell proliferation. These results suggest 6509 that the small molecular heparin mimics approach might be useful in 6510 developing novel anti-angiogenic agents. 6511 SN 0009-2363 6512 PD SEP 6513 PY 2010 6514 VL 58 6515 IS 9 6516 BP 1210 6517 EP 1215 6518 UT ISI:000281436900014 6519 PT J 6520 AU Zhang, HW 6521 Zhang, H 6522 Zhang, YQ 6523 Ng, SS 6524 Ren, FL 6525 Wang, YY 6526 Duan, YQ 6527 Chen, L 6528 Zhai, YG 6529 Guo, QL 6530 Chang, ZJ 6531 AF Zhang, Haiwei 6532 Zhang, Hui 6533 Zhang, Yanquan 6534 Ng, Ser Sur 6535 Ren, Fangli 6536 Wang, Yingying 6537 Duan, Yaqi 6538 Chen, Lin 6539 Zhai, Yonggong 6540 Guo, Qinglong 6541 Chang, Zhijie 6542 TI Dishevelled-DEP domain interacting protein (DDIP) inhibits Wnt 6543 signaling by promoting TCF4 degradation and disrupting the 6544 TCF4/beta-catenin complex 6545 SO CELLULAR SIGNALLING 6546 AB The TCF4/beta-catenin complex, the executor of canonical 6547 Wnt/beta-catenin signaling, is regulated by a variety of factors. Among 6548 these, Dishevelled (Dvl) is a critical regulator that releases 6549 beta-catenin from degradation and stabilizes TCF4/beta-catenin 6550 complex. Here, we report that DDIP (Dishevelled-DEP domain Interacting 6551 Protein, also named as Spats1. spermatogenesis associated, serine-rich 6552 1), a novel protein that interacts with Dvl, regulates Wnt signaling. 6553 We provide evidence that DDIP suppresses Lef-1 luciferase reporter 6554 activity stimulated by Wnt1. Dvl2 or beta-catenin, interacts with the 6555 TCF4/beta-catenin complex, and disrupts the interaction of TCF4 and 6556 beta-catenin by promoting TCF4 degradation through the proteasome 6557 pathway. Our results indicate that DDIP is a negative regulator of the 6558 canonical Wnt signaling. (C) 2010 Elsevier Inc. All rights reserved. 6559 SN 0898-6568 6560 PD NOV 6561 PY 2010 6562 VL 22 6563 IS 11 6564 BP 1753 6565 EP 1760 6566 DI 10.1016/j.cellsig.2010.06.016 6567 UT ISI:000281463500018 6568 PT J 6569 AU Song, M 6570 Zhao, H 6571 Wang, L 6572 Yang, L 6573 Hang, TJ 6574 Wen, AD 6575 AF Song, Min 6576 Zhao, Hua 6577 Wang, Li 6578 Yang, Lin 6579 Hang, Taijun 6580 Wen, Aidong 6581 TI Development and validation of a robust LC-MS-MS with atmospheric 6582 pressure chemical ionization for quantitation of carbazochrome sodium 6583 sulfonate in human plasma: application to a pharmacokinetic study 6584 SO BIOMEDICAL CHROMATOGRAPHY 6585 AB A highly selective and sensitive liquid chromatography coupled with 6586 atmospheric pressure chemical ionization tandem mass spectrometry 6587 (LC-APCI-MS-MS) was developed and validated for the quantitation and 6588 pharmacokinetic study of carbazochrome sodium sulfonate in human 6589 plasma. Protein precipitation with 14% perchloric acid solution was 6590 selected for sample preparation, and amiloride hydrochloride was 6591 employed as an internal standard. The analytes were separated on a 6592 Hypersil ODS-2 column by a multiple-step linear gradient elution with 6593 a mobile phase consisting of 0.2% formic acid solution and methanol 6594 pumped at a flow rate of 1.0 mL/min. The determination was optimized 6595 and carried out with positive atmospheric pressure chemical ionization 6596 by selective reaction monitoring of the ion of m/z 148, the protonated 6597 thermodegraded fragment of the free acidic form of carbazochrome sodium 6598 sulfonate selected as the parent, and the ion of m/z 107 as the optimum 6599 collision induced dissociation (CID) product. The method was fully 6600 validated over a concentration range of 0.5-50 ng/mL, with the lower 6601 limit of quantitation of 0.5 ng/mL. The application of the LC-MS-MS 6602 method was demonstrated for the specific and quantitative analysis of 6603 carbazochrome sodium sulfonate in human plasma from a pharmacokinetic 6604 study in 24 healthy male Chinese volunteers after a single oral 6605 administration of 90 mg carbazochrome sodium sulfonate capsules. 6606 Copyright (C) 2010 John Wiley & Sons, Ltd. 6607 SN 0269-3879 6608 PD SEP 6609 PY 2010 6610 VL 24 6611 IS 9 6612 BP 990 6613 EP 999 6614 DI 10.1002/bmc.1397 6615 UT ISI:000281424600012 6616 PT J 6617 AU Liu, YD 6618 Ma, SP 6619 Qu, R 6620 AF Liu, Yadong 6621 Ma, Shiping 6622 Qu, Rong 6623 TI SCLM, total saponins extracted from Chaihu-jia-longgu-muli-tang, 6624 reduces chronic mild stress-induced apoptosis in the hippocampus in 6625 mice 6626 SO PHARMACEUTICAL BIOLOGY 6627 AB Increasing evidence demonstrates that stress or depression can lead 6628 to atrophy and cell loss in the hippocampus. In contrast, 6629 antidepressant treatment significantly reduces apoptosis in the 6630 dentate granule cell layer and subgranular zone in animal models of 6631 depression. In the present study, we investigated the neuroprotective 6632 action of SCLM, the total saponins extracted from 6633 Chaihu-jia-longgu-muli-tang, a traditional Chinese medicinal formula 6634 which was prescribed 1000 years ago, in the reduction of apoptosis in 6635 hippocampal neurons using an experimental chronic mild stress (CMS) 6636 model. Mice were subjected to the CMS procedure for a period of 21 6637 consecutive days. SCLM (100 mg/kg, p.o.) or fluoxetine (20 mg/kg, p.o.) 6638 was administered during the stress periods. CMS mice showed a decreased 6639 sucrose intake over 21 days, and an increase in the number of 6640 TUNEL-positive neurons as well as up-regulation of the 6641 apoptotic-related factors, such as Bax and caspase-3 in the 6642 hippocampus, compared with control mice. On the other hand, the 6643 administration of SCLM (100 mg/kg) and fluoxetine (20 mg/kg) reversed 6644 these effects induced by CMS, showing a significant increase of sucrose 6645 intake and a dramatic reduction of TUNEL-positive neurons and decreased 6646 expression of Bax and caspase-3 proteins. The present results suggest 6647 that SCLM possesses a significant antidepressant-like property, and 6648 this effect may be through protection against stress-induced neuronal 6649 apoptosis by affecting the expression of Bax and caspase-3 proteins 6650 in the hippocampus. These findings provide important information that 6651 the anti-apoptotic effect of herbal medicine therapy may be beneficial 6652 for the treatment of depression. 6653 SN 1388-0209 6654 PD AUG 6655 PY 2010 6656 VL 48 6657 IS 8 6658 BP 840 6659 EP 848 6660 DI 10.3109/13880200903296154 6661 UT ISI:000281304800001 6662 PT J 6663 AU Song, JX 6664 Kou, JP 6665 Huang, YL 6666 Yu, BY 6667 AF Song, Jiaxi 6668 Kou, Junping 6669 Huang, Yalin 6670 Yu, Boyang 6671 TI Ruscogenin Mainly Inhibits Nuclear Factor-kappa B but Not Akt and 6672 Mitogen-Activated Protein Kinase Signaling Pathways in Human Umbilical 6673 Vein Endothelial Cells 6674 SO JOURNAL OF PHARMACOLOGICAL SCIENCES 6675 AB Our previous results suggested that ruscognin inhibited tumor necrosis 6676 factor alpha (TNF-alpha)-induced leukocyte adhesion, which correlated 6677 with its suppression of intercellular adhesion molecule-1 (ICAM-1) 6678 expression in endothelial cells. In the present studies, we further 6679 examined its effects on the main signaling pathways involved in 6680 upregulation of ICAM-1 induced by TNF-alpha in human umbilical vein 6681 endothelial cells (HUVECs). The results showed that ruscogenin 6682 significantly suppressed p65 phosphorylation, I kappa B-alpha 6683 phosphorylation and degration, and inhibited I kappa B kinase alpha 6684 (IKK alpha) and IKK beta activation induced by TNF-alpha. However, it 6685 exerted weak effects on TNF-alpha-induced phosphorylations of p38, 6686 JNK, ERK1/2, and Akt. Overall, our results indicated that 6687 downregulation of ICAM-1 expression by ruscogenin in HUVECs might be 6688 mediated by nuclear factor-kappa B (NF-kappa B), but not by 6689 mitogen-activated protein kinase (MAPK) and Akt signaling pathways. 6690 SN 1347-8613 6691 PD AUG 6692 PY 2010 6693 VL 113 6694 IS 4 6695 BP 409 6696 EP 413 6697 DI 10.1254/jphs.10076SC 6698 UT ISI:000281166400017 6699 PT J 6700 AU Hong, J 6701 Jiao, Y 6702 He, WJ 6703 Guo, ZJ 6704 Yu, Z 6705 Zhang, JF 6706 Zhu, LG 6707 AF Hong, Jin 6708 Jiao, Yang 6709 He, Weijiang 6710 Guo, Zijian 6711 Yu, Zhen 6712 Zhang, Junfeng 6713 Zhu, Longgen 6714 TI His-Oriented Peptide Hydrolysis Promoted by cis-[Pt(en)(H2O)(2)](2+): 6715 a New Specific Peptide Cleavage Site 6716 SO INORGANIC CHEMISTRY 6717 AB The new specific hydrolysis of histidine-containing peptides promoted 6718 by cis-[Pt(en)(H2O)(2)](2+) was investigated by electrospray 6719 ionization mass spectrometry (ESI-MS) and nuclear magnetic resonance 6720 spectrometry (NMR). MS determination demonstrated that 6721 cis-[Pt(en)(H2O)(2)](2+) anchors to AcGHG with the stoichiometry of 6722 either 1:1 or 2:1 (Pt/peptide), but only with 1:1 stoichoimetiy to 6723 AcGHL. Cis-[Pt(en)(H2O)(2)](2+) is able to promote the cleavage of the 6724 first downstream peptide bond from histidine at 60 degrees C and pH 6725 2.65, and Pt-anchored peptides are the essential intermediates for the 6726 promoted hydrolysis. Moreover, the larger amount of Pt(II) complex 6727 results in higher fragmental yield and higher hydrolysis rate. In the 6728 presence of 1 equiv of Pt(II) complex, H-1 NMR determination confirmed 6729 the apparent first-order kinetics of the Pt(II)-promoted hydrolysis 6730 and the hydrolysis rate for AcGHG and AcGHL is 0.20 day(-1) and 0.14 6731 day(-1), respectively. Moreover, Pt(II) coordinating to histidine 6732 imidazole is the key step to form the Pt(II)-anchored peptides. The 6733 Pt(II)-activating the first His-downstream carbonyl group via synergic 6734 coordinating to His imidazole and carbonyl O atom has been proposed 6735 for the Pt(II)-promoted his-oriented peptide hydrolysis. The lower 6736 rate for AcGHL should be correlated to the steric hindrance of Leu side 6737 chain to the second Pt(II) coordinating to tripeptide. In addition, 6738 the newly confirmed specific His-oriented peptide cleavage site 6739 implies a new potential strategy for target cleavage of peptides or 6740 proteins. 6741 SN 0020-1669 6742 PD SEP 6 6743 PY 2010 6744 VL 49 6745 IS 17 6746 BP 8148 6747 EP 8154 6748 DI 10.1021/ic101191m 6749 UT ISI:000281231800071 6750 PT J 6751 AU Xu, HA 6752 Gao, XH 6753 Song, L 6754 Wang, FY 6755 Xu, Z 6756 Lu, D 6757 Xu, XX 6758 Xia, YF 6759 Dai, Y 6760 AF Xu, Huan 6761 Gao, Xinghua 6762 Song, Jie 6763 Wang, Fengyun 6764 Xu, Zhao 6765 Lu, Dan 6766 Xu, Xianxiang 6767 Xia, Yufeng 6768 Dai, Yue 6769 TI Peoniflorin Prevents the Adhesion Between Inflammatory Endothelial 6770 Cells and Leukocytes Through Inhibiting the Activation of MAPKs and 6771 NF-kappa B 6772 SO DRUG DEVELOPMENT RESEARCH 6773 AB The vascular endothelium can be activated by multiple factors, 6774 including lipopolysaccharide (LPS) functioning as a key component of 6775 the inflammatory response. Activated endothelium promotes the 6776 recruitment of leukocytes mainly by releasing various adhesion 6777 molecules and amplifies inflammation via a feedback loop. Peoniflorin, 6778 the main active constituent of the roots of Paeonia lactiora Pall., 6779 possesses anti-inammatory, anti-infective, and anti-platelet 6780 aggregative properties. To elucidate the anti-inammatory mechanism of 6781 peoniflorin, the present study was conducted to address its effects 6782 on the adhesion of inflammatory endothelial cells to leukocytes. 6783 Peoniflorin substantially reduced adhesion of either human acute 6784 monocytic leukemia cells (THP-1) or human acute promyelocytic leukemia 6785 cells (HL-60) to LPS-stimulated human umbilical vein endothelial cells 6786 (HUVECs). It also markedly down-regulated the expression of E-selectin 6787 at both the gene and protein levels. However, peoniflorin only slightly 6788 reduced expression of intercellular adhesion molecule-1 (ICAM-1). 6789 Signal pathway analysis indicated that peoniflorin reduced 6790 phosphorylation of c-Jun NH2-terminal kinase (JNK) and p38 kinase, as 6791 well as the phosphorylation and degradation of I kappa B-alpha in 6792 HUVECs. These findings suggest that prevention of the adhesion between 6793 inflammatory endothelial cells and leukocytes contributes, at least 6794 partially, to the anti-inflammation action of peoniflorin. The 6795 anti-adhesion mechanisms of peoniflorin were involved in the 6796 down-regulation of the activation of mitogen-activated protein kinases 6797 (MAPKs) and nuclear factor-kappa B (NF-kappa B), and a reduction of 6798 adhesion molecule expressions in endothelial cells. Drug Dev Res 6799 71:275-284, 2010. (C) 2010 Wiley-Liss, Inc. 6800 SN 0272-4391 6801 PD AUG 6802 PY 2010 6803 VL 71 6804 IS 5 6805 BP 275 6806 EP 284 6807 DI 10.1002/ddr.20372 6808 UT ISI:000281337000001 6809 PT J 6810 AU Guo, XA 6811 Chen, CL 6812 Yang, QA 6813 Yin, YM 6814 You, QD 6815 Tang, YQ 6816 AF Guo, Xiang 6817 Chen, Chun-Lin 6818 Yang, Qian 6819 Yin, Yue-Miao 6820 You, Qi-Dong 6821 Tang, Yi-Qun 6822 TI Effects of a Novel Class III Antiarrhythmic Agent, CPUY11018, on Rat 6823 Atrial Fibrillation 6824 SO DRUG DEVELOPMENT RESEARCH 6825 AB CPUY11018 has anti-atrial fibrillation (AF) effects in rats. The 6826 effects of CPUY11018 on the transient outward K+ current (I-to) and 6827 ultra-rapid delayed rectifier K+ current (I-Kur) were studied using 6828 whole-cell patch clamp techniques and an acetylcholine (ACh)-CaCl2 6829 induced AF model. CPUY11018 inhibited I-to and I-kur in a 6830 concentration-dependent manner with IC50 values of 18.5 and 1.7 mu M, 6831 respectively. Inhibition was independent of the depolarizing voltage. 6832 In the AF ACh-CaCl2 model, AF duration was effectively shortened after 6833 treatment with 5 mg/kg CPUY11018 for 4 days. These results indicate 6834 that CPUY11018 is effective in treating AF partly by blocking I-to and 6835 I-kur. Drug Dev Res 71:303-312, 2010. (C) 2010 Wiley-Liss, Inc. 6836 SN 0272-4391 6837 PD AUG 6838 PY 2010 6839 VL 71 6840 IS 5 6841 BP 303 6842 EP 312 6843 DI 10.1002/ddr.20375 6844 UT ISI:000281337000004 6845 PT J 6846 AU Zhang, Y 6847 Huo, MR 6848 Zhou, JP 6849 Xie, SF 6850 AF Zhang, Yong 6851 Huo, Meirong 6852 Zhou, Jianping 6853 Xie, Shaofei 6854 TI PKSolver: An add-in program for pharmacokinetic and pharmacodynamic 6855 data analysis in Microsoft Excel 6856 SO COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE 6857 AB This study presents PKSolver, a freely available menu-driven add-in 6858 program for Microsoft Excel written in Visual Basic for Applications 6859 (VBA), for solving basic problems in pharmacokinetic (PK) and 6860 pharmacodynamic (PD) data analysis. The program provides a range of 6861 modules for PK and PD analysis including noncompartmental analysis 6862 (NCA), compartmental analysis (CA), and pharmacodynamic modeling. Two 6863 special built-in modules, multiple absorption sites (MAS) and 6864 enterohepatic circulation (EHC), were developed for fitting the 6865 double-peak concentration-time profile based on the classical 6866 one-compartment model. In addition, twenty frequently used 6867 pharmacokinetic functions were encoded as a macro and can be directly 6868 accessed in an Excel spreadsheet. To evaluate the program, a detailed 6869 comparison of modeling PK data using PKSolver and professional PK/PD 6870 software package WinNonlin and Scientist was performed. The results 6871 showed that the parameters estimated with PKSolver were satisfactory. 6872 In conclusion, the PKSolver simplified the PK and PD data analysis 6873 process and its output could be generated in Microsoft Word in the form 6874 of an integrated report. The program provides pharmacokinetic 6875 researchers with a fast and easy-to-use tool for routine and basic PK 6876 and PD data analysis with a more user-friendly interface. (C) 2010 6877 Elsevier Ireland Ltd. All rights reserved. 6878 SN 0169-2607 6879 PD SEP 6880 PY 2010 6881 VL 99 6882 IS 3 6883 BP 306 6884 EP 314 6885 DI 10.1016/j.cmpb.2010.01.007 6886 UT ISI:000281337700008 6887 PT J 6888 AU Yang, F 6889 Du, YX 6890 Chen, B 6891 Fan, QF 6892 Xu, GF 6893 AF Yang, Fan 6894 Du, Yingxiang 6895 Chen, Bin 6896 Fan, Qingfeng 6897 Xu, Guangfu 6898 TI Enantiomeric Separation of Nefopam Hydrochloride by Affinity 6899 Electrokinetic Chromatography Using Chondroitin Sulfate A as Chiral 6900 Selector and Its Chiral Recognition Mechanism 6901 SO CHROMATOGRAPHIA 6902 AB In this study, a new approach to the enantioseparation of nefopam 6903 hydrochloride by means of affinity electrokinetic chromatography 6904 (AEKC) with chondroitin sulfate A belonging to linear ionic 6905 polysaccharides has been developed. The difference in the 6906 antinociceptive activity of the enantiomers of nefopam was 6907 demonstrated in some studies, and the method established in this paper 6908 allowed complete separation of nefopam. Especially, there are no 6909 reports concerned with the enantioselective separation of nefopam 6910 using chondroitin sulfate A as chiral selectors in CE. During the course 6911 of this work, both migration time and enantioseparation of nefopam were 6912 influenced by several parameters such as pH of the BGE, selector 6913 concentration, capillary temperature and applied voltage. 6914 Consequently, these parameters were systematically optimized in order 6915 to obtain the optimum enantioseparation of nefopam. Moreover, 6916 comparison of the influences of the studied parameters was further 6917 investigated using univariate analysis of variance as a calculation 6918 method by Statistical Product and Service Solutions (SPSS) in this 6919 paper. Finally, a mechanism of enantiorecognition in AEKC towards the 6920 enantiomers of nefopam with chondroitin sulfate A was described. 6921 SN 0009-5893 6922 PD SEP 6923 PY 2010 6924 VL 72 6925 IS 5-6 6926 BP 489 6927 EP 493 6928 DI 10.1365/s10337-010-1670-2 6929 UT ISI:000281174300017 6930 PT J 6931 AU Wu, GQ 6932 Fan, XB 6933 Wu, HB 6934 Liu, NF 6935 Li, XF 6936 Gou, LX 6937 Nie, Y 6938 Zhao, R 6939 Xi, T 6940 AF Wu, Guoqiu 6941 Fan, Xiaobo 6942 Wu, Hongbin 6943 Liu, Naifeng 6944 Li, Xiaofang 6945 Gou, Lixia 6946 Nie, Yu 6947 Zhao, Rui 6948 Xi, Tao 6949 TI Bioscreening of phage display antibody library and expression of a 6950 humanized single-chain variable fragment antibody against human 6951 connective tissue growth factor (CTGF/CCN2) 6952 SO BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY 6953 AB Excessive expression of CTGF (connective tissue growth factor)/CCN2 6954 has been observed in many fibrotic diseases. The inhibition of the 6955 CTGF/CCN2 by antibody has been shown to be clinically useful for the 6956 management of fibrosis. A phage display humanized single-chain Fv 6957 antibody library was screened using CTGF/C (CTGF/CCN2 C-terminal 6958 domain) as the target. A phage ELISA was performed after four rounds 6959 of biopanning, and ten positive clones were further evaluated by ELISA 6960 and were chosen for DNA sequencing. The DNA encoding scFv (single-chain 6961 variable fragment) containing a full-length variable domain fragment 6962 of heavy chain and light chain of human immunoglobulin was inserted 6963 into pET-32(a)+ vector, and the fusion protein (TrxA-scFv) containing 6964 a thrombin cleavage site was expressed mainly in soluble form. The scFv 6965 was obtained by purified fusion protein digested with thrombin and then 6966 separated from the fusion partner TrxA by gel-filtration 6967 chromatography. An immunological assay showed that the purified scFv 6968 reacted with CTGF/CCN2 in a concentration-dependent manner. The result 6969 of the cell migration assay demonstrated that the scFv at 100 ng/ml 6970 could effectively inhibit the migration of HUVEC (human umbilical-vein 6971 endothelial cells) caused by CTGF/C. The number of migratory cells was 6972 significantly decreased as compared with the negative control (1062 6973 +/- 92 versus 3269 +/- 288, P < 0.001) and the inhibition rate was 90.5%. 6974 SN 0885-4513 6975 PD JUL 6976 PY 2010 6977 VL 56 6978 PN Part 3 6979 BP 95 6980 EP 102 6981 DI 10.1042/BA20100031 6982 UT ISI:000281317000002 6983 PT J 6984 AU Gu, Y 6985 Wang, GJ 6986 Wu, XL 6987 Zheng, YT 6988 Zhang, JW 6989 Ai, H 6990 Sun, JG 6991 Jia, YW 6992 AF Gu, Y. 6993 Wang, G. -J. 6994 Wu, X. -L. 6995 Zheng, Y. -T. 6996 Zhang, J. -W. 6997 Ai, H. 6998 Sun, J. -G. 6999 Jia, Y. -W. 7000 TI Intestinal absorption mechanisms of ginsenoside Rh2: 7001 stereoselectivity and involvement of ABC transporters 7002 SO XENOBIOTICA 7003 AB 1. This study investigated the absorption mechanism of ginsenoside Rh2 7004 to clarify the reasons for its poor absorption. Transepithelial 7005 transport across Caco-2 cell monolayers, cellular uptake, and in situ 7006 rat intestinal perfusion were examined. 7007 2. Cellular uptake of Rh2 was linear from 1 to 50 mu M at 4 degrees 7008 C, whereas it was saturated when the concentration exceeded 10 mu M 7009 at 37 degrees C. At 37 degrees C, the uptake at 10 mu M was linear in 7010 60 min. Intracellular exposure in 240 min was 2173.70 and 979.38 ng . 7011 min/mu g for S and R isomers, respectively. 7012 3. Transepithelial permeability of Rh2 was about 10(-8) to 10(-7) cm/s. 7013 Efflux ratios were above 1.5. Sodium dodecyl sulfate, sodium citrate, 7014 and sodium deoxycholate had no effect on Rh2 permeability. 7015 4. After intestinal perfusion for 3 h, 9.1% of 20(R)- Rh2 and 15.7% 7016 of 20(S)- Rh2 were absorbed. 7017 5. Cyclosporine, quercetin, and probenecid could improve the cellular 7018 uptake, absorptive permeability, and intestinal absorption. 7019 Carrier-mediated transport was the major absorption mechanism. Rh2 was 7020 a substrate of ABC transporters. 7021 6. The ABC-transporter-mediated efflux and the poor permeability were 7022 the major reasons for Rh2 poor absorption. 7. The stereoselective 7023 absorption was significant. R isomer exhibited lower absorption 7024 profiles in all the experiments, possibly due to more potent efflux. 7025 SN 0049-8254 7026 PD SEP 7027 PY 2010 7028 VL 40 7029 IS 9 7030 BP 602 7031 EP 612 7032 DI 10.3109/00498254.2010.500744 7033 UT ISI:000280993500002 7034 PT J 7035 AU Zhao, Q 7036 Wang, J 7037 Zou, MJ 7038 Hu, R 7039 Zhao, L 7040 Qiang, L 7041 Rong, JJ 7042 You, QD 7043 Guo, QL 7044 AF Zhao, Qing 7045 Wang, Jia 7046 Zou, Mei-Juan 7047 Hu, Rong 7048 Zhao, Li 7049 Qiang, Lei 7050 Rong, Jing-Jing 7051 You, Qi-Dong 7052 Guo, Qing-Long 7053 TI Wogonin potentiates the antitumor effects of low dose 5-fluorouracil 7054 against gastric cancer through induction of apoptosis by 7055 down-regulation of NF-kappaB and regulation of its metabolism 7056 SO TOXICOLOGY LETTERS 7057 AB Traditional Chinese medicines have been recognized as a new source of 7058 anticancer drugs or chemotherapy adjuvant to enhance the efficacy of 7059 chemotherapy and to ameliorate the side effects. Wogonin (WOG) has a 7060 potential for therapeutic use in the treatment of antitumor and 7061 chemoprophylaxis 5-Fluorouracil (5-FU) is a key systemic chemotherapy 7062 drug and widely use in the treatment of solid tumors In this study, 7063 we found that combination of WOG and 5-FU inhibited the viability of 7064 MGC-803 cells in a concentration-dependent manner and exhibited a 7065 synergistic anticancer effect (Cl < 1) when 5-FU was used at relatively 7066 low concentrations. The pro-apoptotic activity of two-drug combination 7067 was much stronger than single. Furthermore, WOG could decrease the mRNA 7068 levels of dihydropyrimidine dehydrogenase (DPD), the metabolic enzymes 7069 of 5-FU WOG could inhibit the NF-kappa B nuclear translocation and 7070 I-kappa B phosphorylation. Moreover, combined treatment caused 7071 significantly growth inhibition of human tumor xenografts. in 7072 addition, WOG markedly enhanced the antitumor activity of low dose 5-FU 7073 (i p 10 mg/kg/day), however there is no toxicity and influence on diet 7074 consumption in experimental animals. Taken together, our data's showed 7075 that WOG increased 5-FU retention for a prolonged catabolism by 7076 modulating 5-FU metabolic enzymes and sensitized the MGC-803 cells to 7077 5-FU induced apoptosis by inhibiting the NF-kappa B nuclear 7078 translocation. The anti-gastric cancer effect of two-drug combination 7079 was much stronger than that of WOG or 5-FU alone. These results may 7080 be relevant to design new clinical therapeutic strategies against 7081 gastric cancer in future (C) 2010 Elsevier Ireland Ltd All rights 7082 reserved. 7083 SN 0378-4274 7084 PD SEP 1 7085 PY 2010 7086 VL 197 7087 IS 3 7088 BP 201 7089 EP 210 7090 DI 10.1016/j.toxlet.2010.05.019 7091 UT ISI:000281002700008 7092 PT J 7093 AU Wu, YL 7094 Fan, QQ 7095 Lu, N 7096 Tao, L 7097 Gao, YA 7098 Qi, Q 7099 Guo, QL 7100 AF Wu, Yulin 7101 Fan, Qianqian 7102 Lu, Na 7103 Tao, Lei 7104 Gao, Yuan 7105 Qi, Qi 7106 Guo, Qinglong 7107 TI Breviscapine-induced Apoptosis of Human Hepatocellular Carcinoma Cell 7108 Line HepG2 was Involved in its Antitumor Activity 7109 SO PHYTOTHERAPY RESEARCH 7110 AB Breviscapine is a flavonoid constituent isolated from a traditional 7111 Chinese herb Erigerin breviscapus (Vant.) Hand-Mazz. To investigate 7112 the apoptosis-inducing effect of breviscapine on human hepatocellular 7113 carcinoma cell line HepG2 and explore the relative molecular 7114 mechanisms. HepG2 cells were treated with breviscapine at different 7115 concentrations and the inhibitory rate was analyzed by MTT assay. The 7116 morphological changes in cells were observed under an inverted light 7117 microscope and a fluorescence microscope and the apoptosis rate were 7118 detected by flow cytometry. Western blot was used to evaluate the 7119 protein expression. The viability of HepG2 cells was markedly inhibited 7120 in a concentration-dependent manner and obvious morphological changes 7121 were confirmed, including condensed chromatin and reduction in volume. 7122 The increased percentage of apoptotic cells was displayed by flow 7123 cytometry and the altered expression level of several 7124 apoptosis-associated proteins, Bcl-2, Bax and caspase-3, was detected 7125 by western blot. It is first discovered that breviscapine exhibited 7126 potential antitumor activity, induces remarkable apoptosis in HepG2 7127 cells and promises to be a new candidate in future cancer therapy. 7128 Copyright (C) 2010 John Wiley & Sons, Ltd. 7129 SN 0951-418X 7130 PD AUG 7131 PY 2010 7132 VL 24 7133 IS 8 7134 BP 1188 7135 EP 1194 7136 DI 10.1002/ptr.3002 7137 UT ISI:000281006500013 7138 PT J 7139 AU Zhu, JJ 7140 Zhang, CF 7141 Zhang, MA 7142 Bligh, SWA 7143 Yang, L 7144 Wang, ZM 7145 Wang, ZT 7146 AF Zhu, Jing-Jing 7147 Zhang, Chao-Feng 7148 Zhang, Mian 7149 Bligh, S. W. Annie 7150 Yang, Li 7151 Wang, Zhi-Min 7152 Wang, Zheng-Tao 7153 TI Separation and identification of three epimeric pairs of new C-glucosyl 7154 anthrones from Rumex dentatus by on-line high performance liquid 7155 chromatography-circular dichroism analysis 7156 SO JOURNAL OF CHROMATOGRAPHY A 7157 AB Six C-glucosyl anthrones were characterized as three pairs of epimers 7158 by on-line high performance liquid chromatography-circular dichroism 7159 (HPLC-CD) analysis and isolated from the roots of Rumex dentatus by 7160 column chromatography. Their structures were elucidated by mass 7161 spectrometry, nuclear magnetic spectroscopy and HPLC-CD analysis. They 7162 are 10R-C-beta-D-glucosyl-10-hydroxyemodin-9-anthrone (rumejaposide 7163 E, 1) and 10S-C-beta-D-glucosyl-10-hydroxyemodin-9-anthrone 7164 (rumejaposide F, 2), 10R-C-beta-D-glucosylemodin-9-anthrone 7165 (rumejaposide G, 3) and 10S-C-beta-D-glucosylemodin-9-anthrone 7166 (rumejaposide H. 4). 7167 10S-C-beta-D-glucosyl-10-hydroxychrysophanol-9-anthrone 7168 (cassialoin, 5) and 7169 10R-C-beta-D-glucosyl-10-hydroxychrysophanol-9-anthrone 7170 (rumejaposide I. 6). Rumejaposides F-I (2-4 and 6) were new C-glucosyl 7171 anthrones. Rumejaposide E (1) and cassialoin (5) were isolated for the 7172 first time in Rumex plants. On-line HPLC-UV-CD analysis was a useful 7173 tool for structure elucidating epimeric C-glycosides anthrones 3-6 7174 because of the poor stability of the pure isomers (3 and 4) and the 7175 minute quantity of 5 and 6 in the mixture. (C) 2010 Elsevier B.V. All 7176 rights reserved. 7177 SN 0021-9673 7178 PD AUG 13 7179 PY 2010 7180 VL 1217 7181 IS 33 7182 BP 5384 7183 EP 5388 7184 DI 10.1016/j.chroma.2010.05.039 7185 UT ISI:000280970500009 7186 PT J 7187 AU Gan, L 7188 Han, S 7189 Shen, JQ 7190 Zhu, JB 7191 Zhu, CL 7192 Zhang, XX 7193 Gan, Y 7194 AF Gan, Li 7195 Han, Shun 7196 Shen, Jinqiu 7197 Zhu, Jiabi 7198 Zhu, Chunliu 7199 Zhang, Xinxin 7200 Gan, Yong 7201 TI Self-assembled liquid crystalline nanoparticles as a novel ophthalmic 7202 delivery system for dexamethasone: Improving preocular retention and 7203 ocular bioavailability 7204 SO INTERNATIONAL JOURNAL OF PHARMACEUTICS 7205 AB The object of this study was to design novel self-assembled liquid 7206 crystalline nanoparticles (cubosomes) as an ophthalmic delivery system 7207 for dexamethasone (DEX) to improve its preocular retention and ocular 7208 bioavailability DEX cubosome particles were produced by fragmenting 7209 a cubic crystalline phase of monoolein and water in the presence of 7210 stabilizer Poloxamer 407. Small angle X-ray diffraction (SAXR) 7211 profiles revealed its internal structure as Pn3m space group, 7212 indicating the diamond cubic phase. In vitro, the apparent permeability 7213 coefficient of DEX administered in cubosomes exhibited a 4.5-fold (F1) 7214 and 3 5-fold (F2) increase compared to that of Dex-Na phosphate eye 7215 drops Preocular retention studies revealed that the retention of 7216 cubosomes was significantly longer than that of solution and carbopol 7217 gel, with AUC(0 -> 180min) of Rh B cubosomes being 2-3-fold higher than 7218 that of the other two formulations In vivo pharmacokinetics in aqueous 7219 humor was evaluated by microdialysis, which indicated a 1 8-fold (F1) 7220 increase in AUC(0 -> 240min) of DEX administered in cubosomes relative 7221 to that of Dex-Na phosphate eye drops, with about an 8-fold increase 7222 compared to that of DEX suspension Corneal cross-sections after 7223 incubation with DEX cubosomes demonstrated an unaffected corneal 7224 structure and tissue integrity, which indicated the good 7225 biocompatibility of DEX cubosomes In conclusion, self-assembled liquid 7226 crystalline nanoparticles might represent a promising vehicle for 7227 effective ocular drug delivery Crown Copyright (C) 2010 Published by 7228 Elsevier B V. All rights reserved 7229 SN 0378-5173 7230 PD AUG 30 7231 PY 2010 7232 VL 396 7233 IS 1-2 7234 BP 179 7235 EP 187 7236 DI 10.1016/j.ijpharm.2010.06.015 7237 UT ISI:000280936000025 7238 PT J 7239 AU Tong, L 7240 Xiong, RS 7241 Jiang, H 7242 Jiang, XR 7243 Sun, HB 7244 Jiang, HL 7245 Shen, JS 7246 AF Tong, Ling 7247 Xiong, Ruisheng 7248 Jiang, Hong 7249 Jiang, Xiangrui 7250 Sun, Hongbin 7251 Jiang, Hualiang 7252 Shen, Jingshan 7253 TI IMPROVED TOTAL SYNTHESIS OF RACEMIC RUTAMARIN 7254 SO HETEROCYCLES 7255 AB An improved, convenient and cost-effective process, using 7256 2,4-dihydroxybenzaldehyde 2 as starting material for (+/-)-rutamarin 7257 1, is described. The overall yield of 1 is 44% in eight steps, requiring 7258 no chromatographic purification. 7259 SN 0385-5414 7260 PD JUL 1 7261 PY 2010 7262 VL 81 7263 IS 7 7264 BP 1697 7265 EP 1702 7266 DI 10.3987/COM-10-11962 7267 UT ISI:000281076100009 7268 PT J 7269 AU Zha, XM 7270 Zhang, FR 7271 Shan, JQ 7272 Zhang, YH 7273 Liu, JO 7274 Sun, HB 7275 AF Zha, Xiao Ming 7276 Zhang, Fei Ran 7277 Shan, Jia Qi 7278 Zhang, Yi Hua 7279 Liu, Jun O. 7280 Sun, Hong Bin 7281 TI Synthesis and evaluation of in vitro anticancer activity of novel 7282 solasodine derivatives 7283 SO CHINESE CHEMICAL LETTERS 7284 AB Solasodine 11 is a steroidal alkaloid with various biological 7285 activities. Herein, 8 novel solasodine derivatives were synthesized 7286 and their effect on prostate cancer cell proliferation was assessed 7287 in vitro. Significant improvement in antiproliferative activity was 7288 achieved among some of the synthetic analogs. In particular, 19 7289 exhibited the most potent inhibitory effect against the proliferation 7290 of PC-3 cell line (IC50 = 3.91 mu mol/L). (C) 2010 Jun O. Liu. Published 7291 by Elsevier B.V. on behalf of Chinese Chemical Society. All rights 7292 reserved. 7293 SN 1001-8417 7294 PD SEP 7295 PY 2010 7296 VL 21 7297 IS 9 7298 BP 1087 7299 EP 1090 7300 DI 10.1016/j.cclet.2010.04.020 7301 UT ISI:000280945100018 7302 PT J 7303 AU Yang, QA 7304 Fedida, D 7305 Xu, HJ 7306 Wang, BH 7307 Du, LP 7308 Wang, XJ 7309 Li, MY 7310 You, QD 7311 AF Yang, Qian 7312 Fedida, David 7313 Xu, Hongjian 7314 Wang, Binghe 7315 Du, Lupei 7316 Wang, Xiaojian 7317 Li, Minyong 7318 You, Qidong 7319 TI Structure-Based Virtual Screening and Electrophysiological Evaluation 7320 of New Chemotypes of K(V)1.5 Channel Blockers 7321 SO CHEMMEDCHEM 7322 AB Atrial fibrillation (AF) is the most prevalent nonfatal cardiac rhythm 7323 disorder associated with an increased risk of heart failure and stroke. 7324 Considering the ventricular side effects induced by anti-arrhythmic 7325 agents in current use, K(v)1.5 channel blockers have attracted a great 7326 deal of deliberation owing to their selective actions on atrial 7327 electrophysiology. Herein we report new chemotypes of K(v)1.5 channel 7328 blockers that were identified through a combination of structure-based 7329 virtual screening and in silico druglike property prediction including 7330 six scoring functions, as well as electrophysiological evaluation. 7331 Among them, five of the 18 compounds exhibited >50% blockade ratio at 7332 10 mu m, and have structural features different from conventional 7333 K(v)1.5 channel blockers. These novel scaffolds could serve as hits 7334 for further optimization and SAR studies for the discovery of selective 7335 agents to treat AF. 7336 SN 1860-7179 7337 PD JUL 7338 PY 2010 7339 VL 5 7340 IS 8 7341 BP 1353 7342 EP 1358 7343 DI 10.1002/cmdc.201000162 7344 UT ISI:000281061300020 7345 PT J 7346 AU Rong, JJ 7347 Hu, R 7348 Song, XM 7349 Ha, J 7350 Lu, N 7351 Qi, Q 7352 Tao, L 7353 You, QD 7354 Guo, QL 7355 AF Rong, Jing-Jing 7356 Hu, Rong 7357 Song, Xiu-Ming 7358 Ha, Jun 7359 Lu, Na 7360 Qi, Qi 7361 Tao, Lei 7362 You, Qi-Dong 7363 Guo, Qing-Long 7364 TI Gambogic acid triggers DNA damage signaling that induces 7365 p53/p21(Waf1/CIP1) activation through the ATR-Chk1 pathway 7366 SO CANCER LETTERS 7367 AB Gambogic acid (GA) has been wildly studied to show potent anti-tumor 7368 effects in vivo and in vitro. We have confirmed that GA stabilized and 7369 activated p53 through down-regulating the expression of MDM2 in variety 7370 of cancer cell lines. However, GA-induced p53 activation could be 7371 partially reversed by caffeine, a PI3k inhibitor. Therefore, questions 7372 of whether GA induces post-translational modifications of p53 and 7373 subsequent activation of p53; and if that is the case, which upstream 7374 signaling pathway(s) is (are) responsible for that are proposed. Here, 7375 the relationship between p53 activation and its post-translational 7376 modifications was investigated in the human cancer cell lines HepG2 7377 and A549 in response to GA or adriamycin treatment. GA induces p53 7378 phosphorylation at sites Ser15 and Ser20 in a concentration- or 7379 time-dependent way, which was a direct result of DNA damage, as 7380 gamma-HA2X foci and 'comet' DNA fragments were detected. GA induces 7381 p53 phosphorylation through activation of an ATM- and Rad3-related 7382 pathway, and GA-induced phosphorylation of Chk1 is also involved. Upon 7383 treatment with GA, AIR activation is clearly associated with p53 7384 phosphorylation, as well as activation of its target gene 7385 p21(Waf/CIP1). Furthermore, we found the dephosphorylation of Cdk1 at 7386 Thr161 induced by GA was abrogated, followed by a remarkable disruption 7387 of G2/M arrest when the cells were pre-incubated with caffeine. 7388 Interestingly, the sensitivity to caffeine enhanced the cytotoxicity 7389 of GA as well. Taken together, these data showed an important role of 7390 the DNA damage response mediated by ATR-Chk1 in p53/p21(Waf/CIP1) 7391 activation and downstream G2/M arrest during GA treatment. (C) 2010 7392 Elsevier Ireland Ltd. All rights reserved. 7393 SN 0304-3835 7394 PD OCT 1 7395 PY 2010 7396 VL 296 7397 IS 1 7398 BP 55 7399 EP 64 7400 DI 10.1016/j.canlet.2010.03.016 7401 UT ISI:000281025700008 7402 PT J 7403 AU Chen, FH 7404 Zhang, LB 7405 Qiang, L 7406 Yang, Z 7407 Wu, TA 7408 Zou, MJ 7409 Tao, L 7410 You, QD 7411 Li, ZY 7412 Yang, Y 7413 Guo, QL 7414 AF Chen, Fei-hong 7415 Zhang, Lin-bo 7416 Qiang, Lei 7417 Yang, Zhen 7418 Wu, Tian 7419 Zou, Mei-juan 7420 Tao, Lei 7421 You, Qi-dong 7422 Li, Zhi-yu 7423 Yang, Yong 7424 Guo, Qing-Long 7425 TI Reactive oxygen species-mitochondria pathway involved in 7426 LYG-202-induced apoptosis in human hepatocellular carcinoma HepG(2) 7427 cells 7428 SO CANCER LETTERS 7429 AB Previously, we demonstrated that LYG-202, a newly synthesized 7430 flavonoid with a piperazine substitution, exhibited obvious antitumor 7431 activity in vivo and in vitro. The exact mechanism of this new compound 7432 remains unclear. In the present study, we examined the effects of 7433 LYG-202 on reactive oxygen species (ROS) production and the downstream 7434 signaling pathway in the apoptosis of human hepatocellular carcinoma 7435 HepG2 cells. Pretreatment with NAC (N-acetylcysteine), a ROS 7436 production inhibitor, partly inhibited the apoptosis induced by 7437 LYG-202 via blocking the ROS generation. Further data revealed that 7438 LYG-202 induced ROS accumulation followed by a decrease in 7439 mitochondrial membrane potential (MMP), release of cytochrome c (Cyt 7440 c) and apoptosis-inducing factor (AIF) to cytosol, which induced 7441 apoptosis of the cells. Moreover, the mitogen-activated protein 7442 kinases (MAPK), the downstream effect of ROS accumulation including 7443 c-Jun N-terminal kinase (JNK) and p38 MAPK, could be activated by 7444 LYG-202. Taken together, the generation of ROS might play an important 7445 role in LYG-202-induced mitochondrial apoptosis pathway, which 7446 provided further support for LYG-202 as a novel anticancer therapeutic 7447 candidate. (C) 2010 Elsevier Ireland Ltd. All rights reserved. 7448 SN 0304-3835 7449 PD OCT 1 7450 PY 2010 7451 VL 296 7452 IS 1 7453 BP 96 7454 EP 105 7455 DI 10.1016/j.canlet.2010.04.004 7456 UT ISI:000281025700012 7457 PT J 7458 AU Fan, QQ 7459 Wang, QJ 7460 Zeng, BB 7461 Ji, WH 7462 Ji, H 7463 Wu, YL 7464 AF Fan, Qian-Qian 7465 Wang, Qiu-Juan 7466 Zeng, Bu-Bing 7467 Ji, Wen-Hao 7468 Ji, Hui 7469 Wu, Yu-Lin 7470 TI Apoptosis induction of ZBB-006, a novel synthetic diterpenoid, in the 7471 human hepatocellular carcinoma cell line HepG2 in vitro and in vivo 7472 SO CANCER BIOLOGY & THERAPY 7473 AB Diterpenes, present in many medicinal plants, have been the focus of 7474 continuous studies for the development of new anticancer agents. 7475 ZBB-006 is a new synthetic diterpenoid derivative which exhibited 7476 significant anti-proliferation activity against various cancer cell 7477 lines in our previous study. Here, we investigated the antitumor effect 7478 of ZBB-006 and its potential mechanisms in the human hepatocellular 7479 carcinoma cell line HepG2, both in vitro and in vivo. We found that 7480 oral administration of ZBB-006 effectively suppressed the growth of 7481 HepG2 xenograft tumor in nude mice without body weight decline, 7482 compared with the control group. Meanwhile, the growth inhibitory 7483 effect of ZBB-006 on HepG2 cells was observed with MTT assay. Then 7484 apoptosis induced by ZBB-006 in HepG2 cells was evidenced by DAPAPI 7485 staining and Annexin V/PI double staining assay. ZBB-006 also 7486 dissipated the mitochondrial membrane potential (Delta Psi m) 7487 apparently as revealed by JC-1 staining. Furthermore, the cleavage of 7488 PAPARP, activation of caspase-3 and caspase-9 but not caspase-8 was 7489 demonstrated by western blot assay both in vitro and in vivo. 7490 Additionally, the proapoptotic protein Bax was markedly elevated, 7491 while the antiapoptotic protein Bcl-2 was downregulated. Collectively, 7492 our data indicated that ZBB-006 exerted a strong antitumor effect on 7493 HepG2 cells by initiating the mitochondrial-dependent apoptosis, and 7494 it has potential to be explored as a new promising therapeutic agent 7495 against human hepatoma. 7496 SN 1538-4047 7497 PD AUG 1 7498 PY 2010 7499 VL 10 7500 IS 3 7501 AR 12425 7502 UT ISI:000281005600011 7503 PT J 7504 AU Li, M 7505 Bao, Z 7506 Zhou, J 7507 Luo, N 7508 AF Li, M. 7509 Bao, Z. 7510 Zhou, J. 7511 Luo, N. 7512 TI DIMENSIONS CHARACTERIZING GOOD HEALTH BY CHINESE IN CHINA 7513 SO VALUE IN HEALTH 7514 SN 1098-3015 7515 PD MAY 7516 PY 2010 7517 VL 13 7518 IS 3 7519 BP A17 7520 EP A17 7521 UT ISI:000277121900079 7522 PT J 7523 AU Wang, XJ 7524 Gu, K 7525 Xu, JS 7526 Cao, RY 7527 Li, MH 7528 Wu, J 7529 Li, TM 7530 Liu, JJ 7531 AF Wang, Xue Jun 7532 Gu, Kai 7533 Xu, Jin Shu 7534 Cao, Rong Yue 7535 Li, Ming Hui 7536 Wu, Jie 7537 Li, Tai Ming 7538 Liu, Jing Jing 7539 TI Preparation of a peptide vaccine against GnRH by a bioprocess system 7540 based on asparaginase 7541 SO VACCINE 7542 AB GnRH is a promising target in hormone-dependent cancer immunotherapy. 7543 In our previous study, we have designed and purified a peptide vaccine 7544 GhM (GnRH3-hinge-MVP) by use of the bioprocess system based on 7545 asparaginase. Active immunization with GhM in the presence of CFA/IFA 7546 evoked strong humoral response. In this study, the motif NRLLLTG with 7547 high affinity to nanoparticle carrier VLP HBc Delta-SBD was fused to 7548 the C terminus of GhM to form a new peptide vaccine GhMNR 7549 (GnRH3-hinge-MVP-NRLLLTG). The fusion protein ansB-C-GhMNR was 7550 controlled by vigorous T7lac promotor and expressed effectively as 7551 inclusion bodies after induction by lactose and then purified by means 7552 of cell disruption, washing and cold ethanol fractionation. After 7553 hydrolyzed for 72 h, GhMNR was liberated from the fusion partner ansB-C 7554 and purified by CM52 cation exchange chromatography. These results 7555 suggested that the bioprocess system is suitable for large-scale 7556 expression and purification of the peptide vaccine GhMNR, and even some 7557 other proteins or peptides which may be important for industrial or 7558 laboratory purposes. (C) 2010 Elsevier Ltd. All rights reserved. 7559 SN 0264-410X 7560 PD JUL 12 7561 PY 2010 7562 VL 28 7563 IS 31 7564 BP 4984 7565 EP 4988 7566 DI 10.1016/j.vaccine.2010.05.026 7567 UT ISI:000280659600019 7568 PT J 7569 AU Huang, XJ 7570 Wang, Y 7571 Yin, ZQ 7572 Ye, WC 7573 AF Huang, Xiao-Jun 7574 Wang, Ying 7575 Yin, Zhi-Qi 7576 Ye, Wen-Cai 7577 TI Two new dimeric secoiridoid glycosides from the fruits of Ligustrum 7578 lucidum 7579 SO JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH 7580 AB Two new secoiridoid glycosides, ligusides A and B (1 and 2), as well 7581 as seven known compounds (3-9), were isolated from the fruits of 7582 Ligustrum lucidum. Their structures were elucidated on the basis of 7583 spectroscopic and chemical analysis. 7584 SN 1028-6020 7585 PY 2010 7586 VL 12 7587 IS 8 7588 BP 685 7589 EP 690 7590 DI 10.1080/10286020.2010.490781 7591 UT ISI:000280817100008 7592 PT J 7593 AU Yang, LN 7594 Qian, ZY 7595 Ji, H 7596 Yang, RH 7597 Wang, YH 7598 Xi, LA 7599 Sheng, LA 7600 Zhao, BH 7601 Zhang, XM 7602 AF Yang, Lina 7603 Qian, Zhiyu 7604 Ji, Hui 7605 Yang, Ruhui 7606 Wang, Yuhuan 7607 Xi, Liang 7608 Sheng, Liang 7609 Zhao, Bohua 7610 Zhang, Xiaoming 7611 TI Inhibitory effect on protein kinase C theta by Crocetin attenuates 7612 palmitate-induced insulin insensitivity in 3T3-L1 adipocytes 7613 SO EUROPEAN JOURNAL OF PHARMACOLOGY 7614 AB Epidemiologic and experimental studies have pointed to an etiologic 7615 role of elevated plasma free fatty acids in insulin resistance, which 7616 is frequently associated with a state of low-grade inflammation. In 7617 this study, we investigated the effects of Crocetin, a unique 7618 carotenoid, on insulin resistance induced by palmitate in 3T3-L1 7619 adipocytes. Exposure of palmitate led to an increase in insulin 7620 receptor substrate-1 (IRS-1) serine(307) phosphorylation as well as 7621 activation of c-Jun NH2-terminal kinase (JNK) and inhibitor kappa B 7622 kinase 3 (IKK beta), concomitantly with reductions of IRS-1 function 7623 and glucose metabolism. Interestingly, pretreatment with Crocetin 7624 almost reversed all of these abnormalities in a dose-dependent manner. 7625 IRS-1 serine(307) phosphorylation was significantly reduced by JNK or 7626 IKK beta inhibitor, especially by combination of these two inhibitors. 7627 Moreover, palmitate treatment induced activation of protein kinase C 7628 theta (PKC theta) while blocking PKC theta significantly inhibited JNK 7629 and IKK beta activation induced by palmitate or phorbol 12-myristate 7630 13-acetate (PKC activator, PMA), and attenuated the palmitate-induced 7631 defects in insulin action. Crocetin demonstrated an impressive 7632 suppression in the activation of PKC theta induced not only by palmitate 7633 but also by PMA in a dose-dependent manner. Taken together, Crocetin 7634 inhibited JNK and IKK beta activation via suppression of PKC theta 7635 phosphorylation, attenuating insulin insensitivity induced by 7636 palmitate in 3T3-L1 adipocytes. (C) 2010 Elsevier B.V. All rights 7637 reserved. 7638 SN 0014-2999 7639 PD SEP 10 7640 PY 2010 7641 VL 642 7642 IS 1-3 7643 BP 47 7644 EP 55 7645 DI 10.1016/j.ejphar.2010.05.061 7646 UT ISI:000280681500006 7647 PT J 7648 AU Gao, MM 7649 Ma, C 7650 Liu, WC 7651 Zhu, J 7652 Tian, H 7653 Gao, XD 7654 Yao, WB 7655 AF Gao, Mingming 7656 Ma, Chen 7657 Liu, Wenchao 7658 Zhu, Jing 7659 Tian, Hong 7660 Gao, Xiangdong 7661 Yao, Wenbing 7662 TI Production and purification of an analog of glucagon-like peptide-1 7663 by auto-induction and on-column cleavage in Escherichia coli 7664 SO WORLD JOURNAL OF MICROBIOLOGY & BIOTECHNOLOGY 7665 AB As a promising type 2 anti-diabetic agent, glucagon-like peptide-1 7666 (GLP-1) is attracting more and more interest. Mutated GLP-1 (mGLP-1) 7667 is an analog of native GLP-1. To facilitate the production and 7668 purification of mGLP-1, auto-induction and on-column cleavage was 7669 employed in this study. By using auto-induction system, after 24 h of 7670 shaking culture, about 12.6 g wet bacterial cells could be obtained 7671 from 1 l medium, and this was about 3.6 times more than that of the 7672 IPTG-induction group. After disruption and centrifugation, the fusion 7673 protein was directly purified and cleaved on Ni-Sepharose 6 Fast Flow 7674 column. Then, RESOURCE15 RPC column was used for further purification. 7675 By using these two steps of purification, about 1.58 mg of mGLP-1 with 7676 the purity of up to 98% could be obtained from 1 g wet bacterial cells. 7677 In the bioactivity study, mGLP-1 displayed a significant and 7678 dose-dependent glucose-lowering activity. These results suggested 7679 that auto-induction and on-column cleavage could facilitate the 7680 production and purification of mGLP-1. These methods could also be 7681 applied to the preparation of other proteins and peptides. 7682 SN 0959-3993 7683 PD SEP 7684 PY 2010 7685 VL 26 7686 IS 9 7687 BP 1675 7688 EP 1682 7689 DI 10.1007/s11274-010-0345-3 7690 UT ISI:000280642800016 7691 PT J 7692 AU Yang, L 7693 Xue, XW 7694 Zhang, YH 7695 AF Yang, Lei 7696 Xue, Xiaowen 7697 Zhang, Yihua 7698 TI Simple and Efficient Synthesis of Belinostat 7699 SO SYNTHETIC COMMUNICATIONS 7700 AB A novel synthesis of belinostat (1) starting from 3-nitrobenzaldehyde 7701 has been developed. The key step in this sequence involves the 7702 conversion of (2E)-3-(3-aminophenyl)acrylic acid methyl ester to 7703 (2E)-3-(3-chlorosulfonylphenyl)acrylic acid methyl ester via 7704 diazotization and sulfonylation. 7705 SN 0039-7911 7706 PY 2010 7707 VL 40 7708 IS 17 7709 BP 2520 7710 EP 2524 7711 DI 10.1080/00397910903277870 7712 UT ISI:000280662300003 7713 PT J 7714 AU Luo, Y 7715 Liu, M 7716 Xia, Y 7717 Dai, Y 7718 Chou, G 7719 Wang, Z 7720 AF Luo, Y. 7721 Liu, M. 7722 Xia, Y. 7723 Dai, Y. 7724 Chou, G. 7725 Wang, Z. 7726 TI Therapeutic effect of norisoboldine, an alkaloid isolated from Radix 7727 Linderae, on collagen-induced arthritis in mice 7728 SO PHYTOMEDICINE 7729 AB The alkaloid fraction of Radix Linderae, the main active component of 7730 this herb drug, has been proven to exhibit anti-inflammatory, 7731 analgestic and antimicrobial activities. The present study was 7732 undertaken to investigate the therapeutic potential of norisoboldine, 7733 the major isoquinoline alkaloid present in Radix Linderae, in collagen 7734 II -induced arthritis (CIA) of mice as well as the possible mechanisms. 7735 CIA was induced in mice by immunization with chicken type II collagen 7736 (II). After boosted on day 21, mice were treated with norisoboldine 7737 (10, 20, 40 mg/kg) for twenty consecutive days. The clinical scores, 7738 body weight changes and joint histopathology were evaluated. 7739 Norisoboldine treatment significantly alleviated the severity of the 7740 disease, based on the reduced clinical scores and elevated the lowered 7741 body weights of model mice. Meanwhile, this alkaloid dose-dependently 7742 reduced the infiltration of inflammatory cells, synovial hyperplasia 7743 and protected joint from destruction. Additionally, the serum level 7744 of anti-CII IgG and the CII-stimulated lymphocyte proliferation were 7745 remarkably decreased in the groups administered with norisoboldine. 7746 An assessment of Th1 function using the delayed-type hypersensitivity 7747 model confirmed that norisoboldine also significantly suppressed the 7748 enhanced T cell responses in vivo. These findings suggest that 7749 norisoboldine might be a potential therapeutic agent for rheumatoid 7750 arthritis, and it functions through protecting joint destruction as 7751 well as regulating the abnormal immune responses. (C) 2010 Elsevier 7752 GmbH. All rights reserved. 7753 SN 0944-7113 7754 PD AUG 7755 PY 2010 7756 VL 17 7757 IS 10 7758 BP 726 7759 EP 731 7760 DI 10.1016/j.phymed.2010.01.013 7761 UT ISI:000280538900004 7762 PT J 7763 AU Liu, P 7764 Hu, Y 7765 Guo, DH 7766 Wang, DX 7767 Tu, HH 7768 Ma, L 7769 Xie, TT 7770 Kong, LY 7771 AF Liu, P. 7772 Hu, Y. 7773 Guo, D. -H. 7774 Wang, D. -X. 7775 Tu, H. -H. 7776 Ma, L. 7777 Xie, T. -T. 7778 Kong, L. -Y. 7779 TI Potential antidepressant properties of Radix Polygalae (Yuan Zhi) 7780 SO PHYTOMEDICINE 7781 AB Radix Polygalae ("Yuan Zhi", the roots of Polygala tenuifolia Willd., 7782 YZ) is an important herb used in traditional Chinese medicine to mediate 7783 depression. The present study was designed to verify the antidepressant 7784 effects of the standardized YZ ethanol extract (YZE) and its four 7785 fractions YZ-30, YZ-50, YZ-70 and YZ-90 on the tail suspension (TST) 7786 and forced swimming test (FST). Furthermore, the standardization of 7787 the fractions obtained from the separation procedures was carried out 7788 by high-performance liquid chromatography (HPLC)-fingerprint. The 7789 YZ-50 fraction (Oligosaccharide esters - enriched, oral (200 mg/kg) 7790 showed a significant anti-immobility like effects. The data of YZ-50 7791 on the corticosterone-induced injure of SH-SY5Y human neuroblastoma 7792 cell indicated that YZ-50 may have biological effects on 7793 neuroprotection. Proliferation of cell lines was assessed by 7794 dimethylthiazoldiphenyltetrazoliumbromide (MTT) and 7795 5-bromo-2'-deoxyuridine (BrdU) incorporation assays. It was found that 7796 YZ-50 and its two bioactive compounds, 3,6'-di-o-sinapoyl-sucrose 7797 (DISS) and tenuifoliside A(TEA) showed protection activities in SY5Y 7798 cells from the lesion. By using bioassay-screening methods, our results 7799 indicate that the presence of oligosaccharide esters such as DISS and 7800 TEA in this herb may be responsible for the cytoprotective activity 7801 effects. (C) 2010 Elsevier GmbH. All rights reserved. 7802 SN 0944-7113 7803 PD AUG 7804 PY 2010 7805 VL 17 7806 IS 10 7807 BP 794 7808 EP 799 7809 DI 10.1016/j.phymed.2010.01.004 7810 UT ISI:000280538900014 7811 PT J 7812 AU Wang, XJ 7813 Yang, QA 7814 Li, MY 7815 Yin, DL 7816 You, QD 7817 AF Wang, Xiaojian 7818 Yang, Qian 7819 Li, Minyong 7820 Yin, Dali 7821 You, Qidong 7822 TI In silico binding characteristics between human histamine H-1 receptor 7823 and antagonists 7824 SO JOURNAL OF MOLECULAR MODELING 7825 AB It is widely acknowledged that the H-1 receptor antagonists have 7826 important therapeutic significance in the treatment of various 7827 allergic disorders, but little was known about the binding mode between 7828 the receptor and antagonists since the crystal structure of G-protein 7829 coupling receptors (GPCRs) were hard to obtain. In this paper, a 7830 theoretical three-dimensional model of human histamine H-1 receptor 7831 (HHR1) was developed on the basis of recently reported high resolution 7832 structures of human A(2A) adenosine receptor, human 7833 beta(2)-adrenoceptor and turkey beta(1)-adrenoceptor. Furthermore, 7834 three representative H-1 receptor antagonists were chosen for docking 7835 studies. Subsequently, a qualitative pharmacophore model was developed 7836 by Hiphop algorithm based on the docking conformations of these three 7837 antagonists. In this paper, active environment, certain key residues, 7838 and the corresponding pharmacophore features of H-1 receptor were 7839 identified by such combinations of receptor-based and ligand-based 7840 approaches, which would give sufficient guidance for the rational 7841 design of novel antihistamine agents. 7842 SN 1610-2940 7843 PD AUG 7844 PY 2010 7845 VL 16 7846 IS 9 7847 BP 1529 7848 EP 1537 7849 DI 10.1007/s00894-010-0666-z 7850 UT ISI:000280640700010 7851 PT J 7852 AU Wang, MY 7853 Zhao, FM 7854 Peng, HY 7855 Lou, CH 7856 Li, Y 7857 Ding, X 7858 Yu, XY 7859 Yang, GM 7860 Xu, DQ 7861 Jiang, LH 7862 Zhang, X 7863 Ye, LH 7864 Cai, BC 7865 AF Wang, Ming-Yan 7866 Zhao, Feng-Ming 7867 Peng, Hai-Yan 7868 Lou, Cheng-Hua 7869 Li, Yu 7870 Ding, Xia 7871 Yu, Xiao-Yi 7872 Yang, Guang-Ming 7873 Xu, Dong-Qing 7874 Jiang, Li-Hua 7875 Zhang, Xu 7876 Ye, Li-Hong 7877 Cai, Bao-Chang 7878 TI Investigation on the morphological protective effect of 7879 5-hydroxymethylfurfural extracted from wine-processed Fructus corni 7880 on human L02 hepatocytes 7881 SO JOURNAL OF ETHNOPHARMACOLOGY 7882 AB Aim: To determine the mode of action of 5-hydroxymethylfurfural (5-HMF) 7883 extracted from wine-processed Fructus corni on hepatoprotective 7884 activities, the effects of 5-HMF on H2O2-induced human L02 hepatocytes 7885 injury was examined. 7886 Mthods: Hepatocytes L02 injured by H2O2 was treated by 5-HMF. The 7887 morphological changes of the cells were observed under inverted 7888 phase-contrast, fluorescence, and transmission electron microscopy 7889 and the activities of caspase-9 and caspase-3 were tested by 7890 enzyme-linked immunosorbent detector. 7891 Results: It revealed that 5-HMF improved the morphology of H2O2-treated 7892 human L02 hepatocytes, and also inhibited the level of caspase-9 and 7893 caspase-3 of them. 7894 Conclusions: These results suggested a morphological hepatocyte 7895 protective effect and the anti-apoptosis mechanism by 5-HMF. (C) 2010 7896 Elsevier Ireland Ltd. All rights reserved. 7897 SN 0378-8741 7898 PD JUL 20 7899 PY 2010 7900 VL 130 7901 IS 2 7902 BP 424 7903 EP 428 7904 DI 10.1016/j.jep.2010.05.024 7905 UT ISI:000280622400033 7906 PT J 7907 AU Liu, XY 7908 Yu, BY 7909 Wang, NJ 7910 Zhang, B 7911 Du, F 7912 He, C 7913 Ye, ZG 7914 AF Liu, Xinyi 7915 Yu, Boyang 7916 Wang, Naijie 7917 Zhang, Bei 7918 Du, Feng 7919 He, Cheng 7920 Ye, Zuguang 7921 TI A validated stability-indicating HPLC method for the determination of 7922 PEGylated puerarin in aqueous solutions 7923 SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL 7924 AND LIFE SCIENCES 7925 AB The aim of this study was to develop a validated specific 7926 stability-indicating HPLC method for the quantitative determination 7927 of PEGylated puerarin (PEG-PUE) in aqueous solutions. The method was 7928 validated by subjecting PEG-PUE to forced degradation under stress 7929 conditions of acid, alkali, water hydrolysis, and oxidation. Both 7930 PEG-PUE and puerarin (PUE) were simultaneously determined and 7931 separated on CAPCELL PAK C18 column by gradient elution with 0.2% 7932 aqueous phosphoric acid and acetonitrile as the mobile phase. The flow 7933 rate was 1.0 mL min(-1) and detection wavelength was set at 250 nm. 7934 Both calibration curves showed good linear regression (r >= 0.9998) 7935 within test ranges. The LOD and LOQ of PEG-PUE were determined to be 7936 3 and 9 mu g mL(-1) respectively. Degradation of PEG-PUE followed 7937 pseudo-first-order kinetics with t(1/2) of 59 min at pH 9.0 and 17.79 7938 h at pH 7.4. However, at pH 5.0 and 2.0, there was no significant 7939 degradation of PEG-PUE over time. In conclusion, the method was 7940 observed to have the necessary specificity, precision, and accuracy, 7941 and to be suitable for quantity monitoring the degradation process of 7942 PEG-PUE during stability studies. The degradation studies may give 7943 insight into useful information for formulation development of 7944 PEG-PUE. (C) 2010 Elsevier B.V. All rights reserved. 7945 SN 1570-0232 7946 PD AUG 1 7947 PY 2010 7948 VL 878 7949 IS 23 7950 BP 2061 7951 EP 2066 7952 DI 10.1016/j.jchromb.2010.06.001 7953 UT ISI:000280617400003 7954 PT J 7955 AU Wu, XA 7956 Chen, H 7957 Sun, JG 7958 Peng, Y 7959 Liang, Y 7960 Wang, GJ 7961 Wu, JZ 7962 Zhang, P 7963 AF Wu, Xiao 7964 Chen, Hui 7965 Sun, Jianguo 7966 Peng, Ying 7967 Liang, Yan 7968 Wang, Guangji 7969 Wu, Jizhou 7970 Zhang, Peng 7971 TI Development and validation of a liquid chromatography-mass 7972 spectrometry method for the determination of verticinone in rat plasma 7973 and its application to pharmacokinetic study 7974 SO JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL 7975 AND LIFE SCIENCES 7976 AB We have developed and validated a sensitive liquid 7977 chromatography-electrospray ionization-mass spectrometric 7978 (LC-ESI-MS) method for the quantification of verticinone, a major 7979 active constituent from Fritillaria hupehensis Hsiao et KC Hsia., in 7980 rat plasma. Verticinone and the internal standard (IS), hupehenine, 7981 were extracted from plasma samples by a simple liquid-liquid extraction 7982 with ethyl acetate after being alkalified by 1 M ammonia hydroxide. 7983 Chromatographic separation was achieved on a C-18 column using a 7984 gradient elution program with methanol and water as the mobile phase. 7985 The detection was performed by selected ion monitoring (SIM) mode via 7986 positive electrospray ionization (ESI) interface. The lower limit of 7987 quantification (LLOQ) was 0.1 ng/mL. The calibration curves were linear 7988 (r(2) > 0.998) over the concentration range of 0.1-200 ng/mL. Withinand between-run precision was less than 6.5% and accuracy was within 7989 +/- 10.7%. The validated method was applied to the pharmacokinetic 7990 study of verticinone in rats after a single oral administration of 1 7991 mg/kg. (C) 2010 Elsevier B.V. All rights reserved. 7992 SN 1570-0232 7993 PD AUG 1 7994 PY 2010 7995 VL 878 7996 IS 23 7997 BP 2067 7998 EP 2071 7999 DI 10.1016/j.jchromb.2010.06.004 8000 UT ISI:000280617400004 8001 PT J 8002 AU Xu, M 8003 Dai, DZ 8004 Zhang, Q 8005 Cheng, YS 8006 Dai, Y 8007 AF Xu, M. 8008 Dai, D. Z. 8009 Zhang, Q. 8010 Cheng, Y. S. 8011 Dai, Y. 8012 TI Upregulated NADPH Oxidase Contributes to Diabetic Testicular 8013 Complication and is Relieved by Strontium Fructose 1,6-Diphosphate 8014 SO EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES 8015 AB Diabetes is frequently associated with declining sexual function 8016 resulting from oxidative damage. NADPH oxidase is a major resource of 8017 reactive oxygen species (ROS) in the testes and is likely related to 8018 an activated endothelin-1 (ET-1) system. An activation of NADPH oxidase 8019 - ET-1 pathway was hypothesized in diabetic testopathy. We verified 8020 the hypothesis and tested if strontium fructose 1,6-diphosphate 8021 (FDP-Sr) could relieve these changes in diabetic testis as compared 8022 to testosterone propionate (TP) and sildenafil. Diabetes was produced 8023 in male Sprague-Dawley rats 8 weeks after a single injection of 8024 streptozotocin (STZ), and interventions with testosterone propionate 8025 (TP), sildenafil and FDP-Sr were conducted in the last 4 weeks. Blood 8026 glucose, testosterone, follicle stimulating hormone (FSH), 8027 luteinizing hormone (LH) and expressions of NADPH oxidase subunits and 8028 the ET system were measured. Decreased insulin, FSH, LH and 8029 testosterone in serum were found associating with testicular oxidative 8030 stress in STZ-injected rats. Additionally, over-expressions of NADPH 8031 oxidase p22, p47, p67 subunits and the ET pathway were significant in 8032 the diabetic testis relative to normal and were completely abolished 8033 by FDP-Sr. Both TP and sildenafil were not beneficial to diabetic 8034 testopathy except serum androgen raised by TP. Activated NADPH oxidase 8035 and ET system are significant contributing to testis injury and are 8036 responded to FDP-Sr only, against both TP and sildenafil, by restoring 8037 the testis function and the hypothalamus-pituitary-testis axis. It is 8038 due to its extra-energy supply and an antioxidant activity of FDP-Sr. 8039 SN 0947-7349 8040 PD JUL 8041 PY 2010 8042 VL 118 8043 IS 7 8044 BP 459 8045 EP 465 8046 DI 10.1055/s-0030-1248325 8047 UT ISI:000280643300011 8048 PT J 8049 AU Liu, HY 8050 Wu, SM 8051 Cheng, F 8052 Hu, YZ 8053 Yan, ZY 8054 AF Liu Hai-Yan 8055 Wu Sheng-Mei 8056 Cheng Fang 8057 Hu Yu-Zhu 8058 Yan Zheng-Yu 8059 TI Fluorescence Resonance Energy Transfer Between Quantumn Dots 8060 SO CHINESE JOURNAL OF ANALYTICAL CHEMISTRY 8061 AB The fluorescent resonance energy transfer(FRET) between two kinds of 8062 quantum dots(QDs) with different surface-charge was researched. 8063 Green-emission QDs was modified with amphiphilic surfactants (CTMAB) 8064 and red-emission QDs was modified with thiolglycolic acid (TGA) 8065 separately. The experiments proved that both CTMAB and TGA both could 8066 well turn the oil-soluble QDs into water-soluble ones, as well as 8067 opposite electric charges on the surface. Then the water-soluble QDs 8068 were characterized by agarose gel electrophoresis, fluorescence image 8069 and quantum yield. Taking advantage of the interaction between the 8070 opposite charges, fluorescent resonance energy transfer(FRET) was 8071 detected between two kinds of QDs in phosphate buffer solution(pH 7.5) 8072 with an excitation wavelength of 400 nm, and the FRET efficiencies were 8073 satisfied (quenching efficiency was 0.54 and enhance efficiency was 8074 0.27). 8075 SN 0253-3820 8076 PD JUL 8077 PY 2010 8078 VL 38 8079 IS 7 8080 BP 1036 8081 EP 1039 8082 DI 10.3724/SP.J.1096.2010.01036 8083 UT ISI:000280677000025 8084 PT J 8085 AU Liu, J 8086 Li, HX 8087 Jiang, XQ 8088 Zhang, C 8089 Ping, QN 8090 AF Liu, Jia 8091 Li, Hongxia 8092 Jiang, Xiaoqun 8093 Zhang, Can 8094 Ping, Qineng 8095 TI Novel pH-sensitive chitosan-derived micelles loaded with paclitaxel 8096 SO CARBOHYDRATE POLYMERS 8097 AB A series of pH-sensitive graft copolymers, 8098 N-octyl-N-(2-carboxyl-cyclohexamethenyl) chitosan derivatives were 8099 synthesized and characterized by FTIR, H-1 NMR and elemental analysis, 8100 and their physical properties were measured with differential scanning 8101 calorimetry and X-ray diffraction spectrometry. The critical micelle 8102 concentrations (CMCs) of the modified chitosan determined by using 8103 pyrene as a hydrophobic probe in fluorescence spectroscopy were from 8104 11 to 72 mu g/ml. The graft polymers can form micelles solubilizing 8105 paclitaxel, with drug-loading rate ranging from 30.47% to 48.10% and 8106 entrapment efficiency from 42.22% to 59.24%. Cytotoxicities of carrier 8107 against tumor cells estimated that carriers were nearly non-cytotoxic. 8108 Additionally, the results of pH-sensitivity and drug release 8109 experiments showed that the micelles were highly sensitive to mild 8110 acidic conditions (pH 5.5) while reasonably stable at physiological 8111 conditions (pH 7.4). Therefore, chitosan-derived micelle may be a 8112 potential anti-tumor drug delivery system for chemotherapy of cancer. 8113 (C) 2010 Elsevier Ltd. All rights reserved. 8114 SN 0144-8617 8115 PD SEP 5 8116 PY 2010 8117 VL 82 8118 IS 2 8119 BP 432 8120 EP 439 8121 DI 10.1016/j.carbpol.2010.04.084 8122 UT ISI:000280574600030 8123 PT J 8124 AU Wu, QA 8125 Yuan, QA 8126 Liu, EH 8127 Qi, LW 8128 Bi, ZM 8129 Li, P 8130 AF Wu, Qian 8131 Yuan, Quan 8132 Liu, E-Hu 8133 Qi, Lian-Wen 8134 Bi, Zhi-Ming 8135 Li, Ping 8136 TI Fragmentation study of iridoid glycosides and phenylpropanoid 8137 glycosides in Radix Scrophulariae by rapid resolution liquid 8138 chromatography with diode-array detection and electrospray ionization 8139 time-of-flight mass spectrometry 8140 SO BIOMEDICAL CHROMATOGRAPHY 8141 AB Rapid resolution liquid chromatography (RRLC) coupled with diode array 8142 detection (DAD) and electrospray ionization time-of-flight mass 8143 spectrometry (ESI-TOF MS) method was applied to the mass spectral study 8144 of a series of naturally occurring iridoid glycosides and 8145 phenylpropanoid glycosides in Radix Scrophulariae, which provides 8146 higher speed and increased sensitivity without loss of resolution. With 8147 dynamic adjustment as the key role of the fragmentor voltage and 8148 confirmed with authentic standards, valuable structural information 8149 regarding the nature of both the glycoside skeletons was thus obtained. 8150 Most compositions were found to possess organic acid moiety such as 8151 cinnamoyl, caffeoyl and ferulyol. Besides extensive fragmentation of 8152 the carbohydrate moiety, losses of the hydroxyl and glucose residue 8153 units showed in the spectra, permitting the exploration of the skeleton 8154 and the identity of substituents in the molecule. Ten major iridoid 8155 glycosides and 10 phenylpropanoid glycosides were identified or 8156 tentatively characterized based on their retention times, UV and TOF 8157 MS data. The major fragmentation pathways of PGs in Radix Scrophulariae 8158 obtained through the MS data was schemed systematically for the first 8159 time, which provides a reference for other PGs derivatives. Copyright 8160 (C) 2009 John Wiley & Sons, Ltd. 8161 SN 0269-3879 8162 PD AUG 8163 PY 2010 8164 VL 24 8165 IS 8 8166 BP 808 8167 EP 819 8168 DI 10.1002/bmc.1368 8169 UT ISI:000280542700002 8170 PT J 8171 AU Aa, JY 8172 Wang, GJ 8173 Hao, HP 8174 Huang, Q 8175 Lu, YH 8176 Yan, B 8177 Zha, WB 8178 Liu, LS 8179 Kang, A 8180 AF Aa, Ji-ye 8181 Wang, Guang-ji 8182 Hao, Hai-ping 8183 Huang, Qing 8184 Lu, Yi-hong 8185 Yan, Bei 8186 Zha, Wei-bin 8187 Liu, Lin-sheng 8188 Kang, An 8189 TI Differential regulations of blood pressure and perturbed metabolism 8190 by total ginsenosides and conventional antihypertensive agents in 8191 spontaneously hypertensive rats 8192 SO ACTA PHARMACOLOGICA SINICA 8193 AB Aim: To investigate the regulatory effects of total ginsenosides and 8194 the conventional antihypertensive agents (captopril, amlodipine, 8195 terazosin and hydrochlorothiazide) on the blood pressure and perturbed 8196 metabolism in spontaneously hypertensive rats (SHRs) and to analyze 8197 the cause-effect relationships between high blood pressure and the 8198 metabolic disorders of hypertension. 8199 Methods: SHRs were administrated with total ginsenosides or the 8200 antihypertensive agents for eight weeks. Systolic blood pressure (SP) 8201 was measured every week and low-molecular-weight compounds in blood 8202 plasma were quantitatively analyzed using a nontargeted 8203 high-throughput metabolomic tool: gas chromatography/time of flight 8204 mass spectrometry (GC/TOFMS). The metabolic patterns were evaluated 8205 using principal components analysis and potential markers of 8206 hypertension were identified. 8207 Results: Total ginsenosides and the antihypertensive agents 8208 differentially regulated SP and the metabolic pattern in SHRs. Total 8209 ginsenosides caused a progressive and prolonged reduction of SP and 8210 markedly normalized the perturbed metabolism with 14 of 27 (51.8%) 8211 markers of hypertension which were regulated toward normal. Total 8212 ginsenosides also reduced free fatty acids' level toward normal levels. 8213 In contrast, captopril, amlodipine and terazosin efficiently depressed 8214 SP, but had little effect on metabolic perturbation with only 8 (29.6%), 8215 4 (14.8%), and 4 (14.8%) markers, respectively, which were regulated. 8216 Conclusion: The metabolic changes persisted when the blood pressure 8217 was lowered by the conventional antihypertensive agents, suggesting 8218 that hypertension may not be the cause of the metabolic perturbation 8219 in SHRs. 8220 SN 1671-4083 8221 PD AUG 8222 PY 2010 8223 VL 31 8224 IS 8 8225 BP 930 8226 EP 937 8227 DI 10.1038/aps.2010.86 8228 UT ISI:000280617100006 8229 PT J 8230 AU Wang, J 8231 Liu, JH 8232 Guo, X 8233 Zhang, JA 8234 Yu, BY 8235 AF Wang, Jing 8236 Liu, Ji-hua 8237 Guo, Xu 8238 Zhang, Jian 8239 Yu, Bo-yang 8240 TI A sensitive indirect competitive enzyme-linked immunosorbent assay for 8241 the detection of sarsasapogenin in rat plasma 8242 SO ACTA PHARMACOLOGICA SINICA 8243 AB Aim: To generate a polyclonal antibody against sarsasapogenin and to 8244 develop an indirect competitive enzyme-linked immunosorbent assay 8245 (IC-ELISA) method for the pharmacokinetic study of Sarsasapogenin in 8246 rats. 8247 Methods: The antigen of sarsasapogenin was produced using an active 8248 ester method and subsequently used for raising polyclonal antibodies 8249 in rabbits. The specificity and sensitivity of the antibody were 8250 measured by IC-ELISA. Using the ELISA method, sarsasapogenin levels 8251 were measured in the serum of rats after an oral dose of 100 mg/kg. 8252 Results: Polyclonal antibodies raised against sarsasapogenin-bovine 8253 serum albumin were generated and showed a high reactivity to 8254 sarsasapogenin. The antibodies exhibited minor cross-reactivity to 8255 ruscogenin (23%), diosgenin (22%), 25 (R, S) ruscogenin 8256 I-O-[beta-D-glucopyranosyl (1-->2)][beta-D-xylopyranosyl 8257 (1-->3)]-beta-D-fucopyranoside (26%) and no cross-reactivity to 8258 diammonium glycyrrhizinate and notoginseng R1. The detection range of 8259 sarsasapogenin by this ELISA method was approximately 2.4-760 ng/mL. 8260 The recovery rates of 10 ng/mL, 100 ng/mL, and 500 ng/mL were in the 8261 range of 91.0%-96.2% for intra-assay and 89.0%-92.0% for inter-assay. 8262 The coefficients of variation (CV%) for intra-and inter-assays at the 8263 three different sarsasapogenin levels were 3.1%-8.3% (n=6) and 8264 6.0%-14.1% (n=6), respectively. 8265 Conclusion: The IC-ELISA method is a sensitive test for the 8266 determination of sarsasapogenin concentration in rat plasma and for 8267 pharmacokinetic (PK) studies. 8268 SN 1671-4083 8269 PD AUG 8270 PY 2010 8271 VL 31 8272 IS 8 8273 BP 984 8274 EP 989 8275 DI 10.1038/aps.2010.85 8276 UT ISI:000280617100013 8277 PT J 8278 AU Han, S 8279 Shen, JQ 8280 Gan, Y 8281 Geng, HM 8282 Zhang, XX 8283 Zhu, CL 8284 Gan, L 8285 AF Han, Shun 8286 Shen, Jin-qiu 8287 Gan, Yong 8288 Geng, Hai-ming 8289 Zhang, Xin-xin 8290 Zhu, Chun-liu 8291 Gan, Li 8292 TI Novel vehicle based on cubosomes for ophthalmic delivery of 8293 flurbiprofen with low irritancy and high bioavailability 8294 SO ACTA PHARMACOLOGICA SINICA 8295 AB Aim: To develop a novel vehicle based on cubosomes as an ophthalmic 8296 drug delivery system for flurbiprofen (FB) to reduce ocular irritancy 8297 and improve bioavailability. 8298 Methods: FB-loaded cubosomes were prepared using hot and high-pressure 8299 homogenization. Cubosomes were then characterized by particle size, 8300 zeta potential, encapsulation efficiency, particle morphology, inner 8301 cubic structure and in vitro release. Corneal permeation was evaluated 8302 using modified Franz-type cells. Ocular irritation was then evaluated 8303 using both the Draize method and histological examination. The ocular 8304 pharmacokinetics of FB was determined using microdialysis. 8305 Results: The particle size of each cubosome formulation was about 150 8306 nm. A bicontinuous cubic phase of cubic P-type was determined using 8307 cryo-transmission electron microscopy (cryo-TEM) observation and 8308 small angle X-ray scattering (SAXS) analysis. In vitro corneal 8309 permeation study revealed that FB formulated in cubosomes exhibited 8310 2.5-fold (F1) and 2.0-fold (F2) increase in P-app compared with FB PBS. 8311 In the ocular irritation test, irritation scores for each group were 8312 less than 2, indicating that all formulations exhibited excellent 8313 ocular tolerance. Histological examination revealed that neither the 8314 structure nor the integrity of the cornea was visibly affected after 8315 incubation with FB cubosomes. The AUC of FB administered as FB cubosome 8316 F2 was 486.36+/-38.93 ng.mL(-1).min.mu g(-1), which was significantly 8317 higher than that of FB Na eye drops (P<0.01). Compared with FB Na eye 8318 drops, the T-max of FB cubosome F2 was about 1.6-fold higher and the 8319 MRT was also significantly longer (P<0.001). 8320 Conclusion: This novel low-irritant vehicle based on cubosomes might 8321 be a promising system for effective ocular drug delivery. 8322 SN 1671-4083 8323 PD AUG 8324 PY 2010 8325 VL 31 8326 IS 8 8327 BP 990 8328 EP 998 8329 DI 10.1038/aps.2010.98 8330 UT ISI:000280617100014 8331 PT J 8332 AU Angeli, V 8333 Chen, HL 8334 Mester, Z 8335 Rao, YL 8336 D'Ulivo, A 8337 Bramanti, E 8338 AF Angeli, Valeria 8339 Chen, Huilun 8340 Mester, Zoltan 8341 Rao, Yulan 8342 D'Ulivo, Alessandro 8343 Bramanti, Emilia 8344 TI Derivatization of GSSG by pHMB in alkaline media. Determination of 8345 oxidized glutathione in blood 8346 SO TALANTA 8347 AB Chromatographic determination of glutathione disulfide (GSSG) without 8348 any preliminary reduction has been presented using GSSG derivatization 8349 by p-hydroxymercuribenzoate (pHMB) in strong alkaline medium followed 8350 by the determination of GS-pHMB complex by reversed phase 8351 chromatography coupled to chemical vapour generation and atomic 8352 fluorescence detector (RPC-CVGAFS). A detection limit of 35 nM for GSSG 8353 (corresponding to 1.8 pmol) detected as GS-pHMB species was achieved 8354 based on a signal-to-noise ratio of 3 in buffer and in blood. The 8355 proposed method was applied to the determination of GSSG in whole blood 8356 and validated by the classical determination of GSSG by derivatization 8357 after reduction with dithiothreitol (DTT). (C) 2010 Elsevier B.V. All 8358 rights reserved. 8359 SN 0039-9140 8360 PD JUL 15 8361 PY 2010 8362 VL 82 8363 IS 2 8364 BP 815 8365 EP 820 8366 DI 10.1016/j.talanta.2010.05.065 8367 UT ISI:000280375700059 8368 PT J 8369 AU Qi, J 8370 Xu, DR 8371 Zhou, YF 8372 Qin, MJ 8373 Yu, BY 8374 AF Qi, Jin 8375 Xu, Deran 8376 Zhou, Yi-Feng 8377 Qin, Min-Jian 8378 Yu, Bo-Yang 8379 TI New features on the fragmentation patterns of homoisoflavonoids in 8380 Ophiopogon japonicus by high-performance liquid 8381 chromatography/diode-array detection/electrospray ionization with 8382 multi-stage tandem mass spectrometry 8383 SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY 8384 AB Homoisoflavonoids, a special class of flavonoids, are mainly 8385 distributed in the Liliaceae family and have various biological 8386 activities. Previously, very little research has been reported on the 8387 gas-phase fragmentation patterns of homoisoflavonoids by electrospray 8388 ionization mass spectrometry. In this paper, we report the use of 8389 high-performance liquid chromatography with a diode-array detector 8390 (HPLC-DAD) and electrospray ionization multi-stage tandem mass 8391 spectrometry (ESI-MSn) to study the fragmentation behavior of 11 8392 homoisoflavonoid standards and to analyze homoisoflavonoids in 8393 Ophiopogon japonicus. In total, 28 homoisoflavonoids (including seven 8394 novel constituents) were characterized. The deprotonated [M-H](-) 8395 molecules of the homoisoflavonoids containing a saturated C2-C3 bond 8396 afforded the A or B product ion (base peak) according to whether the 8397 B-ring was substituted with a hydroxyl group. For the homoisoflavonoids 8398 containing a C-2-C-3 double bond, the product ions (A or C ion) were 8399 created from the precursor [M-H](-) ion as the base peak when the B-ring 8400 was substituted with a hydroxyl group. The homoisoflavonoids carrying 8401 a formyl group in the A-ring readily eliminated one molecule of CO to 8402 form the product ion [M+H-CO](-) (base peak) irrespective whether the 8403 C-2-C-3 bond was saturated or not. This product ion afforded the 8404 [M-H-CO-B-ring-CH2+H](-) ion by cleavage of the C3-C9 bond. This latter 8405 product ion always appeared in tandem mass (MS/MS) spectra of type I 8406 homoisoflavonoids. The common features of flavonoids observed during 8407 the gas-phase fragmentation mechanisms were the loss of the following 8408 groups: 15 Da (CH3), 18 Da (H2O), 28 Da (CO), 44 Da (CO2) and 46 Da 8409 (CH2O2). A retro-Diels-Alder (RDA)-like cleavage was also observed for 8410 the homoisoflavonoids. The different gas-phase fragmentation routes 8411 were characterized for the deprotonated molecules obtained from the 8412 various homoisoflavonoids and collision-induced dissociation (CID) 8413 fragmentation differences were noted for the different locations of 8414 the various substituents. In conclusion, we can say that this study 8415 allowed us to structurally elucidate and identify homoisoflavonoids 8416 distributed in related plants and their complex prescriptions. 8417 Copyright (C) 2010 John Wiley & Sons, Ltd. 8418 SN 0951-4198 8419 PD AUG 8420 PY 2010 8421 VL 24 8422 IS 15 8423 BP 2193 8424 EP 2206 8425 DI 10.1002/rcm.4608 8426 UT ISI:000280495700003 8427 PT J 8428 AU Zhou, CH 8429 Xiang, M 8430 He, SY 8431 Qian, ZY 8432 AF Zhou, Cheng-Hua 8433 Xiang, Min 8434 He, Shu-Ying 8435 Qian, Zhi-Yu 8436 TI Crocetin Inhibits Cell Cycle G(1)/S Transition through Suppressing 8437 Cyclin D1 and Elevating p27(kip1) in Vascular Smooth Muscle Cells 8438 SO PHYTOTHERAPY RESEARCH 8439 AB Crocetin is a natural carotenoid compound isolated from Gardenia 8440 jasminoids Ellis. Our previous study shows that crocetin inhibits 8441 angiotensin II (Ang II)-induced vascular smooth muscle cells (VSMCs) 8442 proliferation. To further explore the mechanism by which crocetin 8443 inhibits VSMCs proliferation, in the present study we examined the 8444 effect of crocetin on cell cycle progression and cell cycle regulatory 8445 proteins. Flow cytometry analysis showed that Ang II elicited 8446 significant increase in the percentage of VSMCs in the S phase, with 8447 a concomitant decline in the percentage of VSMCs in the G(0)/G(1) phase. 8448 However, on pretreatment of VSMCs with crocetin, the percentage of 8449 VSMCs in the S phase decreased, while that in the G(0)/G(1) phase 8450 increased significantly. In addition, Ang II-induced increase of cell 8451 proliferation index was also decreased by crocetin. Western blotting 8452 analysis indicated that crocetin markedly inhibited the protein 8453 expression of cyclin D1 but not cyclin E. Crocetin also increased the 8454 level of cyclin-dependent kinase inhibitor (CDKI) p27(kip1) but not 8455 CDKI p27(waf1/cip1). In conclusion, our present results suggest that 8456 the inhibition of cell cycle G(1)/S transition in VSMCs by crocetin 8457 can be attributed, at least in part, to its suppression of cyclin D1 8458 and elevation of CDKI p27(kip1). Copyright (C) 2009 John Wiley & Sons, 8459 Ltd. 8460 SN 0951-418X 8461 PD JUL 8462 PY 2010 8463 VL 24 8464 IS 7 8465 BP 975 8466 EP 981 8467 DI 10.1002/ptr.3039 8468 UT ISI:000280142900004 8469 PT J 8470 AU Wang, YQ 8471 Ye, C 8472 Wu, LH 8473 Hu, YZ 8474 AF Wang, Yunqing 8475 Ye, Chao 8476 Wu, Liheng 8477 Hu, Yuzhu 8478 TI Synthesis and characterization of self-assembled CdHgTe/gelatin 8479 nanospheres as stable near infrared fluorescent probes in vivo 8480 SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 8481 CT 21st International Symposium on Pharmaceutical and Biomedical Analysis 8482 CY OCT 11-14, 2009 8483 CL Orlando, FL 8484 AB This work presented a kind of novel near infrared emitting 8485 CdHgTe/gelatin nanospheres which were synthesized with Cd(NO3)(2), 8486 Hg(NO3)(2). NaHTe and a thiol stabilizer in gelatin solution The 8487 self-assembled nanospheres were megranate-like and nearly 40 nm in 8488 diameter, with CdHgTe QDs uniformly embedded in gelatin matrix. They 8489 exhibited strong fluorescence ranging from 580 to 800 nm that could 8490 be tuned by molar ratios of Hg2+ and gelatin. The full widths at 8491 half-maximum of the emission spectra were in the range of 60-80 nm. 8492 Compared with bare CdHgTe QDs, the photostability of this compact 8493 complex nanostructure remarkably improved. Moreover, the fluorescence 8494 of CdHgTe/gelatin nanospheres was much more resistant to the 8495 interference from certain kinds of endogenous biomolecules such as HSA, 8496 transferrin and hemoglobin Further applications of living cells and 8497 mouse imaging were demonstrated with an in vivo near infrared 8498 fluorescence imaging system The Inherent advantages of high stability 8499 as well as high fluorescence intensity make the nanospheres particular 8500 interested NIR bioprobe candidates for in vivo imaging studies (C) 2010 8501 Elsevier B.V. All rights reserved 8502 SN 0731-7085 8503 PD NOV 2 8504 PY 2010 8505 VL 53 8506 IS 3 8507 BP 235 8508 EP 242 8509 DI 10.1016/j.jpba.2010.02.028 8510 UT ISI:000280435800003 8511 PT J 8512 AU Li, NG 8513 Shi, ZH 8514 Tang, YP 8515 Ma, HY 8516 Yang, JP 8517 Li, BQ 8518 Wang, ZJ 8519 Song, SL 8520 Duan, JA 8521 AF Li, Nian-Guang 8522 Shi, Zhi-Hao 8523 Tang, Yu-Ping 8524 Ma, Hong-Yue 8525 Yang, Jian-Ping 8526 Li, Bao-Quan 8527 Wang, Zhen-Jiang 8528 Song, Shu-Lin 8529 Duan, Jin-Ao 8530 TI Synthetic Strategies in the Construction of Chromones 8531 SO JOURNAL OF HETEROCYCLIC CHEMISTRY 8532 AB Because of important biological applications of chromones, some 8533 synthetic strategies leading to more complex derivatives have been 8534 widely explored in the past years. Thus, the purpose of this review 8535 is to report some recent improvements of the classical synthetic 8536 methods and of some nonclassical methods to obtain simple oxygenated 8537 chromones. The strategies for synthesis of heterocycle analogs 8538 containing phosphorus, nitrogen, and sulfur are also summarized. 8539 SN 0022-152X 8540 PD JUL 8541 PY 2010 8542 VL 47 8543 IS 4 8544 BP 785 8545 EP 799 8546 DI 10.1002/jhet.393 8547 UT ISI:000280450700003 8548 PT J 8549 AU Liu, Y 8550 Zhou, JL 8551 Liu, P 8552 Sun, S 8553 Li, P 8554 AF Liu, Ying 8555 Zhou, Jian-Liang 8556 Liu, Peng 8557 Sun, Shi 8558 Li, Ping 8559 TI Chemical markers' fishing and knockout for holistic activity and 8560 interaction evaluation of the components in herbal medicines 8561 SO JOURNAL OF CHROMATOGRAPHY A 8562 AB A strategy based on chemical markers' fishing and knockout has been 8563 proposed for holistic activity and interaction evaluation of the 8564 bioactive components in herbal medicines (HMs). It was devised to 8565 screen bioactive-compound group that represents the efficacy of HM, 8566 estimate the bioactivity contribution of each component and elucidate 8567 the interactions of multi-components. This strategy was accomplished 8568 through the following steps: (1) screen out the chemical markers 8569 (target peaks) in a HM fingerprint using online two-dimensional 8570 turbulent flow chromatography/liquid chromatography-mass 8571 spectrometry technique, (2) fish target peaks and knockout any 8572 interested peak, and (3) evaluate the bioactivities of fishing and 8573 knockout portions. After comparison of the bioactivities of samples 8574 containing different target peaks, the efficacy of target-peak group, 8575 bioactivity contribution of each compound, and the interactions of 8576 multi-components are elucidated. Using Acetylcholinesterase (AChE) 8577 and Bulbs of Lycoris radiata (L. Herit.) Herb. (BLR) as the experimental 8578 materials, four target peaks were screened out as the AChE binders. 8579 By target peaks' fishing and knockout, combined with activity 8580 evaluation, we observed that the bioactivity of the four-peak mixture 8581 is similar with the global bioactivity of BLR extract, and there are 8582 significant suppressive actions among these four target peaks. These 8583 results indicate that this proposed strategy is a useful approach for 8584 holistic screening of bioactive-compound group and elucidation of the 8585 multi-component interactions in HM. (C) 2010 Elsevier B.V. All rights 8586 reserved. 8587 SN 0021-9673 8588 PD AUG 6 8589 PY 2010 8590 VL 1217 8591 IS 32 8592 BP 5239 8593 EP 5245 8594 DI 10.1016/j.chroma.2010.06.039 8595 UT ISI:000280497300014 8596 PT B 8597 AU Sen, Z 8598 AF Sen, Zhou 8599 ED Jiang, Y; Cheng, G 8600 TI Internal stabilizability for a reaction-diffusion system 8601 SO PROCEEDINGS OF THE 2010 INTERNATIONAL CONFERENCE ON APPLICATION OF 8602 MATHEMATICS AND PHYSICS, VOL 2 - ADVANCES ON APPLIED MATHEMATICS AND 8603 COMPUTATION MATHEMATICS 8604 CT International Conference on Application of Mathematics and Physics 8605 (AMP2010) 8606 CY MAY 08-09, 2010 8607 CL Nanjing, PEOPLES R CHINA 8608 AB This paper is concerned with the problem of internal stabilizability 8609 for a 2 x 2 reaction-diffusion system describing interactions between 8610 a prey population and a predator population. We obtain some results 8611 of internal zero stabilizability of the predator population. 8612 BN 978-1-84626-082-7 8613 PY 2010 8614 BP 133 8615 EP 137 8616 UT ISI:000280135200030 8617 PT J 8618 AU Wang, QO 8619 Hao, HP 8620 Zhu, XX 8621 Yu, G 8622 Lai, L 8623 Liu, YT 8624 Wang, YX 8625 Jiang, S 8626 Wang, GJ 8627 AF Wang, Qiong 8628 Hao, Haiping 8629 Zhu, Xuanxuan 8630 Yu, Guo 8631 Lai, Li 8632 Liu, Yitong 8633 Wang, Yuxin 8634 Jiang, Shan 8635 Wang, Guangji 8636 TI Regioselective Glucuronidation of Tanshinone IIa after Quinone 8637 Reduction: Identification of Human UDP-Glucuronosyltransferases, 8638 Species Differences, and Interaction Potential 8639 SO DRUG METABOLISM AND DISPOSITION 8640 AB We have previously identified that the predominant metabolic pathway 8641 for tanshinone IIa (TSA) in rat is the NAD(P)H:quinone oxidoreductase 8642 1 (NQO1)-mediated quinone reduction and subsequent glucuronidation. 8643 The present study contributes to further research on its 8644 glucuronidation enzyme kinetics, the identification of human 8645 UDP-glucuronosyltransferase (UGT) isoforms, and the interaction 8646 potential with typical UGT substrates. A pair of regioisomers (M1 and 8647 M2) of reduced TSA glucuronides was found from human, rat, and mouse, 8648 whereas only M1 was found in dog liver S9 incubations. The overall 8649 glucuronidation clearance of TSA in human liver S9 was 11.8 +/- 0.8 8650 mu l/min/mg protein, 0.7-, 0.8-, and 3-fold of that in the mouse, rat, 8651 and dog, respectively. Using intrinsic clearance M2/M1 as a 8652 regioselective index, opposite regioselectivity was found between 8653 human (0.7) and mouse (1.3), whereas no significant regioselectivity 8654 was found in rat. In a sequential metabolism system, by applying human 8655 liver cytosol as an NQO1 donor combined with a screening panel of 12 8656 recombinant human UGTs, multiple UGTs were found involved in the M1 8657 formation, whereas only UGT1A9 and, to a very minor extent, UGT1A1 and 8658 UGT1A3 contributed to the M2 formation. Further enzyme kinetics, 8659 correlation, and chemical inhibition studies confirmed that UGT1A9 8660 played a major role in both M1 and M2 formation. In addition, TSA 8661 presented a potent inhibitory effect on the glucuronidation of typical 8662 UGT1A9 substrates propofol and mycophenolic acid, with an IC50 value 8663 of 8.4 +/- 1.8 and 8.9 +/- 1.9 mu M, respectively. This study will help 8664 to guide future studies on characterizing the NQO1-mediated reduction 8665 and subsequent glucuronidation of other quinones. 8666 SN 0090-9556 8667 PD JUL 8668 PY 2010 8669 VL 38 8670 IS 7 8671 BP 1132 8672 EP 1140 8673 DI 10.1124/dmd.109.031864 8674 UT ISI:000280382100016 8675 PT J 8676 AU Chen, YJ 8677 AF Chen, Yijun 8678 TI Hot topic: Biotransformation in Drug Discovery and Development 8679 SO CURRENT ORGANIC CHEMISTRY 8680 SN 1385-2728 8681 PD AUG 8682 PY 2010 8683 VL 14 8684 IS 14 8685 BP 1399 8686 EP 1399 8687 UT ISI:000280474000001 8688 PT J 8689 AU Liu, JH 8690 Yu, BY 8691 AF Liu, Ji-Hua 8692 Yu, Bo-Yang 8693 TI Biotransformation of Bioactive Natural Products for Pharmaceutical 8694 Lead Compounds 8695 SO CURRENT ORGANIC CHEMISTRY 8696 AB Biotransfomation has been increasingly utilized as a tool to generate 8697 pharmaceutical lead compounds from natural products in recent years. 8698 A wide variety of natural pruducts including aromatics, steroids, 8699 alkaloids, coumarins, flavonoids and terpenoids can be biotransformed 8700 by fungi, yeasts, bacteria, plant cells and enzymes derived from these 8701 sources. The biochemical reactions occurring in microorganisms and 8702 plant cells are typically regio- and stereo-selective, which is 8703 difficult to be achieved by chemical methods. In this review we describe 8704 important biotransformations used for the generation of lead compounds 8705 with pharmaceutical utilities and further structural diversification 8706 of complex natural products, especially those from traditional Chinese 8707 medicines. Such approach will ultimately benefit the advancement of 8708 biotransformation and potential therapeutics. 8709 SN 1385-2728 8710 PD AUG 8711 PY 2010 8712 VL 14 8713 IS 14 8714 BP 1400 8715 EP 1406 8716 UT ISI:000280474000002 8717 PT J 8718 AU Wei, MC 8719 Wang, SZ 8720 Shang, GD 8721 AF Wei, Maochen 8722 Wang, Shuzhen 8723 Shang, Guangdong 8724 TI Biosynthetic Pathways and Engineering for Bioactive Natural Products 8725 SO CURRENT ORGANIC CHEMISTRY 8726 AB Natural products synthesized by polyketide synthase (PKS), 8727 non-ribosomal peptide synthetase (NRPS) and the hybrid PKS-NRPS have 8728 been valuable sources for bioactive compounds due to their structural 8729 diversity and wide variety of biological activities. Progresses in the 8730 biosynthetic study of natural products in recent years reinvigorate 8731 the hope of discovering new compounds for clinical use. This review 8732 focuses on the elucidation of biosynthetic pathways of PKS and NRPS, 8733 the more "abnormal" biosynthetic reactions, the manipulation of gene 8734 cluster to increase product yields, as well as the catalytic 8735 applications of the enzymes originated from secondary metabolism. 8736 Genome mining or key regulatory gene activation to obtain "silent" gene 8737 cluster and the progresses on using sequencing data to predict the 8738 generation of natural products are also summarized. 8739 SN 1385-2728 8740 PD AUG 8741 PY 2010 8742 VL 14 8743 IS 14 8744 BP 1433 8745 EP 1446 8746 UT ISI:000280474000005 8747 PT J 8748 AU Huang, Y 8749 Liu, N 8750 Wu, XR 8751 Chen, YJ 8752 AF Huang, Yan 8753 Liu, Nan 8754 Wu, Xuri 8755 Chen, Yijun 8756 TI Dehydrogenases/Reductases for the Synthesis of Chiral Pharmaceutical 8757 Intermediates 8758 SO CURRENT ORGANIC CHEMISTRY 8759 AB The increasing trend of chiral drugs in the pharmaceutical industry 8760 has promoted greatly on the development of numerous biocatalytic routes 8761 in combination with chemical methods. Because the resulting chiral 8762 alcohols are particularly valuable intermediates and precursors for 8763 the synthesis of chiral drugs, dehydrogenases and reductases have been 8764 extensively used in the synthesis of chiral compounds from ketone 8765 substrates with high regio- and stereo-selectivities. In this review, 8766 biocatalytic processes carried out by dehydrogenases and reductases 8767 are described for the synthesis of chiral intermediates for a wide 8768 variety of pharmaceuticals, including antidepressants, 8769 anti-anxieties, anti-asthmatics, anti-hypertensives, 8770 cholesterol-lowering agents, NK1 antagonists, ACE inhibitors and 8771 beta-Lactamase inhibitors. 8772 SN 1385-2728 8773 PD AUG 8774 PY 2010 8775 VL 14 8776 IS 14 8777 BP 1447 8778 EP 1460 8779 UT ISI:000280474000006 8780 PT J 8781 AU Zhang, HJ 8782 He, H 8783 Lu, YN 8784 Gu, Y 8785 Chuong, PH 8786 AF Zhang Huaijing 8787 He Hua 8788 Lue Yanni 8789 Gu Yan 8790 Chuong, Pham-huy 8791 TI EFFECTS OF PAMAM DENDRIMERS ON THE SOLUBILITY OF KETOPROFEN 8792 SO ACTA POLYMERICA SINICA 8793 AB The aim of this study was to study the effect of polyamidoamine (PAMAM) 8794 dendrimers on the aqueous solubility of ketoprofen and investigate the 8795 mechanism of solubilization. PAMAM dendrimers of G1. 0, Gl. 5, G2. 0, 8796 G2. 5, G3. 0 and G3. 5 were used as drug carriers of ketoprofen. The 8797 effects of pH and concentration of the dendrimers on the solubility 8798 of ketoprofen were studied by UV spectroscopy. In addition, the 8799 computational simulation was used to investigate the mechanism of 8800 interaction between PAMAM dendrimers and ketoprofen. Results showed 8801 that the pH, generation size, and concentration influenced the 8802 solubilization of ketoprofen. The solubility of ketoprofen increased 8803 with the increase of pH, generation size, and concentration of PAMAM 8804 dendrimers at pH 4.0 similar to 6.0. Both amino and ester terminated 8805 dendrimers caused the increase in ketoprofen solubility. However, at 8806 each pH, the solubility of ketoprofen was greater in the presence of 8807 amino-terminated dendrimers compared to the ester-terminated 8808 dendrimers possessing the same number of surface functional groups. 8809 The results of computational simulation show that interaction between 8810 ketoprofen and PAMAM dendrimers is mainly electrostatic force. Its 8811 mechanism of solubilization maybe an electrostatic interaction between 8812 the carboxyl group of ketoprofen and the primary amines or tertiary 8813 amines of PAMAM dendrimers. 8814 SN 1000-3304 8815 PD JUL 20 8816 PY 2010 8817 IS 7 8818 BP 876 8819 EP 883 8820 UT ISI:000280431100011 8821 PT J 8822 AU Wu, JJ 8823 Cheng, KW 8824 Zuo, XF 8825 Wang, MF 8826 Li, P 8827 Zhang, LY 8828 Wang, H 8829 Ye, WC 8830 AF Wu, Jia-Jun 8831 Cheng, Ka-Wing 8832 Zuo, Xiao-Feng 8833 Wang, Ming-Fu 8834 Li, Ping 8835 Zhang, Lu-Yong 8836 Wang, Hao 8837 Ye, Wen-Cai 8838 TI Steroidal saponins and ecdysterone from Asparagus filicinus and their 8839 cytotoxic activities 8840 SO STEROIDS 8841 AB Two new spirostanoides, filiasparosides E (1) and F (2), one new 8842 furostanoside, filiasparoside G (3), and one new ecdysterone, 8843 stachysterone A-20, 22-acetonide (4), together with six known 8844 steroidal saponins, asparagusin A (5), filiasparoside A (6), 8845 filiasparoside B (7), aspafilioside A (8), aspafilioside B (9), and 8846 filiasparoside C (10) were isolated from the roots of Asparagus 8847 filicinus Buch.-Ham. Their structures were elucidated on the basis of 8848 spectroscopic and chemical evidence. Compounds 1-10 were investigated 8849 for their cytotoxicities against human breast adenocarcinoma 8850 MDA-MB-231 cell line and compounds 8-10 exhibited cytotoxic activities 8851 with IC50 values ranging from 3.4 to 6.6 mu M. (C)2010 Elsevier Inc. 8852 All rights reserved. 8853 SN 0039-128X 8854 PD OCT 8855 PY 2010 8856 VL 75 8857 IS 10 8858 BP 734 8859 EP 739 8860 DI 10.1016/j.steroids.2010.05.002 8861 UT ISI:000280046700016 8862 PT J 8863 AU Cao, YA 8864 Chen, JJ 8865 Tan, NH 8866 Wu, YP 8867 Yang, J 8868 Wang, QA 8869 AF Cao, Yuan 8870 Chen, Ji-Jun 8871 Tan, Ning-Hua 8872 Wu, Yong-Ping 8873 Yang, Jie 8874 Wang, Qiang 8875 TI Structure determination of selaginellins G and H from Selaginella 8876 pulvinata by NMR spectroscopy 8877 SO MAGNETIC RESONANCE IN CHEMISTRY 8878 AB Selaginellins G (1) and H (2), two new selaginellin derivatives, were 8879 isolated from the whole plant of Selaginella pulvinata. Their 8880 structures were elucidated, and complete assignments of the H-1 and 8881 C-13 NMR spectroscopic data were achieved by 1D and 2D NMR experiments 8882 (HSQC, HMBC, COSY and ROESY). Compound 1 displayed good antifungal 8883 activity against Candida albicans with an IC50 value of 5.3 mu g/ml. 8884 Copyright (C) 2010 John Wiley & Sons, Ltd. 8885 SN 0749-1581 8886 PD AUG 8887 PY 2010 8888 VL 48 8889 IS 8 8890 BP 656 8891 EP 659 8892 DI 10.1002/mrc.2623 8893 UT ISI:000280218800012 8894 PT J 8895 AU Liang, Y 8896 Hao, HP 8897 Kang, A 8898 Xie, L 8899 Xie, T 8900 Zheng, XA 8901 Dai, C 8902 Wan, LR 8903 Sheng, LS 8904 Wang, GJ 8905 AF Liang, Yan 8906 Hao, Haiping 8907 Kang, An 8908 Xie, Lin 8909 Xie, Tong 8910 Zheng, Xiao 8911 Dai, Chen 8912 Wan, Leren 8913 Sheng, Longsheng 8914 Wang, Guangji 8915 TI Qualitative and quantitative determination of complicated herbal 8916 components by liquid chromatography hybrid ion trap time-of-flight 8917 mass spectrometry and a relative exposure approach to herbal 8918 pharmacokinetics independent of standards 8919 SO JOURNAL OF CHROMATOGRAPHY A 8920 AB To date, the pharmacokinetic research of herbal medicines (HMs) is 8921 still in its infancy and is facing critical technical challenges on 8922 the qualitative and quantitative analysis of complicated components 8923 from biological matrices. Additionally, the lack of authentic 8924 standards constitutes another bottleneck on assessing herbal 8925 pharmacokinetics. This present work contributes to the development of 8926 a powerful technical platform for both qualitative and quantitative 8927 pharmacokinetic analysis of herbal components, and a strategy of 8928 relative exposure that provides a practicable pharmacokinetic 8929 assessment independent of authentic standards, based on the use of 8930 liquid chromatography hybrid ion trap time-of-flight mass spectrometry 8931 (LC-IT-TOF/MS). Taking schisandra lignans extract (SLE) as an example, 8932 the LC-IT-TOF/MS assay was initially applied to the global qualitative 8933 analysis of components contained in SLE per se and in the rat plasma 8934 post SLE dosing. Afterwards, this study focused on validating the 8935 quantitative performance of LC-IT-TOF/MS assay by comparison with a 8936 well-established LC-Q/MS assay. For the absolute quantification of 8937 five lignans components with authentic standards, both assays showed 8938 very similar analytical figures of merit such as linearity, precision, 8939 accuracy, and pharmacokinetic parameters. Compared with LC-Q/MS, the 8940 prominent advantage of LC-IT-TOF/MS assay is its much higher 8941 sensitivity. Moreover, a 'relative exposure approach' (REA) that 8942 entails the use of sequentially diluted original herbal preparations 8943 to prepare the 'mixed calibration curves' was developed to assessing 8944 herbal pharmacokinetics independent of specific authentic compounds 8945 for each component. Such an approach was found capable of providing 8946 virtually identical pharmacokinetic parameters as that from the 8947 typical pharmacokinetic assay calibrated by authentic standards, 8948 except for the absolute plasma concentrations. The presently developed 8949 methodology and approach will find its wide use in, but not limited 8950 to, the qualitative and quantitative pharmacokinetic analysis of 8951 herbal medicines. (C) 2010 Elsevier By. All rights reserved. 8952 SN 0021-9673 8953 PD JUL 23 8954 PY 2010 8955 VL 1217 8956 IS 30 8957 BP 4971 8958 EP 4979 8959 DI 10.1016/j.chroma.2010.05.056 8960 UT ISI:000280019300012 8961 PT J 8962 AU Zhou, XW 8963 Li, Y 8964 Jiang, XQ 8965 Qiu, L 8966 Liu, JP 8967 AF Zhou, Xiaowen 8968 Li, Ying 8969 Jiang, Xiaoqun 8970 Qiu, Lu 8971 Liu, Jianping 8972 TI Release of copper and indomethacin from intrauterine devices immersed 8973 in simulated uterine fluid 8974 SO EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE 8975 AB Objectives To study the release of cupric ions and indomethacin from 8976 copper-bearing intrauterine devices (Cu-IUDs) and to assess the 8977 influence of their surface area of copper and the pH of the test medium 8978 on the release of cupric ions. 8979 Methods Cu-IUDs were incubated in simulated uterine fluid (SUF). The 8980 in vitro release of cupric ions and indomethacin was determined by means 8981 of a flame atomic absorption spectrometer and a UV752 8982 spectrophotometer, respectively, over a period of 220 days. The effect 8983 of indomethacin on the pH of the SUF was monitored during the cupric 8984 ions release study. 8985 Results The Cu-IUDs released cupric ions in vitro according to a 8986 biphasic pattern. After an initial burst release, the rate slowed down 8987 and then became steady. The release of indomethacin from two medicated 8988 Cu-IUDs was biphasic and, in both cases, in accordance with the in vitro 8989 dissolution model of the drug. The surface area of copper of Cu-IUDs 8990 and the pH change induced by indomethacin incorporated in their frame 8991 affected the release rate of copper (p < 0.05). 8992 Conclusion The surface area of the copper and the pH of the test medium 8993 modulate the in vitro release of cupric ions from Cu-IUDs. 8994 SN 1362-5187 8995 PD JUN 8996 PY 2010 8997 VL 15 8998 IS 3 8999 BP 205 9000 EP 212 9001 DI 10.3109/13625181003782860 9002 UT ISI:000280194300007 9003 PT J 9004 AU Wang, Y 9005 Song, M 9006 Hang, TJ 9007 Wen, AD 9008 Yang, L 9009 AF Wang, Yu 9010 Song, Min 9011 Hang, Taijun 9012 Wen, Aidong 9013 Yang, Lin 9014 TI LC-MS-MS Simultaneous Determination of Niacin, Niacinamide and 9015 Nicotinuric Acid in Human Plasma LC-MS-MS and Its Application to a Human 9016 Pharmacokinetic Study 9017 SO CHROMATOGRAPHIA 9018 AB A highly selective and sensitive liquid chromatographic tandem mass 9019 spectrometric (LC-MS-MS) method was developed and validated for the 9020 quantitation and pharmacokinetic study of niacin (NA) and its two 9021 metabolites niacinamide (NAM) and nicotinuric acid (NUR) in human 9022 plasma. Protein precipitation with 14% perchloric acid solution was 9023 selected for sample preparation, and ganciclovir was used as an 9024 internal standard. Separation was on a Phenomenex Curosil-PFP (250 mm 9025 x 4.6 mm, 5 mu m) column by a multiple steep steps linear gradient 9026 elution with mobile phase consisting of water and methanol, both 9027 containing 0.1% formic acid, pumped at a flow rate of 1 mL min(-1). 9028 The determination was optimized and carried out with positive 9029 electrospray ionization by selective multiple reaction monitoring. The 9030 method was linear in the concentration range of 15-2,000 ng mL(-1) for 9031 NA, 70-2,000 ng mL(-1) for NAM and 10-2,000 ng mL(-1) for NUR, by 9032 standard addition calibration. The application of LC-MS-MS was 9033 demonstrated for the specific and quantitative analysis of NA, NAM and 9034 NUR in human plasma from a pharmacokinetic study in 12 healthy Chinese 9035 volunteers treated with three incremental doses of niacin 9036 extended-release/lovastatin tablets and an additional steady-state 9037 regime. 9038 SN 0009-5893 9039 PD AUG 9040 PY 2010 9041 VL 72 9042 IS 3-4 9043 BP 245 9044 EP 253 9045 DI 10.1365/s10337-010-1645-3 9046 UT ISI:000280250000008 9047 PT J 9048 AU Xu, GF 9049 Du, YX 9050 Chen, B 9051 Chen, JQ 9052 AF Xu, Guangfu 9053 Du, Yingxiang 9054 Chen, Bin 9055 Chen, Jiaquan 9056 TI Investigation of the Enantioseparation of Basic Drugs with 9057 Erythromycin Lactobionate as a Chiral Selector in CE 9058 SO CHROMATOGRAPHIA 9059 AB The macrocyclic antibiotics including ansamycins, glycopeptides, 9060 aminoglycosides and polypeptides have been demonstrated to exhibit 9061 powerful enantioselectivity towards numerous chiral compounds. By 9062 comparison with the four classes of antibiotics, macrolides are another 9063 type of macrocyclic antibiotics. In this study erythromycin 9064 lactobionate belonging to the group of macrolides is first used as a 9065 chiral selector in CE for the enantiomeric separations of basic drugs. 9066 As observed, erythromycin lactobionate allowed excellent separation 9067 of the enantiomers of 9068 N,N-dimethyl-3-(2-methoxyphenoxy)-3-propylamine, propranolol and 9069 duloxetine, as well as partial enantioresolution of primaquine, 9070 chloroquine and nefopam. In addition, erythromycin lactobionate 9071 possesses advantages such as high solubility and low viscosity in the 9072 solvent and very weak UV absorption. Among several experimental factors 9073 including buffer pH, BGE and erythromycin lactobionate concentrations, 9074 capillary temperature and applied voltage, we found that the 9075 enantioseparations of basic drugs above-mentioned strongly depended 9076 on the pH of BGE and the concentration of the chiral additive. The 9077 optimum pH was in the neutral or weak basic region but varied among 9078 drugs. An erythromycin lactobionate concentration of about 10% (w/v) 9079 and a low capillary temperature of 16 A degrees C were recommended for 9080 the practical analysis. 9081 SN 0009-5893 9082 PD AUG 9083 PY 2010 9084 VL 72 9085 IS 3-4 9086 BP 289 9087 EP 295 9088 DI 10.1365/s10337-010-1647-1 9089 UT ISI:000280250000013 9090 PT J 9091 AU Yin, RT 9092 Zheng, H 9093 Xi, T 9094 Xu, HM 9095 AF Yin, Runting 9096 Zheng, Heng 9097 Xi, Tao 9098 Xu, Han-Mei 9099 TI Effect of RGD-4C Position is More Important Than Disulfide Bonds on 9100 Antiangiogenic Activity of RGD-4C Modified Endostatin Derived 9101 Synthetic Polypeptide 9102 SO BIOCONJUGATE CHEMISTRY 9103 AB ES-2 (IVRRADRAAVP), an endostatin-derived synthetic polypeptide, 9104 contains the amino acids 50-60 of endostatin from its N terminus, and 9105 it had no inhibitory effects on tumor growth in vivo. In order to 9106 increase the targeted delivery of ES-2 to tumors and further enhance 9107 the activity, the polypeptide RGD-4C (ACDCRGDCFC) was introduced into 9108 ES-2, and the effects of RGD-4C position and RGD-4C disulfide bonds 9109 on polypeptides activity were investigated. When RGD-4C polypeptides 9110 (with or without disulfide bonds) were introduced to the N-terminals 9111 of synthesized ES-2, the modified ES-2 showed significant antitumor 9112 activity in vivo. Cell proliferation and chicken chorioallantoic 9113 membrane (CAM) assay results showed that disulfide bonds had no 9114 significant effects on RGD-4C-modified ES-2 antiangiogenic activity. 9115 Furthermore, the target of modified peptides was integrin alpha 5/beta 9116 1, rather than integrin alpha v beta 3 as previous studies mentioned. 9117 SN 1043-1802 9118 PD JUL 9119 PY 2010 9120 VL 21 9121 IS 7 9122 BP 1142 9123 EP 1147 9124 DI 10.1021/bc900292y 9125 UT ISI:000280028100004 9126 PT J 9127 AU Chen, Q 9128 Liu, QM 9129 Li, ZM 9130 Zhong, WY 9131 He, W 9132 Xu, DK 9133 AF Chen, Qing 9134 Liu, Qiongming 9135 Li, Zhoumin 9136 Zhong, Wenying 9137 He, Wei 9138 Xu, Danke 9139 TI A visual chip-based coimmunoprecipitation technique for analysis of 9140 protein-protein interactions 9141 SO ANALYTICAL BIOCHEMISTRY 9142 AB Here we report a visual chip-based coimmunoprecipitation (vChip-coIP) 9143 platform for analysis of protein-protein interactions (PPIs) by 9144 combining advantages of an antibody microarray, traditional coIP, and 9145 a silver enhancement detection method. The chip was fabricated by 9146 spotting anti-Flag antibody on aldehyde-modified slides, and the 9147 resulting platform could assay immunoprecipitate from a small amount 9148 of crude cell lysates containing Flag-bait and Myc-prey. The 9149 interaction signals are visible using biotinylated anti-Myc antibody 9150 and colloidal gold-labeled streptavidin followed by a silver 9151 enhancement detection method. It is shown that vChip-coIP is a simple, 9152 cost-effective, and highly efficient platform for the comprehensive 9153 study of PPIs. (C) 2010 Elsevier Inc. All rights reserved. 9154 SN 0003-2697 9155 PD SEP 15 9156 PY 2010 9157 VL 404 9158 IS 2 9159 BP 244 9160 EP 246 9161 DI 10.1016/j.ab.2010.05.003 9162 UT ISI:000280213400022 9163 PT J 9164 AU Xu, DH 9165 Zhang, YH 9166 Ma, DW 9167 AF Xu, Danhua 9168 Zhang, Yihua 9169 Ma, Dawei 9170 TI Organocatalytic approach to 3,5,6-trisubstituted and 9171 4,6-disubstituted tetrahydropyran-2-ones 9172 SO TETRAHEDRON LETTERS 9173 AB The diarylprolinol ether-catalyzed Michael addition and subsequent 9174 cyclization of ethyl 3-methyl-2-oxobut-3-enoate with aldehydes, and 9175 gamma-substituted beta,gamma-unsaturated-alpha-ketoesters with 9176 acetaldehyde, afforded the corresponding lactals, which were subjected 9177 to oxidation and stereocontrolled hydrogenation to provide 9178 3,5,6-trisubstituted and 4,6-disubstituted tetrahydropyran-2-ones 9179 with excellent enantioselectivities. (C) 2010 Elsevier Ltd. All rights 9180 reserved. 9181 SN 0040-4039 9182 PD JUL 21 9183 PY 2010 9184 VL 51 9185 IS 29 9186 BP 3827 9187 EP 3829 9188 DI 10.1016/j.tetlet.2010.05.077 9189 UT ISI:000279864100033 9190 PT J 9191 AU Conga, RG 9192 Zhang, YH 9193 Tian, WS 9194 AF Conga, Rigang 9195 Zhang, Yihua 9196 Tian, Weisheng 9197 TI A concise synthesis of the steroidal core of clathsterol 9198 SO TETRAHEDRON LETTERS 9199 AB The protected steroidal core of clathsterol, a marine natural product 9200 with remarkable inhibitory activity against HIV-1 reverse 9201 transcriptase, was synthesized starting from readily available 9202 tigogenin. The synthetic strategy involved three key reactions: 9203 abnormal Baeyer-Villiger rearrangement of the spiroketal of tigogenin, 9204 xanthation of steroidal 16-hydroxyl-22-carboxylate dianion and 9205 regioselective epoxide-opening lactonization. (C) 2010 Elsevier Ltd. 9206 All rights reserved. 9207 SN 0040-4039 9208 PD JUL 28 9209 PY 2010 9210 VL 51 9211 IS 30 9212 BP 3890 9213 EP 3892 9214 DI 10.1016/j.tetlet.2010.05.072 9215 UT ISI:000279817400006 9216 PT J 9217 AU He, SJ 9218 Zhu, JB 9219 Xie, FM 9220 AF He, Shengjiang 9221 Zhu, Jiabi 9222 Xie, Fuming 9223 TI Preparation and characterization of tramadol PEG-coated 9224 multivesicular liposomes for sustained release 9225 SO PHARMAZIE 9226 AB The purpose of the present study was to prepare multivesicular 9227 liposomes (MVL) with a high drug loading capacity for intramuscular 9228 sustained release and to investigate their potential applicability 9229 towards tramadol, and to improve the stability of liposomes by coating 9230 PEG. The basic physiochemical properties of tramadol MVLs and 9231 PEG-coated MVLs were studied. The average particle sizes of optimum 9232 preparation were 18.2 mu m and 31.3 mu m. The entrapment efficiency 9233 was up to 80%. The encapsulation efficiency of tramadol MVLs and 9234 PEG-coated MVLs was measured. The results confirmed the possibility 9235 of multivesicular liposomes as a sustained-release delivery system. 9236 Tramadol was continuously released from MVL formulations in PBS (pH6.8) 9237 in vitro, and reached a maximum of 80% within 72 h. The results show 9238 that tramadol PEG-coated MVLs could provide sustained release 9239 according to the first order kinetic equation. 9240 SN 0031-7144 9241 PD JUL 9242 PY 2010 9243 VL 65 9244 IS 7 9245 BP 467 9246 EP 470 9247 DI 10.1691/ph.2010.9357 9248 UT ISI:000279891200004 9249 PT J 9250 AU Chen, YJ 9251 Tao, J 9252 Xiong, F 9253 Zhu, JB 9254 Gu, N 9255 Geng, KK 9256 AF Chen, Y. J. 9257 Tao, J. 9258 Xiong, F. 9259 Zhu, J. B. 9260 Gu, N. 9261 Geng, K. K. 9262 TI Characterization and in vitro cellular uptake of PEG coated iron oxide 9263 nanoparticles as MRI contrast agent 9264 SO PHARMAZIE 9265 AB Monodisperse magnetic iron oxide nanoparticles (MNPs), coated with PEG 9266 at different molecular weight, were prepared via self-assembly method. 9267 The particle diameters were measured by dynamic light scattering and 9268 transmission electron microscope. Increasing the molecular weight of 9269 PEG in the coating polymer increased the overall particles diameter. 9270 As coating thickness increased, the saturation magnetization (Ms) and 9271 T-2 relaxivity decreased. The interactions of these MNPs with 9272 macrophage cells were also investigated. The results showed that 9273 cellular uptakes of MNPs depended on nanoparticle concentration and 9274 surface chemistry. The results of this study will have implications 9275 on the chemical design of nanomaterials for bio-imaging and 9276 bio-detection. 9277 SN 0031-7144 9278 PD JUL 9279 PY 2010 9280 VL 65 9281 IS 7 9282 BP 481 9283 EP 486 9284 DI 10.1691/ph.2010.9372 9285 UT ISI:000279891200007 9286 PT J 9287 AU Ji, BS 9288 Li, M 9289 He, L 9290 AF Ji, Bian-Sheng 9291 Li, Ming 9292 He, Ling 9293 TI Interaction of CJZ3, a lomerizine derivative, with ATPase activity of 9294 human P-glycoprotein in doxorubicin-resistant human myelogenous 9295 leukemia (K562/DOX) cells 9296 SO PHARMAZIE 9297 AB P-Glycoprotein, a 170-180 kDa membrane glycoprotein that mediates 9298 multidrug resistance, hydrolyses ATP to efflux a broad spectrum of 9299 hydrophobic agents. To observe the interaction of a P-gp reversal agent 9300 with P-gp ATPase activity should provide further insights into the 9301 mechanisms of P-gp modulator. In this study, we analysed the effect 9302 of CJZ3, a lomerizine derivative, on the adenosine triphosphatase 9303 (ATPase) activity of human P-glycoprotein. The results showed that the 9304 basal P-gp ATPase activity was increased by CJZ3 with half-maximal 9305 activity concentration (Km) of 6.8 +/- 1.5 mu M, CJZ3 may interact with 9306 P-gp with a higher affinity and exhibit a more potent effect than 9307 verapamil (Ver). Kinetic analysis indicated a noncompetitive 9308 inhibition of Ver-stimulated P-gp ATPase activity and a competitive 9309 inhibition of CJX2-stimulated P-gp ATPase activity by CJZ3, moreover, 9310 the effect of CsA on CJZ3-stimulated and Ver-stimulated P-gp ATPase 9311 activity showed a non-competitive and a competitive inhibition 9312 respectively. CJZ3 and CJX2 can bind P-gp either on overlapping sites 9313 or distinct but interacting sites, while CJZ3 and Ver as well as CsA 9314 can bind P-gp on separated sites in K562/DOX cells. 9315 SN 0031-7144 9316 PD JUL 9317 PY 2010 9318 VL 65 9319 IS 7 9320 BP 515 9321 EP 519 9322 DI 10.1691/ph.2009.9803 9323 UT ISI:000279891200013 9324 PT J 9325 AU Cheng, KG 9326 Liu, J 9327 Sun, HB 9328 Bokor, E 9329 Czifrak, K 9330 Konya, B 9331 Toth, M 9332 Docsa, T 9333 Gergely, P 9334 Somsak, L 9335 AF Cheng, Keguang 9336 Liu, Jun 9337 Sun, Hongbin 9338 Bokor, Eva 9339 Czifrak, Katalin 9340 Konya, Balint 9341 Toth, Marietta 9342 Docsa, Tibor 9343 Gergely, Pal 9344 Somsak, Laszlo 9345 TI Tethered derivatives of D-glucose and pentacyclic triterpenes for 9346 homo/heterobivalent inhibition of glycogen phosphorylase 9347 SO NEW JOURNAL OF CHEMISTRY 9348 AB Propargyl esters of the C-28 carboxylic acids of pentacyclic 9349 triterpenes (oleanolic, ursolic, and maslinic acids) were coupled with 9350 2,3,4,6-tetra-O-acetyl-beta-D-glucopyranosyl azide as well as 9351 N-(omega-azido-[C-2, C-6, and 9352 C-11]alkanoyl)-beta-D-glucopyranosylamines under conditions of 9353 copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) to give 9354 tethered D-glucose-triterpene heteroconjugates. The O-acetyl 9355 protecting groups were removed by base-catalyzed hydrolysis. 9356 N-(omega-Azido-[C-2, C-6, C-11, and 9357 C-16]alkanoyl)-beta-D-glucopyranosylamines were also tethered by 9358 1,7-octadiyne under CuAAC conditions to furnish D-glucose 9359 homoconjugates. O-Deacetylation was carried out by the Zemplen 9360 protocol. The new compounds were assayed against rabbit muscle glycogen 9361 phosphorylase (RMGP) a or b enzymes. Some of the heteroconjugates 9362 inhibited the enzyme in the low micromolar range (IC50 values 40-70 9363 mu M), while the homoconjugates proved inefficient as inhibitors. 9364 SN 1144-0546 9365 PY 2010 9366 VL 34 9367 IS 7 9368 BP 1450 9369 EP 1464 9370 DI 10.1039/b9nj00602h 9371 UT ISI:000279911700028 9372 PT J 9373 AU Yao, Y 9374 Li, XB 9375 Zhao, W 9376 Zeng, YY 9377 Shen, H 9378 Xiang, H 9379 Xiao, H 9380 AF Yao, Yao 9381 Li, Xiao-Bo 9382 Zhao, Wei 9383 Zeng, Yan-Yan 9384 Shen, Hong 9385 Xiang, Hua 9386 Xiao, Hong 9387 TI Anti-obesity effect of an isoflavone fatty acid ester on obese mice 9388 induced by high fat diet and its potential mechanism 9389 SO LIPIDS IN HEALTH AND DISEASE 9390 AB Background: The novel compound 1a is one of the isoflavone fatty acid 9391 esters. In order to investigate the anti-obesity effect of compound 9392 1a and its potential mechanism of influence in adipocyte 9393 differentiation, Obese male C57BL/6J mice induced by high-fat diet 9394 (HFD) and rat preadipocytes (3T3-L1 cell) were used. 9395 Methods: After 4-week HFD induction, the obese model was made 9396 successfully. After treatment with compound 1a, mice plasma 9397 biochemistry parameters were analyzed. In addition, mice hepatic 9398 tissue slice was observed. In in vitro research, 3T3-L1 cell 9399 differentiation by Oil-Red-O staining and adipocyte apoptosis was 9400 detected by flow cytometry. 9401 Results: The in vivo results implied that compound 1a significantly 9402 decreased the body weight, white adipose tissue weight of obesity 9403 mice(p < 0.05), reduced leptin and TG in plasma(p < 0.05), elevated 9404 HDL-C in serum(p < 0.05). The in vitro results suggested that compound 9405 1a could significantly suppress the adipocyte viability and lipid 9406 accumulation in the differentiation of preadipocyte, and induce 9407 apoptosis in both preadipocytes and mature adipocytes(p < 0.05). 9408 Conclusion: Compound 1a regulates serum lipid profiles, decreases 9409 adipose tissue mass and body weight gain by inducing adipocyte 9410 apoptosis in high fat diet induced mice. Thus, it may be used to treat 9411 obese patients with hypercholesterolemia and hypertriglyceridemia. 9412 SN 1476-511X 9413 PD MAY 19 9414 PY 2010 9415 VL 9 9416 AR 49 9417 DI 10.1186/1476-511X-9-49 9418 UT ISI:000279907200001 9419 PT J 9420 AU Cao, RS 9421 Hu, YQ 9422 Wang, Y 9423 Gurley, EC 9424 Studer, EJ 9425 Wang, XA 9426 Hylemon, PB 9427 Pandak, WM 9428 Sanyal, AJ 9429 Zhang, LY 9430 Zhou, HP 9431 AF Cao, Risheng 9432 Hu, Yiqiao 9433 Wang, Yun 9434 Gurley, Emily C. 9435 Studer, Elaine J. 9436 Wang, Xuan 9437 Hylemon, Phillip B. 9438 Pandak, William M. 9439 Sanyal, Arun J. 9440 Zhang, Luyong 9441 Zhou, Huiping 9442 TI Prevention of HIV Protease Inhibitor-Induced Dysregulation of Hepatic 9443 Lipid Metabolism by Raltegravir via Endoplasmic Reticulum Stress 9444 Signaling Pathways 9445 SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 9446 AB Hyperlipidemia associated with the HIV protease inhibitor (PI), the 9447 major component of highly active antiretroviral treatment (HAART) for 9448 HIV infection, has stimulated interest in developing new agents that 9449 minimize these side effects in the clinic. HIV integrase inhibitor is 9450 a new class of anti-HIV agents. Raltegravir is a first-in-its-class 9451 oral integrase inhibitor and has potent inhibitory activity against 9452 HIV-1 strains that are resistant to other antiretroviral regimens. Our 9453 previous studies have demonstrated that HIV PI-induced endoplasmic 9454 reticulum (ER) stress links to dysregulation of lipid metabolism. 9455 However, little information is available as to whether raltegravir 9456 would have similar effects as the HIV PIs. In this study, we examined 9457 the effect of raltegravir on lipid metabolism both in primary rat 9458 hepatocytes and in in vivo mouse models, and we further determined 9459 whether the combination of raltegravir with existing HIV PIs would 9460 potentially exacerbate or prevent the previously observed development 9461 of dyslipidemia. The results indicated that raltegravir did not induce 9462 ER stress or disrupt lipid metabolism either in vitro or in vivo. 9463 However, HIV PI-induced ER stress and lipid accumulation were 9464 significantly inhibited by raltegravir both in in vitro primary rat 9465 hepatocytes and in in vivo mouse liver. High-performance liquid 9466 chromatography analysis further demonstrated that raltegravir did not 9467 affect the uptake and metabolism of HIV PIs in hepatocytes. Thus, 9468 raltegravir has less hepatic toxicity and could prevent HIV PI-induced 9469 dysregulation of lipid metabolism by inhibiting ER stress. These 9470 results suggest that incorporation of this HIV integrase inhibitor may 9471 reduce the side effects associated with current HAART. 9472 SN 0022-3565 9473 PD AUG 10 9474 PY 2010 9475 VL 334 9476 IS 2 9477 BP 530 9478 EP 539 9479 DI 10.1124/jpet.110.168484 9480 UT ISI:000279990700019 9481 PT J 9482 AU Zheng, H 9483 Jiang, YY 9484 Wang, Y 9485 Jia, XM 9486 Yan, TH 9487 Gao, PH 9488 Yan, L 9489 Jiang, LH 9490 Ji, H 9491 Cao, YB 9492 AF Zheng, Hao 9493 Jiang, Yuan-Ying 9494 Wang, Yan 9495 Jia, Xin-Ming 9496 Yan, Tian-Hua 9497 Gao, Ping-Hui 9498 Yan, Lan 9499 Jiang, Ling-Huo 9500 Ji, Hui 9501 Cao, Yong-Bing 9502 TI TOP2 gene disruption reduces drug susceptibility by increasing 9503 intracellular ergosterol biosynthesis in Candida albicans 9504 SO JOURNAL OF MEDICAL MICROBIOLOGY 9505 AB In this study the role of the TOP2 gene in fungal drug susceptibility 9506 was investigated by disrupting and overexpressing the gene in Candida 9507 albicans. MIC determination and a spot assay showed that a top2 9508 Delta/Delta null mutant (strain T2bc) was more resistant to the 9509 antifungals tested than the wildtype (strain CAI4). Real-time RT-PCR 9510 and rhodamine 6G efflux examination showed that TOP2 did not influence 9511 the activity of drug efflux pumps. Sterol analysis with 9512 GC/high-resolution MS indicated that the intracellular ergosterol 9513 composition of the top2 Delta/Delta mutant was significantly 9514 increased. Subsequently, fluorescence polarization measurements also 9515 revealed that Top2-deprived cells displayed a decrease in membrane 9516 fluidity, resulting in enhanced passive diffusion of the drugs. 9517 Quantitative real-time RT-PCR analysis further confirmed that the 9518 ERG11 gene, an essential gene in ergosterol biosynthesis, was 9519 upregulated. These results demonstrate a close relationship between 9520 the TOP2 gene and drug susceptibility in C. albicans. 9521 SN 0022-2615 9522 PD JUL 9523 PY 2010 9524 VL 59 9525 IS 7 9526 BP 797 9527 EP 803 9528 DI 10.1099/jmm.0.018325-0 9529 UT ISI:000279838400008 9530 PT J 9531 AU Yu, N 9532 Xun, Y 9533 Jin, D 9534 Yang, H 9535 Hang, T 9536 Cui, H 9537 AF Yu, N. 9538 Xun, Y. 9539 Jin, D. 9540 Yang, H. 9541 Hang, T. 9542 Cui, H. 9543 TI Effect of Sperminated Pullulans on Drug Permeation Through Isolated 9544 Rabbit Cornea and Determination of Ocular Irritation 9545 SO JOURNAL OF INTERNATIONAL MEDICAL RESEARCH 9546 AB The aim of this study was to investigate the effect of two sperminated 9547 pullulans (SP) with a different number of amino groups (SP-L, amino 9548 group content 0.124 mmol/g polymer; and SP-H, amino group content 0.578 9549 mmol/g polymer) on the permeation of drugs through isolated rabbit 9550 corneas. Determination of corneal hydration levels and Draize eye tests 9551 were performed to assess the safety of SP both in vitro and in vivo. 9552 For 0.2% (w/v) SP-L and 0.2% (w/v) SP-H, the enhancement ratios (ERs) 9553 with dexamethasone of 1.34 and 1.42, respectively, were not 9554 statistically significant. For ofloxacin, tobramycin and sodium 9555 fluorescein, the ERs with 0.2% SP-L were 1.37, 2.02 and 2.12, 9556 respectively, and with 0.2% SP-H the ERs were 1.84, 4.69 and 6.87, 9557 respectively; these ERs were all statistically significant. 9558 Enhancement increased with increasing amino group content of the SP. 9559 The improved transcorneal drug absorption via the paracellular route 9560 indicated opening of the tight junctions in the corneal epithelium. 9561 Irritation tests indicated that 0.2% SP-L and 0.2% SP-H did not damage 9562 the corneal tissues. 9563 SN 0300-0605 9564 PD MAR-APR 9565 PY 2010 9566 VL 38 9567 IS 2 9568 BP 526 9569 EP 535 9570 UT ISI:000279877200015 9571 PT J 9572 AU Li, 9573 AF Li, Xiu-Min 9574 Ma, Hai-Bin 9575 Ma, Zhan-Qiang 9576 Lu-Fan 9577 Chang-Liang 9578 Rong 9579 Shi-Ping 9580 TI Ameliorative and neuroprotective effect in MPTP model of Parkinson's 9581 disease by Zhen-Wu-Tang (ZWT), a traditional Chinese medicine 9582 SO JOURNAL OF ETHNOPHARMACOLOGY 9583 AB Aim of the study: Traditional Chinese medicine Zhen-Wu-Tang (ZWT) is 9584 a well-known PentaHerbs formula from "Treatise on Febrile Disease". 9585 This study is to elucidate its neuroprotective effect and mechanism 9586 of ameliorative effect of the syndrome of Parkinson's disease (PD). 9587 Materials and methods:The ameliorative effect of ZWT on symptom of PD 9588 through behavior tests including: swimming test, the tail suspension 9589 test and open-field test was investigated. The neuroprotective effect 9590 of dopaminergic neurons from the striatum and frontal cortex of brain 9591 was detected by high performance liquid chromatography with 9592 electrochemical detection (HPLC-ECD). 9593 Results: This study proved that ZWT could ameliorate the typical 9594 symptom of PD and protect dopaminergic system. 9595 Conclusion: These results suggested that ZWT possessed protective and 9596 ameliorative properties of dopaminergic neurons. (C) 2010 Elsevier 9597 Ireland Ltd. All rights reserved. 9598 SN 0378-8741 9599 PD JUL 6 9600 PY 2010 9601 VL 130 9602 IS 1 9603 BP 19 9604 EP 27 9605 DI 10.1016/j.jep.2010.03.020 9606 UT ISI:000279886900004 9607 PT J 9608 AU Meng, QG 9609 Yu, M 9610 Gu, B 9611 Li, J 9612 Liu, Y 9613 Zhan, CY 9614 Xie, C 9615 Zhou, JP 9616 Lu, WY 9617 AF Meng, Qinggang 9618 Yu, Mei 9619 Gu, Bing 9620 Li, Jin 9621 Liu, Yu 9622 Zhan, Changyou 9623 Xie, Cao 9624 Zhou, Jianping 9625 Lu, Weiyue 9626 TI Myristic acid-conjugated polyethylenimine for brain-targeting 9627 delivery: in vivo and ex vivo imaging evaluation 9628 SO JOURNAL OF DRUG TARGETING 9629 AB To investigate the potential of myristic acid (MC) to mediate brain 9630 delivery of polyethylenimine (PEI) as a gene delivery system, a 9631 covalent conjugate (MC-PEI) of MC, and PEI was synthesized. A 9632 near-infrared fluorescence probe, IR820 was conjugated to MC-PEI to 9633 explore its in vivo distribution after intravenous (i.v.) 9634 administration in mice. The brain targeting ability of MC-PEI was 9635 evaluated by near-infrared fluorescence imaging and analyzed 9636 semiquantitatively by fluorescence intensity, respectively. 9637 Significant NIR fluorescent signal was detected in the brain 12 h after 9638 i.v. administration and further confirmed by imaging the whole brain 9639 and brain slices. Semiquantitative results from fluorescence intensity 9640 further supported the successful brain delivery of MC-PEI which led 9641 to a very significant increase (similar to 200%) in the brain uptake 9642 after i.v. injection in comparison with unmodified PEI. The capability 9643 of MC-PEI to condense DNA was further confirmed using agarose gel 9644 retardation assay, indicating its potential for gene delivery. The 9645 significant in vivo and ex vivo results suggest that MC-PEI is a 9646 promising brain-targeting drug delivery system, especially for gene 9647 delivery. 9648 SN 1061-186X 9649 PD JUL 9650 PY 2010 9651 VL 18 9652 IS 6 9653 BP 438 9654 EP 446 9655 DI 10.3109/10611860903494229 9656 UT ISI:000279926400004 9657 PT J 9658 AU Cao, J 9659 Xue, B 9660 Li, H 9661 Deng, DW 9662 Gu, YQ 9663 AF Cao, Jie 9664 Xue, Bing 9665 Li, Hui 9666 Deng, Dawei 9667 Gu, Yueqing 9668 TI Facile synthesis of high-quality water-soluble 9669 N-acetyl-L-cysteine-capped Zn1-xCdxSe/ZnS core/shell quantum dots 9670 emitting in the violet-green spectral range 9671 SO JOURNAL OF COLLOID AND INTERFACE SCIENCE 9672 AB In this paper, we report a new facile method to synthesize water-soluble 9673 Zn1-xCdxSe and core/shell Zn1-xCdxSe/ZnS quantum dots (QDs) emitting 9674 in the violet-green spectral range, using N-acetyl-L-cysteine (NAC) 9675 as a stabilizer. The influence of various experimental variables, 9676 including the precursor Zn/Cd/Se/NAC molar ratios, the pH of original 9677 solution and the refluxing time on optical properties were explored 9678 systematically. The obtained aqueous Zn1-xCdxSe QDs exhibit a tunable 9679 photoluminescence (PL) emission (from similar to 415 nm to 506 nm) and 9680 a favorable narrow PL bandwidth (FWHM: 27-38 nm). After coating with 9681 a ZnS shell, the PL emission intensity of the formed core/shell 9682 Zn1-xCdxSe/ZnS QDs is greatly increased (PL quantum yield (QY): similar 9683 to 30%). These resulting Zn1-xCdxSe and core/shell Zn1-xCdxSe/ZnS QDs 9684 were further characterized by transmission electron microscopy (TEM), 9685 energy disperse spectroscopy (EDS) and X-ray diffraction (XRD). In 9686 addition, the cytotoxicity and the fluorescence imaging of 9687 Zn1-xCdxSe/ZnS QDs to MCF-7 cells were preliminarily investigated. The 9688 experimental results show that the as-prepared violet-green-emitting 9689 Zn1-xCdxSe/ZnS QDs have low cytotoxicity, which makes them an ideal 9690 inorganic fluorescent probe for biolabeling and cell imaging. (C) 2010 9691 Elsevier Inc. All rights reserved. 9692 SN 0021-9797 9693 PD AUG 15 9694 PY 2010 9695 VL 348 9696 IS 2 9697 BP 369 9698 EP 376 9699 DI 10.1016/j.jcis.2010.05.007 9700 UT ISI:000279968700011 9701 PT J 9702 AU Yu, Y 9703 Yu, YL 9704 Liu, L 9705 Wang, XT 9706 Lu, SS 9707 Liang, Y 9708 Liu, XD 9709 Xie, L 9710 Wang, GJ 9711 AF Yu, Sen 9712 Yu, Yunli 9713 Liu, Li 9714 Wang, Xinting 9715 Lu, Shousi 9716 Liang, Yan 9717 Liu, Xiaodong 9718 Xie, Lin 9719 Wang, Guangji 9720 TI Increased Plasma Exposures of Five Protoberberine Alkaloids from 9721 Coptidis Rhizoma in Streptozotocin-Induced Diabetic Rats: Is P-GP 9722 Involved? 9723 SO PLANTA MEDICA 9724 AB Our previous study showed a higher exposure of berberine, palmatine, 9725 coptisine, epiberberine and jatrorrhizine in 6-week streptozotocin 9726 (STZ)-induced diabetic rats, after oral administration of Coptidis 9727 Rhizoma extract. The aim of the present study was to investigate whether 9728 the function and expression of intestinal P-glycoprotein (P-GP) was 9729 downregulated in STZ-induced diabetic rats and if the impairment of 9730 P-GP function and expression contributed to the exposure increase of 9731 the five protoberberine alkaloids. Plasma concentration-time profiles 9732 of the drugs in the portal vein were obtained after oral administration 9733 of Coptidis Rhizoma extract. The effective permeability of the drug 9734 across duodenum and ileum were measured using in situ single-pass 9735 intestine perfusion. P-GP function in the rat intestine was assessed 9736 by measuring the absorption of rhodamine 123 (Rho123). P-GP levels were 9737 evaluated using Western blots. It was found that the C-max and AUC(0-8) 9738 values of five alkaloids in the portal vein of diabetic rats were 9739 significantly higher than those in the control rats. Diabetic rats also 9740 exhibitd a higher level of Rho123 in the portal vein, which showed 9741 impairment of P-GP function. A higher effective permeability of the 9742 tested drug was found in the duodenum of diabetic rats using in situ 9743 single-pass intestine perfusion, indicating that berberine and Rho123 9744 transported more easily across the intestinal barrier of diabetic rats. 9745 A lower level of P-GP protein was found in the duodenum, jejunum and 9746 ileum of the diabetic rats as compared with age-matched control rats. 9747 All these results suggested that the function and expression of P-GP 9748 were impaired in the intestine of STZ-induced diabetic rats which, at 9749 least partly, contributed to the exposure increase of the five 9750 protoberberine alkaloids. 9751 SN 0032-0943 9752 PD JUN 9753 PY 2010 9754 VL 76 9755 IS 9 9756 BP 876 9757 EP 881 9758 DI 10.1055/s-0029-1240815 9759 UT ISI:000279668400006 9760 PT J 9761 AU Wang, L 9762 Yin, ZQ 9763 Wang, Y 9764 Zhang, XQ 9765 Li, YL 9766 Ye, WC 9767 AF Wang, Lei 9768 Yin, Zhi-Qi 9769 Wang, Ying 9770 Zhang, Xiao-Qi 9771 Li, Yao-Lan 9772 Ye, Wen-Cai 9773 TI Perisesaccharides A-E, New Oligosaccharides from the Root Barks of 9774 Periploca sepium 9775 SO PLANTA MEDICA 9776 AB Five new oligosaccharides, named perisesaccharides A-E (1-5), were 9777 isolated from the root barks of Periploca sepium. Their structures were 9778 elucidated by NMR and HRESIMS data. The absolute configurations of 9779 these compounds were determined by a combination of X-ray diffraction 9780 analysis, modified Mosher's method, circular dichroism spectroscopy, 9781 and acid hydrolysis. The boat conformation of oleandronic acid 9782 delta-lactone was reported for the first time. 9783 SN 0032-0943 9784 PD JUN 9785 PY 2010 9786 VL 76 9787 IS 9 9788 BP 909 9789 EP 915 9790 DI 10.1055/s-0029-1240842 9791 UT ISI:000279668400012 9792 PT J 9793 AU Zhou, L 9794 Ning, YW 9795 Wei, SH 9796 Feng, YY 9797 Zhou, JH 9798 Yu, BY 9799 Shen, J 9800 AF Zhou, Lin 9801 Ning, Yu-Wei 9802 Wei, Shao-Hua 9803 Feng, Yu-Ying 9804 Zhou, Jia-Hong 9805 Yu, Bo-Yang 9806 Shen, Jian 9807 TI A nanoencapsulated hypocrellin A prepared by an improved microemulsion 9808 method for photodynamic treatment 9809 SO JOURNAL OF MATERIALS SCIENCE-MATERIALS IN MEDICINE 9810 AB A new hypocrellin A (HA) encapsulated silica nanoparticles was prepared 9811 by an improved microemulsion method based on the unique character of 9812 cetyl trimethyl ammonium bromide (CTAB). Stable aqueous dispersions 9813 of the HA-loaded nanoparticles, with the diameter about 50 nm, owned 9814 superior photo-stability and singlet oxygen generation ability to free 9815 HA. In vitro studies demonstrated the active uptake of HA-doped 9816 nanoparticles into the cytosol of HeLa (human cervix epithelioid 9817 carcinoma) cells. Significant morphology change and phototoxicity to 9818 such impregnated tumor cells was observed upon irradiation with light. 9819 Thus, the potential of using this method to prepare silica 9820 nanoparticles as drug carriers for photodynamic therapy has been 9821 demonstrated. 9822 SN 0957-4530 9823 PD JUL 9824 PY 2010 9825 VL 21 9826 IS 7 9827 BP 2095 9828 EP 2101 9829 DI 10.1007/s10856-010-4067-8 9830 UT ISI:000279592600011 9831 PT J 9832 AU Wang, J 9833 Dong, SF 9834 Liu, CH 9835 Wang, W 9836 Sun, SH 9837 Gu, JX 9838 Wang, YA 9839 Boraschi, D 9840 Qu, D 9841 AF Wang, Jing 9842 Dong, Shengfu 9843 Liu, Chunhong 9844 Wang, Wei 9845 Sun, Shuhui 9846 Gu, Jianxin 9847 Wang, Yuan 9848 Boraschi, Diana 9849 Qu, Di 9850 TI beta-Glucan Oligosaccharide Enhances CD8(+) TCells Immune Response 9851 Induced by a DNA Vaccine Encoding Hepatitis B Virus Core Antigen 9852 SO JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY 9853 AB DNA vaccination can induce specific CD8(+) T cell immune response, but 9854 the response level is low in large mammals and human beings. 9855 Coadministration of an adjuvant can optimize protective immunity 9856 elicited by a DNA vaccine. In this study, we investigated the effect 9857 of a synthetic glucohexaose (beta-glu6), an analogue of Lentinan basic 9858 unit, on specific CD8(+) T cell response induced by a DNA vaccine 9859 encoding HBcAg (pB144) in mice. We found that beta-glu6 promoted the 9860 recruitment and maturation of dendritic cells, enhanced the activation 9861 of CD8(+) and CD4(+) T cells and increased the number of specific 9862 CD8(+)/IFN-gamma(+) T cells in lymphoid and nonlymphoid tissues in mice 9863 immunized by pB144. Immunization with pB144 and beta-glu6 increased 9864 the anti-HBc IgG and IgG2a antibody titer. These results demonstrate 9865 that beta-glu6 can enhance the virus-specific CTL and Th1 responses 9866 induced by DNA vaccine, suggesting beta-glu6 as a candidate adjuvant 9867 in DNA vaccination. 9868 SN 1110-7243 9869 PY 2010 9870 AR 645213 9871 DI 10.1155/2010/645213 9872 UT ISI:000279791900001 9873 PT J 9874 AU Huo, MR 9875 Zhang, Y 9876 Zhou, JP 9877 Zou, AF 9878 Yu, D 9879 Wu, YP 9880 Li, J 9881 Li, H 9882 AF Huo, Meirong 9883 Zhang, Yong 9884 Zhou, Jianping 9885 Zou, Aifeng 9886 Yu, Di 9887 Wu, Yiping 9888 Li, Jing 9889 Li, Hong 9890 TI Synthesis and characterization of low-toxic amphiphilic chitosan 9891 derivatives and their application as micelle carrier for antitumor drug 9892 SO INTERNATIONAL JOURNAL OF PHARMACEUTICS 9893 AB A new series of amphiphilically modified chitosan molecules with long 9894 alkyl chains as hydrophobic moieties and glycol groups as hydrophilic 9895 moieties (N-octyl-O-glycol chitosan, OGC) was synthesized for use as 9896 drug carriers. The chemical structure was characterized by Fourier 9897 transform infrared, H-1 nuclear magnetic resonance, and elemental 9898 analysis. OGC could easily self-assemble to form nanomicelles in an 9899 aqueous environment and exhibited a low critical micellar 9900 concentration of 5.3-32.5 mg/L The biocompatibility and low toxicity 9901 of OGC as excipient for the dosage forms aimed at iv. administration 9902 were confirmed by hemolysis, acute toxicity and histopathological 9903 studies. Furthermore, the possibility of solubilizing paclitaxel 9904 (PTX), a water-insoluble antitumor drug, with OGC micelles was also 9905 explored. PTX was successfully loaded into OGC micelles by using a 9906 simple dialysis process. The drug-loading capacity of OGC and stability 9907 of drug-loaded micelles were significantly affected by the degree of 9908 substitution of alkyl chains. Moreover, a series of safety studies 9909 including hemolysis, hypersensitivity, maximum tolerated dose, acute 9910 toxicity, and organ toxicity revealed that the PTX-loaded OGC micelles 9911 had advantages over the commercially available injectable preparation 9912 of PTX (Taxol (R)), in terms of low toxicity levels and increased 9913 tolerated dose. Additionally, cytotoxicity studies showed that the 9914 PTX-loaded OGC micelles were comparable to the commercial formulation, 9915 but the blank micelles were far less toxic than the Cremophor EL 9916 vehicle. These results suggest that OGC is a promising carrier for 9917 injectable Pp( micelles. (C) 2010 Elsevier B.V. All rights reserved. 9918 SN 0378-5173 9919 PD JUL 15 9920 PY 2010 9921 VL 394 9922 IS 1-2 9923 BP 162 9924 EP 173 9925 DI 10.1016/j.ijpharm.2010.05.001 9926 UT ISI:000279720400019 9927 PT J 9928 AU Pan, R 9929 Gao, XH 9930 Li, Y 9931 Xia, YF 9932 Dai, Y 9933 AF Pan, Rong 9934 Gao, Xing-Hua 9935 Li, Ying 9936 Xia, Yu-Feng 9937 Dai, Yue 9938 TI Anti-arthritic effect of scopoletin, a coumarin compound occurring in 9939 Erycibe obtusifolia Benth stems, is associated with decreased 9940 angiogenesis in synovium 9941 SO FUNDAMENTAL & CLINICAL PHARMACOLOGY 9942 AB Scopoletin is the main constituent of coumarin found in the stems of 9943 Erycibe obtusifolia Benth, a traditional Chinese medicine used in the 9944 treatment of rheumatoid arthritis. We have previously demonstrated 9945 that scopoletin is able to decrease the serum level of uric acid in 9946 hyperuricemic mice induced by potassium oxonate, and attenuate croton 9947 oil-induced inflammation. In the present study, we evaluated the 9948 anti-arthritic effects of scopoletin in rat adjuvant-induced arthritis 9949 by assessing paw swelling, pathology, and synovial angiogenesis. It 9950 was found that scopoletin, injected intraperitoneally at doses of 50, 9951 100 mg/kg, reduced both inoculated and non-inoculated paw swelling as 9952 well as articular index scores, and elevated the mean body weight of 9953 adjuvant-induced arthritic rats. Rats treated with higher dose of 9954 scopoletin showed a near-normal histological architecture of the 9955 joints and a reduced new blood vessel formation in the synovial tissues. 9956 Furthermore, scopoletin downregulated the overexpression of vascular 9957 endothelial growth factor, basic fibroblast growth factor and 9958 interleukin 6 in the synovial tissues of adjuvant-induced arthritic 9959 rats. In conclusion, scopoletin is capable of ameliorating clinical 9960 symptoms of rat adjuvant-induced arthritis, by reducing numbers of new 9961 blood vessels in the synovium and the production of important 9962 endogenous angiogenic inducers. Therefore, this compound may be a 9963 potential agent for angiogenesis-related diseases and could serve as 9964 a structural base for screening more potent synthetic analogs. 9965 SN 0767-3981 9966 PD AUG 9967 PY 2010 9968 VL 24 9969 IS 4 9970 BP 477 9971 EP 490 9972 DI 10.1111/j.1472-8206.2009.00784.x 9973 UT ISI:000279611400012 9974 PT J 9975 AU Du, Y 9976 Xu, W 9977 Yao, QZ 9978 Liu, ZL 9979 AF Du Yang 9980 Xu Wen 9981 Yao Qizheng 9982 Liu Zuliang 9983 TI Synthesis and Characterization of 4H-Pyridofuroxan-5-one and Its 9984 Nucleotide Derivative 9985 SO CHINESE JOURNAL OF ORGANIC CHEMISTRY 9986 AB A new compound, 4H-pyridofuroxan-5-one 9987 (4,5-dihydro-[1,2,5]oxadiazolo[3,4-b]pyridine-5-one 1-oxide), and 9988 its nucleotide derivative of tetraacetoxy D-ribose, were synthesized, 9989 and their structures as well as intermediates of each reactions were 9990 confirmed by H-1 NMR, MS techniques and elemental analysis. 9991 SN 0253-2786 9992 PD JUN 9993 PY 2010 9994 VL 30 9995 IS 6 9996 BP 928 9997 EP 932 9998 UT ISI:000279604600023 9999 PT J 10000 AU Yuan, YZ 10001 Zhang, M 10002 Qian, W 10003 Zhang, ZX 10004 AF Yuan Yao-Zuo 10005 Zhang Mei 10006 Qian Wen 10007 Zhang Zheng-Xing 10008 TI Characterization of Related Substances in Etimicin Sulfate Sample by 10009 High Performance Liquid Chromatography-Electrospray Ionization-Ion 10010 Trap-Mass Spectrometry 10011 SO CHINESE JOURNAL OF ANALYTICAL CHEMISTRY 10012 AB A high performance liquid chromatography-electrospray ionization-ion 10013 trap-mass spectrometry (HPLC-ESI-IT-MS") method for the 10014 identification of related substances in etimicin was established. The 10015 analytical conditions were as follows; Phenomnex Gemini NX C-18 (150 10016 mm x 4. 6 mm, 5 mu m) column; the mobile phase; [water-ammonia-glacial 10017 acetic acid (96: 3. 6:0. 4)]-methanol (70: 30); flow rate of mobile 10018 phase; 1 mL/min; temperature of ESI ion source: 350 degrees C; 10019 nebulizing pressure; 275. 8 kPa; dry gas flow; 10 L/min and the analytes 10020 were detected in the positive mode. Eighteen related substances in a 10021 etimicin sample were separated and detected by HPLC-ESI-IT-MS" and 10022 thirteen related substances were deduced, they are gentamicin C-la, 10023 micronomicin and its three isomers, two etimicin's isomers, two 10024 degradation products of etimicin, two homologues of etimicin, and two 10025 other unknown compounds, the other five related substances which MS 10026 and MS2 data were detected can not be elucidated. 10027 SN 0253-3820 10028 PD JUN 10029 PY 2010 10030 VL 38 10031 IS 6 10032 BP 817 10033 EP 822 10034 DI 10.3724/SP.J.1096.2010.00817 10035 UT ISI:000279604300010 10036 PT J 10037 AU Xu, Z 10038 Wang, XB 10039 Dai, Y 10040 Kong, LY 10041 Wang, FY 10042 Xu, HA 10043 Lu, D 10044 Song, J 10045 Hou, ZG 10046 AF Xu, Zhao 10047 Wang, Xiaobing 10048 Dai, Yue 10049 Kong, Lingyi 10050 Wang, Fengyun 10051 Xu, Huan 10052 Lu, Dan 10053 Song, Jie 10054 Hou, Zhiguo 10055 TI (+/-)-Praeruptorin A enantiomers exert distinct relaxant effects on 10056 isolated rat aorta rings dependent on endothelium and nitric oxide 10057 synthesis 10058 SO CHEMICO-BIOLOGICAL INTERACTIONS 10059 AB Praeruptorin A is a coumarin compound naturally occurring in the roots 10060 of Peucedanum praeruptorum Dunn., a commonly used traditional Chinese 10061 medicine for the treatment of certain respiratory diseases and 10062 hypertension. Although previous studies indicated the relaxant effects 10063 of (+/-)-praeruptorin A on tracheal and arterial preparations, little 10064 is known about the functional characteristics of the enantiomers. In 10065 the present study, the two enantiomers were successfully isolated and 10066 identified by using a preparative Daicel Chiralpak AD-H column, and 10067 their relaxant effects on aorta rings were observed and compared. 10068 (+)-Praeruptorin A showed more potent relaxation than (-)-praeruptorin 10069 A against KCl- and phenylephrine-induced contraction of rat isolated 10070 aortic rings with intact endothelium. Removal of the endothelium 10071 remarkably reduced the relaxant effect of (+)-praeruptorin A but not 10072 that of (-)-praeruptorin A. Pretreatment of aortic rings with 10073 N-omega-nitro-L-arginine methyl ester (L-NAME, an inhibitor of nitric 10074 oxide synthase) or methylene blue (MB, a soluble guanylyl cyclase 10075 inhibitor) resulted in similar changes of the relaxant effects of the 10076 two enantiomers to endothelium removal. Molecular docking studies also 10077 demonstrated that (+)-praeruptorin A was in more agreement to nitric 10078 oxide synthase pharmacophores than (-)-praeruptorin A. On the other 10079 hand, the two enantiomers of praeruptorin A could slightly attenuate 10080 the contraction of rat aortic rings induced by internal Ca2+ release 10081 from sarcoplasmic reticulum (SR). These findings indicated that 10082 (+)-praeruptorin A and (-)-praeruptorin A exerted distinct relaxant 10083 effects on isolated rat aorta rings, which might be mainly attributed 10084 to nitric oxide synthesis catalyzed by endothelial nitric oxide 10085 synthase. (C) 2010 Elsevier Ireland Ltd. All rights reserved. 10086 SN 0009-2797 10087 PD JUL 30 10088 PY 2010 10089 VL 186 10090 IS 2 10091 BP 239 10092 EP 246 10093 DI 10.1016/j.cbi.2010.04.024 10094 UT ISI:000279644900016 10095 PT J 10096 AU Zhou, L 10097 Liu, JH 10098 Ma, F 10099 Wei, SH 10100 Feng, YY 10101 Zhou, JH 10102 Yu, BY 10103 Shen, JA 10104 AF Zhou, Lin 10105 Liu, Ji-Hua 10106 Ma, Fei 10107 Wei, Shao-Hua 10108 Feng, Yu-Ying 10109 Zhou, Jia-Hong 10110 Yu, Bo-Yang 10111 Shen, Jian 10112 TI Mitochondria-targeting photosensitizer-encapsulated amorphous 10113 nanocage as a bimodal reagent for drug delivery and biodiagnose in vitro 10114 SO BIOMEDICAL MICRODEVICES 10115 AB The use of ceramic nano-carriers containing anti-cancer drugs for 10116 targeted delivery that span both fundamental and applied research has 10117 attracted the interest of the scientific community. In this paper, a 10118 hydrophobic photodynamic therapy drug, hypocrellin A (HA), was 10119 successfully encapsulated in water-soluble amorphous silica nanocage 10120 (HANC) by an improved sol-gel method. These nanocages are of ultrasmall 10121 size, highly monodispersed, stable in aqueous suspension, and retain 10122 the optical properties of HA. Moreover, these nanocages can be 10123 effectively delivered, subsequently taken up by cancer cells and 10124 finally targeted to mitochondria. In addition, incubation time 10125 dependent photodynamic efficacy difference between HANC and HA was 10126 investigated for the first time. Especially, the nanocages, owning 10127 extremely high stable fluorescence comparing with free HA, also have 10128 potentials as efficient probes for optical biodiagnose in vitro. All 10129 these properties of HANC could possibly make it especially promising 10130 to be used as a bimodal reagent for photodynamic therapy and 10131 biodiagnose. 10132 SN 1387-2176 10133 PD AUG 10134 PY 2010 10135 VL 12 10136 IS 4 10137 BP 655 10138 EP 663 10139 DI 10.1007/s10544-010-9418-1 10140 UT ISI:000279500200010 10141 PT J 10142 AU Zhang, YF 10143 Ye, BP 10144 Wang, DY 10145 AF Zhang, Yanfen 10146 Ye, Boping 10147 Wang, Dayong 10148 TI Effects of Metal Exposure on Associative Learning Behavior in Nematode 10149 Caenorhabditis elegans 10150 SO ARCHIVES OF ENVIRONMENTAL CONTAMINATION AND TOXICOLOGY 10151 AB In the present study, the thermotaxis model was used to evaluate the 10152 effects of metal exposure at different concentrations on associative 10153 learning behavior in nematodes. The examined nematodes were cultured 10154 at 25 or 17A degrees C, and then shifted to 20A degrees C condition. 10155 Based on the ability of nematodes to trace the temperature of 20A 10156 degrees C, exposure to 10 mu M of all examined metals and 2.5 mu M Pb 10157 and Hg caused significant decrease of associative learning behavior 10158 at time intervals of 5 and 18 h; however, exposure to 2.5 mu M Cu, Zn, 10159 and Ag did not influence associative learning behavior. Moreover, 10160 exposure to 2.5 and 10 mu M of examined metals did not influence body 10161 bend and thermotaxis to cultivation temperature, whereas exposure to 10162 50 mu M of examined metals caused significant reduction of body bend 10163 and thermotaxis to cultivation temperature. Furthermore, Pb and Hg were 10164 the more toxic among the examined metals, with severe toxicity on 10165 associative learning behavior, thermotaxis, and locomotion behavior 10166 in nematodes. 10167 SN 0090-4341 10168 PD JUL 10169 PY 2010 10170 VL 59 10171 IS 1 10172 BP 129 10173 EP 136 10174 DI 10.1007/s00244-009-9456-y 10175 UT ISI:000279581100014 10176 PT J 10177 AU Wei, MC 10178 Deng, J 10179 Feng, K 10180 Yu, BY 10181 Chen, YJ 10182 AF Wei, Maochen 10183 Deng, Jing 10184 Feng, Kun 10185 Yu, Boyang 10186 Chen, Yijun 10187 TI Universal Method Facilitating the Amplification of Extremely GC-Rich 10188 DNA Fragments from Genomic DNA 10189 SO ANALYTICAL CHEMISTRY 10190 AB Polymerase chain reaction (PCR) is a basic technique with wide 10191 applications in molecular biology. Despite the development of 10192 different methods with various modifications, the amplification of 10193 GC-rich DNA fragments is frequently troublesome due to the formation 10194 of complex secondary structure and poor denaturation. Given the fact 10195 that GC-rich genes are closely related to transcriptional regulation, 10196 transcriptional silencing, and disease progression, we developed a PCR 10197 method combining a stepwise procedure and a mixture of additives in 10198 the present work. Our study demonstrated that the PCR method could 10199 successfully amplify targeted DNA fragments up to 1.2 Kb with GC content 10200 as high as 83.5% from different species. Compared to all currently 10201 available methods, our work showed satisfactory, adaptable, fast and 10202 efficient (SAFE) results on the amplification of GC-rich targets, which 10203 provides a versatile and valuable tool for the diagnosis of genetic 10204 disorders and for the study of functions and regulations of various 10205 genes. 10206 SN 0003-2700 10207 PD JUL 15 10208 PY 2010 10209 VL 82 10210 IS 14 10211 BP 6303 10212 EP 6307 10213 DI 10.1021/ac100797t 10214 UT ISI:000279727800053 10215 PT J 10216 AU Huang, FH 10217 Zhang, XY 10218 Zhang, LY 10219 Li, Q 10220 Ni, B 10221 Zheng, XL 10222 Chen, AJ 10223 AF Huang, Fang-hua 10224 Zhang, Xin-yue 10225 Zhang, Lu-yong 10226 Li, Qin 10227 Ni, Bin 10228 Zheng, Xiao-liang 10229 Chen, Ai-jun 10230 TI Mast cell degranulation induced by chlorogenic acid 10231 SO ACTA PHARMACOLOGICA SINICA 10232 AB Aim: To investigate the mechanism of chlorogenic acid (CA)-induced 10233 anaphylactoid reactions. Methods: Degranulation of peritoneal mast 10234 cells was assayed by using alcian blue staining in guinea pigs, and 10235 the degranulation index (DI) was calculated. CA-induced degranulation 10236 of RBL-2H3 cells was also observed and assayed using light microscopy, 10237 transmission electron microscopy, flow cytometry, and 10238 beta-hexosaminidase release. 10239 Results: CA 0.2, 1.0, and 5.0 mmol/L was able to promote degranulation 10240 of peritoneal mast cells in guinea pigs in vitro, but it did not increase 10241 the degranulation of peritoneal mast cells in CA-sensitized guinea pigs 10242 compared with control (P>0.05). Treatment with CA 0.2, 1.0, and 5.0 10243 mmol/L for 30, 60, and 120 min induced degranulation in RBL-2H3 cells 10244 in a dose-and time-dependent manner (P<0.01). Under transmission 10245 electron microscope typical characteristics of degranulation, 10246 including migration of granular vesicles toward the plasma membrane 10247 and integration combined with exocytosis, were observed, after CA or 10248 C48/80 treatment. Fluorescent microscopy and flow cytometric analysis 10249 showed that CA induced concentration-dependent translocation of 10250 phosphatidylserine in RBL-2H3 cells. beta-hexosaminidase release in 10251 RBL-2H3 cells was significantly increased after incubation with 1 10252 mmol/L CA for 60 min and 5 mmol/L CA for 30 min (P<0.01). 10253 Conclusion: CA induces degranulation of peritoneal mast cells and 10254 RBL-2H3 cells in guinea pigs, which might be one of the mechanisms of 10255 the generation of anaphylactoid reactions induced by CA. 10256 SN 1671-4083 10257 PD JUL 10258 PY 2010 10259 VL 31 10260 IS 7 10261 BP 849 10262 EP 854 10263 DI 10.1038/aps.2010.63 10264 UT ISI:000279538400011 10265 PT J 10266 AU Liu, JJ 10267 Ma, XA 10268 Cai, LB 10269 Cui, YG 10270 Liu, JY 10271 AF Liu, Jin-Juan 10272 Ma, Xiang 10273 Cai, Ling-Bo 10274 Cui, Yu-Gui 10275 Liu, Jia-Yin 10276 TI Downregulation of both gene expression and activity of Hsp27 improved 10277 maturation of mouse oocyte in vitro 10278 SO REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY 10279 AB Background: Heat shock protein 27 (Hsp27), a member of the small heat 10280 shock protein family, is an apoptosis regulator. Our previous proteomic 10281 study showed that Hsp27 mainly expressed in human oocyte, and that Hsp27 10282 expression was downregulated in the ovaries derived from women with 10283 the polycystic ovary syndrome (PCOS), a well known endocrinal disorder 10284 with abnormal apoptotic activity and folliculogenesis. However, the 10285 exact effects of Hsp27 downregulation on oocyte development have not 10286 yet been clarified. 10287 Methods: The expression of Hsp27 gene was downregulated in the mouse 10288 oocytes cultured in vitro using siRNA adenovirus infection, while the 10289 activity of Hsp27 was decreased by microinjection of polyclonal Hsp27 10290 antibody into the cytoplasm of germinal vesicle (GV) oocytes. Oocyte 10291 maturation rate was evaluated by morphological observation. Early 10292 stage of apoptosis was determined using Annexin-V staining analysis 10293 and some critical apoptotic factors and cytokines were also monitored 10294 at both mRNA level by real time RT-PCR and protein expression level 10295 by immunofluorescence and western blot. 10296 Results: Hsp27 expressed at high level in maturing oocytes. Infection 10297 with AdshHsp27, and microinjection of Hsp27 antibody into GV oocytes, 10298 resulted in the improved oocyte development and maturation. Germinal 10299 vesicle breakdown (GVBD) rates were significantly increased in two 10300 AdshHsp27-treated groups (88.7%, 86.0%) and Hsp27 antibody-injected 10301 group (77.0%) when compared with control (76.2% in AdGFP, 64.4% in 10302 IgG-injected), respectively. In addition, the rates of metaphase II 10303 (MII) development in two AdshHsp27-treated groups (73.8%, 76.4%) and 10304 Hsp27 antibody-injected group (67.3%) were higher than that in the 10305 controls (59.6% in AdGFP, 55.1% in IgG-injected). We also found that 10306 the rates of early stage of apoptosis in Hsp27 downregulated groups 10307 (46.5% and 45.6%) were higher than that in control group (34.1%) after 10308 8 h of IVM. Similarly, downregulation of Hsp27 caused a significantly 10309 enhanced the expression of apoptotic factors (caspase 8, caspase 3) 10310 and cytokines (bmp 15 and gdf 9). 10311 Conclusions: Downregulation of Hsp27 improved the maturation of mouse 10312 oocytes, while increased early stage of apoptosis in oocytes by 10313 inducing the activation of extrinsic, caspase 8-mediated pathway. 10314 SN 1477-7827 10315 PD MAY 14 10316 PY 2010 10317 VL 8 10318 AR 47 10319 DI 10.1186/1477-7827-8-47 10320 UT ISI:000279509200002 10321 PT J 10322 AU Cao, X 10323 Yao, Z 10324 Shao, M 10325 Chen, H 10326 Ye, W 10327 Yao, X 10328 AF Cao, X. 10329 Yao, Z. 10330 Shao, M. 10331 Chen, H. 10332 Ye, W. 10333 Yao, X. 10334 TI Pharmacokinetics of methyl protodioscin in rats 10335 SO PHARMAZIE 10336 AB Methyl protodioscin (MPD), a natural furostanol saponin, showed 10337 distinct antitumor activity and is distributed in many traditional 10338 Chinese medicines. The pharmacokinetics, distribution and excretion 10339 of MPD were first investigated after i.v. injection to rats in this 10340 study. The dose-dependent pharmacokinetics of MPD were characterized 10341 after i.v. injection (20, 40 and 120 mg/kg of MPD) to rats. A good 10342 linearity (r = 0.9989, P < 0.05) was found in the regression analysis 10343 of the AUC(0-t) -dose. The plasma concentrations of MPD declined 10344 rapidly with an elimination half-life (t(1/2)) from 25.56 to 29.32 min. 10345 The MPD kinetics was in line with one-compartment model after i.v. 10346 injection. 23.43% and 32.86% of MPD was recovered in urine and bile, 10347 respectively. The concentrations of MPD in plasma and most examined 10348 tissues 5 h after injection were close to or below the Low Limit of 10349 Quantification (LLOQ). This indicated that MPD was distributed and 10350 eliminated rapidly in rats. 10351 SN 0031-7144 10352 PD MAY 10353 PY 2010 10354 VL 65 10355 IS 5 10356 BP 359 10357 EP 362 10358 DI 10.1691/ph.2010.9785 10359 UT ISI:000279426600010 10360 PT J 10361 AU Perera, PK 10362 Li, YM 10363 Peng, C 10364 Fang, WR 10365 Han, CF 10366 AF Perera, Pathirage Kamal 10367 Li, Yunman 10368 Peng, Cheng 10369 Fang, Weirong 10370 Han, Caifeng 10371 TI Immunomodulatory activity of a Chinese herbal drug Yi Shen Juan Bi in 10372 adjuvant arthritis 10373 SO INDIAN JOURNAL OF PHARMACOLOGY 10374 AB Objective: To investigate the immunomodulating mechanisms of a Chinese 10375 herbal medicine Yi Shen Juan Bi (YJB) in treatment of adjuvant arthritis 10376 (AA) in rats. Materials and Methods: Levels of serum tumor necrosis 10377 factor alpha (TNF-) and interleukin-1 (IL-1) were measured by the 10378 Enzyme-Linked Immunosorbent Assay (ELISA). Expression of TNF- mRNA and 10379 IL-1 mRNA in synovial cells was measured with the semi-quantitative 10380 technique of reverse transcription-polymerase chain reaction 10381 (RT-PCR), while caspase-3 was examined by western blot analysis. 10382 Results: The administration of YJB significantly decreased the 10383 production of serum TNF- and IL-1. It also decreased significantly the 10384 TNF- mRNA, IL-1 mRNA, and caspase-3 expression in synoviocytes. 10385 Conclusions: YJB produces the immunomodulatory effects by 10386 downregulating the over-activated cytokines, while it activates 10387 caspase-3, which is the key executioner of apoptosis in the immune 10388 system. This may be the one of the underlying mechanisms that explains 10389 how YJB treats the rheumatoid arthritis. 10390 SN 0253-7613 10391 PD MAR-APR 10392 PY 2010 10393 VL 42 10394 IS 2 10395 BP 65 10396 EP 69 10397 DI 10.4103/0253-7613.64489 10398 UT ISI:000279251500002 10399 PT J 10400 AU Wang, Y 10401 Yin, HP 10402 Lv, XB 10403 Wang, YF 10404 Gao, HY 10405 Wang, M 10406 AF Wang, Ying 10407 Yin, Hongping 10408 Lv, Xiaobo 10409 Wang, Yufeng 10410 Gao, Hongyan 10411 Wang, Min 10412 TI Protection of chronic renal failure by a polysaccharide from Cordyceps 10413 sinensis 10414 SO FITOTERAPIA 10415 AB A water-soluble polysaccharide (CPS-2), isolated from the cultured 10416 Cordyceps sinensis, was obtained by hot-water extraction, 10417 anion-exchange and gel permeation chromatography. Its structural 10418 characteristics were investigated by PMP pre-column derivation, 10419 periodate oxidation, methylation analysis, FTIR and NMR spectroscopy. 10420 CPS-2 was found to be mostly of alpha-(1 -> 4)-D-glucose and alpha-(1 10421 -> 3)-D-mannose, branched with alpha-(1 -> 4,6)-D-glucose every twelve 10422 residues on average. CPS-2 had a molecular weight of 4.39 x 10(4) Da. 10423 The protective effect of CPS-2 on the model of chronic renal failure 10424 was established by fulgerizing kidney. The changes in blood urea 10425 nitrogen and serum creatinine revealed that CPS-2 could significantly 10426 relieve renal failure caused by fulgerizing kidney. (C) 2009 Elsevier 10427 B.V. All rights reserved. 10428 SN 0367-326X 10429 PD JUL 10430 PY 2010 10431 VL 81 10432 IS 5 10433 BP 397 10434 EP 402 10435 DI 10.1016/j.fitote.2009.11.008 10436 UT ISI:000279306700018 10437 PT J 10438 AU Xia, ZX 10439 Qu, W 10440 Lu, HY 10441 Fu, JQ 10442 Ren, YL 10443 Liang, JY 10444 AF Xia, Zhengxiang 10445 Qu, Wei 10446 Lu, Haiying 10447 Fu, Juqin 10448 Ren, Yanli 10449 Liang, Jingyu 10450 TI Sesquiterpene lactones from Sonchus arvensis L. and their 10451 antibacterial activity against Streptococcus mutans ATCC 25175 10452 SO FITOTERAPIA 10453 AB Two new sesquiterpene lactones,1 beta-sulfate-5 alpha, 6 beta 10454 H-eudesma-3-en-12, 6 alpha-olide (1) and 1 beta-(p-hydroxyphenyl 10455 acetyl)-15-O-beta-D-glucopyranosyl-5 alpha, 6 beta 10456 H-eudesma-3-en-12, 6 alpha-olide (2) were isolated from Sonchus 10457 arvensis L (Asteraceae), together with eight known compounds. Their 10458 structures were elucidated through spectroscopic and chemical methods. 10459 They were evaluated for antibacterial activity. Among them, compounds 10460 1 and 7 exhibited antibacterial activity against oral pathogen 10461 Streptococcus mutans ATCC 25175 with MIC values of 15.6 and 62.5 mu 10462 g/ml, respectively. (c) 2010 Elsevier B.V. All rights reserved. 10463 SN 0367-326X 10464 PD JUL 10465 PY 2010 10466 VL 81 10467 IS 5 10468 BP 424 10469 EP 428 10470 DI 10.1016/j.fitote.2009.12.001 10471 UT ISI:000279306700022 10472 PT J 10473 AU Fu, JH 10474 Sun, HS 10475 Wang, Y 10476 Zheng, WQ 10477 Shi, ZY 10478 Wang, QJ 10479 AF Fu, J. -h. 10480 Sun, H. -s. 10481 Wang, Y. 10482 Zheng, W. -q. 10483 Shi, Z. -y. 10484 Wang, Q. -j. 10485 TI The Effects of a Fat- and Sugar-Enriched Diet and Chronic Stress on 10486 Nonalcoholic Fatty Liver Disease in Male Wistar Rats 10487 SO DIGESTIVE DISEASES AND SCIENCES 10488 AB The pathogenesis of nonalcoholic fatty liver disease (NAFLD) is still 10489 under debate. The aim of this study was to investigate the effects of 10490 a long-term fat- and sugar-enriched diet (FSED) and chronic stress (CS) 10491 on NAFLD. 10492 Male Wistar rats were fed on either a standard diet or a FSED and given 10493 CS, a random electric foot shock (2 hr/morning and afternoon per day), 10494 or not for 12 weeks. After the experimental period, epididymal adipose 10495 tissue weight, sign of visceral obesity (VO), and hepatic index (HI) 10496 were measured. At sacrifice blood samples and liver were obtained. 10497 Histology of the liver was blindly determined by a pathologist. 10498 Histopathologically, moderate to severe steatosis, ballooning 10499 hepatocytes, and portal or lobules inflammation were observed in the 10500 FSED+CS group. However, mild to moderate steatosis with a few portal 10501 inflammation in the FSED group and mild steatosis or not with a few 10502 portal inflammation in the CS group were found correspondingly. In 10503 addition, more severe blood-fat disorder, high HI, fatty metabolic 10504 dysfunction, oxidative stress, high expressions of C-reactive protein 10505 mRNA and low expressions of peroxisome proliferator-activated receptor 10506 alpha mRNA in the liver were also revealed in the FSED+CS group. But, 10507 the degree of VO was not different between the FSED and FSED+CS groups. 10508 The observations strongly suggest that chronic stress can aggravate 10509 fat- and sugar-enriched diet-induced NAFLD from steatosis to 10510 steatohepatitis in male Wistar rats, although VO is not changed. 10511 SN 0163-2116 10512 PD AUG 10513 PY 2010 10514 VL 55 10515 IS 8 10516 BP 2227 10517 EP 2236 10518 DI 10.1007/s10620-009-1019-6 10519 UT ISI:000279294200014 10520 PT J 10521 AU Chen, JQ 10522 Hu, ZJ 10523 Wang, D 10524 Gao, CJ 10525 Ji, R 10526 AF Chen, Jian-qiu 10527 Hu, Zhi-jun 10528 Wang, Duo 10529 Gao, Cong-jie 10530 Ji, Rong 10531 TI Photocatalytic mineralization of dimethoate in aqueous solutions using 10532 TiO2: Parameters and by-products analysis 10533 SO DESALINATION 10534 AB Photocatalytic mineralization of dimethoate using nanosized TiO2 at 10535 different conditions has been investigated. The objective of this work 10536 was to study the influence on the photocatalytic mineralization of 10537 dimethoate, of various parameters and identify intermediates formed 10538 during photocatalytic treatment. The mineralization efficiency of 10539 dimethoate increased with elevated concentration of humic acid up to 10540 5 mg/L, while the efficiency reduced when the concentration was above 10541 5 mg/L due to competitive adsorption. The presence of CH3COCH3 can 10542 significantly inhibit dimethoate mineralization and the half-life of 10543 mineralization efficiency was increased by about 3 times. The photo 10544 mineralization efficiency changed with increasing concentrations of 10545 inorganic ions. With respect to the ions of Fe3+, Cu2+, Zn2+, HCO3and NO3-, the mineralization efficiency increased with increasing 10546 concentration of ions and reached a maximum at optimal concentrations, 10547 which was followed by a decrease with a further increase in ion 10548 concentrations. By contrast, the mineralization of dimethoate was 10549 strongly inhibited by Cl- and Cr3+ ions. Intermediate products from 10550 dimethoate were identified by means of GC MS and four possible 10551 by-products were identified. A proposed mineralization pathway for 10552 dimethoate is presented. (C) 2010 Elsevier B.V. All rights reserved. 10553 SN 0011-9164 10554 PD AUG 10555 PY 2010 10556 VL 258 10557 IS 1-3 10558 BP 28 10559 EP 33 10560 DI 10.1016/j.desal.2010.03.053 10561 UT ISI:000279229400005 10562 PT J 10563 AU Wang, JX 10564 Yang, Y 10565 Ma, JH 10566 Zhang, L 10567 Guo, QL 10568 You, QD 10569 AF Wang Jin-Xin 10570 Yang Yan 10571 Ma Jun-Hai 10572 Zhang Lei 10573 Guo Qing-Long 10574 You Qi-Dong 10575 TI Synthesis of Gambogic Acid Oxidative Analogues and Their Dimension 10576 Quantity Structure-activity Relationship Analysis 10577 SO CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE 10578 AB 35,40-Dihydroxyl-6-methoxyl-gambogic acid methyl ester(1), 9, 10579 10-dihydroxy1-6-methoxyl-gambogie acid methyl ester(2) and 10580 2-deisohexylene-2-(2-formyl)ethy1-6-methoxyl-gambogic acid methyl 10581 ester(3) were first synthesized. And their antitumour activities on 10582 several cancer lines were tested. Meanwhile via Tripos Sci QSAR 10583 software calculation the QSAR equation explains the relationship 10584 between activity and structure with 2D QSAR method, and the biological 10585 activities are closely related to polarity volume ratio, the absolute 10586 value of the total charge, valence connectivity indexes and molecular 10587 volume. Our research can provide some guide meaning for the following 10588 research on studies of gambogic acid derivates. 10589 SN 0251-0790 10590 PD JUN 10 10591 PY 2010 10592 VL 31 10593 IS 6 10594 BP 1172 10595 EP 1178 10596 UT ISI:000279304500023 10597 PT J 10598 AU Gao, YA 10599 Qian, SA 10600 Zhang, JJ 10601 AF Gao, Yuan 10602 Qian, Shuai 10603 Zhang, Jianjun 10604 TI Physicochemical and Pharmacokinetic Characterization of a Spray-Dried 10605 Cefpodoxime Proxetil Nanosuspension 10606 SO CHEMICAL & PHARMACEUTICAL BULLETIN 10607 AB Cefpodoxime proxetil (CP) is a prodrug, the third generation 10608 cephem-type broad-spectrum antibiotic administered orally. However, 10609 CP was found to be a poorly water-soluble drug with low bioavailability 10610 when orally administered. In the present investigation, the 10611 spray-dried cefpodoxime proxetil nanosuspension (SDN) was prepared. 10612 The physicochemical properties were characterized by rheological 10613 evaluation, particle size measurement and its distribution, dynamics 10614 of reconstitution, in-vitro dissolution testing, surface morphology, 10615 surface area and pore size measurements. The pharmacokinetic study of 10616 SDN, in comparison to a marketed cefpodoxime proxetil for oral 10617 suspension (MS), was also performed in rabbits after a single oral dose. 10618 It was found that SDN exhibited a significant decrease in t(max), a 10619 1.60-fold higher area under curve (AUC) and 2.33-fold higher maximum 10620 plasma concentration (C-max) than MS. 10621 SN 0009-2363 10622 PD JUL 10623 PY 2010 10624 VL 58 10625 IS 7 10626 BP 912 10627 EP 917 10628 UT ISI:000279213500006 10629 PT J 10630 AU Chen, ND 10631 Yue, L 10632 Zhang, JA 10633 Kou, JP 10634 Yu, BY 10635 AF Chen, Nai-Dong 10636 Yue, Lei 10637 Zhang, Jian 10638 Kou, Jun-Ping 10639 Yu, Bo-Yang 10640 TI One unique steroidal sapogenin obtained through the microbial 10641 transformation of ruscogenin by Phytophthora cactorum ATCC 32134 and 10642 its potential inhibitory effect on tissue factor (TF) procoagulant 10643 activity 10644 SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 10645 AB With the aim to obtain more effective tissue factor (TF) inhibitors, 10646 the microbial transformation of three steroidal sapogenins, ruscogenin 10647 (1), diosgenin (2) and sarsasapogenin (3), was carried out and only 10648 ruscogenin was selectivity converted to 1-hydroxy-spirost-4-en-3-one 10649 (4) by Phytophthora cactorum ATCC 32134. The in vitro anti-TF 10650 procoagulant activity of this metabolite was enhanced almost 10 times 10651 to an IC50 value of 0.29 mu M. The chemical assignments of compound 10652 4 were made unambiguously using ESI-MS, IR and 2D NMR spectroscopy. 10653 (C) 2010 Elsevier Ltd. All rights reserved. 10654 SN 0960-894X 10655 PD JUL 15 10656 PY 2010 10657 VL 20 10658 IS 14 10659 BP 4015 10660 EP 4017 10661 DI 10.1016/j.bmcl.2010.05.103 10662 UT ISI:000279258800003 10663 PT J 10664 AU Liu, XH 10665 Liu, HF 10666 Shen, X 10667 Song, BA 10668 Bhadury, PS 10669 Zhu, HL 10670 Liu, JX 10671 Qi, XB 10672 AF Liu, Xin-Hua 10673 Liu, Hui-Feng 10674 Shen, Xu 10675 Song, Bao-An 10676 Bhadury, Pinaki S. 10677 Zhu, Hai-Liang 10678 Liu, Jin-Xing 10679 Qi, Xing-Bao 10680 TI Synthesis and molecular docking studies of novel 2-chloro-pyridine 10681 derivatives containing flavone moieties as potential antitumor agents 10682 SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 10683 AB A series of novel 2-chloro-pyridine derivatives containing flavone, 10684 chrome or dihydropyrazole moieties as potential telomerase inhibitors 10685 were synthesized. The bioassay tests showed that compounds 6e and 6f 10686 exhibited some effect against gastric cancer cell SGC-7901 with IC50 10687 values of 22.28 +/- 6.26 and 18.45 +/- 2.79 mu g/mL, respectively. All 10688 title compounds were assayed for telomerase inhibition by a modified 10689 TRAP assay, the results showed that compound 6e can strongly inhibit 10690 telomerase with IC50 value of 0.8 alpha 0.07 mu M. Docking simulation 10691 was performed to position compound 6e into the active site of telomerase 10692 (3DU6) to determine the probable binding model. (C) 2010 Elsevier Ltd. 10693 All rights reserved. 10694 SN 0960-894X 10695 PD JUL 15 10696 PY 2010 10697 VL 20 10698 IS 14 10699 BP 4163 10700 EP 4167 10701 DI 10.1016/j.bmcl.2010.05.080 10702 UT ISI:000279258800039 10703 PT J 10704 AU Liu, K 10705 Wang, H 10706 An, YA 10707 Liu, BL 10708 Huang, F 10709 AF Liu Kang 10710 Wang Heng 10711 An Yuan 10712 Liu Baolin 10713 Huang Fang 10714 TI Resveratrol modulates adipokine expression and improves insulin 10715 sensitivity in adipocytes: Relative to inhibition of inflammatory 10716 responses 10717 SO BIOCHIMIE 10718 AB Resveratrol is a potent inhibitor of inflammation and has anti-diabetic 10719 potentiality, however whether its anti-inflammatory potency 10720 contributes to the amelioration of diabetes or insulin resistance 10721 remains to be determined. This study aims at evaluating the effects 10722 of resveratrol on inflammation-related adipokines expression and 10723 insulin sensitivity in adipocytes. We stimulated RAW264.7 cells with 10724 LPS and collected the supernatant as a conditioned medium (CM) for the 10725 culture of adipocytes. Resveratrol, at concentrations ranging from 0.1 10726 to 10 mu M, effectively inhibited lipopolysaccharide (LPS)-induced 10727 INF-alpha and IL-6 production with the downregulation of relative genes 10728 expression in macrophages. Exposing differentiated 3T3-L1 cells to 10729 RAW264.7 CM resulted in gene over-expressions of TNF-alpha, IL-6 and 10730 resistin, however, mRNA expression of adiponectin and PPAR gamma were 10731 down-regulated. Pretreatment of CM from resveratrol-treated 10732 macrophages reduced the elevated levels of TNF-alpha and IL-6, and 10733 significantly reversed inflammation-related changes in adipokine gene 10734 expression in 3T3-L1 adipocytes. Resveratrol suppressed extracellular 10735 receptor-activated kinase (ERK) and transcription factor-kappa B 10736 (NF-kappa B) activation by reducing the phosphorylation of ERK1/2 and 10737 NF-kappa B p65: moreover, it modulated insulin signaling transduction 10738 by modification of Ser/Thr phosphorylation of insulin receptor 10739 substrate-1 (IRS-1) and downstream AKT (T308), and thereby improved 10740 insulin sensitivity in adiposities. These results demonstrated that 10741 resveratrol modulated adipokines expression and improved insulin 10742 sensitivity which relative to inhibition of inflammatory-like response 10743 in adipocytes. (C) 2010 Elsevier Masson SAS. All rights reserved. 10744 SN 0300-9084 10745 PD JUL 10746 PY 2010 10747 VL 92 10748 IS 7 10749 BP 789 10750 EP 796 10751 DI 10.1016/j.biochi.2010.02.024 10752 UT ISI:000279474800008 10753 PT J 10754 AU Zhu, YA 10755 Yu, JN 10756 Tong, SS 10757 Wang, L 10758 Peng, M 10759 Cao, X 10760 Xu, XM 10761 AF Zhu, Yuan 10762 Yu, Jiangnan 10763 Tong, Shanshan 10764 Wang, Li 10765 Peng, Min 10766 Cao, Xia 10767 Xu, Ximing 10768 TI Preparation and In Vitro Evaluation of Povidone-Sodium 10769 Cholate-Phospholipid Mixed Micelles for the Solubilization of Poorly 10770 Soluble Drugs 10771 SO ARCHIVES OF PHARMACAL RESEARCH 10772 AB Mixed micelles made of polyvinylpyrrolidone (PVP), sodium cholate, and 10773 phospholipids were prepared to improve the solubility of poorly 10774 water-soluble drugs. Sylibin, a drug used in treating liver diseases, 10775 was incorporated into the mixed micelles. The formulation of sylibin 10776 containing PVP-sodium cholate-phospholipid mixed micelles with an 10777 optimized composition (PVP/sodium cholate/phospholipid/silybin = 10778 3:3:4:1 similar to 2 by weight) was obtained based on the study of 10779 pseudoternary phase diagrams. The critical micelle concentration was 10780 used to evaluate the micellar stability towards dilution. The results 10781 showed that addition of PVP to sodium-cholate-phospholipid mixed 10782 micelles increased stability. The solubility of sylibin in PVP-sodium 10783 cholate-phospholipid mixed micelles was higher than that in pure water 10784 or in sodium cholate-phospholipid mixed micelles. In a stability study, 10785 we found that PVP-sodium cholate-phospholipid mixed micelles showed 10786 good stability. After 3 months storage at 40 degrees C, just 2.6% 10787 sylibin was lost with only minor changes of the particle size when 10788 compared to a reference formulation containing sodium cholate and 10789 phospholipid mixed micelles. In addition, the developed formulation 10790 significantly improved in vitro drug release. The time required to 10791 release 50% sylibin (t50%) from sodium cholate and phospholipid mixed 10792 micelles was 326 h, while the t50% from PVP-sodium cholate-phospholipid 10793 mixed micelles was only 51.1 h. Our results suggest that these mixed 10794 micelles might have significant potential application to the 10795 biomedical field. 10796 SN 0253-6269 10797 PD JUN 10798 PY 2010 10799 VL 33 10800 IS 6 10801 BP 911 10802 EP 917 10803 DI 10.1007/s12272-010-0614-6 10804 UT ISI:000279357300015 10805 PT J 10806 AU Li, H 10807 Sun, ZY 10808 Zhong, WY 10809 Hao, N 10810 Xu, DK 10811 Chen, HY 10812 AF Li, Hui 10813 Sun, Ziyin 10814 Zhong, Wenying 10815 Hao, Nan 10816 Xu, Danke 10817 Chen, Hong-Yuan 10818 TI Ultrasensitive Electrochemical Detection For DNA Arrays Based on 10819 Silver Nanoparticle Aggregates 10820 SO ANALYTICAL CHEMISTRY 10821 AB Multiplexed DNA target detection is of great significance in many 10822 fields including clinical diagnostics, environmental monitoring, 10823 biothreat detection and forensics. Although the emergence of DNA chip 10824 technology has accelerated this process, it is still a challenge to 10825 perform ultrasensitive DNA assay at low attomol concentrations so that 10826 DNA detection can be directly achieved without a PCR protocol. In this 10827 work, an oligonucleotide-functionalized silver nanoparticle tag has 10828 been successfully developed for multiplexed DNA electrochemical 10829 detection with ultrahigh sensitivity. The multiprobes containing 10830 oligo(d)A and the reporting probes were anchored onto the silver 10831 nanopartides, followed by hybridizing with the silver nanoparticle 10832 conjugate modified with oligo(d)T. The-hybridization-induced tag was 10833 found to show an aggregated nanostructare 10 times larger than the 10834 individual nanoparticle, as revealed by TEM. For sandwich-based 10835 assays, the tag was specifically coupled to a gold electrode surface 10836 via target DNA. Compared to a single nanoparticle label, this novel 10837 tag has shown excellent electroactive property and produces 10(3)-fold 10838 amplification in the differential pulse voltammetric (DPV) method. 10839 Hepatitis B virus (HBV) sequence was employed as a sample model, and 10840 we have achieved a detection limit of 5 aM (similar to 120 molecules 10841 in 40 mu L volume), demonstrating ultrasensitive measurement for DNA. 10842 The property of the electrochemical process involving silver 10843 aggregates was further investigated and the integrative oxidation of 10844 the silver tag was observed. We further demonstrated the multiplexed 10845 DNA target detection using array chips functionalized with Herpes 10846 simplex virus (HSV), Epstein Barr-virus (EBV) and cytomegalovirus 10847 (CMV) sequences, which shows effective recognition of the relative 10848 sequences individually or simultaneously. The method offers a uniquely 10849 new approach for DNA detection with ultrahigh sensitivity as well as 10850 advantages of rapidity, throughput, and miniaturization. 10851 SN 0003-2700 10852 PD JUL 1 10853 PY 2010 10854 VL 82 10855 IS 13 10856 BP 5477 10857 EP 5483 10858 DI 10.1021/ac101193e 10859 UT ISI:000279253300014 10860 PT J 10861 AU Li, J 10862 Zhang, LA 10863 Jiang, ZZ 10864 Shu, B 10865 Li, F 10866 Bao, QL 10867 Zhang, LY 10868 AF Li, Ji 10869 Zhang, Liang 10870 Jiang, Zhenzhou 10871 Shu, Bin 10872 Li, Fu 10873 Bao, Qingli 10874 Zhang, Luyong 10875 TI Toxicities of aristolochic acid I and aristololactam I in cultured 10876 renal epithelial cells 10877 SO TOXICOLOGY IN VITRO 10878 AB Aristolochic acid nephropathy, a progressive tubulointerstitial renal 10879 disease, is primarily caused by aristolochic acid I (AA-I) 10880 intoxication. Aristololactam I (AL-I), the main metabolite of AA-I, 10881 may also participate in the processes that lead to renal damage. To 10882 investigate the role and mechanism of the AL-I-mediated cytotoxicity, 10883 we determined and compared the cytotoxic effects of AA-I and AL-I on 10884 cells of the human proximal tubular epithelial (HK-2) cell line. To 10885 this end, we treated HK-2 cells with AA-I and AL-I and assessed the 10886 cytotoxicity of these agents by using the 10887 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MU) 10888 assay, flow cytometry, and an assay to determine the activity of caspase 10889 3. The proliferation of HK-2 cells was inhibited in a concentrationand time-dependent manner. Cell-cycle analysis revealed that the cells 10890 were arrested in the S-phase. Apoptosis was evidenced by the results 10891 of the annexin V/propidium iodide (PI) assay and the occurrence of a 10892 sub-G1 peak. In addition, AA-I and AL-I increased caspase 3-like 10893 activity in a concentration-dependent manner. These results also 10894 suggested that the cytotoxic potency of AL-I is higher than that of 10895 AA-I and that the cytotoxic effects of these molecules are mediated 10896 through the induction of apoptosis in a caspase 3-dependent pathway. 10897 (C) 2010 Published by Elsevier Ltd. 10898 SN 0887-2333 10899 PD JUN 10900 PY 2010 10901 VL 24 10902 IS 4 10903 BP 1092 10904 EP 1097 10905 DI 10.1016/j.tiv.2010.03.012 10906 UT ISI:000279124900006 10907 PT J 10908 AU Zhong, QF 10909 Sun, LP 10910 AF Zhong, Qi-Fei 10911 Sun, Li-Ping 10912 TI An efficient synthesis of 6,9-disubstituted purin-8-ones via 10913 copper-catalyzed coupling/cyclization 10914 SO TETRAHEDRON 10915 AB An efficient and novel synthesis of 6,9-disubstituted purin-8-ones has 10916 been developed. Starting from dichloropyrimidin-5-ylcarbamate, 10917 CuCl/amino acid catalyzed coupling/cyclization reaction with amines 10918 was achieved to afford 9-substituted 6-chloropurin-8-ones. Then a 10919 microwave-assisted amination procedure was carried out for the 10920 synthesis of 6,9-disubstituted purin-8-ones in moderate to good 10921 yields. (C) 2010 Elsevier Ltd. All rights reserved. 10922 SN 0040-4020 10923 PD JUL 3 10924 PY 2010 10925 VL 66 10926 IS 27-28 10927 BP 5107 10928 EP 5111 10929 DI 10.1016/j.tet.2010.04.106 10930 UT ISI:000279126700026 10931 PT J 10932 AU Cirioni, O 10933 Wu, GQ 10934 Li, LX 10935 Orlando, F 10936 Silvestri, C 10937 Ghiselli, R 10938 Shen, ZL 10939 Scalise, A 10940 Gabrielli, E 10941 Scuppa, D 10942 Romiti, C 10943 Provinciali, M 10944 Guerrieri, M 10945 Giacometti, A 10946 AF Cirioni, Oscar 10947 Wu, Guoqiu 10948 Li, Linxian 10949 Orlando, Fiorenza 10950 Silvestri, Carmela 10951 Ghiselli, Roberto 10952 Shen, Zilong 10953 Scalise, Alessandro 10954 Gabrielli, Eleonora 10955 Scuppa, Daniele 10956 Romiti, Chiara 10957 Provinciali, Mauro 10958 Guerrieri, Mario 10959 Giacometti, Andrea 10960 TI S-thanatin enhances the efficacy of tigecycline in an experimental rat 10961 model of polymicrobial peritonitis 10962 SO PEPTIDES 10963 AB We investigated the efficacy of the peptide s-thanatin alone and in 10964 combination with tigecycline in an animal model of sepsis induced by 10965 cecal ligation and puncture. Adult male Wistar rats were randomized 10966 to receive intravenously isotonic sodium chloride solution, 5 mg/kg 10967 s-thanatin, 2 mg/kg tigecycline, 5 mg/kg s-thanatin combined with 2 10968 mg/kg tigecycline. The experiment was also performed with 10969 administration of the drugs 360 min after the surgical procedure to 10970 better investigate the clinical situation where there is an interval 10971 between the onset of sepsis and the initiation of therapy. Lethality, 10972 bacterial growth in blood, peritoneum, spleen and liver, and NO indices 10973 were evaluated. All compounds reduced the lethality when compared to 10974 control. In all experiments, the compounds reduced significantly 10975 bacterial growth and lethality compared with saline treatment. 10976 Treatment with s-thanatin resulted in significant decrease in plasma 10977 NO levels compared to tigecycline and control group. The combination 10978 between s-thanatin and tigecycline proved to be the most effective 10979 treatment in reducing all variables measured. S-thanatin may have 10980 potential therapeutic usefulness alone and when associated to 10981 tigecycline in polymicrobial peritonitis. (C) 2010 Elsevier Inc. All 10982 rights reserved. 10983 SN 0196-9781 10984 PD JUL 10985 PY 2010 10986 VL 31 10987 IS 7 10988 BP 1231 10989 EP 1236 10990 DI 10.1016/j.peptides.2010.03.034 10991 UT ISI:000279078700002 10992 PT J 10993 AU Geng, Y 10994 Xiang, BR 10995 AF Geng, Ying 10996 Xiang, Bingren 10997 TI Net analyte signal based two-dimensional (NAS 2D) correlation near 10998 infrared spectroscopy 10999 SO JOURNAL OF MOLECULAR STRUCTURE 11000 CT 5th International Symposium on Two Dimensional Correlation 11001 Spectroscopy 11002 CY AUG 05-07, 2009 11003 CL Wroclaw, POLAND 11004 AB A new method of analysis, based on the net analyte signal presented 11005 by Lorber is proposed for the two-dimensional correlation near infrared 11006 spectroscopy. A spectra data set under the static perturbation of 11007 concentration was collected. NAS is manipulated for removing the 11008 information that was unrelated to a certain analyte. To demonstrate 11009 the potential of NAS 2D correlation spectroscopy, a set of 11010 concentration-dependent near infrared spectra of Sinomenine 11011 Hydrochloride in methanol was used as an example. The results show that 11012 NAS 2D, reconstructed from a series of principal factors can extract 11013 more subtle and useful spectra features, and make the band assignment 11014 explicable for structure analysis. (C) 2010 Elsevier B.V. All rights 11015 reserved. 11016 SN 0022-2860 11017 PD JUN 16 11018 PY 2010 11019 VL 974 11020 IS 1-3 11021 SI Sp. Iss. SI 11022 BP 173 11023 EP 178 11024 DI 10.1016/j.molstruc.2010.03.023 11025 UT ISI:000279029300027 11026 PT J 11027 AU Sun, W 11028 Du, YX 11029 Wang, YQ 11030 AF Sun, Wen 11031 Du, Yingxiang 11032 Wang, Yunqing 11033 TI Study on fluorescence properties of carbogenic nanoparticles and their 11034 application for the determination of ferrous succinate 11035 SO JOURNAL OF LUMINESCENCE 11036 AB A new type of fluorescent nanomaterial named carbogenic nanoparticles 11037 (NPs) has drawn considerable attention recently. In this study, we 11038 adopted a direct and simple synthetic method to produce the carbogenic 11039 NPs and investigated the fluorescence properties of the as-prepared 11040 carbogenic NPs in detail. It was found that the fluorescence of 11041 carbogenic NPs was stable with the variance of environmental conditions 11042 such as pH, temperature and UV irradiation. More interestingly, we 11043 found carbogenic NPs exhibited high selectivity and sensitivity 11044 towards ferric ions. Under optimum conditions, a good linear 11045 relationship could be obtained between the fluorescence intensity and 11046 concentration of ferric ions in the range of 5.0 x 10(-5)-5.0 x 10(-4) 11047 mol L-1, and the limit of detection is 11.21 mu mol L-1. Based on the 11048 fluorescence quenching of carbogenic NPs, a rapid and specific 11049 quantitative method was proposed for the determination of ferrous 11050 succinate. The content of ferrous succinate in commercial tablets 11051 determined by the present method was agreed with the spectrophotometric 11052 method results and the reproducibility and the recovery of the proposed 11053 method were satisfactory. (C) 2010 Elsevier B.V. All rights reserved. 11054 SN 0022-2313 11055 PD AUG 11056 PY 2010 11057 VL 130 11058 IS 8 11059 BP 1463 11060 EP 1469 11061 DI 10.1016/j.jlumin.2010.03.013 11062 UT ISI:000279139300024 11063 PT J 11064 AU Wu, Y 11065 Li, XD 11066 Lin, RC 11067 Jin, SH 11068 AF Wu, Yi 11069 Li, Xiao D. 11070 Lin, Rui C. 11071 Jin, Shao H. 11072 TI Development of a Size-Exclusion HPLC Method with Evaporative 11073 Light-Scattering Detection for the Quantitation of Polysorbate 80 in 11074 Houttuynia cordata Injection 11075 SO JOURNAL OF AOAC INTERNATIONAL 11076 AB A rapid and accurate size-exclusion HPLC method for the quantitation 11077 of polysorbate 80 (PS80) in Houttuynia cordata injection, a Chinese 11078 traditional medicine, was developed and validated. The assay was 11079 conducted on an Agilent 1100 HPLC system with a TosoHaas TSKgel G2000 11080 SWXL column (30 cm x 7.8 mm, 5 mu m particle size) and an Alltech 11081 evaporative light-scattering detector (ELSD) 2000. The mobile phase 11082 was 20 mmoL/L ammonium acetate-acetonitrile (90 + 10, v/v) delivered 11083 at a flow rate of 0.6 mL/min under isocratic conditions. The ELSD was 11084 operated in the impactor "off" mode, the drift tube temperature was 11085 set at 110 degrees C, and nitrogen flow was maintained at 2.3 L/min. 11086 The LOD was 0.25 mg/mL. Linearity was obtained between the log of 11087 concentration (C) and the log of peak area (Y) of PS80 in the range 11088 of 0.5-20 mg/mL according to the equation: Log Y = 1.4529 Log C 0.8232 11089 (r(2) = 0.9976). An RSD of 1.6% (n = 6) for the determination 11090 demonstrated the good precision of the optimized method. PS80 content 11091 in several commercial H. cordata injection products from different 11092 manufacturers was determined. The data for PS80 content is useful in 11093 evaluation of the safety of the products from different manufacturers. 11094 SN 1060-3271 11095 PD MAY-JUN 11096 PY 2010 11097 VL 93 11098 IS 3 11099 BP 917 11100 EP 921 11101 UT ISI:000279140000026 11102 PT J 11103 AU Zhou, YY 11104 Du, YZ 11105 Wang, L 11106 Yuan, H 11107 Zhou, JP 11108 Hu, FQ 11109 AF Zhou, Yue-Yu 11110 Du, Yong-Zhong 11111 Wang, Ling 11112 Yuan, Hong 11113 Zhou, Jian-Ping 11114 Hu, Fu-Qiang 11115 TI Preparation and pharmacodynamics of stearic acid and poly 11116 (lactic-co-glycolic acid) grafted chitosan oligosaccharide micelles 11117 for 10-hydroxycamptothecin 11118 SO INTERNATIONAL JOURNAL OF PHARMACEUTICS 11119 AB Stearic acid (SA) and poly (lactic-co-glycolic acid) (PLGA) grafted 11120 chitosan oligosaccharide (SA-CSO-PLGA SCP) tripolymer was synthesized 11121 via the reaction between the carboxyl group of SA or PLGA with 11122 carboxylic side group, and the amine group of CSO in the presence of 11123 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC). The degrees of 11124 amino-substitution for SA and PLGA were assayed through 2, 4, 11125 6-trinitrobenzene sulfonic acid (TNBS) test and C-13 NMR spectrum, 11126 which were 8.15% and 5.82%, respectively; the critical micelle 11127 concentrations of SCP in PBS (pH 7.4) and deionized water (DI water) 11128 were about 34.9 and 14.5 mu g/ml, respectively. Using 11129 10-hydroxycamptothecin (HCPT) as a model drug, the drug-loaded 11130 micelles showed above 86% encapsulation efficiency, which not only 11131 enhanced the solubility of HCFT in aqueous medium markedly, but also 11132 protected the lactone ring of HCPT. Cellular uptakes of SCP micelles 11133 against A549, MCF-7 and HepG-2 tumor cells showed a faster cellular 11134 internalization. Comparing to the commercial HCFT injection, 11135 HCPT-loaded micelles showed higher cytotoxicities against A549, MCF-7 11136 and HepG-2 cells. The increased folds were 22, 18 and 15, respectively. 11137 These results suggested the SCP could be applied as a carrier for 11138 hydrophobic drugs. (c) 2010 Elsevier B.V. All rights reserved. 11139 SN 0378-5173 11140 PD JUN 30 11141 PY 2010 11142 VL 393 11143 IS 1-2 11144 BP 143 11145 EP 151 11146 DI 10.1016/j.ijpharm.2010.04.025 11147 UT ISI:000279208700018 11148 PT J 11149 AU Luo, YD 11150 Wu, SS 11151 Li, XY 11152 Li, P 11153 AF Luo, Yongdong 11154 Wu, Shuisheng 11155 Li, Xiaoyan 11156 Li, Ping 11157 TI LC-ESI-MS-MS Determination of Rat Plasma Protein Binding of Major 11158 Flavonoids of Flos Lonicerae Japonicae by Centrifugal Ultrafiltration 11159 SO CHROMATOGRAPHIA 11160 AB Centrifugal ultrafiltration (CU) and a fast liquid chromatography with 11161 electrospray ionization tandem mass spectrometric (LC-ESI-MS-MS) 11162 method have been developed for drug-protein binding analysis of four 11163 flavonoids of Flos Lonicerae Japonicae (FLJ). A rapid separation of 11164 free drug from the plasma was achieved by CU and the simultaneous 11165 analysis of four flavonoids of FLJ in rat plasma was by fast 11166 LC-ESI-MS-MS. The chromatographic analytical time decreased to 6.5 min 11167 without sacrificing resolution using a 4.6 mm x 50 mm, 1.8 mu m particle 11168 size reverse phase column and MS-MS mode performed for multiple 11169 reaction monitoring (MRM). The protein binding rates of four flavonoids 11170 were in the range of 66.8 +/- A 7.4 to 81.3 +/- A 5.1% after oral 11171 administration of the flavonoid fraction of FLJ. All values were almost 11172 similar to 70.0% at 30, 45 and 80 min. Its result suggests that these 11173 flavonoids in rat plasma perform high protein binding rates and present 11174 a stable binding in a longer time. Meanwhile, it reveals that the 11175 elimination of these flavonoids may be relatively moderate in the body, 11176 the performance of a certain degree of accumulation may be speculated 11177 and make further impacts on the pharmacokinetic parameters. 11178 SN 0009-5893 11179 PD JUL 11180 PY 2010 11181 VL 72 11182 IS 1-2 11183 BP 71 11184 EP 77 11185 DI 10.1365/s10337-010-1618-6 11186 UT ISI:000279026300010 11187 PT J 11188 AU Zhang, Q 11189 Liang, JY 11190 Li, QS 11191 Min, ZD 11192 AF Zhang, Qiong 11193 Liang, Jing Yu 11194 Li, Qing Shan 11195 Min, Zhi Da 11196 TI New limonoids from the fruits of Melia toosendan 11197 SO CHINESE CHEMICAL LETTERS 11198 AB Two new limonoids, 1 alpha-Tigloyloxy-3 alpha-acetoxyl-7 11199 alpha-hydroxyl-12 alpha-ethoxyl nimbolinin (1) and1 11200 alpha-Benzoyloxy-3 alpha-acetoxyl-7 alpha-hydroxyl-12 alpha-ethoxyl 11201 (2), were isolated from the fruits of Melia toosendan. Their structures 11202 were established on the basis of various NMR spectroscopic analyses, 11203 including 2D-NMR techniques (HSQC, HMBC, NOESY) and HR-ESI-MS. (C) 2010 11204 Qiong Zhang. Published by Elsevier B.V. on behalf of Chinese Chemical 11205 Society. All rights reserved. 11206 SN 1001-8417 11207 PD JUL 11208 PY 2010 11209 VL 21 11210 IS 7 11211 BP 838 11212 EP 841 11213 DI 10.1016/j.cclet.2010.02.018 11214 UT ISI:000279039000022 11215 PT J 11216 AU Zhang, F 11217 Fang, CG 11218 Wu, YT 11219 Wang, YT 11220 Li, AM 11221 Zhang, ZB 11222 AF Zhang Feng 11223 Fang Cheng-Gang 11224 Wu You-Ting 11225 Wang Yuan-Tao 11226 Li Ai-Min 11227 Zhang Zhi-Bing 11228 TI Absorption of CO2 in the aqueous solutions of functionalized ionic 11229 liquids and MDEA 11230 SO CHEMICAL ENGINEERING JOURNAL 11231 AB Four ionic liquids (ILs) tetramethylammonium glycinate (=[Gly]), 11232 tetraethylammonium glycinate ([N-2222][Gly])), tetramethylammonium 11233 lysinate ([N-1111][Lys]) and tetraethylammonium lysinate 11234 ([N-2222][Lys]) were synthesized and mixed with water or 11235 N-methyldiethanolamine (MDEA) aqueous solutions to form a new type of 11236 solvents for the uptake of CO2. The solubility or absorption of CO2 11237 in these IL+MDEA aqueous solutions was investigated over a wide range 11238 of IL concentrations (5-100%), temperature (298-318 K) and partial 11239 pressure of CO2 (4-400 kPa). The results indicated that ionic liquid 11240 could greatly enhance the absorption and increased the absorption rate 11241 of CO2 in MDEA aqueous solutions. It had been found that the aqueous 11242 solutions of 15% IL and 15% MDEA had higher absorption rate and larger 11243 uptake than other IL+MDEA solutions of 30% total amines. Temperature 11244 (298-318 K) seemed to have some influence on the absorption of CO2 in 11245 IL+MDEA aqueous solutions. Noticeably, due to the two amino groups in 11246 a molecular, the mole absorption of the 30% lysine based ionic liquids 11247 aqueous solutions was 0.98 ([N-1111][Lys]) and 1.21 ([N-2222][Lys]) 11248 mole CO2, being about 2-3 times the absorption capacity of MDEA under 11249 the same condition. Regeneration under the condition of temperature 11250 353 K. 4 kPa for 240 min showed that aqueous solution of 15% IN, 15% 11251 MDEA had significant regeneration efficiency (over 98%). (c) 2010 11252 Elsevier B.V. All rights reserved. 11253 SN 1385-8947 11254 PD JUN 1 11255 PY 2010 11256 VL 160 11257 IS 2 11258 BP 691 11259 EP 697 11260 DI 10.1016/j.cej.2010.04.013 11261 UT ISI:000279137900037 11262 PT J 11263 AU Chen, JH 11264 Zhang, XG 11265 Jiang, YT 11266 Yan, LY 11267 Tang, L 11268 Yin, YW 11269 Cheng, DS 11270 Chen, J 11271 Wang, M 11272 AF Chen, Jian-Hua 11273 Zhang, Xin-Guo 11274 Jiang, Yu-tao 11275 Yan, Lu-Ying 11276 Tang, Li 11277 Yin, Yi-Wei 11278 Cheng, Dai-Shuang 11279 Chen, Jing 11280 Wang, Min 11281 TI Bioactivity and pharmacokinetics of two human serum albumin-thymosin 11282 alpha 1-fusion proteins, rHSA-T alpha 1 and rHSA-L-T alpha 1, expressed 11283 in recombinant Pichia pastoris 11284 SO CANCER IMMUNOLOGY IMMUNOTHERAPY 11285 AB Thymosin-alpha 1 (T alpha 1) is indicated for the treatment of certain 11286 viral infections, including hepatitis B and C, and cancers, such as 11287 melanoma. In this paper, the fusion genes encoding human serum albumin 11288 (HSA) and T alpha 1 with (rHSA-L-T alpha 1) and without a linker peptide 11289 (rHSA-T alpha 1) were constructed and overexpressed in P. pastoris. 11290 Through the process of ion interaction chromatography (Q-Sepharose 11291 F.F), hydrophobic interaction chromatography (Phenyl Sepharose HP) and 11292 affinity chromatography (Blue Sepharose F.F), the purity of fusion 11293 proteins was greater than 97%. In contrast to the reactivity of normal 11294 spleen cells to Con A, the data of in vitro murine spleen lymphocytes 11295 proliferation experiment suggested that spleen cells achieved a higher 11296 degree of T cell maturation after rHSA-L-T alpha 1, rHSA-T alpha 1 and 11297 T alpha 1 treatments, respectively. Moreover, rHSA-L-T alpha 1, rHSA-T 11298 alpha 1 and T alpha 1 can also antagonize dexamethasone-induced 11299 apoptosis of thymocyte sub-populations. In hydrocortisone-induced 11300 immunosuppression mice (in vivo experiments), after subcutaneous 11301 injections with two fusion proteins and T alpha 1 for seven consecutive 11302 days, the net increment of body weight, the spleen index and the thymus 11303 index were significantly improved. Simultaneously, the increase in SOD 11304 level and the decrease in MDA level in plasma were observed. The 11305 pharmacokinetic data of rHSA-L-T alpha 1 and rHSA-T alpha 1 11306 administered in rats showed an improved pharmacokinetic profile with 11307 a conspicuous prolonged half life. The analysis of bioactivity and 11308 pharmacokinetics suggested that fusion proteins rHSA-L-T alpha 1 and 11309 rHSA-T alpha 1 were new drug candidates. 11310 SN 0340-7004 11311 PD SEP 11312 PY 2010 11313 VL 59 11314 IS 9 11315 BP 1335 11316 EP 1345 11317 DI 10.1007/s00262-010-0862-9 11318 UT ISI:000279198000004 11319 PT J 11320 AU Ma, L 11321 Ji, JL 11322 Ji, H 11323 Yu, X 11324 Ding, LJ 11325 Liu, K 11326 Li, YQ 11327 AF Ma, L. 11328 Ji, J. L. 11329 Ji, H. 11330 Yu, X. 11331 Ding, L. J. 11332 Liu, K. 11333 Li, Y. Q. 11334 TI Telmisartan alleviates rosiglitazone-induced bone loss in 11335 ovariectomized spontaneous hypertensive rats 11336 SO BONE 11337 AB In the present study, we systematically examined telmisartan, an 11338 angiotensin AT(1) receptor antagonist, on rosiglitazone-induced bone 11339 loss in ovariectomized spontaneously hypertensive rats. Telmisartan 11340 (5 mg/kg/d, 90 days) was found to be able to significantly alleviate 11341 rosiglitazone (10 mg/kg/d, 90 days)-induced decrease in BMD of femur 11342 and lumbar vertebrae. The BMD changes were associated with positive 11343 biomechanical changes of lumbar vertebrae, improvements in 11344 microarchitecture of tibial metaphysic and normalized serum 11345 osteocalcin (OC) levels and urinary deoxypyridinoline/creatinine 11346 (DPD/Cr) ratio. MicroCT analysis of the tibial metaphysis showed that 11347 telmisartan significantly prevented the decreases in bone 11348 volume/tissue volume (BV/TV), connect density (Conn. D.), trabecular 11349 number (Tb. N.) and trabecular thickness (Tb. Th.), and increase in 11350 trabecular separation (Tb. Sp.) induced by rosiglitazone. 11351 Histomorphometric analysis also showed that telmisartan had protective 11352 effects on rosiglitazone-reduced bone formation indices such as 11353 histomorphometric bone volume fraction (BV/TV-Histo), mineralizing 11354 surface/bone surface (MS/BS), mineral apposition rate (MAR) and bone 11355 formation rate (BFR/BS). Our study clearly showed that telmisartan 11356 alleviated rosiglitazone-induced bone loss in ovariectomized 11357 spontaneous hypertensive rats. The relief of bone loss provides a 11358 possible therapeutic application of telmisartan with rosiglitazone for 11359 the treatment of elderly women patients afflicted with metabolic 11360 syndrome. (C) 2010 Elsevier Inc. All rights reserved. 11361 SN 8756-3282 11362 PD JUL 11363 PY 2010 11364 VL 47 11365 IS 1 11366 BP 5 11367 EP 11 11368 DI 10.1016/j.bone.2010.03.016 11369 UT ISI:000279150400001 11370 PT J 11371 AU Sun, L 11372 Lin, SS 11373 Zhao, RP 11374 Yu, BY 11375 Yuan, ST 11376 Zhang, LY 11377 AF Sun, Li 11378 Lin, Sensen 11379 Zhao, Renping 11380 Yu, Boyang 11381 Yuan, Shengtao 11382 Zhang, Luyong 11383 TI The Saponin Monomer of Dwarf Lilyturf Tuber, DT-13, Reduces Human 11384 Breast Cancer Cell Adhesion and Migration during Hypoxia via Regulation 11385 of Tissue Factor 11386 SO BIOLOGICAL & PHARMACEUTICAL BULLETIN 11387 AB Adhesion and migration of tumor cells are crucial steps in tumor 11388 invasion and metastasis. In the present study, we investigated the 11389 effects of saponin monomer 13 of dwarf lilyturf tuber (DT-13) on 11390 metastasis of human breast cancer cells (MDA-MB-435) during hypoxia. 11391 The effects and molecular mechanisms of DT-13 on MDA-MB-435 cells 11392 metastatic phenotype in vitro and in vivo were evaluated by RNA 11393 interference; quantitative real-time polymerase chain reaction 11394 (qRT-PCR) and Western blot assays. DT-13 had no significant effects 11395 on cell adhesion and migration under normoxia conditions. Under hypoxic 11396 conditions, IVIDA-MB-435 adhesion to vitronectin was inhibited by 11397 about 43.5% or 60.8% after exposure of the cells to DT-13 at 1 mu M 11398 or 10 mu M, respectively. DT-13 decreased the migratory response by 11399 hypoxia at 1 or 10 mu M, and inhibition ratios were 20% and 30%, 11400 respectively. DT-13 inhibited hypoxia-induced expression of alpha v 11401 beta 3 integrin, tissue factor (TF) and early growth response gene-1 11402 (Egr-1) and decreased excretion of matrix metalloproteinase 9 (MMP-9) 11403 of MDA-MB-435 cells under hypoxic conditions. After Egr-1 short 11404 interference RNA (siRNA) treatment, DT-13 could still inhibit the 11405 up-regulation of TF mRNA and protein levels and its pro-coagulant 11406 activity (PCA) under hypoxia. In nude mice, DT-13 decreased 11407 extravasation of MDA-MB-435 cells in the lung after tail vein 11408 injection. Our data suggest that DT-13 inhibits MDA-MB-435 cells 11409 metastasis during hypoxia via regulation of TF, and the effect of DT-13 11410 on TF is partly mediated by Egr-1. 11411 SN 0918-6158 11412 PD JUL 11413 PY 2010 11414 VL 33 11415 IS 7 11416 BP 1192 11417 EP 1198 11418 UT ISI:000279199800019 11419 PT J 11420 AU Lu, ML 11421 Cao, X 11422 Yang, X 11423 Zheng, H 11424 Liu, N 11425 Jiang, Y 11426 Lin, DH 11427 Chen, YJ 11428 AF Lu, Meiling 11429 Cao, Xu 11430 Yang, Xin 11431 Zheng, Heng 11432 Liu, Nan 11433 Jiang, Yun 11434 Lin, Donghai 11435 Chen, Yijun 11436 TI A diketoreductase exhibits unique renaturation profile from 11437 thermal-induced protein unfolding 11438 SO AMINO ACIDS 11439 AB Proteins can refold from thermal-induced denaturation. 11440 Apo-diketoreductase exhibited a unique refolding profile, in which the 11441 degree of refolding from higher temperature was more complete. Partial 11442 aggregation and structural change may provide possible explanation on 11443 this phenomenon. 11444 SN 0939-4451 11445 PD JUL 11446 PY 2010 11447 VL 39 11448 IS 2 11449 BP 609 11450 EP 613 11451 DI 10.1007/s00726-010-0491-9 11452 UT ISI:000279190400032 11453 PT J 11454 AU Cheng, YS 11455 Dai, DZ 11456 Dai, Y 11457 AF Cheng, Yu-Si 11458 Dai, De-Zai 11459 Dai, Yin 11460 TI Testis dysfunction by isoproterenol is mediated by upregulating 11461 endothelin receptor A, leptin and protein kinase C epsilon and is 11462 attenuated by an endothelin receptor antagonist CPU0213 11463 SO REPRODUCTIVE TOXICOLOGY 11464 AB This study has examined whether upregulation of endothelin receptor 11465 A, leptin and phosphorylated protein kinase C epsilon contributes to 11466 stress-induced testicular damaged and its possible reversal by 11467 endothelial (ET) antagonism. Adult male Sprague-Dawley rats were 11468 randomly divided into control and isoproterenol (ISO 1 mg/kg, 11469 subcutaneous (s.c.), 10 days) groups, and intervened with the ET 11470 receptor antagonist CPU0213 (20 mg/kg, s.c.), on days 6-10. In ISO 11471 group, testicular succinate dehydrogenase, lactate dehydrogenase, 11472 acid phosphotase, and gamma-glutamyl transpeptidase, and serum 11473 testosterone decreased, whereas FSH increased, relative to control. 11474 The seminiferous tubules were damaged in association with testicular 11475 upregulation of protein abundance of leptin and pPKC epsilon, and mRNA 11476 and protein expression of leptin receptor (OBRb) and ETA. CPU0213 was 11477 effective in ameliorating these abnormalities. Over-expression of ETA 11478 and leptin accounting for the testis dysfunction is likely to be 11479 mediated by pPKC epsilon in the ISO treated rats. The upregulated ET 11480 pathway appears to be critical in pathologies of the testis. (C) 2010 11481 Elsevier Inc. All rights reserved. 11482 SN 0890-6238 11483 PD JUL 11484 PY 2010 11485 VL 29 11486 IS 4 11487 BP 421 11488 EP 426 11489 DI 10.1016/j.reprotox.2010.03.001 11490 UT ISI:000278951900006 11491 PT J 11492 AU Xu, FG 11493 Liu, Y 11494 Song, R 11495 Dong, HJ 11496 Zhang, ZJ 11497 AF Xu, Fengguo 11498 Liu, Ying 11499 Song, Rui 11500 Dong, Haijuan 11501 Zhang, Zunjian 11502 TI HPLC/DAD Comparison of Sixteen Bioactive Components Between 11503 Da-Cheng-Qi Decoction and its Parent Herbal Medicines 11504 SO NATURAL PRODUCT COMMUNICATIONS 11505 AB Differences in the contents of sixteen bioactive components (three 11506 tannins, five anthraquinones, six flavonoids and two neolignans) 11507 between Da-Cheng-Qi decoction (DCQD) and its three constitutional 11508 herbal medicines (Radix et Rhizoma Rhei, Cortex Magnoliae officinalis, 11509 and Fructus Aurantii Immaturus) were compared using validated HPLC/DAD 11510 methods. The results indicated that there existed some kinds of 11511 interactions between these constitutional natural medicines during the 11512 DCQD preparation procedure, which could either enhance or depress the 11513 extractive rates of bioactive components. 11514 SN 1934-578X 11515 PD JUN 11516 PY 2010 11517 VL 5 11518 IS 6 11519 BP 893 11520 EP 896 11521 UT ISI:000278891800014 11522 PT J 11523 AU Liang, Y 11524 Kang, A 11525 Xie, T 11526 Zheng, XA 11527 Dai, C 11528 Hao, HP 11529 A, JY 11530 Sheng, LS 11531 Xie, L 11532 Wang, GJ 11533 AF Liang, Yan 11534 Kang, An 11535 Xie, Tong 11536 Zheng, Xiao 11537 Dai, Chen 11538 Hao, Haiping 11539 A, Jiye 11540 Sheng, Longsheng 11541 Xie, Lin 11542 Wang, Guang-ji 11543 TI Influence of segmental and selected ion monitoring on quantitation of 11544 multi-component using high-pressure liquid chromatography-quadrupole 11545 mass spectrometry: Simultaneous detection of 16 saponins in rat plasma 11546 as a case 11547 SO JOURNAL OF CHROMATOGRAPHY A 11548 AB Quadrupole (Q) mass spectrometers are the most popular analytical tools 11549 due to their reliability, effectiveness, and low cost. However, they 11550 are not suitable for quantitative analysis of multi-component since 11551 the sensitivity will get worse rapidly with the increasing number of 11552 m/z detected. The present work, for the first time, attempted to analyze 11553 of 16 saponins simultaneously using an approach of segmental and 11554 selected ion monitoring (SSIM) based on LC-Q/MS, and systematically 11555 investigated the influence of different SSIM modes on signal 11556 level/noise level (S/N), lower limits of quantification (LLOQ), upper 11557 limits of quantification (ULOQs), etc. Our results showed that a proper 11558 SSIM mode could not only provide much higher sensitivity for all the 11559 targeting analytes, but also dramatically broadened their dynamic 11560 ranges. The developed methodology could effectively break the 11561 application bottleneck on the quantitative analysis of multi-component 11562 with LC-Q/MS, and would be applied widely in related fields for 11563 multi-component analysis, such as environmental monitoring, 11564 metabonomics, Chinese herbal medicine research. (C) 2010 Elsevier B.V. 11565 All rights reserved. 11566 SN 0021-9673 11567 PD JUN 25 11568 PY 2010 11569 VL 1217 11570 IS 26 11571 BP 4501 11572 EP 4506 11573 DI 10.1016/j.chroma.2010.04.054 11574 UT ISI:000278920900033 11575 PT J 11576 AU Chen, X 11577 Luo, JG 11578 Kong, LY 11579 AF Chen, Xia 11580 Luo, Jian-Guang 11581 Kong, Ling-Yi 11582 TI Two new triterpenoid saponins from Dianthus superbus L. 11583 SO JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH 11584 AB Two new triterpenoid saponins (1 and 2) were isolated from the dried 11585 aerial parts of Dianthus superbus L. (Caryophyllaceae). Their 11586 structures were elucidated on the basis of spectral data to be 11587 3-O--D-glucopyranosyl olean-9(11),12-diene-23,28-dioic acid 11588 28-O--D-glucopyranoside (1) and 3-O--D-glucopyranosyl 11589 olean-11,13(18)-diene-23,28-dioic acid 28-O--D-glucopyranoside (2). 11590 SN 1028-6020 11591 PY 2010 11592 VL 12 11593 IS 6 11594 BP 458 11595 EP 463 11596 DI 10.1080/10286020.2010.493326 11597 UT ISI:000278787000007 11598 PT J 11599 AU Zan, K 11600 Zhou, SX 11601 Chen, XQ 11602 Fu, Q 11603 Tu, PF 11604 AF Zan, Ke 11605 Zhou, Si-Xiang 11606 Chen, Xiao-Qing 11607 Fu, Qiang 11608 Tu, Peng-Fei 11609 TI Prostaglandin-like fatty acid derivatives from Artemisia anomala 11610 SO JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH 11611 AB Four prostaglandin-like fatty acid derivatives anomalone A-D (1-4) 11612 were isolated from the aerial part of Artemisia anomala S. Moore. Their 11613 structures were determined on the basis of extensive spectroscopic 11614 analyses. 11615 SN 1028-6020 11616 PY 2010 11617 VL 12 11618 IS 6 11619 BP 492 11620 EP 497 11621 DI 10.1080/10286020.2010.489825 11622 UT ISI:000278787000012 11623 PT J 11624 AU Xu, D 11625 Wang, F 11626 Gu, HY 11627 Wang, J 11628 Guo, QL 11629 Zhang, YL 11630 Wang, ZY 11631 AF Xu, Dan 11632 Wang, Feng 11633 Gu, Hongyan 11634 Wang, Jia 11635 Guo, Qinglong 11636 Zhang, Yanli 11637 Wang, Ziyu 11638 TI Hybrid cells differentiate to hepatic lineage cells and repair 11639 oxidative damage 11640 SO CELLULAR & MOLECULAR BIOLOGY LETTERS 11641 AB Hybrid cells derived from stem cells play an important role in 11642 organogenesis, tissue regeneration and cancer formation. However, the 11643 fate of hybrid cells and their range of function are poorly understood. 11644 Fusing stem cells and somatic cells induces somatic cell reprogramming, 11645 and the resulting hybrid cells are embryonic stem cell-like cells. 11646 Therefore, we hypothesize that fusion-induced hybrid cells may behave 11647 like ES cells in certain microenvironments. In this study, human 11648 hepatic cells were induced to apoptosis with H2O2, and then co-cultured 11649 with hybrid cells that had been derived from mouse ES cells and human 11650 hepatic cells using a transwell. After co-culturing, the degree of 11651 apoptosis was evaluated using Annexin-V/PI double-staining analysis, 11652 flow cytometry and Western-blot. We observed that H2O2-induced cell 11653 apoptosis was inhibited by co-culture. In addition, the activity of 11654 injury-related enzymes (GSH-Px, LDH and SOD) and the level of albumin 11655 release in the co-culture system trended toward the level of normal 11656 undamaged hepatic cells. The stably increased levels of secretion of 11657 ALB in the co-culture system also confirmed that co-culture with hybrid 11658 cells helped in recovery from injury. The fate of the hybrid cells was 11659 studied by analyzing their gene expression and protein expression 11660 profiles. The results of RT-PCR indicated that during co-culturing, 11661 like ES cells, hybrid cells differentiated into hepatic lineage cells. 11662 Hybrid cells transcripted genes from both parental cell genomes. Via 11663 immunocytochemical analysis, hepatic directional differentiation of 11664 the hybrid cells was also confirmed. After injecting the hybrid cells 11665 into the mouse liver, the GFP-labeled transplanted cells were 11666 distributed in the hepatic lobules and engrafted into the liver 11667 structure. This research expands the knowledge of fusion-related 11668 events and the possible function of hybrid cells. Moreover, it could 11669 indicate a new route of differentiation from pluripotent cells to 11670 tissue-specific cells via conditional co-culture. 11671 SN 1425-8153 11672 PD SEP 11673 PY 2010 11674 VL 15 11675 IS 3 11676 BP 451 11677 EP 472 11678 DI 10.2478/s11658-010-0018-0 11679 UT ISI:000278930100007 11680 PT J 11681 AU Shao, L 11682 Huang, J 11683 Jing, L 11684 Chen, JY 11685 Kan, SD 11686 Wang, M 11687 Li, JA 11688 Chen, DJ 11689 AF Shao, Lei 11690 Huang, Jia 11691 Jing, Lan 11692 Chen, Ji-Ye 11693 Kan, Shi-Dong 11694 Wang, Min 11695 Li, Ji-An 11696 Chen, Dai-Jie 11697 TI Overexpression of aveBIV leading to the improvement of 11698 4'-epidaunorubicin production in Streptomyces coeruleorubidus strain 11699 SIPI-A0707 11700 SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY 11701 AB The 4'-epidaunorubicin is the semisynthesis precursor of epirubicin 11702 which is a clinically useful antitumor drug thought to have slightly 11703 less cardiotoxicity than doxorubin. The 4'-epidaunorubicin was formed 11704 by overexpression of heterologous Streptomyces avermitilis aveBIV in 11705 Streptomyces coeruleorubidus SIPI-A0707 dnmV mutant blocked in the 11706 biosynthesis of daunosamine, the deoxysugar component of daunorubicin. 11707 But there was a low-yield production of 4'-epidaunorubicin. In our 11708 study, product yields were enhanced considerably by increasing aveBIV 11709 gene copy number or changing means of aveBIV integration. The 11710 4'-epidaunorubicin titer was improved by around threefold in the 11711 recombinant strain DYG1006 with the aveBIV increased threefold copy 11712 numbers. The transcript levels of aveBIV gene meet the expectation of 11713 fermentation levels of 4'-epidaunorubicin. The method described here 11714 provides the means to produce 4'-epidaunorubicin efficiently on an 11715 industrial scale. 11716 SN 0175-7598 11717 PD JUL 11718 PY 2010 11719 VL 87 11720 IS 3 11721 BP 1057 11722 EP 1064 11723 DI 10.1007/s00253-010-2541-3 11724 UT ISI:000278810200022 11725 PT J 11726 AU Cui, YX 11727 Wu, ZM 11728 Liu, XX 11729 Ni, R 11730 Zhu, XX 11731 Ma, LL 11732 Liu, JP 11733 AF Cui, Yanxia 11734 Wu, Zimei 11735 Liu, Xiaoxu 11736 Ni, Rui 11737 Zhu, Xuanxuan 11738 Ma, Lulu 11739 Liu, Jianping 11740 TI Preparation, Safety, Pharmacokinetics, and Pharmacodynamics of 11741 Liposomes Containing Brucea javanica Oil 11742 SO AAPS PHARMSCITECH 11743 AB Brucea javanica oil-loaded liposomes (BJOL) were prepared through thin 11744 film hydration method and characterized by transmission electron 11745 microscope, dynamic light scattering, and differential scanning 11746 calorimetry. Acute toxicity of B. javanica oil (BJO) in liposomes was 11747 assessed by determining the number of deaths of Kunming mice over 11748 intravenous treatment for 2 weeks. The pharmacokinetic behavior of the 11749 main active component (oleic acid) was studied in SD rats. The 11750 pharmacodynamics of BJOL was investigated using MMC-7721 cell lines 11751 and mice with Lewis lung cancer. The commercial emulsion of BJO (BJOE) 11752 was used as a reference. The data showed that BJOL had an average 11753 diameter of 108.2 nm with a zeta potential of -57.0 mV, drug loading 11754 of 3.60%, and entrapment efficiency of 92.40%. The area under curve 11755 of BJO in liposomes and emulsions were 2.31 and 1.15 mg min/ml, 11756 respectively. Compared with BJOE, mean residence time and elimination 11757 half-time (t (1/2)) increased 2.8- and 4.0-fold, respectively, and the 11758 clearance (CL) decreased 0.5-fold. In the acute toxicity test, the 11759 median lethal dose (LD50) of BJOE was 7.35 g/kg. In contrast, all mice 11760 treated with liposomes survived even at the highest dosage (12.70 11761 g/kg). The IC50 value of BJOL group was one third of that of BJOE group 11762 (p < 0.01), and a less weight loss was observed in the BJOL-treated 11763 animals (p < 0.05). In conclusion, the present study suggests that BJOL 11764 significantly decreased toxicity of BJO and enhance the antitumor 11765 activity. Therefore, liposomes may be a potential effective delivery 11766 vehicle for this lipophilic antitumor drug. 11767 SN 1530-9932 11768 PD JUN 11769 PY 2010 11770 VL 11 11771 IS 2 11772 BP 878 11773 EP 884 11774 DI 10.1208/s12249-010-9454-4 11775 UT ISI:000278921400044 11776 PT J 11777 AU Shang, JH 11778 Cai, XH 11779 Feng, T 11780 Zhao, YL 11781 Wang, JK 11782 Zhang, LY 11783 Yan, M 11784 Luo, XD 11785 AF Shang, Jian-Hua 11786 Cai, Xiang-Hai 11787 Feng, Tao 11788 Zhao, Yun-Li 11789 Wang, Jing-Kun 11790 Zhang, Lu-Yong 11791 Yan, Ming 11792 Luo, Xiao-Dong 11793 TI Pharmacological evaluation of Alstonia scholaris: Anti-inflammatory 11794 and analgesic effects 11795 SO JOURNAL OF ETHNOPHARMACOLOGY 11796 AB Ethnopharmacological relevance: Alstonia scholaris (Apocynaceae) has 11797 been historically used in "dai" ethnopharmacy to treat chronic 11798 respiratory diseases. The leaf extract, developed as a commercially 11799 available traditional Chinese medicine, used to release tracheitis and 11800 cold symptom, has also been prescribed in hospitals and sold over the 11801 counter in drug stores. 11802 Aim of the study: The investigation evaluated the anti-inflammatory 11803 and analgesic activities of the ethanolic extract, fractions and main 11804 alkaloids of Alstonia scholaris leaf to provide experimental evidence 11805 for its traditional and modern clinical use. Besides, to discover the 11806 active fraction and components for further better use in Chinese 11807 medicine is hopeful. 11808 Materials and methods: The leaf of Alstonia scholaris was extracted 11809 with ethanol and then separated into different fractions. Furthermore, 11810 alkaloids were isolated by phytochemical method. The analgesic 11811 activities were investigated using acetic acid-induced writhing, 11812 hot-plate and formalin tests in mice. The anti-inflammatory activities 11813 were carried out in vivo and in vitro, including xylene-induced ear 11814 edema and carrageenan-induced air pouch formation in mice, and COX-1, 11815 -2 and 5-LOX inhibition. 11816 Results: It has been exhibited that the EtOAc and alkaloid fractions 11817 reduced acetic acid-induced writhing response in mice, significantly. 11818 The ethanolic extract, Et0Ac and alkaloid fractions remarkably 11819 inhibited xylene-induced ear edema. Further investigation was focused 11820 on the alkaloids fraction and three main alkaloids isolated from the 11821 alkaloids fraction, in different animal models. Alkaloids reduced 11822 acetic acid-induced writhing response, and xylene-induced ear edema 11823 in mice. In the hot-plate test, alkaloids did not increase the latency 11824 period of mice obviously. In the formalin test, alkaloids did not 11825 inhibit the licking time in first phase, but significantly inhibited 11826 the licking time in second phase of mice. Alkaloids increased 11827 significantly SOD activity and decreased levels of NO. PGE2 and MDA 11828 significantly, in air pouch mice model. Moreover, some alkaloids 11829 isolated from the leaf of Alstonia scholaris exhibited inhibition of 11830 COX-1, COX-2 and 5-LOX in vitro anti-inflammatory assay, which 11831 supported alkaloids as the bioactive fraction. 11832 Conclusions: The alkaloids fraction of Alstonia scholaris leaf, three 11833 main alkaloids, picrinine, vallesamine and scholaricine, may produce 11834 the anti-inflammatory and analgesic effect peripherally based on 11835 several in vivo assays. In in vitro tests, alkaloids exhibited 11836 inhibition of inflammatory mediators (COX-1, COX-2 and 5-LOX), which 11837 is accordant with results on animal models. Besides, COX-2/5-LOX dual 11838 inhibitors found in the experiment, such as 16-formyl-5 11839 alpha-methoxystrictamine, picralinal, and tubotaiwine might be 11840 valuable for further attention. (C) 2010 Published by Elsevier Ireland 11841 Ltd. 11842 SN 0378-8741 11843 PD MAY 27 11844 PY 2010 11845 VL 129 11846 IS 2 11847 BP 174 11848 EP 181 11849 DI 10.1016/j.jep.2010.02.011 11850 UT ISI:000278651300004 11851 PT J 11852 AU Liu, W 11853 Xu, J 11854 Jing, P 11855 Yao, WB 11856 Gao, XD 11857 Yu, LL 11858 AF Liu, Wei 11859 Xu, Jing 11860 Jing, Pu 11861 Yao, Wenbing 11862 Gao, Xiangdong 11863 Yu, Liangli (Lucy) 11864 TI Preparation of a hydroxypropyl Ganoderma lucidum polysaccharide and 11865 its physicochemical properties 11866 SO FOOD CHEMISTRY 11867 AB A hydroxypropyl Ganoderma lucidum polysaccharide (H-GLP) was prepared 11868 from a low-value water-insoluble polysaccharide from G. lucidum (GLP) 11869 using propylene oxide under an alkaline condition. The H-GLP was 11870 characterised for its chemical structure with IR and C-13 NMR spectra 11871 and analysed for its mono-sugar composition, molecular weight, and 11872 hydroxypropyl content. H-GLP contained mannose, glucose, and galactose 11873 in a mole ratio of 1.0:36.5:3.59, respectively, with an average 11874 molecular weight of 788 kDa and a hydroxypropyl content of 12.05%. H-GLP 11875 also had an excellent water solubility of more than 50 mg/mL, suggesting 11876 that hydroxypropylation might serve as an effective approach to enhance 11877 water solubility of GLP. H-GLP was also compared to the original GLP 11878 and ascorbic acid for antioxidant properties. H-GLP showed much 11879 stronger free radical scavenging capacity against hydroxyl and 11880 superoxide anion radicals and hydrogen peroxide than GLP. These results 11881 suggested the potential of hydroxypropylation in developing 11882 water-soluble antioxidative polysaccharides from GLP to enhance the 11883 profitability of G. lucidium production and processing industries. (C) 11884 2010 Elsevier Ltd. All rights reserved. 11885 SN 0308-8146 11886 PD OCT 15 11887 PY 2010 11888 VL 122 11889 IS 4 11890 BP 965 11891 EP 971 11892 DI 10.1016/j.foodchem.2009.11.087 11893 UT ISI:000278582400005 11894 PT J 11895 AU Liu, F 11896 Yu, LQ 11897 Jiang, C 11898 Yang, L 11899 Wu, WT 11900 You, QD 11901 AF Liu, Fei 11902 Yu, Li-Qin 11903 Jiang, Cheng 11904 Yang, Lei 11905 Wu, Wu-Tong 11906 You, Qi-Dong 11907 TI Discovery of tetrahydro-beta-carbolines as inhibitors of the mitotic 11908 kinesin KSP 11909 SO BIOORGANIC & MEDICINAL CHEMISTRY 11910 AB Inhibitors of kinesin spindle protein (KSP) are a promising class of 11911 anticancer agents that cause mitotic arrest in cells from a failure 11912 to form functional bipolar mitotic spindles. Here, we report the 11913 synthesis and biological evaluation of a novel series of 11914 tetrahydro-beta-carboline analogs based on the structure of the known 11915 KSP inhibitor HR22C16. Preferred compounds 11b, 12a and 19b were 11916 identified as potent inhibitors in a KSP ATPase assay with good 11917 anti-proliferative activity in A549 cells. (C) 2010 Elsevier Ltd. All 11918 rights reserved. 11919 SN 0968-0896 11920 PD JUN 15 11921 PY 2010 11922 VL 18 11923 IS 12 11924 BP 4167 11925 EP 4177 11926 DI 10.1016/j.bmc.2010.05.024 11927 UT ISI:000278480900001 11928 PT J 11929 AU Zan, M 11930 Chen, XQ 11931 Fu, Q 11932 Shi, SP 11933 Zhou, SX 11934 Xiao, MT 11935 Tu, PF 11936 AF Zan, Me 11937 Chen, Xiao-Qing 11938 Fu, Qiang 11939 Shi, She-Po 11940 Zhou, Si-Xiang 11941 Xiao, Mei-Tian 11942 Tu, Peng-Fei 11943 TI 1, 10-Secoguaianolides from Artemisia anomala (Asteraceae) 11944 SO BIOCHEMICAL SYSTEMATICS AND ECOLOGY 11945 SN 0305-1978 11946 PD JUN 11947 PY 2010 11948 VL 38 11949 IS 3 11950 BP 431 11951 EP 434 11952 DI 10.1016/j.bse.2010.01.015 11953 UT ISI:000278709900022 11954 PT J 11955 AU Wang, L 11956 Yin, ZQ 11957 Cai, Y 11958 Zhang, XQ 11959 Yao, XS 11960 Ye, WC 11961 AF Wang, Lei 11962 Yin, Zhi-Qi 11963 Cai, Yan 11964 Zhang, Xiao-Qi 11965 Yao, Xin-Sheng 11966 Ye, Wen-Cai 11967 TI Amaryllidaceae alkaloids from the bulbs of Lycoris radiata 11968 SO BIOCHEMICAL SYSTEMATICS AND ECOLOGY 11969 SN 0305-1978 11970 PD JUN 11971 PY 2010 11972 VL 38 11973 IS 3 11974 BP 444 11975 EP 446 11976 DI 10.1016/j.bse.2010.02.005 11977 UT ISI:000278709900026 11978 PT J 11979 AU Wu, XR 11980 Wang, LL 11981 Wang, SZ 11982 Chen, YJ 11983 AF Wu, Xuri 11984 Wang, Lili 11985 Wang, Shuzhen 11986 Chen, Yijun 11987 TI Stereoselective introduction of two chiral centers by a single 11988 diketoreductase: an efficient biocatalytic route for the synthesis of 11989 statin side chains 11990 SO AMINO ACIDS 11991 AB Statins, including atorvastatin (Lipitor(A (R))), are the top-selling 11992 drugs in the world. The biocatalytic production of chiral side chains 11993 of statin drugs is of great interest to academia and industry. 11994 Stereoselective double reduction of a beta,delta-diketo ester 11995 catalyzed by a diketoreductase offers a simple and efficient route for 11996 the preparation of statin side chains. Comparison of different cofactor 11997 regeneration systems resulted in an easy and cost-effective process 11998 for this enzymatic reduction. 11999 SN 0939-4451 12000 PD JUN 12001 PY 2010 12002 VL 39 12003 IS 1 12004 BP 305 12005 EP 308 12006 DI 10.1007/s00726-009-0390-0 12007 UT ISI:000278519200027 12008 PT J 12009 AU Fu, MJ 12010 Zhuang, JJ 12011 Hou, FZ 12012 Ning, XB 12013 Zhan, QB 12014 Shao, Y 12015 AF Fu Mao-Jing 12016 Zhuang Jian-Jun 12017 Hou Feng-Zhen 12018 Ning Xin-Bao 12019 Zhan Qing-Bo 12020 Shao Yi 12021 TI Extracting human gait series based on the wavelet transform 12022 SO ACTA PHYSICA SINICA 12023 AB The wavelet transform was applied to process the accelerometer signals 12024 derived from human walking. The accelerometer signals were first 12025 decomposed at different levels utilizing the multi-scale and 12026 multi-resolution characteristics of the discrete wavelet transform 12027 After the determination of both the mother wavelet and the optimal 12028 decomposition level, human gait series can thus be extracted from the 12029 eigen scale of the accelerometer signal Compared with the method that 12030 detects peak values directly from accelerometer signals by 12031 thresholding, the wavelet transform gives higher detection rate of peak 12032 values on the eigen scale of the accelerometer signals Even when the 12033 accelerometer signals are exposed to serious noise, experimental 12034 results still demonstrate that the wavelet approach can guarantee the 12035 precision of the extracted gait series, which is of vital importance 12036 for the subsequent analyses It can be concluded that wavelet transform 12037 is an effective tool for the extraction of gait rhythmicity. The wavelet 12038 transform will be helpful in identifying the characteristics of other 12039 physiological signals. 12040 SN 1000-3290 12041 PD JUN 12042 PY 2010 12043 VL 59 12044 IS 6 12045 BP 4343 12046 EP 4350 12047 UT ISI:000278672300104 12048 PT J 12049 AU Wang, Y 12050 Li, ZH 12051 Zhong, WY 12052 Li, H 12053 Xu, DK 12054 Chen, HY 12055 AF Wang Ying 12056 Li ZhongHui 12057 Zhong WenYing 12058 Li Hui 12059 Xu DanKe 12060 Chen HongYuan 12061 TI Rhodamine B doped silica nanoparticle labels for protein microarray 12062 detection 12063 SO SCIENCE CHINA-CHEMISTRY 12064 AB A core-shell Rhodamine B-doped SiO2 nanoparticle was synthesized and 12065 its fluorescent intensity was found to be 1000 times higher than that 12066 of individual Rhodamine B molecule. The doped nanoparticles were 12067 further conjugated with streptavidin and the resulting nanoparticles 12068 were used in the detection of reverse-phase protein microarrays, in 12069 which human IgG of various concentrations was first immobilized on 12070 aldehyde-modified glass slides and then biotinlyated goat anti human 12071 IgG as well as the labeled nanoparticles were sequentially conjugated. 12072 The calibration curve is linear over the range from 800 fg to 500 pg 12073 and the limit of detection is 100 fg, which is 8 times lower than that 12074 of streptavidin-labeled Cy3 fluorescent dyes. The dye-doped SiO2 12075 nanoparticles show potentials for the protein array detection. 12076 SN 1674-7291 12077 PD APR 12078 PY 2010 12079 VL 53 12080 IS 4 12081 BP 747 12082 EP 751 12083 DI 10.1007/s11426-010-0104-1 12084 UT ISI:000278263400007 12085 PT J 12086 AU Liu, H 12087 Xu, JP 12088 Qu, LB 12089 Xiang, BR 12090 AF Liu Hao 12091 Xu JianPing 12092 Qu LingBo 12093 Xiang BingRen 12094 TI Generalized two-dimensional correlation near-infrared spectroscopy 12095 and principal component analysis of the structures of methanol and 12096 ethanol 12097 SO SCIENCE CHINA-CHEMISTRY 12098 AB Liquid state methanol and ethanol under different temperatures have 12099 been investigated by FT-NIR (Fourier transform near-infrared) 12100 spectroscopy, generalized two-dimensional (2D) correlation 12101 spectroscopy, and PCA (principal component analysis). First, the 12102 FT-NIR spectra were measured over a temperature range of 30-64 (or 12103 30-71) degrees C, and then the 2D correlation spectra were computed. 12104 Combining near-infrared spectroscopy, generalized 2D correlation 12105 spectroscopy, and references, we analyzed the molecular structures 12106 (especially the hydrogen bond) of methanol and ethanol, and performed 12107 the NIR band assignments. The PCA method was employed to verify the 12108 results of the 2D analysis. This study will be helpful to the 12109 understanding of these reagents. 12110 SN 1674-7291 12111 PD MAY 12112 PY 2010 12113 VL 53 12114 IS 5 12115 BP 1155 12116 EP 1160 12117 DI 10.1007/s11426-010-0172-2 12118 UT ISI:000278263500027 12119 PT J 12120 AU Gao, YA 12121 Zu, HI 12122 Zhang, JJ 12123 AF Gao Yuan 12124 Zu Hui 12125 Zhang Jianjun 12126 TI Pharmaceutical Cocrystals 12127 SO PROGRESS IN CHEMISTRY 12128 AB Different solid forms of identical drug may have diverse 12129 physicochemical properties, therapeutic/toxicological effects and 12130 formulation profiles. Compared to solvates and salts which are limited 12131 to small numbers of nontoxic solvents and ionizable drugs, cocrystals 12132 represent the very promising designable solid forms of active 12133 pharmaceutical ingredients, due to their extensive species and wide 12134 application scope. In this article, progress on pharmaceutical 12135 cocrystals, including the formation principles, cocrystal design, 12136 physicochemical properties and preparation techniques, is addressed. 12137 Cocrystals have great potentials in pharmaceutical sciences. 12138 SN 1005-281X 12139 PD MAY 12140 PY 2010 12141 VL 22 12142 IS 5 12143 BP 829 12144 EP 836 12145 UT ISI:000278187300007 12146 PT J 12147 AU Lei, BK 12148 Zha, WB 12149 Wang, Y 12150 Wen, C 12151 Studer, EJ 12152 Wang, XA 12153 Jin, F 12154 Wang, GJ 12155 Zhang, LY 12156 Zhou, HP 12157 AF Lei, Bokai 12158 Zha, Weibin 12159 Wang, Yun 12160 Wen, Cong 12161 Studer, Elaine J. 12162 Wang, Xuan 12163 Jin, Fang 12164 Wang, Guangji 12165 Zhang, Luyong 12166 Zhou, Huiping 12167 TI Development of a Novel Self-Microemulsifying Drug Delivery System for 12168 Reducing HIV Protease Inhibitor-Induced Intestinal Epithelial Barrier 12169 Dysfunction 12170 SO MOLECULAR PHARMACEUTICS 12171 AB The development of HIV protease inhibitors (Pis) has been one of the 12172 most significant advances of the past decade in controlling HIV 12173 infection. Unfortunately, the benefits of HIV Pis are compromised by 12174 serious side effects. One of the most frequent and deleterious side 12175 effects of HIV Pls is severe gastrointestinal (GI) disorders including 12176 mucosal erosions, epithelial barrier dysfunction, and leak-flux 12177 diarrhea, which occurs in 16-62% of patients on HIV Pls. Although the 12178 underlying mechanisms behind HIV Pl-associated serious adverse side 12179 effects remain to be identified, our recent studies have shown that 12180 activation of endoplasmic reticulum (ER) stress response plays a 12181 critical role in HIV Pl-induced GI complications. The objective of this 12182 study was to develop a novel self-microemulsifying drug delivery system 12183 (SMEDDS) using various antioxidants as surfactants and cosurfactants 12184 to reduce the GI side effects of the most commonly used HIV PI, 12185 ritonavir. The biological activities of this SMSDDS of ritonavir were 12186 compared with that of Norvir, which is currently used in the clinic. 12187 Rat normal intestinal epithelial cells (IEC-6) and mouse Raw 264.7 12188 macrophages were used to examine the effect of new SMEDDS of ritonavir 12189 on activation of ER stress and oxidative stress. Sprague-Dawley rats 12190 and C571BL6 mice were used for pharmacokinetic studies and in vivo 12191 studies. The intracellular and plasma drug concentrations were 12192 determined by HPLC analysis. Activation of ER stress was detected by 12193 Western blot analysis and secreted alkaline phosphatase (SEAP) 12194 reporter assay. Reactive oxygen species (ROS) was measured using 12195 dichlorodihydrofluorescein diacetate as a probe. Cell viability was 12196 determined by Roche's cell proliferation reagent WST-1. Protein levels 12197 of inflammatory cytokines (TNF-alpha and IL-6) were determined by 12198 enzyme-linked immunosorbent assays (ELISA). The intestinal 12199 permeability was assessed by luminal enteral administration of 12200 fluorescein isothiocyanate conjugated dextran (FITC-dextran, 4 kDa). 12201 The pathologic changes in intestine were determined by histological 12202 examination. The results indicated that incorporation of antioxidants 12203 in this new SMEDDS not only significantly reduced ritonavir-induced 12204 ER stress activation, ROS production and apoptosis in intestinal 12205 epithelial cells and macrophages, but also improved the solubility, 12206 stability and bioavailability of ritonavir, and significantly reduced 12207 ritonavir-induced disruption of intestinal barrier function in vivo. 12208 In conclusion, this new SMEDDS of ritonavir has less GI side effects 12209 compared to Norvir. This new SMEDDS can be used for other HIV Pls and 12210 any insoluble antiviral drug with serious GI side effects. 12211 SN 1543-8384 12212 PD MAY-JUN 12213 PY 2010 12214 VL 7 12215 IS 3 12216 BP 844 12217 EP 853 12218 DI 10.1021/mp100003r 12219 UT ISI:000278452100022 12220 PT J 12221 AU Wang, Q 12222 Wu, XM 12223 Zhang, DY 12224 AF Wang, Quan 12225 Wu, Xiao Ming 12226 Zhang, Da Yong 12227 TI RESEARCH PROGRESS ON PREDICTION MODELS FOR PHYSICAL PROPERTIES OF IONIC 12228 LIQUID 12229 SO MODERN PHYSICS LETTERS B 12230 CT 3rd International Symposium on Physics of Fluids 12231 CY JUN 15-18, 2009 12232 CL Jiuzhaigou, PEOPLES R CHINA 12233 AB The field of ionic liquid has gained rapid growth in recent years and 12234 occupied a forefront in green chemistry. As a useful instrument to the 12235 research and development of novel ionic liquids, the physical 12236 properties are of utmost importance. Thus, great efforts have been made 12237 to obtain these important data, as it is far from getting sufficient 12238 physiochemical information for intensive and extensive investigation 12239 which consequently becomes a bottleneck for the theoretical and 12240 applicable research of ionic liquids. Additionally, with the given 12241 immeasurable possible ionic liquids by various cation and anion 12242 combinations, it is an impossible task to find an ideal ionic liquid 12243 with desired physical properties using conventionally "try and error" 12244 process. For these reasons, exploration of novel prediction models for 12245 physical properties of ionic liquid is imperative. This paper gives 12246 an overview of recent progress of various prediction models. 12247 SN 0217-9849 12248 PD MAY 30 12249 PY 2010 12250 VL 24 12251 IS 13 12252 BP 1487 12253 EP 1490 12254 DI 10.1142/S0217984910023931 12255 UT ISI:000278194400054 12256 PT J 12257 AU Ni, SJ 12258 Zhang, HB 12259 Huang, WL 12260 Zhou, JP 12261 Qian, H 12262 Chen, W 12263 AF Ni, Shuaijian 12264 Zhang, Huibin 12265 Huang, Wenlong 12266 Zhou, Jinpei 12267 Qian, Hai 12268 Chen, Wei 12269 TI The application of an aryl hydrazine linker prevents beta-elimination 12270 side products in the SPPS of C-terminal cysteine peptides 12271 SO JOURNAL OF PEPTIDE SCIENCE 12272 AB Solid-phase synthesis allows for the preparation of some complex 12273 cysteine-containing peptides with both a high yield and purity. 12274 However, side reactions during chain elongation such as modification 12275 of amino acid residues have been found in C-terminal cysteine peptides. 12276 We identified 3-(1-piperidinyI)-alanine peptides, corroborated the 12277 mechanism of the side reaction, and introduced an efficient approach 12278 for the Fmoc-based synthesis of C-terminal cysteine peptides using an 12279 aryl hydrazine linker. Copyright (C) 2010 European Peptide Society and 12280 John Wiley & Sons, Ltd. 12281 SN 1075-2617 12282 PD JUN 12283 PY 2010 12284 VL 16 12285 IS 6 12286 BP 309 12287 EP 313 12288 DI 10.1002/psc.1240 12289 UT ISI:000278392200008 12290 PT J 12291 AU Fan, JH 12292 Liu, K 12293 Zhang, ZA 12294 Luo, TJ 12295 Xi, ZL 12296 Song, JN 12297 Liu, BL 12298 AF Fan, Jinghua 12299 Liu, Kang 12300 Zhang, Zhongai 12301 Luo, Tianjiong 12302 Xi, Zhilei 12303 Song, Junna 12304 Liu, Baolin 12305 TI Modified Si-Miao-San extract inhibits the release of inflammatory 12306 mediators from lipopolysaccharide-stimulated mouse macrophages 12307 SO JOURNAL OF ETHNOPHARMACOLOGY 12308 AB Ethnopharmacological relevance: Modified Si-Miao-San (mSMS) is a 12309 prescription modified from Si-Miao-San which is an ancient Chinese 12310 prescription used to treat various ailments. 12311 Aim of the study: Modified Si-Miao-San (mSMS) has been used for the 12312 treatment of infectious and inflammatory disorders in the clinic. This 12313 study was aimed to investigate its anti-inflammatory activity and 12314 underlying mechanism at cellular and molecular levels. 12315 Materials and methods: We stimulated RAW264.7 cells with 12316 Lipopolysaccharide (LPS) and observed effects of mSMS on the release 12317 of inflammatory mediators such as: tumor necrosis factor-alpha 12318 (TNF-alpha), interleukin-6 (IL-6), NO, and relative gene expressions. 12319 Meanwhile, we also investigated the modulation of mSMS in inflammatory 12320 signal transduction mediated through extracellular signal-regulated 12321 protein kinase (ERK) and nuclear factor-kappa B (NF-kappa B) pathway. 12322 Results: Our findings demonstrated that mSMS significantly inhibited 12323 the excessive production of NO, TNF-alpha and IL-6 and the over 12324 expression of relative genes in LPS-stimulated macrophages. In 12325 addition, mSMS suppressed LPS-induced ERK1/2-phosphorylation and 12326 inhibited the activation of NF-kappa B by attenuation of I kappa B-alpha 12327 degradation. 12328 Conclusions: Our results suggest that the anti-inflammatory properties 12329 of mSMS might result from the inhibition of inflammatory mediators, 12330 such as NO, TNF-alpha and IL-6, via suppression of ERK and NF-kappa 12331 B dependent pathways. (C) 2010 Elsevier Ireland Ltd. All rights 12332 reserved. 12333 SN 0378-8741 12334 PD MAY 4 12335 PY 2010 12336 VL 129 12337 IS 1 12338 BP 5 12339 EP 9 12340 DI 10.1016/j.jep.2010.02.002 12341 UT ISI:000278239600002 12342 PT J 12343 AU Du, YZ 12344 Lu, P 12345 Zhou, JP 12346 Yuan, H 12347 Hu, FQ 12348 AF Du, Yong-Zhong 12349 Lu, Ping 12350 Zhou, Jian-Ping 12351 Yuan, Hong 12352 Hu, Fu-Qiang 12353 TI Stearic acid grafted chitosan oligosaccharide micelle as a promising 12354 vector for gene delivery system: Factors affecting the complexation 12355 SO INTERNATIONAL JOURNAL OF PHARMACEUTICS 12356 AB Stearic acid (SA) grafted chitosan oligosaccharide (CSO-SA) with 12357 different molecular weight of chitosan oligosaccharide (CSO) and graft 12358 ratio of stearic acid were synthesized by coupling reaction of SA and 12359 CSO. The cationic polymeric micelles of CSO-SA via self-assemble formed 12360 and used for gene delivery of fish sperm DNA. Factors affecting 12361 complexation and stability of the complexes of CSO-SA micelles and DNA 12362 were investigated. The results indicated that pKa of CSO-SA with 3 kDa 12363 of CSO decreased from 8.16 to 6.02 as the substitution degree of amino 12364 groups of CSO in CSO-SA increased from 9.79% to 63.41%, whereas the 12365 molecular weight (M-W) of CSO less affected the pKa. As for the 12366 stability of complexes, ethidium bromide assay data demonstrated that 12367 the complexes consisting of CSO-SA with lower amino substitution degree 12368 or smaller molecular weight of CSO were more stable than that with the 12369 higher amino substitution degree or molecular weight of CSO. The 12370 results also presented that the low pH and ionic strength environment 12371 were in favor for the stability of complexes. (C) 2010 Elsevier B.V. 12372 All rights reserved. 12373 SN 0378-5173 12374 PD MAY 31 12375 PY 2010 12376 VL 391 12377 IS 1-2 12378 BP 260 12379 EP 266 12380 DI 10.1016/j.ijpharm.2010.02.017 12381 UT ISI:000278342900032 12382 PT J 12383 AU Zhang, WL 12384 Gu, XA 12385 Bai, H 12386 Yang, RH 12387 Dong, CD 12388 Liu, JP 12389 AF Zhang, Wen-Li 12390 Gu, Xiao 12391 Bai, Hui 12392 Yang, Ru-Hui 12393 Dong, Chen-Dong 12394 Liu, Jian-Ping 12395 TI Nanostructured lipid carriers constituted from high-density 12396 lipoprotein components for delivery of a lipophilic cardiovascular 12397 drug 12398 SO INTERNATIONAL JOURNAL OF PHARMACEUTICS 12399 AB To investigate the possibility of reconstituted protein-free 12400 high-density lipoprotein (HDL) being a carrier for delivering a 12401 lipophilic cardiovascular drug, Tanshinone IIA-loaded HDL-like 12402 nanostructured lipid carriers (TA-NLC) were prepared by a 12403 nanoprecipitation/solvent diffusion method. The physicochemical 12404 parameters of TA-NLC were characterized in terms of particle size, zeta 12405 potential, morphology, entrapment efficiency, differential scanning 12406 calorimetry (DSC) and stability. A novel two-step method has been 12407 employed to determine entrapment efficiency of TA-NLC. The binding 12408 properties of TA-NLC to apolipoproteins were investigated by in vitro 12409 incubation competition assay in the presence of native HDL and 12410 electrophoresis test. Phagocytosis and cytotoxicity was evaluated 12411 using mouse macrophage cell line RAW 264.7 with TA-NLC and incubated 12412 TA-NLC with native HDL (TA-NLC-apo). The results showed that TA-NLC 12413 had an average diameter of 8.0 +/- 1.2 nm, zeta potential of -29.0 +/0.0 mV, drug loading of 6.17 +/- 0.3% and entrapment efficiency of 97.84 12414 +/- 1.2%. TA-NLC were demonstrated spheres with drug incorporated in 12415 lipid core forming a shell-core structure. DSC analysis showed that 12416 TA was dispersed in NLC in an amorphous state. The incorporation of 12417 glycerol trioleate to NLC led to crystal order disturbance. Agarose 12418 gel electrophoresis and sodium dodecyl sulfate polyacrylamide gel 12419 electrophoresis (SDS-SPAGE) patterns indicated that TA-NLC could bind 12420 to apolipoprotein A-I (apoA-I) specifically in vitro. Phagocytosis 12421 studies showed significant differences in uptake between TA-NLC and 12422 TA-NLC-apo and demonstrated that TA-NLC incubated with native HDL could 12423 turn endogenous by association to apolipoproteins, which cannot 12424 trigger immunological responses and could escape from recognition by 12425 macrophages. (C) 2010 Elsevier B.V. All rights reserved. 12426 SN 0378-5173 12427 PD MAY 31 12428 PY 2010 12429 VL 391 12430 IS 1-2 12431 BP 313 12432 EP 321 12433 DI 10.1016/j.ijpharm.2010.03.011 12434 UT ISI:000278342900038 12435 PT J 12436 AU Hu, GQ 12437 Zhang, ZQ 12438 Xie, SQ 12439 Huang, WL 12440 AF Hu, Guo Qiang 12441 Zhang, Zhong Quan 12442 Xie, Song Qiang 12443 Huang, Wen Long 12444 TI Synthesis and antitumor evaluation of C3/C3 fluoroquinolone dimers 12445 (I): Tethered with a fused heterocyclic 12446 s-triazolo[2,1-b][1,3,4]thiadiazole 12447 SO CHINESE CHEMICAL LETTERS 12448 AB Five C3/C3 fluoroquinolone dimers tethered with a fused heterocyclic 12449 ring of s-triazolo[2,1-b][1,3,4]thiadiazole derived from 12450 antibacterial quinolones were synthesized and characterized, and their 12451 in vitro antitumor activity against L1210, CHO cell lines was evaluated 12452 via the respective IC50 values. (C) 2010 Guo Qiang Hu. Published by 12453 Elsevier B.V. on behalf of Chinese Chemical Society. All rights 12454 reserved. 12455 SN 1001-8417 12456 PD JUN 12457 PY 2010 12458 VL 21 12459 IS 6 12460 BP 661 12461 EP 663 12462 DI 10.1016/j.cclet.2010.01.037 12463 UT ISI:000278442300007 12464 A Qian, Y 12465 U Liang, JY 12466 Qu, W 12467 Che, YY 12468 A Qian, Yong 12469 F Liang, Jing Yu 12470 Qu, Wei 12471 Che, YanYun 12472 Two new homoisoflavanones from Polygonatum odoratum (Mill.) Druce 12473 CHINESE CHEMICAL LETTERS 12474 A Two new homoisoflavanones were isolated from the rhizomes of 12475 B Polygonatum odoratum (Mill.) Druce and their structures were 12476 elucidated as 12477 (3R)-5,7-dihydroxy-8-methoxy-3-(4-methoxybenzyl)-6-methylchrom-an4-one (1) and 12478 (3R)-5,7,8-trihydroxy-3-(4-hydroxybenzyl)-6-methylchroman-4-one 12479 (2), on the basis of sp-ectral analysis. (C) 2010 Jing Yu Liang. 12480 Published by Elsevier B.V. on behalf of Chinese Chemical Society. All 12481 rights reserved. 12482 1001-8417 12483 2010 12484 10.1016/j.cclet.2010.01.040 12485 ISI:000278442300019 12486 PT J 12487 AU Ou, Y 12488 Zheng, S 12489 Lin, L 12490 Jiang, QH 12491 Yang, XG 12492 AF Ou, Yu 12493 Zheng, Shan 12494 Lin, Lin 12495 Jiang, Qizhou 12496 Yang, Xuegan 12497 TI Protective effect of C-phycocyanin against carbon 12498 tetrachloride-induced hepatocyte damage in vitro and in vivo 12499 SO CHEMICO-BIOLOGICAL INTERACTIONS 12500 AB This study focused on the hepatoprotective activity of C-phycocyanin 12501 (C-PC) against carbon tetrachloride-induced hepatocyre damage in vitro 12502 and in vivo. In in vitro study, human hepatocyte cell line L02 was used. 12503 C-PC showed its capability to reverse CCl4-induced L02 cells viability 12504 loss, alanine transaminase (ALT) leakage and morphological changes. 12505 C-PC also showed the following positive effects: prevent the 12506 CCl4-induced overproduction of intracellular reactive oxygen species 12507 (ROS) and malondialdehyde (MDA); prevent changes in superoxide 12508 dismutase (SOD) activity; and reduce glutathione (GSH) level. In vivo, 12509 CPC showed its capability to decrease serum ALT and aspartate 12510 transaminase (AST) levels in CCl4-induced liver damage in mice. The 12511 histological observations supported the results obtained from serum 12512 enzymes assays. C-PC also showed the following effects in mice liver: 12513 prevent the CCl4-induced MDA formation and GSH depletion; prevent SOD 12514 and glutathione peroxidase (GSH-Px) activity; and prevent the 12515 elevation of transforming growth factor-beta1 (TGF-beta(1)) and 12516 hepatocyte growth factor (HGF) mRNAs. Both the in vitro and in vivo 12517 results suggested that C-PC was useful in protecting against 12518 CCl4-induced hepatocyte damage. One of the mechanisms is believed to 12519 be through C-PCs scavenging ability to protect the hepatocytes from 12520 free radicals damage induced by CCl4. In addition, C-PC may be able 12521 to block inflammatory infiltration through its anti-inflammatory 12522 activities by inhibiting TGF-beta 1 and HGF expression. (C) 2010 12523 Elsevier Ireland Ltd. All rights reserved. 12524 SN 0009-2797 12525 PD APR 29 12526 PY 2010 12527 VL 185 12528 IS 2 12529 BP 94 12530 EP 100 12531 DI 10.1016/j.cbi.2010.03.013 12532 UT ISI:000278440300002 12533 PT J 12534 AU Yu, LY 12535 Deng, HS 12536 Xiang, BR 12537 AF Yu, Liyan 12538 Deng, Haishan 12539 Xiang, Bingren 12540 TI Liquid chromatography-tandem mass/mass spectrometry method for the 12541 quantification of rabeprazole in human plasma and application to a 12542 pharmacokinetic study 12543 SO ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH 12544 AB A rapid, simple and sensitive reversed-phase high-performance liquid 12545 chromatographic-tandem mass/mass spectrometry (HPLC/MS/MS) method has 12546 been developed for the measurement of rabeprazole (CAS 117976-89-3) 12547 concentrations in human plasma and its use in bioavailability studies 12548 has been evaluated. The method was linear in the concentration range 12549 of 0.05-2.5 mu g/ml. The lower limit of quantification (LLOQ) was 0.05 12550 mu g/ml in 1 ml plasma sample. The intra- and inter-day relative 12551 standard deviation across three validation runs over the entire 12552 concentration range was less than 8.2% and 7.53%, respectively. This 12553 method was successfully applied for the evaluation of pharmacokinetic 12554 profiles of rabeprazole tablet in 18 healthy volunteers. The main 12555 pharmacokinetic parameters obtained were: AUC(0-t) 1415.88 +/- 505.46 12556 and 1457.44 +/- 524.40 ng . h/ml, AUC(0-infinity) 1439.10 +/- 507.47 12557 and 1479.81 +/- 527.83 ng h/ml, C-max 678.24 +/- 278.93 and 657.83 +/250.86 ng/ml, t(1/2) 1.48 +/- 0.19 and 1.38 +/- 0.24 h, t(max) 3.8 +/0.8 and 3.7 +/- 0.5 h for the test and reference formulations, 12558 respectively. No statistical differences were observed for C-max and 12559 the area under the plasma concentration time curve for rabeprazole. 12560 90% confidence limits calculated for C-max and AUC from zero to infinity 12561 (AUC(0-infinity)) of rabeprazole were included in the bioequivalence 12562 range (0.8-1.25 for AUC). 12563 SN 0004-4172 12564 PY 2010 12565 VL 60 12566 IS 5 12567 BP 262 12568 EP 266 12569 UT ISI:000278351000006 12570 PT J 12571 AU Yu, JN 12572 Zhu, YA 12573 Wang, L 12574 Peng, M 12575 Tong, SS 12576 Cao, X 12577 Qiu, H 12578 Xu, XM 12579 AF Yu, Jiang-nan 12580 Zhu, Yuan 12581 Wang, Li 12582 Peng, Min 12583 Tong, Shan-shan 12584 Cao, Xia 12585 Qiu, Hui 12586 Xu, Xi-ming 12587 TI Enhancement of oral bioavailability of the poorly water-soluble drug 12588 silybin by sodium cholate/phospholipid-mixed micelles 12589 SO ACTA PHARMACOLOGICA SINICA 12590 AB Aim: To evaluate a mixed micellar drug delivery system composed of 12591 sodium cholate and phospholipid for oral administration of silybin, 12592 a promising hepatoprotectants. 12593 Methods: The optimum formulation of sodium cholate/phospholipid-mixed 12594 micelles containing silybin was obtained based on the study of 12595 pseudo-ternary phase diagram. The dissolution of silybin-mixed 12596 micelles was investigated. The pharmacokinetic characteristics and 12597 bioavailability after oral administration of silybin-mixed micelles 12598 and silybin-N-methylglucamine were compared in dogs. 12599 Results: The mean particle size of prepared mixed micelles was 75.9 12600 +/- 4.2 nm. The largest solubility of silybin was found to be 10.0 +/1.1 mg/mL in the optimum formulation of mixed micelles. The 12601 silybin-sodium cholate/phospholipid-mixed micelles showed a very slow 12602 release of silybin 17.5% (w/w) within 72 h in phosphate buffer (pH 7.4) 12603 and 15.6% (w/w) in HCl solution (pH 1.2). After oral administration 12604 to dogs, the relative bioavailability of mixed micelles versus 12605 silybin-N-methylglucamine in dogs was 252.0%. 12606 Conclusion: Sodium cholate/phospholipid-mixed micelles are promising 12607 carriers in orally delivery of silybin, considering their capability 12608 of enhancing bioavailability and large-scale production. 12609 SN 1671-4083 12610 PD JUN 12611 PY 2010 12612 VL 31 12613 IS 6 12614 BP 759 12615 EP 764 12616 DI 10.1038/aps.2010.55 12617 UT ISI:000278341900015 12618 PT J 12619 AU Di, LL 12620 Wang, Y 12621 Lin, GW 12622 Lu, T 12623 AF Di, Li Li 12624 Wang, Yue 12625 Lin, Guo Wu 12626 Lu, Tao 12627 TI Aquabis(1H-benzimidazole-2-carboxylato-kappa O-2,N-3)zinc(II) 12628 SO ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE 12629 AB In the title compound, [Zn(C8H5N2O2)(2)(H2O)], the Zn-II ion is 12630 coordinated in each case by a carboxylate O atom and an imidazole N 12631 atom from two different benzimidazole-2-carboxylate (BIC) ligands and 12632 one water O atom in a trigonal-bipyramidal geometry. In the complex 12633 molecule, the two benzimidazole planes are twisted, making a dihedral 12634 angle of 55.93 (11)degrees. The three-dimensional framework is 12635 organized by intermolecular N-H center dot center dot center dot O 12636 hydrogen bonding and OH center dot center dot center dot O interactions 12637 and pi-pi interactions between adjacent benzimidazole rings 12638 [centroid-centroid distance = 3.586 (3) angstrom]. 12639 SN 1600-5368 12640 PD JUN 12641 PY 2010 12642 VL 66 12643 PN Part 6 12644 BP M610 12645 EP U193 12646 DI 10.1107/S1600536810015631 12647 UT ISI:000278263300009 12648 PT J 12649 AU Qi, JP 12650 Sun, MJ 12651 Ping, QE 12652 Zhuang, JE 12653 Li, JR 12654 Peddie, F 12655 Song, YM 12656 AF Qi, Jianping 12657 Sun, Minjie 12658 Ping, Qineng 12659 Zhuang, Jie 12660 Li, Jiangran 12661 Peddie, Frank 12662 Song, Yunmei 12663 TI The Mechanisms for Enhanced Oral Absorption of Hydroxysafflor Yellow 12664 A by Chuanxiong Volatile Oil 12665 SO PLANTA MEDICA 12666 AB The aims of this study were to investigate the effect of Ligusticum 12667 chuanxiong volatile oil (CVO) on the oral absorption of hydroxysafflor 12668 yellow A (HSYA). The effects were studied both in vitro and in vivo. 12669 The contents of CVO were measured by GC-MS. The Caco-2 cell model was 12670 used to evaluate HSYA permeation with or without the presence of CVO. 12671 Transepithelial electrical resistance (TEER) of the Caco-2 cell 12672 monolayers was monitored and the alteration in the subcellular 12673 localization of claudin-1, the tight junction protein, was observed 12674 by immunofluorescence. The irritation of CVO on rat intestine was 12675 studied by paraffin slice technology. Our results demonstrated that 12676 CVO mainly contained ligustilide (47.82%). The Papp of HSYA was 12677 improved by 5.34-fold and 4.62-fold in the presence of 0.02 mg/mL and 12678 0.01 mg/mL of CVO, respectively. After opening of the tight junctions 12679 of the Caco-2 cell monolayer, TEER decreased, the position of claudin-1 12680 changed, and its expression increased. CVO at different concentrations 12681 10, 25, 100 and 200 mg/kg) caused no significant irritation on rat 12682 intestine. The bioavailability of HSYA in rats was increased by 12683 6.48-fold and 4.91-fold when 100 and 25mg/kg of CVO were 12684 co-administrated, respectively. CVO was an effective absorption 12685 enhancer for oral delivery of BCS III drugs. It can cause redistribution 12686 of claudin-1 proteins and open the tight junctions. 12687 SN 0032-0943 12688 PD MAY 12689 PY 2010 12690 VL 76 12691 IS 8 12692 BP 786 12693 EP 792 12694 DI 10.1055/s-0029-1240705 12695 UT ISI:000278064200005 12696 PT J 12697 AU Chen, YQ 12698 Zhang, WD 12699 Kong, LY 12700 Lu, T 12701 Shen, YH 12702 AF Chen, Y. Q. 12703 Zhang, W. D. 12704 Kong, L. Y. 12705 Lu, T. 12706 Shen, Y. H. 12707 TI Delavayol, a novel sesquiterpene from Incarvillea delavayi Bureau et 12708 Franchet 12709 SO NATURAL PRODUCT RESEARCH 12710 AB To investigate the chemical constituents from Incarvillea delavayi 12711 Bureau et Franchet, a new sesquiterpene, named delavayol, together with 12712 three known ones, was isolated by column chromatography. Spectroscopic 12713 and chemical evidence revealed the structures to be 12714 8,9-dihydroxy-1(10)-eremophiliene-11,12-diol (1), oleanolic acid 12715 (2), myrianthic acid (3), and sitoindoside I (4). Compounds 3 and 4 12716 were isolated from the genus Incarvillea for the first time. 12717 SN 1478-6419 12718 PY 2010 12719 VL 24 12720 IS 10 12721 BP 915 12722 EP 919 12723 DI 10.1080/14786410802421026 12724 UT ISI:000278007000003 12725 PT J 12726 AU Yang, MH 12727 Luo, JG 12728 Huang, XF 12729 Kong, LY 12730 AF Yang, Ming Hua 12731 Luo, Jian Guang 12732 Huang, Xue Feng 12733 Kong, Ling Yi 12734 TI Flavonol glycosides with -D-aldohexoses from Rhododendron irroratum 12735 SO NATURAL PRODUCT RESEARCH 12736 AB Two new flavonol glycosides which contain rare -D-galactose or 12737 -D-glucose were obtained from the flowers of Rhododendron irroratum 12738 Franch., namely myricetin 3-O--D-galactoside-3'-O--D-glucoside (1) 12739 and myricetin 3-O--D-galactoside-3'-O--D-galactoside (2). Their 12740 structures were determined by UV, IR, HR-ESI-MS, ESI-MS, 1D- and 2D-NMR 12741 techniques. 12742 SN 1478-6419 12743 PY 2010 12744 VL 24 12745 IS 10 12746 BP 920 12747 EP 925 12748 DI 10.1080/14786410802425811 12749 UT ISI:000278007000004 12750 PT J 12751 AU Yin, RJ 12752 Huang, XF 12753 Kong, LY 12754 AF Yin, Ren-Jie 12755 Huang, Xue-Feng 12756 Kong, Ling-Yi 12757 TI Constituents from the heartwoods of Osmanthus armatus 12758 SO NATURAL PRODUCT RESEARCH 12759 AB A new ester, armatuside (1), along with 13 known compounds (2-14), were 12760 obtained from the ethanolic extract of the heartwoods of Osmanthus 12761 armatus. The structures of all compounds were deduced using 1D, and 12762 2D NMR spectroscopic methods. The absolute configuration of 1 was 12763 deduced by chemical correlation with a known compound. Compounds 2-14 12764 were isolated from the plant for the first time. 12765 SN 1478-6419 12766 PY 2010 12767 VL 24 12768 IS 10 12769 BP 948 12770 EP 952 12771 DI 10.1080/14786410802689713 12772 UT ISI:000278007000008 12773 PT J 12774 AU Zheng, YF 12775 Dai, DZ 12776 Dai, Y 12777 AF Zheng, Yu-Fen 12778 Dai, De-Zai 12779 Dai, Yin 12780 TI NaHS ameliorates diabetic vascular injury by correcting depressed 12781 connexin 43 and 40 in the vasculature in streptozotocin-injected rats 12782 SO JOURNAL OF PHARMACY AND PHARMACOLOGY 12783 AB Objectives Cardiovascular complication contributes an important role 12784 to morbidity and mortality in patients with diabetes. We hypothesized 12785 that these abnormalities are mainly mediated by oxidative stress, 12786 endothelial dysfunction and impaired intracellular communications. 12787 Thus, we examined vasoactivity and expression of connexin (Cx) 43 and 12788 40, protein kinase C-epsilon (PKC epsilon) and NADPH oxidase of the 12789 vasculature of thoracic aorta in streptozotocin (STZ)-injected rats, 12790 and whether NaHS could reverse these abnormalities compared with 12791 aminoguanidine. 12792 Methods Male Sprague-Dawley rats were administered with STZ (60 mg/kg, 12793 i.p.) to induce diabetes. Diabetic rats were divided into untreated 12794 and treated groups in the 5th-8th week and intervention with either 12795 NaHS (5 mg/kg daily, s.c.) or aminoguanidine (100 mg/kg daily, p.o.) 12796 was made. 12797 Key findings In rats with untreated diabetes, hyperglycaemia, 12798 increased activity of inducible nitric oxide (NO) synthase, increased 12799 NO, mild vascular spasm, reduced NO bioavailability and diminished 12800 vasorelaxation were found. These findings were accompanied by 12801 downregulated Cx43 and Cx40, and upregulated PKC epsilon and NADPH 12802 oxidase subunits p22(phox)/p47(phox)/p67(phox) in the thoracic aorta. 12803 NaHS appears to be as effective as aminoguanidine in attenuating these 12804 abnormalities. 12805 Conclusions NaHS shows promise in relieving diabetic vascular 12806 abnormality by upregulating junctional connexin Cx40 and Cx43, via 12807 normalizing NADPH oxidase and PKC epsilon in the vasculature. 12808 SN 0022-3573 12809 PD MAY 12810 PY 2010 12811 VL 62 12812 IS 5 12813 BP 615 12814 EP 621 12815 DI 10.1211/jpp.62.05.0009 12816 UT ISI:000278158000009 12817 PT J 12818 AU Luo, J 12819 Wang, JS 12820 Wang, XB 12821 Luo, JG 12822 Kong, LY 12823 AF Luo, Jun 12824 Wang, Jun-Song 12825 Wang, Xiao-Bing 12826 Luo, Jian-Guang 12827 Kong, Ling-Yi 12828 TI Chuktabularins E-T, 16-Norphragmalin Limonoids from Chukrasia 12829 tabularis var. velutina 12830 SO JOURNAL OF NATURAL PRODUCTS 12831 AB Chuktabularins E-T (1-16), 16 new 16-norphragmalin limonoids, together 12832 with four known compounds, chuktabularins A D, were isolated from the 12833 stem bark of Chukrasia tabularis var. veltaina. These compounds possess 12834 a biosynthetically extended propionyl or acetyl group at C-15 and a 12835 characteristic ketal moiety between the limonoid skeleton and the acyl 12836 substituent at C-15. The structures of these compounds were established 12837 on the basis of detailed spectroscopic analysis, and that of 1 was 12838 confirmed by a single-crystal X-ray diffraction experiment, 12839 representing the first verification of the skeleton of 12840 16-norphragmalin limonoids. Chuktabularins K-O (7-11) were found to 12841 be the first 19-acetoxylated 16-norphragmalin limonoids. 12842 Variable-temperature H-1 NMR experiments suggested that 7 exists as 12843 an equilibrium mixture of conformational isomers in solution. The 12844 absolute configuration of 5 was determined by the CD exciton chirality 12845 method on its 11,12-di-p-chlorobenzoate (5a), and those of 1-4 and 6-16 12846 were proposed by correlating with 5 spectroscopically and 12847 biogenetically. 12848 SN 0163-3864 12849 PD MAY 12850 PY 2010 12851 VL 73 12852 IS 5 12853 BP 835 12854 EP 843 12855 DI 10.1021/np900734c 12856 UT ISI:000278080900009 12857 PT J 12858 AU Chen, XM 12859 Lu, T 12860 Lu, SA 12861 Li, HF 12862 Yuan, HL 12863 Ran, T 12864 Liu, HC 12865 Chen, YD 12866 AF Chen, Xiu-Mei 12867 Lu, Tao 12868 Lu, Shuai 12869 Li, Hui-Fang 12870 Yuan, Hao-Liang 12871 Ran, Ting 12872 Liu, Hai-Chun 12873 Chen, Ya-Dong 12874 TI Structure-based and shape-complemented pharmacophore modeling for the 12875 discovery of novel checkpoint kinase 1 inhibitors 12876 SO JOURNAL OF MOLECULAR MODELING 12877 AB Checkpoint kinase 1 (Chk1), a member of the serine/threonine kinase 12878 family, is an attractive therapeutic target for anticancer combination 12879 therapy. A structure-based modeling approach complemented with shape 12880 components was pursued to develop a reliable pharmacophore model for 12881 ATP-competitive Chk1 inhibitors. Common chemical features of the 12882 pharmacophore model were derived by clustering multiple 12883 structure-based pharmacophore features from different Chk1-ligand 12884 complexes in comparable binding modes. The final model consisted of 12885 one hydrogen bond acceptor (HBA), one hydrogen bond donor (HBD), two 12886 hydrophobic (HY) features, several excluded volumes and shape 12887 constraints. In the validation study, this feature-shape query yielded 12888 an enrichment factor of 9.196 and performed fairly well at 12889 distinguishing active from inactive compounds, suggesting that the 12890 pharmacophore model can serve as a reliable tool for virtual screening 12891 to facilitate the discovery of novel Chk1 inhibitors. Besides, these 12892 pharmacophore features were assumed to be essential for Chk1 12893 inhibitors, which might be useful for the identification of potential 12894 Chk1 inhibitors. 12895 SN 1610-2940 12896 PD JUL 12897 PY 2010 12898 VL 16 12899 IS 7 12900 BP 1195 12901 EP 1204 12902 DI 10.1007/s00894-009-0630-y 12903 UT ISI:000278027600003 12904 PT J 12905 AU Zheng, YT 12906 Zhou, F 12907 Wu, XL 12908 Wen, XZ 12909 Li, YN 12910 Yan, B 12911 Zhang, JW 12912 Hao, G 12913 Ye, WC 12914 Wang, GJ 12915 AF Zheng, Yuanting 12916 Zhou, Fang 12917 Wu, Xiaolan 12918 Wen, Xiaozhou 12919 Li, Yannan 12920 Yan, Bei 12921 Zhang, Jingwei 12922 Hao, Gang 12923 Ye, Wencai 12924 Wang, Guangji 12925 TI 23-Hydroxybetulinic acid from Pulsatilla chinensis (Bunge) Regel 12926 synergizes the antitumor activities of doxorubicin in vitro and in vivo 12927 SO JOURNAL OF ETHNOPHARMACOLOGY 12928 AB Ethnopharmacological revelance: Pulsatilla chinensis (Bunge) Regel 12929 has been used as adjuvant in chemotherapy in traditional Chinese 12930 medicine. 23-Hydroxybetulinic acid, an isolated pentacyclic 12931 triterpene, is the major active constituent of Pulsatilla chinensis 12932 (Bunge) Regel. 12933 Aim of this study: To evaluate the combinational anticancer effect of 12934 23-hydroxybetulinic acid and doxorubicin in vitro and in vivo. 12935 Materials and methods: The effect of combination treatment with 12936 23-hydroxybetulinic acid and doxorubicin was evaluated with a 12937 quantitative combination index method based on the median-effect 12938 analysis in various cancer cell lines. And in vivo efficacy of 12939 combination chemotherapy was also evaluated using ICR mice bearing 12940 sarcoma 180 carcinoma tumors. 12941 Results: 23-Hydroxybetulinic acid showed a synergistic cytotoxic 12942 effect on multiple cancer cell lines by combined use with doxorubicin. 12943 In vivo studies further demonstrated that co-administration of 23-HBA 12944 significantly improved the sensitivity of the tumor to doxorubicin 12945 through increasing intra-tumor doxorubicin concentration and 12946 inhibiting doxorubicin-induced up-regulation of P-gp in tumor. 12947 Conclusion: These results suggest that the combined therapy with 12948 23-hydroxybetulinic acid and doxorubicin may be a new promising 12949 strategy to promote the clinical chemotherapy, which needs further 12950 verification. (C) 2010 Elsevier Ireland Ltd. All rights reserved. 12951 SN 0378-8741 12952 PD APR 21 12953 PY 2010 12954 VL 128 12955 IS 3 12956 BP 615 12957 EP 622 12958 DI 10.1016/j.jep.2010.02.004 12959 UT ISI:000278160200011 12960 PT J 12961 AU Chang, JS 12962 Huypens, P 12963 Zhang, YB 12964 Black, C 12965 Kralli, A 12966 Gettys, TW 12967 AF Chang, Ji Suk 12968 Huypens, Peter 12969 Zhang, Yubin 12970 Black, Chelsea 12971 Kralli, Anastasia 12972 Gettys, Thomas W. 12973 TI Regulation of NT-PGC-1 alpha Subcellular Localization and Function by 12974 Protein Kinase A-dependent Modulation of Nuclear Export by CRM1 12975 SO JOURNAL OF BIOLOGICAL CHEMISTRY 12976 AB Peroxisome proliferator-activated receptor gamma co-activator-1 alpha 12977 (PGC-1 alpha) plays a central role in the regulation of cellular energy 12978 metabolism and metabolic adaptation to environmental and nutritional 12979 stimuli. We recently described a novel, biologically active splice 12980 variant of PGC-1 alpha (NT-PGC-1 alpha, amino acids 1-270) that retains 12981 the ability to interact with and transactivate nuclear hormone 12982 receptors through its N-terminal transactivation domain. Whereas PGC-1 12983 alpha is an unstable nuclear protein sensitive to ubiquitin-mediated 12984 targeting to the proteasome, NT-PGC-1 alpha is relatively stable and 12985 predominantly cytoplasmic, suggesting that its ability to interact 12986 with and activate nuclear receptors and transcription factors is 12987 dependent upon regulated access to the nucleus. We provide evidence 12988 that NT-PGC-1 alpha interacts with the nuclear exportin, CRM1, through 12989 a specific leucine-rich domain (nuclear export sequence) that 12990 regulates its export to the cytoplasm. The nuclear export of NT-PGC-1 12991 alpha is inhibited by protein kinase A-dependent phosphorylation of 12992 Ser-194, Ser-241, and Thr-256 on NT-PGC-1 alpha, which effectively 12993 increases its nuclear concentration. Using site-directed mutagenesis 12994 to prevent or mimic phosphorylation at these sites, we show that the 12995 transcriptional activity of NT-PGC-1 alpha is regulated in part through 12996 regulation of its subcellular localization. These findings suggest 12997 that the function of NT-PGC-1 alpha as a transcriptional co-activator 12998 is regulated by protein kinase A-dependent inhibition of CRM1-mediated 12999 export from the nucleus. 13000 SN 0021-9258 13001 PD JUN 4 13002 PY 2010 13003 VL 285 13004 IS 23 13005 BP 18039 13006 EP 18050 13007 DI 10.1074/jbc.M109.083121 13008 UT ISI:000278133400079 13009 PT J 13010 AU Shen, Y 13011 Li, YQ 13012 Li, SP 13013 Ma, L 13014 Ding, LJ 13015 Ji, H 13016 AF Shen, Yang 13017 Li, Yong-Qi 13018 Li, Shao-Ping 13019 Ma, Lin 13020 Ding, Li-Ju 13021 Ji, Hui 13022 TI Alleviation of ovariectomy-induced osteoporosis in rats by Panax 13023 notoginseng saponins 13024 SO JOURNAL OF NATURAL MEDICINES 13025 AB To examine the effects of Panax notoginseng saponins (PNS), the main 13026 active components of Panax notoginseng, on ovariectomy-induced 13027 osteoporosis in rats. A total of 72 six-month-old female rats were 13028 randomly assigned to sham-operated group and five ovariectomized (OVX) 13029 groups: OVX with distilled water (5 ml/kg/day, p.o.), OVX with graded 13030 doses of PNS (75, 150, 300 mg/kg/day, p.o.), and OVX with nilestriol 13031 (1 mg/kg/week, p.o.). Animals were sacrificed after a 13-week treatment 13032 course. Compared with the OVX group, PNS administration prevented 13033 OVX-induced decrease in bone mineral density (BMD) of lumbar vertebrae 13034 and total femur, and significantly increased bone structural 13035 biomechanical properties. Improvements of BMD and biomechanical 13036 properties were accompanied by the beneficial changes of PNS on 13037 trabecular microarchitecture in the tibial metaphysis. PNS at the 13038 highest dose significantly prevent decrease in trabecular bone volume 13039 over bone total volume, trabecular number, trabecular thickness, 13040 connectivity density, and increase in trabecular separation and 13041 structure model index in OVX rats. The bone-modulating effects of PNS 13042 may be due to the increased bone formation and decreased bone 13043 resorption, as was evidenced by the elevated level of serum alkaline 13044 phosphatase and decreased level of urinary deoxypyridinoline. PNS 13045 treatment is able to enhance BMD, bone strength, and prevent the 13046 deterioration of trabecular microarchitecture without hyperplastic 13047 effect on uterus. Therefore, PNS might be a potential alternative 13048 medicine for the prevention and treatment of postmenopausal 13049 osteoporosis. 13050 SN 1340-3443 13051 PD JUL 13052 PY 2010 13053 VL 64 13054 IS 3 13055 BP 336 13056 EP 345 13057 DI 10.1007/s11418-010-0416-7 13058 UT ISI:000278134500013 13059 A Chen, ZP 13060 U Zhu, JB 13061 Chen, HX 13062 Xiao, YY 13063 Feng, MS 13064 Cai, H 13065 Chen, J 13066 Cai, BC 13067 A Chen, Zhi-Peng 13068 F Zhu, Jia-Bi 13069 Chen, Hong-Xuan 13070 Xiao, Yan-Yu 13071 Feng, Ming-Sheng 13072 Cai, Hao 13073 Chen, Jun 13074 Cai, Bao-Chang 13075 T Synthesis of a novel polymer bile salts-(polyethylene 13076 I glycol)(2000)-bile salts and its application to the liver-selective 13077 targeting of liposomal DDB 13078 DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY 13079 A Purpose: The objective of this study was to achieve a sustained and 13080 B targeted delivery of liposome to the liver, by modifying the 13081 phospholipid [phosphatidylcholine (PC)/cholesterol (10 : 1) liposomes 13082 with a novel polymer bile salts-(polyethylene glycol)(2000)-bile salts 13083 (BP2B). Methods: First, we generated a novel BP2B by 13084 N,N'-dicyclohexylcarbodiimide/4-dimethylaminopyridine 13085 esterification method and confirmed by Fourier transform infraredand 13086 H-1-NMR spectra. Second, we prepared the BP2B-modified liposomes 13087 (BP2BL) that included BP2B, and the effect of the weight ratios of 13088 BP2B/PC on entrapment efficiency was investigated and BP2B/PC = 3% 13089 (w/w) was determined as the optimum ratio for the 13090 4,4'-dimethoxy-5,6,5',6'-bi(methylenedioxy)-2,2'-bicarbomethoxybip 13091 henyl liposomes. And then, the ability of the liver target of BP2BL 13092 was studied by calculating the targeted parameters. Results and 13093 Discussion: All the results revealed that the introduction of 13094 polyoxyethylene chains could control interactions of bile salt 13095 moieties on liposome surfaces with the receptor compared with 13096 traditional liposomes (CL), marking BP2BL as a suitable carrier for 13097 hepatic parenchymal cell-specific and sustained targeting. It was 13098 suggested that liposomes containing such novel BP2B have great 13099 potential as drug delivery carriers for the liver-selective targeting 13100 that has targeted and sustained drug delivery. 13101 0363-9045 13102 2010 13103 10.3109/03639040903410342 13104 ISI:000278127500005 13105 PT J 13106 AU Chen, GH 13107 Luo, XC 13108 Zhang, JB 13109 Huang, WL 13110 AF Chen Guo-Hua 13111 Luo Xiao-Chuan 13112 Zhang Jiang-Bo 13113 Huang Wen-Long 13114 TI Synthesis and Biological Activities of 1-Acetyl-5-substituted 13115 Indoline Compounds 13116 SO CHEMICAL JOURNAL OF CHINESE UNIVERSITIES-CHINESE 13117 AB As benign prostate hyperplasia(BPH) is a common disease in elderly men, 13118 it is urgent to find new alpha(1)-adrenoceptor(AR) antagonists, the 13119 first choice for the therapy of BPH. On the basis of hybridization 13120 principle with 1-acetylindoline as the starting compound, two series 13121 of indoline derivatives 1-acetyl-5-{2-[4-(substituted phenoxy) ethyl] 13122 piperazin-l-yl} alkyl indoline and 1-acetyl-5-{2-[4-(substituted 13123 phenyl) piperazin-1-yl] alkyl} indoline were designed and synthesized. 13124 The structures of the target compounds were confirmed by H-1 NMR, 13125 elemental analysis, IR and MS. Preliminary pharmacological test show 13126 all the target compounds exhibit certain antagonism of alpha(1)-AR. 13127 Compounds 9h and 12l perform better than piperazine, and are worth of 13128 further research. 13129 SN 0251-0790 13130 PD MAY 10 13131 PY 2010 13132 VL 31 13133 IS 5 13134 BP 970 13135 EP 975 13136 UT ISI:000278159700022 13137 PT J 13138 AU Deng, J 13139 Wei, MC 13140 Yu, BY 13141 Chen, YJ 13142 AF Deng, Jing 13143 Wei, Maochen 13144 Yu, Boyang 13145 Chen, Yijun 13146 TI Efficient amplification of genes involved in microbial secondary 13147 metabolism by an improved genome walking method 13148 SO APPLIED MICROBIOLOGY AND BIOTECHNOLOGY 13149 AB Genome walking is a commonly used technique for the identification of 13150 DNA sequences adjacent to known regions. Despite the development of 13151 various genome walking methods, nonspecific products are often 13152 produced in certain circumstances, especially when GC-rich DNA 13153 sequences are dealt with. To effectively resolve such technical issues, 13154 a simple nested polymerase chain reaction-based genome walking method 13155 has been developed by implementing a progressively decreased annealing 13156 temperature from 70A degrees C to 47.5A degrees C in the first round 13157 of amplification and a high annealing temperature of 65A degrees C in 13158 the second round of amplification. During the entire process, a lower 13159 ramp rate of 1.5A degrees C s(-1) and cooling rate of 2.5A degrees C 13160 s(-1) are performed to reach the annealing temperature. Using this 13161 method, we successfully obtained the upstream and downstream sequences 13162 of three GC-rich genes involved in the biosynthetic pathways of 13163 secondary metabolites from two bacterial genomes. The efficient 13164 amplification of DNA target longer than 1.5 Kb with GC content up to 13165 75.0% indicates that the present technique could be a valuable tool 13166 for the investigation of biosynthetic pathways of various secondary 13167 metabolites. 13168 SN 0175-7598 13169 PD JUN 13170 PY 2010 13171 VL 87 13172 IS 2 13173 BP 757 13174 EP 764 13175 DI 10.1007/s00253-010-2569-4 13176 UT ISI:000277959500036 13177 PT J 13178 AU Song, QX 13179 Jing, H 13180 Wu, HP 13181 Zhou, GH 13182 Kajiyama, T 13183 Kambara, H 13184 AF Song, Qinxin 13185 Jing, Hua 13186 Wu, Haiping 13187 Zhou, Guohua 13188 Kajiyama, Tomoharu 13189 Kambara, Hideki 13190 TI Gene expression analysis on a photodiode array-based bioluminescence 13191 analyzer by using sensitivity-improved SRPP 13192 SO ANALYST 13193 AB Most methods used for gene expression analysis are based on 13194 dye-labeling, which requires costly instruments. Recently a dye-free 13195 gene expression analysis method-SRPP (Sequence-tagged 13196 reverse-transcription polymerase chain reaction coupled with 13197 pyrosequencing) was developed to compare relative gene expression 13198 levels in different tissues, but the throughput of the SRPP assay is 13199 very limited due to the use of a photomultiplier tube (PMT)-based 13200 pyrosequencer for the detection. To increase the throughput of the SRPP 13201 assay, an inexpensive photodiode (PD) array-based bioluminescence 13202 analyzer (termed as "PD-based pyrosequencer'') was coupled to SRPP; 13203 however the low sensitivity of PD limited the wide application of SRPP. 13204 To enable SRPP analyzing low abundance genes in clinical samples, 13205 sequence-tagged gene-specific primers instead of sequence-tagged poly 13206 (T)(n) primers were used for reverse-transcription, and the SRPP 13207 sensitivity was thus improved more than 10 times. This improvement 13208 compensates the sensitivity loss due to the use of PD in a 13209 pyrosequencer. The accurate determination of the expression levels of 13210 ten prognostic marker genes (AL080059, MMP9, EXT1, ORC6L, AF052162, 13211 C9orf30, FBXO31, IGFBP5, ESM1, and RUNDC1) differing between normal 13212 tissues and tumor tissues of breast cancer patients demonstrated that 13213 SRPP using gene-specific RT primers coupled with the PD array-based 13214 bioluminescence analyzer is reliable, inexpensive, and sensitive in 13215 gene expression analysis. 13216 SN 0003-2654 13217 PY 2010 13218 VL 135 13219 IS 6 13220 BP 1315 13221 EP 1319 13222 DI 10.1039/c0an00012d 13223 UT ISI:000278011800020 13224 PT J 13225 AU Zhang, Y 13226 Chen, YD 13227 You, QD 13228 Zou, LY 13229 Yang, Y 13230 AF Zhang Yuan 13231 Chen Ya-Dong 13232 You Qi-Dong 13233 Zou Li-Yun 13234 Yang Yan 13235 TI Homology Modeling and Molecular Docking Studies on the Selectivity of 13236 HDAC1/HDAC8 13237 SO ACTA PHYSICO-CHIMICA SINICA 13238 AB Histone deacetylases (HDACs) have emerged as important anti. tumor 13239 targets in recent years. As HDACs comprise multiple isoforms and there 13240 are different physiological functions among various isoforms, the 13241 development of selective HDAC inhibitors has attracted a great deal 13242 of attention. This study focused on the discovery of selective HDAC1, 13243 HDAC8 inhibitors and specifically a homology model for HDAC1 was 13244 generated. A comparison was made between the HDAC1 homology model and 13245 the crystal structure of HDAC8, which showed that some active site 13246 residues were different from each other and these residues played 13247 important roles in the selectivity between HDAC1 and HDAC8. Two linear 13248 regression models were established based on the inhibitory activities 13249 against HDAC1, HDAC8 and the docking scores of 52 compounds. The 13250 developed linear regression models for HDAC1 and HDAC8 have non. cross 13251 validated correlation coefficients R-2 of 0.82 and 0.80, respectively, 13252 which indicates that the results are statistically significant. These 13253 models were used to predict the activities of the synthesized compounds 13254 and these prediction results can provide further insights into the 13255 selectivity of HDAC1, HDAC8. 13256 SN 1000-6818 13257 PD JUN 13258 PY 2010 13259 VL 26 13260 IS 6 13261 BP 1676 13262 EP 1686 13263 UT ISI:000278106600033 13264 PT J 13265 AU Liu, R 13266 Wang, M 13267 Duan, JA 13268 Guo, JM 13269 Tang, YP 13270 AF Liu, Rui 13271 Wang, Min 13272 Duan, Jin-ao 13273 Guo, Jian-ming 13274 Tang, Yu-ping 13275 TI Purification and identification of three novel antioxidant peptides 13276 from Cornu Bubali (water buffalo horn) 13277 SO PEPTIDES 13278 AB Cornu Bubali (water buffalo horn, WBH) has been used in Traditional 13279 Chinese Medicine (TCM) for thousands of years. In the present study, 13280 three peptides with antioxidant properties were purified from aqueous 13281 extract of Cornu Bubali (water buffalo horn, WBH) by consecutive 13282 chromatographic methods including gel filtration chromatography, 13283 ion-exchange chromatography and high performance liquid 13284 chromatography. The sequences of the three peptides were identified 13285 to be Gln-Tyr-Asp-Gln-Gly-Val (WBH-1, 708 Da), 13286 Tyr-Glu-Asp-Cys-Thr-Asp-Cys-Gly-Asn (WBH-2, 1018 Da) and 13287 Ala-Ala-Asp-Asn-Ala-Asn-Glu-Leu-Phe-Pro-Pro-Asn (WBH-3, 1271 Da) by 13288 matrix assisted laser desorption ionization 13289 time-of-flight/time-of-flight mass spectrometry (MALDI-LIFT-TOF/TOF 13290 MS). The antioxidant activity of these peptides was tested using 13291 1-dipheny1-2-picrylhydrazyl (DPPH) scavenging assay directly. 13292 Methylthiazol tetrazolium (MTT) assay and lactate dehydrogenase (LDH) 13293 release assay were also used to evaluate the protection of peptides 13294 against hydrogen peroxide (H2O2) induced injury. The results showed 13295 that these peptides could reduce the DPPH radical and protect rat 13296 cerebral microvascular endothelial cells (rCMECs) against 13297 H2O2-induced injury, thus demonstrating that these peptides had 13298 antioxidant activity. These results suggest that WBH-1, WBH-2 and 13299 WBH-3, isolated from the aqueous extract of water buffalo horn are 13300 natural antioxidants and may contribute to the efficacy of WBH. (C) 13301 2010 Elsevier Inc. All rights reserved. 13302 SN 0196-9781 13303 PD MAY 13304 PY 2010 13305 VL 31 13306 IS 5 13307 BP 786 13308 EP 793 13309 DI 10.1016/j.peptides.2010.02.016 13310 UT ISI:000277768400002 13311 PT J 13312 AU Xu, FG 13313 Liu, Y 13314 Song, R 13315 Dong, HJ 13316 Zhang, ZJ 13317 AF Xu, Fengguo 13318 Liu, Ying 13319 Song, Rui 13320 Dong, Haijuan 13321 Zhang, Zunjian 13322 TI Constituents of Da-Cheng-Qi Decoction and its Parent Herbal Medicines 13323 Determined by LC-MS/MS 13324 SO NATURAL PRODUCT COMMUNICATIONS 13325 AB Da-Cheng-Qi decoction (DCQD) is a purgative prescription used in China 13326 and East Asia. To profile the constituents of this complex traditional 13327 Chinese medicine (TCM), a high-performance liquid chromatographic, 13328 electrospray ionization, tandem mass spectrometric (HPLC-ESI/MS/MS) 13329 analytical method was developed. After separation on a reversed-phase 13330 C18 analytical column using gradient elution, samples were analyzed 13331 by ESI-MS/MS in negative mode. As a result, a total of 37 compounds 13332 were detected, of which two tannins, three anthraquinones, two 13333 sennosides, Five flavonoids and two lignans were unambiguously 13334 identified by comparison with standard compounds, and sixteen 13335 compounds were either tentatively identified or deduced according to 13336 their MS/MS data. The fragmentation pathways of many of the observed 13337 compounds, such as the tannins and lignans are reported for the first 13338 time. In addition, the identity of each peak in DCQD was explored by 13339 comparison with those of its three constituent herbs. The results 13340 indicated that tannins, anthraquinones and sennosides in DCQD 13341 originated from Radix et Rhizoma Rhei, flavonoids from Fructus Aurantii 13342 Immaturus, and lignans from Cortex Magnoliae officinalis. The present 13343 study provides an example of chemical constitution profiling in complex 13344 TCM systems using LC/MS/MS. 13345 SN 1934-578X 13346 PD MAY 13347 PY 2010 13348 VL 5 13349 IS 5 13350 BP 789 13351 EP 794 13352 UT ISI:000277750200023 13353 PT J 13354 AU Xu, FG 13355 Liu, Y 13356 Dong, HJ 13357 Song, R 13358 Zhang, ZJ 13359 AF Xu, Fengguo 13360 Liu, Ying 13361 Dong, Haijuan 13362 Song, Rui 13363 Zhang, Zunjian 13364 TI Pharmacokinetic Comparison in Rats of Six Bioactive Compounds Between 13365 Da-Cheng-Qi Decoction and its Parent Herbal Medicines 13366 SO NATURAL PRODUCT COMMUNICATIONS 13367 AB Da-Cheng-Qi decoction (DCQD) is a purgative compound prescription used 13368 in China and East Asia. In this paper, pharmacokinetic differences of 13369 six major active components (rhein, emodin, aloe-emodin, magnolol, 13370 naringenin and hesperetin) between DCQD and its three constitutional 13371 herbal medicines i.e. Radix et Rhizoma Rhei, Cortex Magnoliae 13372 officinalis and Fructus Aurantii Immantrus were investigated in rats 13373 after oral administration. Plasma samples were analyzed for the 13374 quantification of the six active components using validated LC-MS/MS 13375 methods. Unpaired Student's t-test was used for statistical 13376 comparison. Significant differences (p<0.05) in the main 13377 pharmacokinetic parameters for rhein, emodin, aloe-emodin, magnolol, 13378 naringenin and hesperetin were found between DCQD and the decoction 13379 of its constitutional single herbal medicines, which demonstrated the 13380 presence of drug-drug interactions between these constitutional raw 13381 materials of DCQD occurring either in the procedure of decoction or 13382 during ADME process. 13383 SN 1934-578X 13384 PD MAY 13385 PY 2010 13386 VL 5 13387 IS 5 13388 BP 795 13389 EP 800 13390 UT ISI:000277750200024 13391 PT J 13392 AU Zhou, JP 13393 Qian, H 13394 Zhang, HB 13395 Gao, H 13396 Huang, WL 13397 Zhu, XY 13398 Ni, SAJ 13399 Zhang, CT 13400 AF Zhou, Jinpei 13401 Qian, Hai 13402 Zhang, Huibin 13403 Gao, Hui 13404 Huang, Wenlong 13405 Zhu, Xiaoyun 13406 Ni, Shuaijian 13407 Zhang, Chuntao 13408 TI Design, Synthesis and Biological Evaluation of Benzopyran Derivatives 13409 as K-ATP Channel Openers 13410 SO LETTERS IN DRUG DESIGN & DISCOVERY 13411 AB In order to complete the SAR and discover new potent and selective PCOs, 13412 some changes were made to the C-4 and C-2 substitutions of cromakalim. 13413 A series of 4 -amino acid substituted -2, 2-dialkylchromans 13414 structurally related to cromakalim were synthesized and evaluated, as 13415 ATP-sensitive potassium channel openers (8a-l). Preliminary 13416 biological tests suggested that these compounds exhibited potent to 13417 mild relaxation activity of the KCl-contracted rat aortic strips. 13418 Compounds 8b (IC50 = 0.25 mu M), 8f (IC50 = 6.44 mu M) and 8j (IC50 13419 = 8.65 mu M) exhibited commendable opening activity of potassium 13420 channels. In addition to anti-hypertension, these compounds can also 13421 be considered as lead candidates for the further development of 13422 myocardial antiischemic drugs. 13423 SN 1570-1808 13424 PD JUL 13425 PY 2010 13426 VL 7 13427 IS 6 13428 BP 415 13429 EP 420 13430 UT ISI:000277887000005 13431 PT J 13432 AU Dong, Y 13433 Xiang, BR 13434 Wang, T 13435 Liu, H 13436 Qu, LB 13437 AF Dong, Ying 13438 Xiang, Bingren 13439 Wang, Teng 13440 Liu, Hao 13441 Qu, Lingbo 13442 TI Rough set-based SAR analysis: An inductive method 13443 SO EXPERT SYSTEMS WITH APPLICATIONS 13444 AB Rough set algorithm was used as a new methodology to build 13445 structure-activity relationship (SAR) models in this paper. It acted 13446 as feature selector and nonlinear rule generator. The SAR model 13447 expressed as human readable if-then rules was developed for the 13448 inhibition of the serine/threonine kinase CDK1/cyclinB by compounds 13449 from the indirubin inhibitor family. The feature selection ability of 13450 rough set algorithm was compared with the build-in approaches 13451 (CfsSubsetEval and ConsistencySubsetEval) in Weka under leave-one-out 13452 (LOO) and 10-fold cross-validation. Through training a set of 31 13453 objects, a rule-based SAR model had been built with a reduct generated 13454 by rough set. The predictability of the model was evaluated by an 13455 external test set of 16 compounds. The existing powerful approaches, 13456 such as the decision tree learners, neural network, support vector 13457 classifier and LogitBoost approaches, were used to verify the 13458 performance of rough set method. It revealed that rough set method 13459 should play important role in data preprocessing and model building 13460 of nonlinear SAR analysis. The advantages and limitations of rough 13461 set-based SAR analysis were discussed. The results were satisfactorily 13462 in accordance with the available understanding of cocrystal structures 13463 and 3D QSAR models. (C) 2009 Elsevier Ltd. All rights reserved. 13464 SN 0957-4174 13465 PD JUL 13466 PY 2010 13467 VL 37 13468 IS 7 13469 BP 5032 13470 EP 5039 13471 DI 10.1016/j.eswa.2009.12.008 13472 UT ISI:000277726300036 13473 PT J 13474 AU Zhou, YQ 13475 Li, WZ 13476 Chen, LY 13477 Ma, SW 13478 Ping, L 13479 Yang, ZL 13480 AF Zhou, Yongqiang 13481 Li, Weize 13482 Chen, Lvyi 13483 Ma, Shuwei 13484 Ping, Li 13485 Yang, Zhonglin 13486 TI Enhancement of intestinal absorption of akebia saponin D by borneol 13487 and probenecid in situ and in vitro 13488 SO ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY 13489 AB Akebia saponin D is a typical bioactive triterpenoid saponin isolated 13490 the rhizome of Dipsacus asper Wall. Our previous studies demonstrated 13491 that the oral bioavailability of akebia saponin D was very low, but 13492 the underlying mechanisms remained unknown. The present study aims to 13493 investigate the intestinal absorptive characteristics of akebia 13494 saponin D as well as the absorptive transport behavior influenced by 13495 co-administration of three absorption-enhancing agents and three 13496 efflux protein inhibitors using an in vitro everted gut sac method and 13497 an in situ intestinal perfusion model. The results showed that akebia 13498 saponin D had a quite limited intestinal permeability, and there was 13499 a non-linear increase in transepithelial transportation with 13500 increasing concentrations of akebia saponin D. The absorption of akebia 13501 saponin D was intestinal segment selective and the small intestine was 13502 the best absorptive site. Among three absorption promoters, borneol 13503 could significantly improve the permeability of akebia saponin D across 13504 ileum, while Tween-80 and DMSO had almost no absorption-enhancing 13505 effect. In addition, verapamil, probenecid and pantoprazole in the 13506 perfusates were used in this study as modulators of transporters such 13507 as P-glycoprotein, MRPs and BCRP in the intestinal mucosa, 13508 respectively. The results exhibited that the ileal permeability of 13509 akebia saponin D was markedly elevated by the co-administration of 13510 probenecid, indicating that akebia saponin D may be likely a substrate 13511 of MRPs. The above-mentioned results suggest that akebia saponin D has 13512 a poor intestinal absorption not only due to its poor transepithelial 13513 permeability but also owing to the contribution of efflux transporters 13514 such as MRPs in the intestine. (C) 2010 Elsevier B.V. All rights 13515 reserved. 13516 SN 1382-6689 13517 PD MAY 13518 PY 2010 13519 VL 29 13520 IS 3 13521 BP 229 13522 EP 234 13523 DI 10.1016/j.etap.2010.01.004 13524 UT ISI:000277906800006 13525 PT J 13526 AU Gao, F 13527 Ding, L 13528 Ma, PC 13529 Wu, F 13530 AF Gao, Fang 13531 Ding, Li 13532 Ma, Pengcheng 13533 Wu, Fei 13534 TI Simultaneous Analysis of Zofenopril and Its Active Metabolite 13535 Zofenoprilat in Human Plasma by LC-ESI-MS Using Pre-Column 13536 Derivatization with p-Bromophenacyl Bromide 13537 SO CHROMATOGRAPHIA 13538 AB Zofenoprilat is an active metabolite of zofenopril, which is very 13539 unstable in plasma because of oxidative degradation of its thiol group. 13540 In this method, p-bromophenacyl bromide was used as derivatization 13541 reagent, immediately after plasma separation, to react with the free 13542 thiol group of zofenoprilat and form the derivative 13543 zofenoprilat-p-BPB. After acidification with 50% acetic acid, the 13544 derivatized plasma samples were extracted with methyl tert-butyl ether 13545 and separated on a C-18 column with 40:60 (v/v) 10 mM ammonium acetate 13546 buffer solution containing 0.1% formic acid-acetonitrile as mobile 13547 phase. Calibration plots were linear over the concentration range 1-500 13548 ng mL(-1) for zofenopril and 2-1,800 ng mL(-1) for zofenoprilat. The 13549 method was successfully used to study the bioavailability of zofenopril 13550 calcium capsules relative to that of zofenopril calcium tablets in 13551 healthy Chinese volunteers. 13552 SN 0009-5893 13553 PD JUN 13554 PY 2010 13555 VL 71 13556 IS 11-12 13557 BP 1007 13558 EP 1014 13559 DI 10.1365/s10337-010-1606-x 13560 UT ISI:000277936600006 13561 PT J 13562 AU Song, R 13563 Xu, L 13564 Zhang, ZJ 13565 Tian, Y 13566 Xu, FG 13567 Dong, HJ 13568 AF Song, Rui 13569 Xu, Lei 13570 Zhang, Zunjian 13571 Tian, Yuan 13572 Xu, Fengguo 13573 Dong, Haijuan 13574 TI Determination of Gallic Acid in Rat Plasma by LC-MS-MS 13575 SO CHROMATOGRAPHIA 13576 AB Liquid chromatography-electrospray ionization tandem mass 13577 spectrometry has been used for rapid, selective, and sensitive 13578 quantitative analysis of gallic acid in rat plasma. Sample pretreatment 13579 involved a one-step extraction using ethyl acetate with protocatechic 13580 acid as internal standard. Separation was on a C-18 column using an 13581 isocratic mobile phase, consisting of methanol-0.1% aqueous formic 13582 acid (40:60, v/v) at 0.2 mL min(-1). The stability of gallic acid was 13583 evaluated in acidified and non-acidified plasma. The method was 13584 validated then successfully applied to a pharmacokinetic study in rats 13585 after oral administration of rhubarb extract. 13586 SN 0009-5893 13587 PD JUN 13588 PY 2010 13589 VL 71 13590 IS 11-12 13591 BP 1107 13592 EP 1111 13593 DI 10.1365/s10337-010-1565-2 13594 UT ISI:000277936600020 13595 PT J 13596 AU Xie, HT 13597 Wang, GJ 13598 Xu, MJ 13599 Jia, YW 13600 Li, H 13601 Sun, JG 13602 Li, P 13603 AF Xie, Hai-Tang 13604 Wang, Guang-Ji 13605 Xu, Mei-Juan 13606 Jia, Yuan-Wei 13607 Li, Hao 13608 Sun, Jian-Guo 13609 Li, Peng 13610 TI A New LC-MS-MS Method for Quantitative Analysis of Adefovir, and Its 13611 Use for Pharmacokinetic Studies in Healthy Chinese Volunteers 13612 SO CHROMATOGRAPHIA 13613 AB A rapid and sensitive liquid chromatographic-tandem mass spectrometric 13614 method for analysis of adefovir in human plasma has been developed and 13615 validated. After protein precipitation and evaporation, 10 mu L 13616 supernatant was injected for reversed-phase LC separation. Adefovir 13617 and the internal standard (acyclovir) were monitored in selected 13618 reaction monitoring (SRM) mode at m/z 274.10 -> 256.00 and 226.10 -> 13619 152.00, respectively. The calibration plot was linear over the 13620 concentration range 0.5-100 ng mL(-1), and correlation coefficients 13621 were > 0.999. Mean intra-day and inter-day accuracy ranged from 89.43 13622 to 93.20% and from 91.40 to 95.57%, respectively, and mean intra-day 13623 and inter-day precision was between 2.40 and 7.66% and between 5.60 13624 and 10.47%, respectively. The method was successfully applied to a 13625 Phase I pharmacokinetic study of adefovir after oral administration 13626 of adefovir dipivoxil capsules at doses of 5, 10, and 20 mg to 13627 twenty-four healthy Chinese volunteers. 13628 SN 0009-5893 13629 PD APR 13630 PY 2010 13631 VL 71 13632 IS 7-8 13633 BP 587 13634 EP 593 13635 DI 10.1365/s10337-010-1474-4 13636 UT ISI:000277710400005 13637 PT J 13638 AU Fan, XM 13639 Ji, YB 13640 Zhu, DN 13641 AF Fan, Xiao-Mei 13642 Ji, Yi-Bing 13643 Zhu, Da-Ni 13644 TI An Integrated Approach Based on Experimental Designs for Fingerprint 13645 Development of the Complex Herbal Prescription Sheng-Mai-San by MEKC 13646 SO CHROMATOGRAPHIA 13647 AB An integrated strategy based on experimental designs for the 13648 development, optimization and validation of the fingerprint method of 13649 Sheng-Mai-San by MEKC has been described. Orthogonal and sequential 13650 uniform designs were employed to select important experimental 13651 parameters and optimize CE conditions. Method validation was performed 13652 in terms of injection precision, sample stability test and robustness 13653 testing. Additionally, conventional modeling method was used to 13654 predict the optimum separation conditions for comparative purpose. The 13655 strategy described can also be utilized for fingerprint development 13656 in the quality control of other herbal medicines. 13657 SN 0009-5893 13658 PD APR 13659 PY 2010 13660 VL 71 13661 IS 7-8 13662 BP 667 13663 EP 677 13664 DI 10.1365/s10337-010-1519-8 13665 UT ISI:000277710400016 13666 A Liu, B 13667 U You, QD 13668 Li, ZY 13669 A Liu, Bao 13670 F You, Qi Dong 13671 Li, Zhi Yu 13672 T Design, synthesis and antitumor activity of 13673 I 6,7-disubstituted-4-(heteroarylamino)quinoline-3-carbonitrile 13674 derivatives 13675 CHINESE CHEMICAL LETTERS 13676 A A series of new 13677 B 6,7-disubstituted-4-(benzothiazol-6-ylamino)quinoline-3-carbonitri 13678 le derivatives (12a-I) were synthesized. The cytotoxicity of 12 new 13679 compounds was evaluated in AGS, HepG2 and HT-29 cell lines The results 13680 showed that compounds 12g, 12h, 12i, 12k and 121 displayed more potent 13681 cytotoxic activities than Bosutinib, compound 121 exhibited the most 13682 potent antitumor activity among the tested compounds. (C) 2010 Qi Dong 13683 You Published by Elsevier B V. on behalf of Chinese Chemical Society. 13684 All rights reserved. 13685 1001-8417 13686 2010 13687 10.1016/j.cclet.2010.01.016 13688 ISI:000277862400012 13689 PT J 13690 AU Wang, QZ 13691 Liang, JY 13692 Feng, X 13693 AF Wang, Qi Zhi 13694 Liang, Jing Yu 13695 Feng, Xu 13696 TI Evodiagenine and dievodiamine, two new indole alkaloids from Evodia 13697 rutaecarpa 13698 SO CHINESE CHEMICAL LETTERS 13699 AB Two new indole alkaloids, evodiagenine 1 and dievodiamine 2 were 13700 isolated from the fruits of Evodia rutaecarpa (Juss) Benth. The 13701 structure of compounds 1 and 2 were elucidated by comprehensive 13702 spectroscopic analysis and compound 1 was confirmed by X-ray 13703 crystallographic analysis (C) 2009 Xu Feng. Published by Elsevier B.V. 13704 on behalf of Chinese Chemical Society. All rights reserved. 13705 SN 1001-8417 13706 PD MAY 13707 PY 2010 13708 VL 21 13709 IS 5 13710 BP 596 13711 EP 599 13712 DI 10.1016/j.cclet.2009.12.002 13713 UT ISI:000277862400023 13714 PT J 13715 AU Ye, XL 13716 Zhou, W 13717 Li, YQ 13718 Sun, YH 13719 Zhang, YH 13720 Ji, H 13721 Lai, YS 13722 AF Ye, Xiaolei 13723 Zhou, Wu 13724 Li, Yongqi 13725 Sun, Yihua 13726 Zhang, Yihua 13727 Ji, Hui 13728 Lai, Yisheng 13729 TI Darbufelone, a novel anti-inflammatory drug, induces growth inhibition 13730 of lung cancer cells both in vitro and in vivo 13731 SO CANCER CHEMOTHERAPY AND PHARMACOLOGY 13732 AB Inflammation plays a crucial role in the development of lung cancer. 13733 Accumulated studies have proved that non-steroidal anti-inflammatory 13734 drugs (NSAIDs) which block inflammation by their actions on arachidonic 13735 acid (AA) metabolism have a potential role in cancer chemotherapy and 13736 chemoprevention. The aim of our study was to investigate whether 13737 darbufelone, a novel anti-inflammatory drug, has anticancer effects 13738 in lung cancer. 13739 Human non-small cell lung cancer cell lines were treated with 13740 darbufelone at various doses and time points for analysis of cell 13741 viability, cell cycle, and apoptosis in vitro. The in vivo effect of 13742 darbufelone was assessed in Lewis lung carcinoma mice model. 13743 Darbufelone inhibited the proliferation of non-small cell lung cancer 13744 cell lines in a dose-dependent manner, and induced cell cycle arrest 13745 at G0/G1 phase through up-regulation of p27 expression. Treatment with 13746 darbufelone also induced apoptosis by activating caspase-3 and 13747 caspase-8. Lewis lung carcinoma growth was also significantly 13748 inhibited by darbufelone treatment at daily dose of 80 mg/kg. 13749 Taken together, these studies suggested that darbufelone, an 13750 anti-inflammation drug, might represent a novel therapeutic approach 13751 for lung cancer treatment. 13752 SN 0344-5704 13753 PD JUL 13754 PY 2010 13755 VL 66 13756 IS 2 13757 BP 277 13758 EP 285 13759 DI 10.1007/s00280-009-1161-z 13760 UT ISI:000277785600009 13761 PT J 13762 AU Jin, L 13763 Zhu, AH 13764 Wang, Y 13765 Lu, Y 13766 Liu, JJ 13767 AF Jin Liang 13768 Zhu Aihua 13769 Wang Yu 13770 Lu Yong 13771 Liu Jingjing 13772 TI HSP65 serves as an immunogenic carrier for a diabetogenic peptide P277 13773 inducing anti-inflammatory immune response in NOD mice by nasal 13774 administration 13775 SO VACCINE 13776 AB Mucosal administration of autoantigen 1451,65 can induce 13777 anti-inflammatory immune response and decrease organ-specific 13778 inflammation and disease in several models of autoimmunity, such as 13779 arthritis and atherosclerosis We have been interested in whether the 13780 HSP65 serves as an immunogenic carrier for a diabetogenic peptide P277 13781 can also Induce anti-inflammatory immune response in NOD mice by 13782 mucosal administration Thus, the dual functions of anti-type 1 diabetes 13783 of HSP65 and P277 will be obtained To test this hypothesis, we examined 13784 the effect of intranasal vaccination with P277 tandem repeat sequences 13785 carried by HSP65 in the absence of adjuvants on autoimmune diabetes 13786 in NOD mice. We found a significant decrease in the incidence of 13787 diabetes, inhibition of insulitis, reduction in IgG2a isotype 13788 antibodies to P277 and proinflammatory cytokines IFN-gamma and IL-2 13789 secretion, increased IgG1, IgG2b subclass antibodies to P277 and 13790 anti-inflammatory cytokmes IL-10 and IL-4 secretion, and reduced 13791 proliferation in nasal administration of the fusion protein HSP65-6 13792 x P277 Our results demonstrate that HSP65 may serve as a particularly 13793 advantageous carrier for P277-based vaccines and mucosal 13794 administration may be a therapeutic approach for treatment of type 1 13795 diabetes. (C) 2010 Elsevier Ltd. All rights reserved 13796 SN 0264-410X 13797 PD APR 26 13798 PY 2010 13799 VL 28 13800 IS 19 13801 BP 3312 13802 EP 3317 13803 DI 10.1016/j.vaccine.2010.02.100 13804 UT ISI:000277677000008 13805 PT J 13806 AU Liu, L 13807 Jiang, ZZ 13808 Liu, J 13809 Huang, X 13810 Wang, T 13811 Liu, J 13812 Zhang, Y 13813 Zhou, ZX 13814 Guo, JL 13815 Yang, LN 13816 Chen, Y 13817 Zhang, LY 13818 AF Liu, Li 13819 Jiang, Zhenzhou 13820 Liu, Jing 13821 Huang, Xin 13822 Wang, Tao 13823 Liu, Jun 13824 Zhang, Yun 13825 Zhou, Zhixing 13826 Guo, Jianlu 13827 Yang, Lina 13828 Chen, Yun 13829 Zhang, Luyong 13830 TI Sex differences in subacute toxicity and hepatic microsomal metabolism 13831 of triptolide in rats 13832 SO TOXICOLOGY 13833 AB Triptolide, a major active component of Tripterygium wilfordii Hook 13834 F (TWHF), has multiple pharmacological activities. However, its 13835 clinical use is often limited by its severe toxicity. In the present 13836 study, we evaluated the oral toxicity of triptolide in Sprague-Dawley 13837 rats for 28 days at the dosages of 0, 200 and 400 mu g/kg/day, 13838 respectively. Significant difference in the toxicity of triptolide at 13839 400 mu g/kg was found between different sexes. The triptolide-treated 13840 female rats showed many abnormalities, including anorexia, diarrhea, 13841 leanness, suppression of weight gain and food intake, fatty liver, 13842 splenomegaly and atrophy of ovaries. In contrast, no such abnormalities 13843 were observed in male rats except for the significant reproductive 13844 toxicity. Furthermore, the metabolism of triptolide in liver 13845 microsomes from both sexes was investigated by HPLC. A greater rate 13846 of triptolide metabolism was observed in male rat hepatic microsomes, 13847 suggesting that one of the cytochrome P450s (CYPs) responsible for 13848 triptolide metabolism is male-specific or predominant at least. The 13849 inhibition experiments with CYP inhibitors showed that CYP3A and CYP2B 13850 were mainly involved in the metabolism of triptolide. In addition, 13851 since CYP3A2 is a male-predominant form in rats, significant sex 13852 difference in the metabolism of triptolide disappeared in vitro after 13853 anti-rat CYP3A2 antibody pretreatment. Results suggested that CYP3A2 13854 made an important contribution to the sex-related metabolism of 13855 triptolide, which may result in the sex differences in triptolide 13856 toxicity. (C) 2010 Elsevier Ireland Ltd. All rights reserved. 13857 SN 0300-483X 13858 PD APR 30 13859 PY 2010 13860 VL 271 13861 IS 1-2 13862 BP 57 13863 EP 63 13864 DI 10.1016/j.tox.2010.03.004 13865 UT ISI:000277739900009 13866 PT J 13867 AU Yue, L 13868 Zhang, F 13869 Wang, ZX 13870 AF Yue, Long 13871 Zhang, Feng 13872 Wang, Zhixiang 13873 TI Study on Ultrasonic Extraction of Gastrodin from Gastrodia elata Bl. 13874 SO SEPARATION SCIENCE AND TECHNOLOGY 13875 AB Gastrodin, a pharmacologically active constituent, was ultrasonically 13876 extracted from gastrodia elata Bl. in the aqueous solution. The effects 13877 of six parameters including ethanol-water compositions, extraction 13878 time, extraction temperature, particle size, solvent volume, and 13879 ultrasonic power on the extraction yield of gastrodin were 13880 investigated. According to the orthogonal design, the optimal 13881 extraction conditions was explored as extraction temperature 60 13882 degrees C, extraction time 50 minutes, ultrasonic power 126W, solvent 13883 volume 8mL center dot g-1, ethanol-water compositions 70%, and particle 13884 size 10-20 mesh. Though the yield of gastrodin via ultrasonic 13885 extraction was about 0.01% lower than that from the reflux extraction, 13886 the extraction time of the ultrasonic extraction was greatly shortened. 13887 Therefore, ultrasonic extraction has high efficiency and is proved to 13888 be very valuable in the extraction of gastrodin from gastrodia elata 13889 SN 0149-6395 13890 PY 2010 13891 VL 45 13892 IS 6 13893 BP 832 13894 EP 838 13895 DI 10.1080/01496390903566671 13896 UT ISI:000277727800014 13897 PT J 13898 AU Ya, J 13899 Zhang, XQ 13900 Wang, Y 13901 Zhang, QW 13902 Chen, JX 13903 Ye, WC 13904 AF Ya, Ji 13905 Zhang, Xiao-Qi 13906 Wang, Ying 13907 Zhang, Qing-Wen 13908 Chen, Jian-Xin 13909 Ye, Wen-Cai 13910 TI Two new phenolic compounds from the roots of Ficus hirta 13911 SO NATURAL PRODUCT RESEARCH 13912 AB A new prenylcoumarin, 5-methoxyl-4,2'-epoxy-3-(4', 13913 5'-dihydroxyphenyl)-linear pyranocoumarin (1), and a new flavonoid, 13914 3-acetyl-3,5,4'-trihydroxy-7-methoxylflavone (2), were isolated from 13915 the roots of Ficus hirta. Their structures were elucidated by 13916 spectroscopic methods including 1D-, 2D- NMR and HR-ESI-MS. 13917 SN 1478-6419 13918 PY 2010 13919 VL 24 13920 IS 7 13921 BP 621 13922 EP 625 13923 DI 10.1080/14786410902847377 13924 UT ISI:000277661200003 13925 PT J 13926 AU Zhang, ZB 13927 Li, ZC 13928 Tian, J 13929 Jiang, W 13930 Wang, Y 13931 Zhang, XJ 13932 Li, ZR 13933 You, QD 13934 Shapiro, JI 13935 Si, SY 13936 Xie, ZJ 13937 AF Zhang, Zhongbing 13938 Li, Zhichuan 13939 Tian, Jiang 13940 Jiang, Wei 13941 Wang, Yin 13942 Zhang, Xiaojin 13943 Li, Zhuorong 13944 You, Qidong 13945 Shapiro, Joseph I. 13946 Si, Shuyi 13947 Xie, Zijian 13948 TI Identification of Hydroxyxanthones as Na/K-ATPase Ligands 13949 SO MOLECULAR PHARMACOLOGY 13950 AB We have screened a chemical library and identified several novel 13951 structures of Na/K-ATPase inhibitors. One group of these inhibitors 13952 belongs to polyphenolic xanthone derivatives. Functional 13953 characterization reveals the following properties of this group of 13954 inhibitors. First, like ouabain, they are potent inhibitors of the 13955 purified Na/K-ATPase. Second, their effects on the Na/K-ATPase depend 13956 on the number and position of phenolic groups. Methylation of these 13957 phenolic groups reduces the inhibitory effect. Third, further 13958 characterization of the most potent xanthone derivative, MB7 13959 (3,4,5,6-tetrahydroxyxanthone), reveals that it does not change either 13960 Na+ or ATP affinity of the enzyme. Finally, unlike that of ouabain, 13961 the inhibitory effect of MB7 on Na/K-ATPase is not antagonized by K+. 13962 Moreover, MB7 does not activate the receptor Na/K-ATPase/Src complex 13963 and fails to stimulate protein kinase cascades in cultured cells. Thus, 13964 we have identified a group of novel Na/K-ATPase ligands that can inhibit 13965 the pumping function without stimulating the signaling function of 13966 Na/K-ATPase. 13967 SN 0026-895X 13968 PD JUN 13969 PY 2010 13970 VL 77 13971 IS 6 13972 BP 961 13973 EP 967 13974 DI 10.1124/mol.110.063974 13975 UT ISI:000277751600009 13976 PT J 13977 AU Feng, X 13978 Wang, JS 13979 Luo, J 13980 Kong, LY 13981 AF Feng, Xin 13982 Wang, Jun-Song 13983 Luo, Jun 13984 Kong, Ling-Yi 13985 TI A pair of sesquiterpene glucosides from the leaves of Nicotiana tabacum 13986 SO JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH 13987 AB A pair of sesquiterpene glucosides, 13988 3-hydroxysolavetivone--d-glucoside A (1) and 13989 3-hydroxysolavetivone--d-glucoside B (2), have been isolated from the 13990 leaves of Nicotiana tabacum. The former is a new compound, while the 13991 latter is a known one. Their structures were established by 13992 spectroscopic methods including 1H, 13C, and 2D NMR. The relative 13993 configuration of C-3 in compound 2 was revised by NOESY experiment. 13994 SN 1028-6020 13995 PY 2010 13996 VL 12 13997 IS 3 13998 BP 252 13999 EP 256 14000 DI 10.1080/10286020903550947 14001 UT ISI:000277569900013 14002 PT J 14003 AU Liu, W 14004 Wang, HY 14005 Pang, XB 14006 Yao, WB 14007 Gao, XD 14008 AF Liu, Wei 14009 Wang, Hengyu 14010 Pang, Xiubing 14011 Yao, Wenbing 14012 Gao, Xiangdong 14013 TI Characterization and antioxidant activity of two low-molecular-weight 14014 polysaccharides purified from the fruiting bodies of Ganoderma lucidum 14015 SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES 14016 AB Two low-molecular-weight polysaccharides, GLP(L)1 and GLP(L)2, 14017 purified from a crude Ganoderma lucidum polysaccharide preparation 14018 GLPP were investigated for their physicochemical properties. structure 14019 characterization and antioxidant activities The results indicated that 14020 GLP(L)1 was a glucan with an average molecular weight of 5 2 kDa, while 14021 GLP(L)2 was composed of glucose, galactose and mannose in a ratio of 14022 29 1 8 1.0 with the average molecular weight of 15.4 kDa GLP(L)1 and 14023 GLP(L)2 had similar structure characteristic which contained linkages 14024 such as -> 3)-Glcp-(1 ->,-> 4)-Glcp-(1 ->,-> 6)-Glcp-(1 ->,-> 14025 3,6)-Glcp-(1 ->, and -> 4,6 )-Glcp-(1 -> in the percentage ratio of 14026 21.9 20 3 23.7 24 0 3 7 and 23 0 34 6 7 0 14.1 3.0 in the backbone or 14027 branches, respectively Antioxidant results showed that both GLP(L)1 14028 and GLP(L)2 exhibited antioxidant activities while GLP(L)1 was more 14029 effective in free radicals scavenging and Fe2+ chelating. 14030 Low-molecular-weight polysaccharide seems to play an important role 14031 in the exploration of natural antioxidants in food industry and 14032 pharmaceuticals (C) 2010 Elsevier B V All rights reserved 14033 SN 0141-8130 14034 PD MAY 1 14035 PY 2010 14036 VL 46 14037 IS 4 14038 BP 451 14039 EP 457 14040 DI 10.1016/j.ijbiomac.2010.02.006 14041 UT ISI:000277676700011 14042 PT J 14043 AU Cao, Y 14044 Tan, NH 14045 Chen, JJ 14046 Zeng, GZ 14047 Ma, YB 14048 Wu, YP 14049 Yan, H 14050 Yang, J 14051 Lu, LF 14052 Wang, Q 14053 AF Cao, Yuan 14054 Tan, Nin-Hua 14055 Chen, Ji-Jun 14056 Zeng, Guang-Zhi 14057 Ma, Yun-Bao 14058 Wu, Yong-Ping 14059 Yan, He 14060 Yang, Jie 14061 Lu, Lai-Feng 14062 Wang, Qiang 14063 TI Bioactive flavones and biflavones from Selaginella moellendorffii 14064 Hieron 14065 SO FITOTERAPIA 14066 AB Three new flavones named 5-carboxymethyl-4',7-dihydroxyflavone (1), 14067 its ethyl ester (2) and butyl ester (3) were isolated from the herb 14068 Selaginella moellendorffii Hieron., together with ten known compounds. 14069 Their structures were elucidated on the basis of spectroscopic and 14070 chemical analysis. Selected compounds were evaluated for their 14071 anti-HBV and cytotoxic activity. Among them, compounds 2 and 3 14072 displayed inhibitory activity in vitro on hepatitis B virus (HBV) 14073 surface antigen (HBsAg) secretion of the Hep G2.2.15 cell line with 14074 IC50 values of 0.17 mg/ml and 0.46 mg/ml, and on HBV e antigen (HBeAg) 14075 secretion with IC50 values of 0.42 mg/ml and 0.42 mg/ml, respectively. 14076 Compounds 7.8. 10 and 12 exhibited selective cytotoxicity against the 14077 three human cancer cell lines tested. (C) 2009 Elsevier By. All rights 14078 reserved. 14079 SN 0367-326X 14080 PD JUN 14081 PY 2010 14082 VL 81 14083 IS 4 14084 BP 253 14085 EP 258 14086 DI 10.1016/j.fitote.2009.09.007 14087 UT ISI:000277699400006 14088 PT J 14089 AU Peng, HJ 14090 Dai, DZ 14091 Ji, H 14092 Dai, Y 14093 AF Peng, Hong-Jun 14094 Dai, De-Zai 14095 Ji, Hui 14096 Dai, Yin